primaryid,caseid,drug_seq,role_cod,drugname,prod_ai,val_vbm,route,dose_vbm,cum_dose_chr,cum_dose_unit,dechal,rechal,lot_num,exp_dt,nda_num,dose_amt,dose_unit,dose_form,dose_freq,year_x,quarter_x,pt,drug_rec_act,year_y,quarter_y,caseversion,i_f_code,event_dt,mfr_dt,init_fda_dt,fda_dt,rept_cod,auth_num,mfr_num,mfr_sndr,lit_ref,age,age_cod,age_grp,sex,e_sub,wt,wt_cod,rept_dt,to_mfr,occp_cod,reporter_country,occr_country,year,quarter,age_group
121379632,12137963,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Transplacental,10.0MG UNKNOWN,,,,,,,,10.0,MG,TABLET,,2020,Q1,Congenital hydrocephalus,,2020,Q1,2,F,,20200127.0,20160302,20200205,EXP,,GB-ASTRAZENECA-2016SE19198,ASTRAZENECA,,20.0,WK,,,Y,,,20200205.0,,,GB,GB,2020,Q1,Youth
121543472,12154347,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Transplacental,"10 MG, UNK",,,Y,U,,,,10.0,MG,,,2020,Q1,Congenital hydrocephalus,,2020,Q1,2,F,,20200302.0,20160307,20200310,EXP,GB-MHRA-ADR 23357992,GB-MYLANLABS-2016M1008480,MYLAN,,20.0,WK,,,Y,,,20200310.0,,MD,GB,GB,2020,Q1,Youth
121543472,12154347,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Transplacental,"10 MG, UNK",,,Y,U,,,,10.0,MG,,,2020,Q1,Foetal exposure during pregnancy,,2020,Q1,2,F,,20200302.0,20160307,20200310,EXP,GB-MHRA-ADR 23357992,GB-MYLANLABS-2016M1008480,MYLAN,,20.0,WK,,,Y,,,20200310.0,,MD,GB,GB,2020,Q1,Youth
121543472,12154347,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Transplacental,UNK,,,Y,U,,,,,,,,2020,Q1,Congenital hydrocephalus,,2020,Q1,2,F,,20200302.0,20160307,20200310,EXP,GB-MHRA-ADR 23357992,GB-MYLANLABS-2016M1008480,MYLAN,,20.0,WK,,,Y,,,20200310.0,,MD,GB,GB,2020,Q1,Youth
121543472,12154347,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Transplacental,UNK,,,Y,U,,,,,,,,2020,Q1,Foetal exposure during pregnancy,,2020,Q1,2,F,,20200302.0,20160307,20200310,EXP,GB-MHRA-ADR 23357992,GB-MYLANLABS-2016M1008480,MYLAN,,20.0,WK,,,Y,,,20200310.0,,MD,GB,GB,2020,Q1,Youth
121618052,12161805,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Transplacental,"10 MILLIGRAMS, UNK",,,,,,,,10.0,MG,,,2020,Q1,Congenital hydrocephalus,,2020,Q1,2,F,,20200127.0,20160309,20200211,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2016RR-112871,RANBAXY,,20.0,WK,,,Y,,,20200211.0,,HP,NL,GB,2020,Q1,Youth
122367383,12236738,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Transplacental,10 MILLIGRAM,,,D,,,,,10.0,MG,,,2020,Q1,Congenital hydrocephalus,,2020,Q1,3,F,,20200203.0,20160405,20200213,EXP,,GB-AUROBINDO-AUR-APL-2016-02203,AUROBINDO,,20.0,WK,,,Y,,,20200213.0,,MD,GB,GB,2020,Q1,Youth
122367383,12236738,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Transplacental,10 MILLIGRAM,,,D,,,,,10.0,MG,,,2020,Q1,Foetal exposure during pregnancy,,2020,Q1,3,F,,20200203.0,20160405,20200213,EXP,,GB-AUROBINDO-AUR-APL-2016-02203,AUROBINDO,,20.0,WK,,,Y,,,20200213.0,,MD,GB,GB,2020,Q1,Youth
134651252,13465125,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,U,,,202293.0,5.0,MG,TABLET,QD,2020,Q1,Diabetic ketoacidosis,,2020,Q1,2,F,20161216.0,20170418.0,20170421,20200213,EXP,,US-ASTRAZENECA-2017SE41074,ASTRAZENECA,,35.0,YR,,F,Y,101.0,KG,20200213.0,,PH,US,US,2020,Q1,Adult
143924332,14392433,2,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,140.0,MG,Y,U,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Lip swelling,,2020,Q1,2,F,20170922.0,20171220.0,20180116,20200120,EXP,,GB-ASTRAZENECA-2018SE06193,ASTRAZENECA,,26308.0,DY,,F,Y,104.0,KG,20200120.0,,MD,GB,GB,2020,Q1,Elderly
143924332,14392433,2,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,140.0,MG,Y,U,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Skin ulcer,,2020,Q1,2,F,20170922.0,20171220.0,20180116,20200120,EXP,,GB-ASTRAZENECA-2018SE06193,ASTRAZENECA,,26308.0,DY,,F,Y,104.0,KG,20200120.0,,MD,GB,GB,2020,Q1,Elderly
148354035,14835403,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q1,Decreased vibratory sense,,2020,Q1,5,F,2016.0,20200213.0,20180502,20200225,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN DESPITE GOOD COMPLIANCE.. AERZTE WOCHE. 2018;33:7,61.0,YR,,F,Y,97.0,KG,20200226.0,,MD,DE,DE,2020,Q1,Adult
148354035,14835403,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q1,Diabetes mellitus inadequate control,,2020,Q1,5,F,2016.0,20200213.0,20180502,20200225,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN DESPITE GOOD COMPLIANCE.. AERZTE WOCHE. 2018;33:7,61.0,YR,,F,Y,97.0,KG,20200226.0,,MD,DE,DE,2020,Q1,Adult
148354035,14835403,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q1,Gastrointestinal disorder,,2020,Q1,5,F,2016.0,20200213.0,20180502,20200225,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN DESPITE GOOD COMPLIANCE.. AERZTE WOCHE. 2018;33:7,61.0,YR,,F,Y,97.0,KG,20200226.0,,MD,DE,DE,2020,Q1,Adult
148354035,14835403,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q1,Limb discomfort,,2020,Q1,5,F,2016.0,20200213.0,20180502,20200225,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN DESPITE GOOD COMPLIANCE.. AERZTE WOCHE. 2018;33:7,61.0,YR,,F,Y,97.0,KG,20200226.0,,MD,DE,DE,2020,Q1,Adult
148354035,14835403,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q1,Neuropathy peripheral,,2020,Q1,5,F,2016.0,20200213.0,20180502,20200225,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN DESPITE GOOD COMPLIANCE.. AERZTE WOCHE. 2018;33:7,61.0,YR,,F,Y,97.0,KG,20200226.0,,MD,DE,DE,2020,Q1,Adult
148354035,14835403,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q1,Pain in extremity,,2020,Q1,5,F,2016.0,20200213.0,20180502,20200225,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN DESPITE GOOD COMPLIANCE.. AERZTE WOCHE. 2018;33:7,61.0,YR,,F,Y,97.0,KG,20200226.0,,MD,DE,DE,2020,Q1,Adult
148354035,14835403,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q1,Sensory disturbance,,2020,Q1,5,F,2016.0,20200213.0,20180502,20200225,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN DESPITE GOOD COMPLIANCE.. AERZTE WOCHE. 2018;33:7,61.0,YR,,F,Y,97.0,KG,20200226.0,,MD,DE,DE,2020,Q1,Adult
148354035,14835403,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q1,Sleep disorder,,2020,Q1,5,F,2016.0,20200213.0,20180502,20200225,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN DESPITE GOOD COMPLIANCE.. AERZTE WOCHE. 2018;33:7,61.0,YR,,F,Y,97.0,KG,20200226.0,,MD,DE,DE,2020,Q1,Adult
148354035,14835403,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q1,Temperature perception test abnormal,,2020,Q1,5,F,2016.0,20200213.0,20180502,20200225,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN DESPITE GOOD COMPLIANCE.. AERZTE WOCHE. 2018;33:7,61.0,YR,,F,Y,97.0,KG,20200226.0,,MD,DE,DE,2020,Q1,Adult
148354035,14835403,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q1,Visual impairment,,2020,Q1,5,F,2016.0,20200213.0,20180502,20200225,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN DESPITE GOOD COMPLIANCE.. AERZTE WOCHE. 2018;33:7,61.0,YR,,F,Y,97.0,KG,20200226.0,,MD,DE,DE,2020,Q1,Adult
153245584,15324558,1,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,QD,2020,Q1,Decreased vibratory sense,,2020,Q1,4,F,2016.0,20200217.0,20180828,20200226,EXP,DE-EMA-DD-20180608-ISHAEVHP-143511,DE-TORRENT-00009642,TORRENT,,61.0,YR,A,F,Y,97.0,KG,20200226.0,,HP,DE,DE,2020,Q1,Adult
153245584,15324558,1,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,QD,2020,Q1,Diabetes mellitus inadequate control,,2020,Q1,4,F,2016.0,20200217.0,20180828,20200226,EXP,DE-EMA-DD-20180608-ISHAEVHP-143511,DE-TORRENT-00009642,TORRENT,,61.0,YR,A,F,Y,97.0,KG,20200226.0,,HP,DE,DE,2020,Q1,Adult
153245584,15324558,1,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,QD,2020,Q1,Gastrointestinal disorder,,2020,Q1,4,F,2016.0,20200217.0,20180828,20200226,EXP,DE-EMA-DD-20180608-ISHAEVHP-143511,DE-TORRENT-00009642,TORRENT,,61.0,YR,A,F,Y,97.0,KG,20200226.0,,HP,DE,DE,2020,Q1,Adult
153245584,15324558,1,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,QD,2020,Q1,Limb discomfort,,2020,Q1,4,F,2016.0,20200217.0,20180828,20200226,EXP,DE-EMA-DD-20180608-ISHAEVHP-143511,DE-TORRENT-00009642,TORRENT,,61.0,YR,A,F,Y,97.0,KG,20200226.0,,HP,DE,DE,2020,Q1,Adult
153245584,15324558,1,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,QD,2020,Q1,Neuropathy peripheral,,2020,Q1,4,F,2016.0,20200217.0,20180828,20200226,EXP,DE-EMA-DD-20180608-ISHAEVHP-143511,DE-TORRENT-00009642,TORRENT,,61.0,YR,A,F,Y,97.0,KG,20200226.0,,HP,DE,DE,2020,Q1,Adult
153245584,15324558,1,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,QD,2020,Q1,Pain in extremity,,2020,Q1,4,F,2016.0,20200217.0,20180828,20200226,EXP,DE-EMA-DD-20180608-ISHAEVHP-143511,DE-TORRENT-00009642,TORRENT,,61.0,YR,A,F,Y,97.0,KG,20200226.0,,HP,DE,DE,2020,Q1,Adult
153245584,15324558,1,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,QD,2020,Q1,Sensory disturbance,,2020,Q1,4,F,2016.0,20200217.0,20180828,20200226,EXP,DE-EMA-DD-20180608-ISHAEVHP-143511,DE-TORRENT-00009642,TORRENT,,61.0,YR,A,F,Y,97.0,KG,20200226.0,,HP,DE,DE,2020,Q1,Adult
153245584,15324558,1,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,QD,2020,Q1,Sleep disorder,,2020,Q1,4,F,2016.0,20200217.0,20180828,20200226,EXP,DE-EMA-DD-20180608-ISHAEVHP-143511,DE-TORRENT-00009642,TORRENT,,61.0,YR,A,F,Y,97.0,KG,20200226.0,,HP,DE,DE,2020,Q1,Adult
153245584,15324558,1,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,QD,2020,Q1,Temperature perception test abnormal,,2020,Q1,4,F,2016.0,20200217.0,20180828,20200226,EXP,DE-EMA-DD-20180608-ISHAEVHP-143511,DE-TORRENT-00009642,TORRENT,,61.0,YR,A,F,Y,97.0,KG,20200226.0,,HP,DE,DE,2020,Q1,Adult
153245584,15324558,1,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,QD,2020,Q1,Visual impairment,,2020,Q1,4,F,2016.0,20200217.0,20180828,20200226,EXP,DE-EMA-DD-20180608-ISHAEVHP-143511,DE-TORRENT-00009642,TORRENT,,61.0,YR,A,F,Y,97.0,KG,20200226.0,,HP,DE,DE,2020,Q1,Adult
154521622,15452162,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2020,Q1,Diabetic mononeuropathy,,2020,Q1,2,F,,20200316.0,20181001,20200326,EXP,,"IE-IMPAX LABORATORIES, INC-2018-IPXL-03129",AMNEAL,"SIDDIQUE N, DURCAN R, SMYTH S, KYAW TUN T, SREENAN S, MCDERMOTT JH. ACUTE DIABETIC NEUROPATHY PRECIPITATED BY TIGHTENING OF GLYCAEMIC CONTROL-CASE SERIES AND REVIEW. ENDOCRINOL. DIABETES METAB. CASE REP.. 2018;187(SUPPL 5):S221-2",58.0,YR,,M,Y,,,20200326.0,,HP,IE,IE,2020,Q1,Adult
154521622,15452162,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2020,Q1,IIIrd nerve paralysis,,2020,Q1,2,F,,20200316.0,20181001,20200326,EXP,,"IE-IMPAX LABORATORIES, INC-2018-IPXL-03129",AMNEAL,"SIDDIQUE N, DURCAN R, SMYTH S, KYAW TUN T, SREENAN S, MCDERMOTT JH. ACUTE DIABETIC NEUROPATHY PRECIPITATED BY TIGHTENING OF GLYCAEMIC CONTROL-CASE SERIES AND REVIEW. ENDOCRINOL. DIABETES METAB. CASE REP.. 2018;187(SUPPL 5):S221-2",58.0,YR,,M,Y,,,20200326.0,,HP,IE,IE,2020,Q1,Adult
1565076311,15650763,15,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,TABLET,,2020,Q1,Chest pain,,2020,Q1,11,F,,20200129.0,20181123,20200211,EXP,,PT-AUROBINDO-AUR-APL-2018-056484,AUROBINDO,,54.0,YR,,F,Y,,,20200211.0,,CN,PT,PT,2020,Q1,Adult
1565076311,15650763,15,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,TABLET,,2020,Q1,Headache,,2020,Q1,11,F,,20200129.0,20181123,20200211,EXP,,PT-AUROBINDO-AUR-APL-2018-056484,AUROBINDO,,54.0,YR,,F,Y,,,20200211.0,,CN,PT,PT,2020,Q1,Adult
1565076311,15650763,15,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,TABLET,,2020,Q1,Ischaemic stroke,,2020,Q1,11,F,,20200129.0,20181123,20200211,EXP,,PT-AUROBINDO-AUR-APL-2018-056484,AUROBINDO,,54.0,YR,,F,Y,,,20200211.0,,CN,PT,PT,2020,Q1,Adult
156930683,15693068,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q1,Immune-mediated hepatitis,,2020,Q1,3,F,,20200211.0,20181206,20200219,EXP,,CA-TEVA-2018-CA-983715,TEVA,,65.0,YR,,M,Y,,,20200219.0,,MD,CA,CA,2020,Q1,Elderly
157035622,15703562,9,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,,,2020,Q1,Chest pain,,2020,Q1,2,F,,20200129.0,20181210,20200207,EXP,,PT-AUROBINDO-AUR-APL-2018-059436,AUROBINDO,,54.0,YR,,F,Y,,,20200208.0,,PH,PT,PT,2020,Q1,Adult
157035622,15703562,9,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,,,2020,Q1,Ischaemic stroke,,2020,Q1,2,F,,20200129.0,20181210,20200207,EXP,,PT-AUROBINDO-AUR-APL-2018-059436,AUROBINDO,,54.0,YR,,F,Y,,,20200208.0,,PH,PT,PT,2020,Q1,Adult
159004823,15900482,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q1,Blister,,2020,Q1,3,F,201901.0,20200124.0,20190201,20200131,EXP,,GB-ASTRAZENECA-2019SE14419,ASTRAZENECA,,58.0,YR,,M,Y,137.6,KG,20200131.0,,,GB,GB,2020,Q1,Adult
159004823,15900482,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q1,Cellulitis,,2020,Q1,3,F,201901.0,20200124.0,20190201,20200131,EXP,,GB-ASTRAZENECA-2019SE14419,ASTRAZENECA,,58.0,YR,,M,Y,137.6,KG,20200131.0,,,GB,GB,2020,Q1,Adult
159004823,15900482,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q1,Dermatitis,,2020,Q1,3,F,201901.0,20200124.0,20190201,20200131,EXP,,GB-ASTRAZENECA-2019SE14419,ASTRAZENECA,,58.0,YR,,M,Y,137.6,KG,20200131.0,,,GB,GB,2020,Q1,Adult
159004823,15900482,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q1,Feeling hot,,2020,Q1,3,F,201901.0,20200124.0,20190201,20200131,EXP,,GB-ASTRAZENECA-2019SE14419,ASTRAZENECA,,58.0,YR,,M,Y,137.6,KG,20200131.0,,,GB,GB,2020,Q1,Adult
159004823,15900482,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q1,Peripheral swelling,,2020,Q1,3,F,201901.0,20200124.0,20190201,20200131,EXP,,GB-ASTRAZENECA-2019SE14419,ASTRAZENECA,,58.0,YR,,M,Y,137.6,KG,20200131.0,,,GB,GB,2020,Q1,Adult
159004823,15900482,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q1,Purpura,,2020,Q1,3,F,201901.0,20200124.0,20190201,20200131,EXP,,GB-ASTRAZENECA-2019SE14419,ASTRAZENECA,,58.0,YR,,M,Y,137.6,KG,20200131.0,,,GB,GB,2020,Q1,Adult
159004823,15900482,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q1,Vasculitis,,2020,Q1,3,F,201901.0,20200124.0,20190201,20200131,EXP,,GB-ASTRAZENECA-2019SE14419,ASTRAZENECA,,58.0,YR,,M,Y,137.6,KG,20200131.0,,,GB,GB,2020,Q1,Adult
160271415,16027141,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q1,Cellulitis,,2020,Q1,5,F,20181224.0,20200306.0,20190303,20200313,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-019559,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,130.0,KG,20200313.0,,HP,DE,DE,2020,Q1,Adult
160271415,16027141,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q1,Lymphangitis,,2020,Q1,5,F,20181224.0,20200306.0,20190303,20200313,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-019559,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,130.0,KG,20200313.0,,HP,DE,DE,2020,Q1,Adult
160271415,16027141,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q1,Necrosis,,2020,Q1,5,F,20181224.0,20200306.0,20190303,20200313,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-019559,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,130.0,KG,20200313.0,,HP,DE,DE,2020,Q1,Adult
160271415,16027141,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q1,Soft tissue infection,,2020,Q1,5,F,20181224.0,20200306.0,20190303,20200313,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-019559,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,130.0,KG,20200313.0,,HP,DE,DE,2020,Q1,Adult
160901482,16090148,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,U,,,202293.0,10.0,MG,TABLET,,2020,Q1,Fournier's gangrene,,2020,Q1,2,F,20190213.0,20200227.0,20190319,20200302,EXP,,GB-ASTRAZENECA-2019SE42128,ASTRAZENECA,,58.0,YR,,M,Y,78.0,KG,20200302.0,,,GB,GB,2020,Q1,Adult
160901482,16090148,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,U,,,202293.0,10.0,MG,TABLET,,2020,Q1,Septic shock,,2020,Q1,2,F,20190213.0,20200227.0,20190319,20200302,EXP,,GB-ASTRAZENECA-2019SE42128,ASTRAZENECA,,58.0,YR,,M,Y,78.0,KG,20200302.0,,,GB,GB,2020,Q1,Adult
163963103,16396310,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,ONGOING = CHECKED,,,,, UNKNOWN,,,,,,,2020,Q1,Hypokalaemia,,2020,Q1,3,F,20180611.0,20200224.0,20190605,20200302,EXP,,PHHY2019GR129022,NOVARTIS,,51.0,YR,,F,Y,98.0,KG,20200302.0,,HP,GR,GR,2020,Q1,Adult
164305473,16430547,11,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DOSAGE FORM, BID, (1 DF, BID)",,,U,,,,,1.0,DF,,Q12H,2020,Q1,Blood cholesterol increased,,2020,Q1,3,F,,20200127.0,20190614,20200210,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-210400,RANBAXY,,72.0,YR,,M,Y,,,20200210.0,,HP,NL,ES,2020,Q1,Elderly
164305473,16430547,11,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DOSAGE FORM, BID, (1 DF, BID)",,,U,,,,,1.0,DF,,Q12H,2020,Q1,Blood triglycerides increased,,2020,Q1,3,F,,20200127.0,20190614,20200210,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-210400,RANBAXY,,72.0,YR,,M,Y,,,20200210.0,,HP,NL,ES,2020,Q1,Elderly
164305473,16430547,11,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DOSAGE FORM, BID, (1 DF, BID)",,,U,,,,,1.0,DF,,Q12H,2020,Q1,Fatigue,,2020,Q1,3,F,,20200127.0,20190614,20200210,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-210400,RANBAXY,,72.0,YR,,M,Y,,,20200210.0,,HP,NL,ES,2020,Q1,Elderly
164305473,16430547,11,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DOSAGE FORM, BID, (1 DF, BID)",,,U,,,,,1.0,DF,,Q12H,2020,Q1,Hyperglycaemia,,2020,Q1,3,F,,20200127.0,20190614,20200210,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-210400,RANBAXY,,72.0,YR,,M,Y,,,20200210.0,,HP,NL,ES,2020,Q1,Elderly
164305473,16430547,11,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DOSAGE FORM, BID, (1 DF, BID)",,,U,,,,,1.0,DF,,Q12H,2020,Q1,Hypertension,,2020,Q1,3,F,,20200127.0,20190614,20200210,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-210400,RANBAXY,,72.0,YR,,M,Y,,,20200210.0,,HP,NL,ES,2020,Q1,Elderly
164305473,16430547,11,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DOSAGE FORM, BID, (1 DF, BID)",,,U,,,,,1.0,DF,,Q12H,2020,Q1,Overdose,,2020,Q1,3,F,,20200127.0,20190614,20200210,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-210400,RANBAXY,,72.0,YR,,M,Y,,,20200210.0,,HP,NL,ES,2020,Q1,Elderly
164305473,16430547,11,SS,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DOSAGE FORM, BID, (1 DF, BID)",,,U,,,,,1.0,DF,,Q12H,2020,Q1,Treatment noncompliance,,2020,Q1,3,F,,20200127.0,20190614,20200210,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-210400,RANBAXY,,72.0,YR,,M,Y,,,20200210.0,,HP,NL,ES,2020,Q1,Elderly
164648342,16464834,19,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE;METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DOSAGE FORM, BID",,,U,U,,,,1.0,DF,,BID,2020,Q1,Blood cholesterol increased,,2020,Q1,2,F,,20200124.0,20190621,20200207,EXP,,ES-SYNTHON BV-IN51PV19_48906,SYNTHON,,72.0,YR,,M,Y,,,20200207.0,,PH,ES,ES,2020,Q1,Elderly
164648342,16464834,19,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE;METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DOSAGE FORM, BID",,,U,U,,,,1.0,DF,,BID,2020,Q1,Blood triglycerides increased,,2020,Q1,2,F,,20200124.0,20190621,20200207,EXP,,ES-SYNTHON BV-IN51PV19_48906,SYNTHON,,72.0,YR,,M,Y,,,20200207.0,,PH,ES,ES,2020,Q1,Elderly
164648342,16464834,19,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE;METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DOSAGE FORM, BID",,,U,U,,,,1.0,DF,,BID,2020,Q1,Fatigue,,2020,Q1,2,F,,20200124.0,20190621,20200207,EXP,,ES-SYNTHON BV-IN51PV19_48906,SYNTHON,,72.0,YR,,M,Y,,,20200207.0,,PH,ES,ES,2020,Q1,Elderly
164648342,16464834,19,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE;METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DOSAGE FORM, BID",,,U,U,,,,1.0,DF,,BID,2020,Q1,Hyperglycaemia,,2020,Q1,2,F,,20200124.0,20190621,20200207,EXP,,ES-SYNTHON BV-IN51PV19_48906,SYNTHON,,72.0,YR,,M,Y,,,20200207.0,,PH,ES,ES,2020,Q1,Elderly
164648342,16464834,19,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE;METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DOSAGE FORM, BID",,,U,U,,,,1.0,DF,,BID,2020,Q1,Hypertension,,2020,Q1,2,F,,20200124.0,20190621,20200207,EXP,,ES-SYNTHON BV-IN51PV19_48906,SYNTHON,,72.0,YR,,M,Y,,,20200207.0,,PH,ES,ES,2020,Q1,Elderly
164648342,16464834,19,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE;METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DOSAGE FORM, BID",,,U,U,,,,1.0,DF,,BID,2020,Q1,Overdose,,2020,Q1,2,F,,20200124.0,20190621,20200207,EXP,,ES-SYNTHON BV-IN51PV19_48906,SYNTHON,,72.0,YR,,M,Y,,,20200207.0,,PH,ES,ES,2020,Q1,Elderly
164648342,16464834,19,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE;METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DOSAGE FORM, BID",,,U,U,,,,1.0,DF,,BID,2020,Q1,Treatment noncompliance,,2020,Q1,2,F,,20200124.0,20190621,20200207,EXP,,ES-SYNTHON BV-IN51PV19_48906,SYNTHON,,72.0,YR,,M,Y,,,20200207.0,,PH,ES,ES,2020,Q1,Elderly
165400582,16540058,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, EACH MORNING",,,U,,,,,10.0,MG,,QD,2020,Q1,Hypoglycaemia,,2020,Q1,2,F,20190520.0,20200302.0,20190708,20200309,EXP,GB-MHRA-ADR 24411937,GB-ELI_LILLY_AND_COMPANY-GB201907000457,ELI LILLY AND CO,,63.0,YR,,F,Y,123.0,KG,20200309.0,,MD,GB,GB,2020,Q1,Adult
165425882,16542588,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,EACH MORNING.,,,U,,,,,10.0,MG,TABLET,QD,2020,Q1,Hypoglycaemia,,2020,Q1,2,F,20190520.0,20200305.0,20190709,20200324,EXP,GB-MHRA-ADR 24411937,GB-TORRENT-00021345,TORRENT,,63.0,YR,A,F,Y,123.0,KG,20200316.0,,MD,GB,GB,2020,Q1,Adult
165637272,16563727,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, DAILY",,,U,,,,,10.0,MG,TABLET,,2020,Q1,Hypoglycaemia,,2020,Q1,2,F,20190520.0,20200229.0,20190712,20200311,EXP,,GB-AUROBINDO-AUR-APL-2019-039421,AUROBINDO,,63.0,YR,,F,Y,123.0,KG,20200311.0,,MD,GB,GB,2020,Q1,Adult
165662723,16566272,1,PS,DAPAGLIFLOZINA,DAPAGLIFLOZIN,1,Oral,,,,,,,,202293.0,,,TABLET,,2020,Q1,Haematuria,,2020,Q1,3,F,201907.0,20200108.0,20190712,20200116,EXP,,AR-ASTRAZENECA-2019SE98466,ASTRAZENECA,,73.0,YR,,,Y,,,20200116.0,,MD,AR,AR,2020,Q1,Elderly
165662723,16566272,1,PS,DAPAGLIFLOZINA,DAPAGLIFLOZIN,1,Oral,,,,,,,,202293.0,,,TABLET,,2020,Q1,Urinary retention,,2020,Q1,3,F,201907.0,20200108.0,20190712,20200116,EXP,,AR-ASTRAZENECA-2019SE98466,ASTRAZENECA,,73.0,YR,,,Y,,,20200116.0,,MD,AR,AR,2020,Q1,Elderly
165662723,16566272,1,PS,DAPAGLIFLOZINA,DAPAGLIFLOZIN,1,Oral,,,,,,,,202293.0,,,TABLET,,2020,Q1,Urinary tract infection,,2020,Q1,3,F,201907.0,20200108.0,20190712,20200116,EXP,,AR-ASTRAZENECA-2019SE98466,ASTRAZENECA,,73.0,YR,,,Y,,,20200116.0,,MD,AR,AR,2020,Q1,Elderly
165699222,16569922,7,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q1,Acute coronary syndrome,,2020,Q1,2,F,,20200206.0,20190715,20200214,EXP,,CA-AUROBINDO-AUR-APL-2019-038917,AUROBINDO,,56.0,YR,,M,Y,80.0,KG,20200214.0,,MD,CA,CA,2020,Q1,Adult
165699222,16569922,7,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q1,Angina unstable,,2020,Q1,2,F,,20200206.0,20190715,20200214,EXP,,CA-AUROBINDO-AUR-APL-2019-038917,AUROBINDO,,56.0,YR,,M,Y,80.0,KG,20200214.0,,MD,CA,CA,2020,Q1,Adult
165699222,16569922,7,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q1,Blood cholesterol increased,,2020,Q1,2,F,,20200206.0,20190715,20200214,EXP,,CA-AUROBINDO-AUR-APL-2019-038917,AUROBINDO,,56.0,YR,,M,Y,80.0,KG,20200214.0,,MD,CA,CA,2020,Q1,Adult
165699222,16569922,7,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q1,Blood creatine phosphokinase increased,,2020,Q1,2,F,,20200206.0,20190715,20200214,EXP,,CA-AUROBINDO-AUR-APL-2019-038917,AUROBINDO,,56.0,YR,,M,Y,80.0,KG,20200214.0,,MD,CA,CA,2020,Q1,Adult
165699222,16569922,7,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q1,Blood parathyroid hormone increased,,2020,Q1,2,F,,20200206.0,20190715,20200214,EXP,,CA-AUROBINDO-AUR-APL-2019-038917,AUROBINDO,,56.0,YR,,M,Y,80.0,KG,20200214.0,,MD,CA,CA,2020,Q1,Adult
165699222,16569922,7,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q1,Blood triglycerides increased,,2020,Q1,2,F,,20200206.0,20190715,20200214,EXP,,CA-AUROBINDO-AUR-APL-2019-038917,AUROBINDO,,56.0,YR,,M,Y,80.0,KG,20200214.0,,MD,CA,CA,2020,Q1,Adult
165699222,16569922,7,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q1,Coronary artery stenosis,,2020,Q1,2,F,,20200206.0,20190715,20200214,EXP,,CA-AUROBINDO-AUR-APL-2019-038917,AUROBINDO,,56.0,YR,,M,Y,80.0,KG,20200214.0,,MD,CA,CA,2020,Q1,Adult
165699222,16569922,7,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q1,High density lipoprotein decreased,,2020,Q1,2,F,,20200206.0,20190715,20200214,EXP,,CA-AUROBINDO-AUR-APL-2019-038917,AUROBINDO,,56.0,YR,,M,Y,80.0,KG,20200214.0,,MD,CA,CA,2020,Q1,Adult
165699222,16569922,7,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q1,Low density lipoprotein increased,,2020,Q1,2,F,,20200206.0,20190715,20200214,EXP,,CA-AUROBINDO-AUR-APL-2019-038917,AUROBINDO,,56.0,YR,,M,Y,80.0,KG,20200214.0,,MD,CA,CA,2020,Q1,Adult
165699222,16569922,7,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q1,Muscular weakness,,2020,Q1,2,F,,20200206.0,20190715,20200214,EXP,,CA-AUROBINDO-AUR-APL-2019-038917,AUROBINDO,,56.0,YR,,M,Y,80.0,KG,20200214.0,,MD,CA,CA,2020,Q1,Adult
165699222,16569922,7,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q1,Myalgia,,2020,Q1,2,F,,20200206.0,20190715,20200214,EXP,,CA-AUROBINDO-AUR-APL-2019-038917,AUROBINDO,,56.0,YR,,M,Y,80.0,KG,20200214.0,,MD,CA,CA,2020,Q1,Adult
165699222,16569922,7,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q1,Myopathy,,2020,Q1,2,F,,20200206.0,20190715,20200214,EXP,,CA-AUROBINDO-AUR-APL-2019-038917,AUROBINDO,,56.0,YR,,M,Y,80.0,KG,20200214.0,,MD,CA,CA,2020,Q1,Adult
165699222,16569922,7,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q1,Total cholesterol/HDL ratio increased,,2020,Q1,2,F,,20200206.0,20190715,20200214,EXP,,CA-AUROBINDO-AUR-APL-2019-038917,AUROBINDO,,56.0,YR,,M,Y,80.0,KG,20200214.0,,MD,CA,CA,2020,Q1,Adult
165774482,16577448,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2020,Q1,Immune-mediated hepatitis,,2020,Q1,2,F,,20200228.0,20190716,20200306,EXP,,CA-CELGENEUS-CAN-20190702673,CELGENE,,65.0,YR,,M,Y,,,20200306.0,,HP,CA,CA,2020,Q1,Elderly
166649883,16664988,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,TABLET,,2020,Q1,Acute kidney injury,,2020,Q1,3,F,,20200122.0,20190803,20200204,EXP,,GB-AUROBINDO-AUR-APL-2019-045068,AUROBINDO,,39.0,YR,,M,Y,,,20200204.0,,HP,GB,GB,2020,Q1,Adult
166649883,16664988,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,3,F,,20200122.0,20190803,20200204,EXP,,GB-AUROBINDO-AUR-APL-2019-045068,AUROBINDO,,39.0,YR,,M,Y,,,20200204.0,,HP,GB,GB,2020,Q1,Adult
166649883,16664988,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,TABLET,,2020,Q1,Hypotension,,2020,Q1,3,F,,20200122.0,20190803,20200204,EXP,,GB-AUROBINDO-AUR-APL-2019-045068,AUROBINDO,,39.0,YR,,M,Y,,,20200204.0,,HP,GB,GB,2020,Q1,Adult
166649883,16664988,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,TABLET,,2020,Q1,Intentional overdose,,2020,Q1,3,F,,20200122.0,20190803,20200204,EXP,,GB-AUROBINDO-AUR-APL-2019-045068,AUROBINDO,,39.0,YR,,M,Y,,,20200204.0,,HP,GB,GB,2020,Q1,Adult
166799682,16679968,11,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q1,Drug ineffective,,2020,Q1,2,F,,20190730.0,20190807,20200114,PER,,PHHY2019CZ181589,NOVARTIS,CHLUP R. TREATMENT OPTIONS FOR TYPE 2 DIABETES IN A PATIENT WITH IMPAIRED COGNITIVE FUNCTION. KAZUISTIKY V DIABETOLOGII. 2019;2:35-40,77.0,YR,,F,Y,,,20200114.0,,HP,CZ,CZ,2020,Q1,Elderly
168249325,16824932,12,SS,Dapagliflozine,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",7880.0,MG,Y,U,,,,10.0,MG,TABLET,QD,2020,Q1,Diabetic ketoacidosis,,2020,Q1,5,F,20190824.0,20191224.0,20190918,20200106,EXP,,NL-AUROBINDO-AUR-APL-2019-061211,AUROBINDO,,54.0,YR,,F,Y,84.5,KG,20200107.0,,HP,NL,NL,2020,Q1,Adult
168249325,16824932,12,SS,Dapagliflozine,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",7880.0,MG,Y,U,,,,10.0,MG,TABLET,QD,2020,Q1,Ketoacidosis,,2020,Q1,5,F,20190824.0,20191224.0,20190918,20200106,EXP,,NL-AUROBINDO-AUR-APL-2019-061211,AUROBINDO,,54.0,YR,,F,Y,84.5,KG,20200107.0,,HP,NL,NL,2020,Q1,Adult
168249325,16824932,13,SS,Dapagliflozine,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",7880.0,MG,Y,U,,,,10.0,MG,TABLET,QD,2020,Q1,Diabetic ketoacidosis,,2020,Q1,5,F,20190824.0,20191224.0,20190918,20200106,EXP,,NL-AUROBINDO-AUR-APL-2019-061211,AUROBINDO,,54.0,YR,,F,Y,84.5,KG,20200107.0,,HP,NL,NL,2020,Q1,Adult
168249325,16824932,13,SS,Dapagliflozine,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",7880.0,MG,Y,U,,,,10.0,MG,TABLET,QD,2020,Q1,Ketoacidosis,,2020,Q1,5,F,20190824.0,20191224.0,20190918,20200106,EXP,,NL-AUROBINDO-AUR-APL-2019-061211,AUROBINDO,,54.0,YR,,F,Y,84.5,KG,20200107.0,,HP,NL,NL,2020,Q1,Adult
168337723,16833772,7,SS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",7880.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q1,Diabetic ketoacidosis,,2020,Q1,3,F,20190824.0,20200316.0,20190920,20200320,EXP,,PHHY2019NL215353,NOVARTIS,,19763.0,DY,,F,Y,84.5,KG,20200320.0,,HP,COUNTRY NOT SPECIFIED,NL,2020,Q1,Elderly
168337723,16833772,8,SS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",7880.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q1,Diabetic ketoacidosis,,2020,Q1,3,F,20190824.0,20200316.0,20190920,20200320,EXP,,PHHY2019NL215353,NOVARTIS,,19763.0,DY,,F,Y,84.5,KG,20200320.0,,HP,COUNTRY NOT SPECIFIED,NL,2020,Q1,Elderly
168337723,16833772,9,SS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",7880.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q1,Diabetic ketoacidosis,,2020,Q1,3,F,20190824.0,20200316.0,20190920,20200320,EXP,,PHHY2019NL215353,NOVARTIS,,19763.0,DY,,F,Y,84.5,KG,20200320.0,,HP,COUNTRY NOT SPECIFIED,NL,2020,Q1,Elderly
168743623,16874362,12,SS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,7220.0,MG,Y,,,,,10.0,MG,TABLET,QD,2020,Q1,Diabetic ketoacidosis,,2020,Q1,3,F,20190824.0,20200209.0,20191001,20200220,EXP,,NL-BAUSCH-BL-2019-054808,BAUSCH AND LOMB,,19763.0,DY,,F,Y,84.5,KG,20200220.0,,MD,NL,NL,2020,Q1,Elderly
168743623,16874362,13,SS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,7220.0,MG,Y,,,,,10.0,MG,TABLET,QD,2020,Q1,Diabetic ketoacidosis,,2020,Q1,3,F,20190824.0,20200209.0,20191001,20200220,EXP,,NL-BAUSCH-BL-2019-054808,BAUSCH AND LOMB,,19763.0,DY,,F,Y,84.5,KG,20200220.0,,MD,NL,NL,2020,Q1,Elderly
169089412,16908941,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,TABLET,,2020,Q1,Acute kidney injury,,2020,Q1,2,F,,20200226.0,20191011,20200303,EXP,,GB-MYLANLABS-2019M1095490,MYLAN,"MCKEAG C, MCDERMOTT M.. IATROGENIC EUGLYCAEMIC DKA FOLLOWING POLYPHARMACY OVERDOSE.. ENDOCRINE UPDATE - SOCIETY FOR ENDOCRINOLOGY. 2019",39.0,YR,,M,Y,,,20200303.0,,HP,GB,GB,2020,Q1,Adult
169089412,16908941,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,TABLET,,2020,Q1,Drug abuse,,2020,Q1,2,F,,20200226.0,20191011,20200303,EXP,,GB-MYLANLABS-2019M1095490,MYLAN,"MCKEAG C, MCDERMOTT M.. IATROGENIC EUGLYCAEMIC DKA FOLLOWING POLYPHARMACY OVERDOSE.. ENDOCRINE UPDATE - SOCIETY FOR ENDOCRINOLOGY. 2019",39.0,YR,,M,Y,,,20200303.0,,HP,GB,GB,2020,Q1,Adult
169089412,16908941,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,2,F,,20200226.0,20191011,20200303,EXP,,GB-MYLANLABS-2019M1095490,MYLAN,"MCKEAG C, MCDERMOTT M.. IATROGENIC EUGLYCAEMIC DKA FOLLOWING POLYPHARMACY OVERDOSE.. ENDOCRINE UPDATE - SOCIETY FOR ENDOCRINOLOGY. 2019",39.0,YR,,M,Y,,,20200303.0,,HP,GB,GB,2020,Q1,Adult
169089412,16908941,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,TABLET,,2020,Q1,Hypotension,,2020,Q1,2,F,,20200226.0,20191011,20200303,EXP,,GB-MYLANLABS-2019M1095490,MYLAN,"MCKEAG C, MCDERMOTT M.. IATROGENIC EUGLYCAEMIC DKA FOLLOWING POLYPHARMACY OVERDOSE.. ENDOCRINE UPDATE - SOCIETY FOR ENDOCRINOLOGY. 2019",39.0,YR,,M,Y,,,20200303.0,,HP,GB,GB,2020,Q1,Adult
169089412,16908941,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,TABLET,,2020,Q1,Intentional overdose,,2020,Q1,2,F,,20200226.0,20191011,20200303,EXP,,GB-MYLANLABS-2019M1095490,MYLAN,"MCKEAG C, MCDERMOTT M.. IATROGENIC EUGLYCAEMIC DKA FOLLOWING POLYPHARMACY OVERDOSE.. ENDOCRINE UPDATE - SOCIETY FOR ENDOCRINOLOGY. 2019",39.0,YR,,M,Y,,,20200303.0,,HP,GB,GB,2020,Q1,Adult
169089412,16908941,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,TABLET,,2020,Q1,Intentional product misuse,,2020,Q1,2,F,,20200226.0,20191011,20200303,EXP,,GB-MYLANLABS-2019M1095490,MYLAN,"MCKEAG C, MCDERMOTT M.. IATROGENIC EUGLYCAEMIC DKA FOLLOWING POLYPHARMACY OVERDOSE.. ENDOCRINE UPDATE - SOCIETY FOR ENDOCRINOLOGY. 2019",39.0,YR,,M,Y,,,20200303.0,,HP,GB,GB,2020,Q1,Adult
169603912,16960391,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, DAILY",,,U,,,,,10.0,MG,,,2020,Q1,Diabetes mellitus inadequate control,,2020,Q1,2,F,,20200220.0,20191025,20200305,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-225273,RANBAXY,,62.0,YR,,M,Y,81.0,KG,20200306.0,,HP,PL,PL,2020,Q1,Adult
169603912,16960391,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, DAILY",,,U,,,,,10.0,MG,,,2020,Q1,Tuberculosis,,2020,Q1,2,F,,20200220.0,20191025,20200305,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-225273,RANBAXY,,62.0,YR,,M,Y,81.0,KG,20200306.0,,HP,PL,PL,2020,Q1,Adult
169921792,16992179,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"1 DOSAGE FORM, DAILY, EVERY MORNING",116.0,DF,,,,,,1.0,DF,,,2020,Q1,Gastric ulcer,,2020,Q1,2,F,20190902.0,20200108.0,20191105,20200123,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-225771,RANBAXY,,50.0,YR,,M,Y,91.0,KG,20200123.0,,HP,GB,GB,2020,Q1,Adult
170383062,17038306,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MILLIGRAM, QD",,,Y,,,,,5.0,MG,TABLET,QD,2020,Q1,Adrenal disorder,,2020,Q1,2,F,20181206.0,20200228.0,20191115,20200306,EXP,,JP-009507513-1910JPN000523J,MERCK,,73.0,YR,,F,Y,47.0,KG,20200306.0,,CN,JP,JP,2020,Q1,Elderly
170383062,17038306,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MILLIGRAM, QD",,,Y,,,,,5.0,MG,TABLET,QD,2020,Q1,Interstitial lung disease,,2020,Q1,2,F,20181206.0,20200228.0,20191115,20200306,EXP,,JP-009507513-1910JPN000523J,MERCK,,73.0,YR,,F,Y,47.0,KG,20200306.0,,CN,JP,JP,2020,Q1,Elderly
170930102,17093010,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,2,F,20191023.0,20200212.0,20191129,20200217,EXP,,GB-ASTRAZENECA-2019SF69373,ASTRAZENECA,,54.0,YR,,M,Y,,,20200217.0,,,GB,GB,2020,Q1,Adult
170930102,17093010,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q1,Malaise,,2020,Q1,2,F,20191023.0,20200212.0,20191129,20200217,EXP,,GB-ASTRAZENECA-2019SF69373,ASTRAZENECA,,54.0,YR,,M,Y,,,20200217.0,,,GB,GB,2020,Q1,Adult
170949336,17094933,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q1,Febrile neutropenia,,2020,Q1,6,F,,20200224.0,20191130,20200306,EXP,,PT-AUROBINDO-AUR-APL-2019-075818,AUROBINDO,,58.0,YR,,F,Y,,,20200306.0,,HP,PT,PT,2020,Q1,Adult
170949336,17094933,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q1,Flushing,,2020,Q1,6,F,,20200224.0,20191130,20200306,EXP,,PT-AUROBINDO-AUR-APL-2019-075818,AUROBINDO,,58.0,YR,,F,Y,,,20200306.0,,HP,PT,PT,2020,Q1,Adult
170949336,17094933,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q1,Gingival oedema,,2020,Q1,6,F,,20200224.0,20191130,20200306,EXP,,PT-AUROBINDO-AUR-APL-2019-075818,AUROBINDO,,58.0,YR,,F,Y,,,20200306.0,,HP,PT,PT,2020,Q1,Adult
170949336,17094933,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q1,Gingival swelling,,2020,Q1,6,F,,20200224.0,20191130,20200306,EXP,,PT-AUROBINDO-AUR-APL-2019-075818,AUROBINDO,,58.0,YR,,F,Y,,,20200306.0,,HP,PT,PT,2020,Q1,Adult
170949336,17094933,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q1,Headache,,2020,Q1,6,F,,20200224.0,20191130,20200306,EXP,,PT-AUROBINDO-AUR-APL-2019-075818,AUROBINDO,,58.0,YR,,F,Y,,,20200306.0,,HP,PT,PT,2020,Q1,Adult
170949336,17094933,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q1,Iatrogenic injury,,2020,Q1,6,F,,20200224.0,20191130,20200306,EXP,,PT-AUROBINDO-AUR-APL-2019-075818,AUROBINDO,,58.0,YR,,F,Y,,,20200306.0,,HP,PT,PT,2020,Q1,Adult
170949336,17094933,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q1,Leukopenia,,2020,Q1,6,F,,20200224.0,20191130,20200306,EXP,,PT-AUROBINDO-AUR-APL-2019-075818,AUROBINDO,,58.0,YR,,F,Y,,,20200306.0,,HP,PT,PT,2020,Q1,Adult
170949336,17094933,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q1,Lymphocyte morphology abnormal,,2020,Q1,6,F,,20200224.0,20191130,20200306,EXP,,PT-AUROBINDO-AUR-APL-2019-075818,AUROBINDO,,58.0,YR,,F,Y,,,20200306.0,,HP,PT,PT,2020,Q1,Adult
170949336,17094933,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q1,Mouth ulceration,,2020,Q1,6,F,,20200224.0,20191130,20200306,EXP,,PT-AUROBINDO-AUR-APL-2019-075818,AUROBINDO,,58.0,YR,,F,Y,,,20200306.0,,HP,PT,PT,2020,Q1,Adult
170949336,17094933,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q1,Myalgia,,2020,Q1,6,F,,20200224.0,20191130,20200306,EXP,,PT-AUROBINDO-AUR-APL-2019-075818,AUROBINDO,,58.0,YR,,F,Y,,,20200306.0,,HP,PT,PT,2020,Q1,Adult
170949336,17094933,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q1,Neutropenia,,2020,Q1,6,F,,20200224.0,20191130,20200306,EXP,,PT-AUROBINDO-AUR-APL-2019-075818,AUROBINDO,,58.0,YR,,F,Y,,,20200306.0,,HP,PT,PT,2020,Q1,Adult
170949336,17094933,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q1,Pyrexia,,2020,Q1,6,F,,20200224.0,20191130,20200306,EXP,,PT-AUROBINDO-AUR-APL-2019-075818,AUROBINDO,,58.0,YR,,F,Y,,,20200306.0,,HP,PT,PT,2020,Q1,Adult
1710513313,17105133,10,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,TABLETS,,2020,Q1,Hypoglycaemia,Hypoglycaemia,2020,Q1,13,F,20191118.0,20200218.0,20191203,20200224,PER,,GB-EISAI MEDICAL RESEARCH-EC-2019-066343,EISAI,,70.0,YR,,M,Y,81.0,KG,20200224.0,,MD,GB,GB,2020,Q1,Elderly
171296712,17129671,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Gingival oedema,,2020,Q1,2,F,,20200217.0,20191209,20200224,EXP,,PT-MYLANLABS-2019M1119018,MYLAN,"COUTO C, VASCONCELOS G, S? AJ, MESQUITA M.. FEBRILE NEUTROPENIA, AN EXCLUSION ETIOLOGY;NEUTROPENIA FEBRIL ? UMA ETIOLOGIA DE EXCLUSAO. CONGRESSO NACIONAL DE MEDICINA INTERNA: DOENCAS INFECCIOSAS E PARASITARIAS; CONG. 2019;25",58.0,YR,,F,Y,,,20200224.0,,HP,PT,PT,2020,Q1,Adult
171296712,17129671,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Headache,,2020,Q1,2,F,,20200217.0,20191209,20200224,EXP,,PT-MYLANLABS-2019M1119018,MYLAN,"COUTO C, VASCONCELOS G, S? AJ, MESQUITA M.. FEBRILE NEUTROPENIA, AN EXCLUSION ETIOLOGY;NEUTROPENIA FEBRIL ? UMA ETIOLOGIA DE EXCLUSAO. CONGRESSO NACIONAL DE MEDICINA INTERNA: DOENCAS INFECCIOSAS E PARASITARIAS; CONG. 2019;25",58.0,YR,,F,Y,,,20200224.0,,HP,PT,PT,2020,Q1,Adult
171296712,17129671,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Iatrogenic injury,,2020,Q1,2,F,,20200217.0,20191209,20200224,EXP,,PT-MYLANLABS-2019M1119018,MYLAN,"COUTO C, VASCONCELOS G, S? AJ, MESQUITA M.. FEBRILE NEUTROPENIA, AN EXCLUSION ETIOLOGY;NEUTROPENIA FEBRIL ? UMA ETIOLOGIA DE EXCLUSAO. CONGRESSO NACIONAL DE MEDICINA INTERNA: DOENCAS INFECCIOSAS E PARASITARIAS; CONG. 2019;25",58.0,YR,,F,Y,,,20200224.0,,HP,PT,PT,2020,Q1,Adult
171296712,17129671,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Leukopenia,,2020,Q1,2,F,,20200217.0,20191209,20200224,EXP,,PT-MYLANLABS-2019M1119018,MYLAN,"COUTO C, VASCONCELOS G, S? AJ, MESQUITA M.. FEBRILE NEUTROPENIA, AN EXCLUSION ETIOLOGY;NEUTROPENIA FEBRIL ? UMA ETIOLOGIA DE EXCLUSAO. CONGRESSO NACIONAL DE MEDICINA INTERNA: DOENCAS INFECCIOSAS E PARASITARIAS; CONG. 2019;25",58.0,YR,,F,Y,,,20200224.0,,HP,PT,PT,2020,Q1,Adult
171296712,17129671,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Lymphocyte morphology abnormal,,2020,Q1,2,F,,20200217.0,20191209,20200224,EXP,,PT-MYLANLABS-2019M1119018,MYLAN,"COUTO C, VASCONCELOS G, S? AJ, MESQUITA M.. FEBRILE NEUTROPENIA, AN EXCLUSION ETIOLOGY;NEUTROPENIA FEBRIL ? UMA ETIOLOGIA DE EXCLUSAO. CONGRESSO NACIONAL DE MEDICINA INTERNA: DOENCAS INFECCIOSAS E PARASITARIAS; CONG. 2019;25",58.0,YR,,F,Y,,,20200224.0,,HP,PT,PT,2020,Q1,Adult
171296712,17129671,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Mouth ulceration,,2020,Q1,2,F,,20200217.0,20191209,20200224,EXP,,PT-MYLANLABS-2019M1119018,MYLAN,"COUTO C, VASCONCELOS G, S? AJ, MESQUITA M.. FEBRILE NEUTROPENIA, AN EXCLUSION ETIOLOGY;NEUTROPENIA FEBRIL ? UMA ETIOLOGIA DE EXCLUSAO. CONGRESSO NACIONAL DE MEDICINA INTERNA: DOENCAS INFECCIOSAS E PARASITARIAS; CONG. 2019;25",58.0,YR,,F,Y,,,20200224.0,,HP,PT,PT,2020,Q1,Adult
171296712,17129671,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Myalgia,,2020,Q1,2,F,,20200217.0,20191209,20200224,EXP,,PT-MYLANLABS-2019M1119018,MYLAN,"COUTO C, VASCONCELOS G, S? AJ, MESQUITA M.. FEBRILE NEUTROPENIA, AN EXCLUSION ETIOLOGY;NEUTROPENIA FEBRIL ? UMA ETIOLOGIA DE EXCLUSAO. CONGRESSO NACIONAL DE MEDICINA INTERNA: DOENCAS INFECCIOSAS E PARASITARIAS; CONG. 2019;25",58.0,YR,,F,Y,,,20200224.0,,HP,PT,PT,2020,Q1,Adult
171296712,17129671,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Neutropenia,,2020,Q1,2,F,,20200217.0,20191209,20200224,EXP,,PT-MYLANLABS-2019M1119018,MYLAN,"COUTO C, VASCONCELOS G, S? AJ, MESQUITA M.. FEBRILE NEUTROPENIA, AN EXCLUSION ETIOLOGY;NEUTROPENIA FEBRIL ? UMA ETIOLOGIA DE EXCLUSAO. CONGRESSO NACIONAL DE MEDICINA INTERNA: DOENCAS INFECCIOSAS E PARASITARIAS; CONG. 2019;25",58.0,YR,,F,Y,,,20200224.0,,HP,PT,PT,2020,Q1,Adult
171296712,17129671,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Pyrexia,,2020,Q1,2,F,,20200217.0,20191209,20200224,EXP,,PT-MYLANLABS-2019M1119018,MYLAN,"COUTO C, VASCONCELOS G, S? AJ, MESQUITA M.. FEBRILE NEUTROPENIA, AN EXCLUSION ETIOLOGY;NEUTROPENIA FEBRIL ? UMA ETIOLOGIA DE EXCLUSAO. CONGRESSO NACIONAL DE MEDICINA INTERNA: DOENCAS INFECCIOSAS E PARASITARIAS; CONG. 2019;25",58.0,YR,,F,Y,,,20200224.0,,HP,PT,PT,2020,Q1,Adult
171657642,17165764,13,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE W/METFO,,2,,1700/ 10MG QD,,,,,,,,,,,QD,2020,Q1,Bladder tamponade,,2020,Q1,2,F,20191006.0,20200120.0,20191217,20200203,EXP,,DE-JNJFOC-20191209452,JOHNSON AND JOHNSON,,71.0,YR,,M,Y,93.0,KG,20200203.0,,MD,DE,DE,2020,Q1,Elderly
171657642,17165764,13,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE W/METFO,,2,,1700/ 10MG QD,,,,,,,,,,,QD,2020,Q1,Haematuria,,2020,Q1,2,F,20191006.0,20200120.0,20191217,20200203,EXP,,DE-JNJFOC-20191209452,JOHNSON AND JOHNSON,,71.0,YR,,M,Y,93.0,KG,20200203.0,,MD,DE,DE,2020,Q1,Elderly
171796162,17179616,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Nausea,,2020,Q1,2,F,,20191211.0,20191219,20200109,EXP,,GB-ASTRAZENECA-2019SF79740,ASTRAZENECA,,44.0,YR,,M,Y,108.0,KG,20200109.0,,MD,GB,GB,2020,Q1,Adult
171796162,17179616,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Urine ketone body present,,2020,Q1,2,F,,20191211.0,20191219,20200109,EXP,,GB-ASTRAZENECA-2019SF79740,ASTRAZENECA,,44.0,YR,,M,Y,108.0,KG,20200109.0,,MD,GB,GB,2020,Q1,Adult
171796162,17179616,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Vomiting,,2020,Q1,2,F,,20191211.0,20191219,20200109,EXP,,GB-ASTRAZENECA-2019SF79740,ASTRAZENECA,,44.0,YR,,M,Y,108.0,KG,20200109.0,,MD,GB,GB,2020,Q1,Adult
172090596,17209059,7,SS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",7220.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q1,Diabetic ketoacidosis,,2020,Q1,6,F,20190824.0,20200304.0,20191227,20200310,EXP,,NL-MYLANLABS-2019M1128221,MYLAN,,54.0,YR,,F,Y,84.5,KG,20200310.0,,HP,NL,NL,2020,Q1,Adult
172090596,17209059,7,SS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",7220.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q1,Ketoacidosis,,2020,Q1,6,F,20190824.0,20200304.0,20191227,20200310,EXP,,NL-MYLANLABS-2019M1128221,MYLAN,,54.0,YR,,F,Y,84.5,KG,20200310.0,,HP,NL,NL,2020,Q1,Adult
172090596,17209059,8,SS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",7220.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q1,Diabetic ketoacidosis,,2020,Q1,6,F,20190824.0,20200304.0,20191227,20200310,EXP,,NL-MYLANLABS-2019M1128221,MYLAN,,54.0,YR,,F,Y,84.5,KG,20200310.0,,HP,NL,NL,2020,Q1,Adult
172090596,17209059,8,SS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",7220.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q1,Ketoacidosis,,2020,Q1,6,F,20190824.0,20200304.0,20191227,20200310,EXP,,NL-MYLANLABS-2019M1128221,MYLAN,,54.0,YR,,F,Y,84.5,KG,20200310.0,,HP,NL,NL,2020,Q1,Adult
172090596,17209059,9,SS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",7220.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q1,Diabetic ketoacidosis,,2020,Q1,6,F,20190824.0,20200304.0,20191227,20200310,EXP,,NL-MYLANLABS-2019M1128221,MYLAN,,54.0,YR,,F,Y,84.5,KG,20200310.0,,HP,NL,NL,2020,Q1,Adult
172090596,17209059,9,SS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",7220.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q1,Ketoacidosis,,2020,Q1,6,F,20190824.0,20200304.0,20191227,20200310,EXP,,NL-MYLANLABS-2019M1128221,MYLAN,,54.0,YR,,F,Y,84.5,KG,20200310.0,,HP,NL,NL,2020,Q1,Adult
172248961,17224896,6,SS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,7220.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q1,Ketoacidosis,,2020,Q1,1,I,20190824.0,20191227.0,20200102,20200102,EXP,,NL-EMD SERONO-E2B_90073678,EMD SERONO INC,,54.0,YR,,F,Y,85.0,KG,20200102.0,,MD,NL,NL,2020,Q1,Adult
172279671,17227967,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,QD,2020,Q1,Condition aggravated,,2020,Q1,1,I,2019.0,20191227.0,20200103,20200103,EXP,GB-MHRA-INPA15EA018-1A75-46D4-8D30-FA3A46D759E4,GB-GLAXOSMITHKLINE-GB2019236420,GLAXOSMITHKLINE,,57.0,YR,,M,Y,108.0,KG,20200103.0,,MD,GB,GB,2020,Q1,Adult
172279671,17227967,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,QD,2020,Q1,Cough,,2020,Q1,1,I,2019.0,20191227.0,20200103,20200103,EXP,GB-MHRA-INPA15EA018-1A75-46D4-8D30-FA3A46D759E4,GB-GLAXOSMITHKLINE-GB2019236420,GLAXOSMITHKLINE,,57.0,YR,,M,Y,108.0,KG,20200103.0,,MD,GB,GB,2020,Q1,Adult
172279671,17227967,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,QD,2020,Q1,Dyspnoea,,2020,Q1,1,I,2019.0,20191227.0,20200103,20200103,EXP,GB-MHRA-INPA15EA018-1A75-46D4-8D30-FA3A46D759E4,GB-GLAXOSMITHKLINE-GB2019236420,GLAXOSMITHKLINE,,57.0,YR,,M,Y,108.0,KG,20200103.0,,MD,GB,GB,2020,Q1,Adult
172357851,17235785,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,N,,,,10.0,MG,,QD,2020,Q1,Diabetic ketoacidosis,,2020,Q1,1,I,20191222.0,,20200103,20200103,DIR,,,FDA-CTU,,32.0,YR,,M,N,91.5,KG,20200103.0,N,PH,US,US,2020,Q1,Young Adult
172367011,17236701,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,4.0,DF,U,, LA2241,,202293.0,1.0,DF,TABLET,QD,2020,Q1,Ketoacidosis,,2020,Q1,1,I,20191218.0,20191227.0,20200106,20200106,EXP,,CN-ASTRAZENECA-2020SE00077,ASTRAZENECA,,61.0,YR,,F,Y,55.0,KG,20200106.0,,HP,CN,CN,2020,Q1,Adult
172405251,17240525,15,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,1 DF,186.04167,DF,,, UNKNOWN,,,1.0,DF,,,2020,Q1,Palpitations,,2020,Q1,1,I,20191203.0,20191230.0,20200107,20200107,EXP,GB-MHRA-TPP3132931C2911612YC1575536474789,GB-TEVA-2019-GB-1162299,TEVA,,57.0,YR,,F,Y,159.0,KG,20200107.0,,HP,GB,GB,2020,Q1,Adult
172441691,17244169,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"10 MG, DAILY",,,U,,,,,10.0,MG,,QD,2020,Q1,Cellulitis,,2020,Q1,1,I,,20191231.0,20200107,20200107,EXP,GB-MHRA-EYC 00215111,GB-ELI_LILLY_AND_COMPANY-GB202001000486,ELI LILLY AND CO,,64.0,YR,,F,Y,,,20200107.0,,CN,GB,GB,2020,Q1,Adult
172441691,17244169,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"10 MG, DAILY",,,U,,,,,10.0,MG,,QD,2020,Q1,Erythema,,2020,Q1,1,I,,20191231.0,20200107,20200107,EXP,GB-MHRA-EYC 00215111,GB-ELI_LILLY_AND_COMPANY-GB202001000486,ELI LILLY AND CO,,64.0,YR,,F,Y,,,20200107.0,,CN,GB,GB,2020,Q1,Adult
172441691,17244169,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"10 MG, DAILY",,,U,,,,,10.0,MG,,QD,2020,Q1,Rash,,2020,Q1,1,I,,20191231.0,20200107,20200107,EXP,GB-MHRA-EYC 00215111,GB-ELI_LILLY_AND_COMPANY-GB202001000486,ELI LILLY AND CO,,64.0,YR,,F,Y,,,20200107.0,,CN,GB,GB,2020,Q1,Adult
172453847,17245384,14,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,2.5 MILLIGRAM,,,U,,,,,2.5,MG,,,2020,Q1,Myocarditis,,2020,Q1,7,F,20191225.0,20200210.0,20200108,20200212,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-124057,BRISTOL MYERS SQUIBB,,58.0,YR,,M,Y,79.0,KG,20200212.0,,HP,JP,JP,2020,Q1,Adult
172541422,17254142,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,TABLET,QD,2020,Q1,Cerebral infarction,,2020,Q1,2,F,20191204.0,20200302.0,20200109,20200317,EXP,,CN-PFIZER INC-2020008865,PFIZER,,76.0,YR,,F,Y,62.0,KG,20200317.0,,MD,CN,CN,2020,Q1,Elderly
172555192,17255519,10,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,,2020,Q1,Ischaemic stroke,,2020,Q1,2,F,20190817.0,20200219.0,20200110,20200227,EXP,LU-AFSSAPS-NY20192013,LU-OCTA-GAM00120LU,OCTAPHARMA,,68.0,YR,E,M,Y,112.0,KG,20200226.0,,HP,LU,LU,2020,Q1,Elderly
172604301,17260430,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,, UNKNOWN,,,,,,,2020,Q1,Acute coronary syndrome,,2020,Q1,1,I,,20200104.0,20200112,20200112,EXP,,CA-DRREDDYS-USA/CAN/20/0118264,DR REDDYS,,56.0,YR,,M,Y,82.0,KG,20200113.0,,MD,CA,CA,2020,Q1,Adult
172604301,17260430,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,, UNKNOWN,,,,,,,2020,Q1,Angina unstable,,2020,Q1,1,I,,20200104.0,20200112,20200112,EXP,,CA-DRREDDYS-USA/CAN/20/0118264,DR REDDYS,,56.0,YR,,M,Y,82.0,KG,20200113.0,,MD,CA,CA,2020,Q1,Adult
172604301,17260430,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,, UNKNOWN,,,,,,,2020,Q1,Blood cholesterol increased,,2020,Q1,1,I,,20200104.0,20200112,20200112,EXP,,CA-DRREDDYS-USA/CAN/20/0118264,DR REDDYS,,56.0,YR,,M,Y,82.0,KG,20200113.0,,MD,CA,CA,2020,Q1,Adult
172604301,17260430,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,, UNKNOWN,,,,,,,2020,Q1,Blood creatine phosphokinase increased,,2020,Q1,1,I,,20200104.0,20200112,20200112,EXP,,CA-DRREDDYS-USA/CAN/20/0118264,DR REDDYS,,56.0,YR,,M,Y,82.0,KG,20200113.0,,MD,CA,CA,2020,Q1,Adult
172604301,17260430,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,, UNKNOWN,,,,,,,2020,Q1,Blood parathyroid hormone increased,,2020,Q1,1,I,,20200104.0,20200112,20200112,EXP,,CA-DRREDDYS-USA/CAN/20/0118264,DR REDDYS,,56.0,YR,,M,Y,82.0,KG,20200113.0,,MD,CA,CA,2020,Q1,Adult
172604301,17260430,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,, UNKNOWN,,,,,,,2020,Q1,Blood triglycerides increased,,2020,Q1,1,I,,20200104.0,20200112,20200112,EXP,,CA-DRREDDYS-USA/CAN/20/0118264,DR REDDYS,,56.0,YR,,M,Y,82.0,KG,20200113.0,,MD,CA,CA,2020,Q1,Adult
172604301,17260430,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,, UNKNOWN,,,,,,,2020,Q1,Coronary artery stenosis,,2020,Q1,1,I,,20200104.0,20200112,20200112,EXP,,CA-DRREDDYS-USA/CAN/20/0118264,DR REDDYS,,56.0,YR,,M,Y,82.0,KG,20200113.0,,MD,CA,CA,2020,Q1,Adult
172604301,17260430,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,, UNKNOWN,,,,,,,2020,Q1,High density lipoprotein decreased,,2020,Q1,1,I,,20200104.0,20200112,20200112,EXP,,CA-DRREDDYS-USA/CAN/20/0118264,DR REDDYS,,56.0,YR,,M,Y,82.0,KG,20200113.0,,MD,CA,CA,2020,Q1,Adult
172604301,17260430,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,, UNKNOWN,,,,,,,2020,Q1,Low density lipoprotein increased,,2020,Q1,1,I,,20200104.0,20200112,20200112,EXP,,CA-DRREDDYS-USA/CAN/20/0118264,DR REDDYS,,56.0,YR,,M,Y,82.0,KG,20200113.0,,MD,CA,CA,2020,Q1,Adult
172604301,17260430,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,, UNKNOWN,,,,,,,2020,Q1,Muscular weakness,,2020,Q1,1,I,,20200104.0,20200112,20200112,EXP,,CA-DRREDDYS-USA/CAN/20/0118264,DR REDDYS,,56.0,YR,,M,Y,82.0,KG,20200113.0,,MD,CA,CA,2020,Q1,Adult
172604301,17260430,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,, UNKNOWN,,,,,,,2020,Q1,Myalgia,,2020,Q1,1,I,,20200104.0,20200112,20200112,EXP,,CA-DRREDDYS-USA/CAN/20/0118264,DR REDDYS,,56.0,YR,,M,Y,82.0,KG,20200113.0,,MD,CA,CA,2020,Q1,Adult
172604301,17260430,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,, UNKNOWN,,,,,,,2020,Q1,Myopathy,,2020,Q1,1,I,,20200104.0,20200112,20200112,EXP,,CA-DRREDDYS-USA/CAN/20/0118264,DR REDDYS,,56.0,YR,,M,Y,82.0,KG,20200113.0,,MD,CA,CA,2020,Q1,Adult
172604301,17260430,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,, UNKNOWN,,,,,,,2020,Q1,Total cholesterol/HDL ratio increased,,2020,Q1,1,I,,20200104.0,20200112,20200112,EXP,,CA-DRREDDYS-USA/CAN/20/0118264,DR REDDYS,,56.0,YR,,M,Y,82.0,KG,20200113.0,,MD,CA,CA,2020,Q1,Adult
172675431,17267543,1,PS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,100.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Diabetic ketoacidosis,,2020,Q1,1,I,20191226.0,20200108.0,20200114,20200114,EXP,,NL-ASTRAZENECA-2020SE03104,ASTRAZENECA,,63.0,YR,,F,Y,64.0,KG,20200114.0,,MD,NL,NL,2020,Q1,Adult
172696371,17269637,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,10.0,MG,Y,, 1903140,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Blood ketone body increased,,2020,Q1,1,I,20200102.0,20200106.0,20200114,20200114,EXP,,CN-ASTRAZENECA-2020SE03548,ASTRAZENECA,,20819.0,DY,,M,Y,69.0,KG,20200114.0,,HP,CN,CN,2020,Q1,Elderly
172730542,17273054,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,, UNKNOWN,,202293.0,10.0,MG,TABLET,,2020,Q1,Arterial disorder,,2020,Q1,2,F,20200107.0,20200207.0,20200115,20200214,EXP,,GB-ASTRAZENECA-2020SE04741,ASTRAZENECA,,24837.0,DY,,M,Y,111.0,KG,20200214.0,,MD,GB,GB,2020,Q1,Elderly
172730542,17273054,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,, UNKNOWN,,202293.0,10.0,MG,TABLET,,2020,Q1,Peripheral vascular disorder,,2020,Q1,2,F,20200107.0,20200207.0,20200115,20200214,EXP,,GB-ASTRAZENECA-2020SE04741,ASTRAZENECA,,24837.0,DY,,M,Y,111.0,KG,20200214.0,,MD,GB,GB,2020,Q1,Elderly
172766132,17276613,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2020,Q1,Diabetes mellitus inadequate control,,2020,Q1,2,F,2019.0,20200129.0,20200116,20200204,EXP,,NVSC2020PL006489,NOVARTIS,,62.0,YR,,M,Y,81.0,KG,20200204.0,,HP,PL,PL,2020,Q1,Adult
172766132,17276613,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2020,Q1,Hyperglycaemia,,2020,Q1,2,F,2019.0,20200129.0,20200116,20200204,EXP,,NVSC2020PL006489,NOVARTIS,,62.0,YR,,M,Y,81.0,KG,20200204.0,,HP,PL,PL,2020,Q1,Adult
172766132,17276613,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2020,Q1,Tuberculosis,,2020,Q1,2,F,2019.0,20200129.0,20200116,20200204,EXP,,NVSC2020PL006489,NOVARTIS,,62.0,YR,,M,Y,81.0,KG,20200204.0,,HP,PL,PL,2020,Q1,Adult
172778751,17277875,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,,,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20190414.0,20200116,20200116,EXP,,US-ASTRAZENECA-2019SE58041,ASTRAZENECA,"KOLBE K, HATTON C, CO I. THE MODEL PATIENT: WHEN DIET AND MEDICATION ADHERENCE RESULT IN LIFE-THREATENING ACIDOSIS. 2019 INTERNATIONAL CONFERENCE OF THE AMERICAN THORACIC SOCIETY (ATS) 2019;A1732 / P962.",53.0,YR,,M,Y,,,20200116.0,,HP,US,US,2020,Q1,Adult
172790051,17279005,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2020,Q1,Accidental exposure to product by child,,2020,Q1,1,I,20190930.0,20200110.0,20200116,20200116,EXP,,AU-SA-2020SA008101,SANOFI AVENTIS,,4.0,YR,C,M,Y,,,20200116.0,,MD,AU,AU,2020,Q1,Child
172790051,17279005,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2020,Q1,Bradycardia,,2020,Q1,1,I,20190930.0,20200110.0,20200116,20200116,EXP,,AU-SA-2020SA008101,SANOFI AVENTIS,,4.0,YR,C,M,Y,,,20200116.0,,MD,AU,AU,2020,Q1,Child
172792381,17279238,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,, UNKNOWN,,,10.0,MG,TABLET,,2020,Q1,Genital blister,,2020,Q1,1,I,20191208.0,20200108.0,20200116,20200116,EXP,,GB-ASTRAZENECA-2020SE05141,ASTRAZENECA,,68.0,YR,,F,Y,,,20200116.0,,MD,GB,GB,2020,Q1,Elderly
172792381,17279238,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,, UNKNOWN,,,10.0,MG,TABLET,,2020,Q1,Genital ulceration,,2020,Q1,1,I,20191208.0,20200108.0,20200116,20200116,EXP,,GB-ASTRAZENECA-2020SE05141,ASTRAZENECA,,68.0,YR,,F,Y,,,20200116.0,,MD,GB,GB,2020,Q1,Elderly
172795492,17279549,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, DAILY",,,Y,U,,,,10.0,MG,,QD,2020,Q1,Diabetes mellitus inadequate control,,2020,Q1,2,F,2019.0,20200304.0,20200116,20200310,EXP,,PL-MYLANLABS-2020M1005013,MYLAN,"KORZENIEWSKA-DYL, I. WHEN DIABETES AND TUBERCULOSIS GO HAND IN HAND.. DIABETOLOGIA PO DYPLOMIE. 2019;1:1-8",62.0,YR,,M,Y,81.0,KG,20200310.0,,HP,PL,PL,2020,Q1,Adult
172795492,17279549,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, DAILY",,,Y,U,,,,10.0,MG,,QD,2020,Q1,Hyperglycaemia,,2020,Q1,2,F,2019.0,20200304.0,20200116,20200310,EXP,,PL-MYLANLABS-2020M1005013,MYLAN,"KORZENIEWSKA-DYL, I. WHEN DIABETES AND TUBERCULOSIS GO HAND IN HAND.. DIABETOLOGIA PO DYPLOMIE. 2019;1:1-8",62.0,YR,,M,Y,81.0,KG,20200310.0,,HP,PL,PL,2020,Q1,Adult
172795492,17279549,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, DAILY",,,Y,U,,,,10.0,MG,,QD,2020,Q1,Tuberculosis,,2020,Q1,2,F,2019.0,20200304.0,20200116,20200310,EXP,,PL-MYLANLABS-2020M1005013,MYLAN,"KORZENIEWSKA-DYL, I. WHEN DIABETES AND TUBERCULOSIS GO HAND IN HAND.. DIABETOLOGIA PO DYPLOMIE. 2019;1:1-8",62.0,YR,,M,Y,81.0,KG,20200310.0,,HP,PL,PL,2020,Q1,Adult
172852542,17285254,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,, UNKNOWN,,,,,,,2020,Q1,Pruritus,,2020,Q1,2,F,20191225.0,20200228.0,20200117,20200310,EXP,GB-MHRA-EYC 00215554,GB-NOVOPROD-706796,NOVO NORDISK,,73.0,YR,,F,Y,,,20200310.0,,HP,GB,GB,2020,Q1,Elderly
172852542,17285254,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,, UNKNOWN,,,,,,,2020,Q1,Rash,,2020,Q1,2,F,20191225.0,20200228.0,20200117,20200310,EXP,GB-MHRA-EYC 00215554,GB-NOVOPROD-706796,NOVO NORDISK,,73.0,YR,,F,Y,,,20200310.0,,HP,GB,GB,2020,Q1,Elderly
172967061,17296706,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2020,Q1,Blood glucose increased,,2020,Q1,1,I,201707.0,20200114.0,20200121,20200121,EXP,GB-MHRA-EYC 00173721,NVSC2020GB009019,NOVARTIS,,71.0,YR,,M,Y,115.21,KG,20200121.0,,HP,GB,GB,2020,Q1,Elderly
172967061,17296706,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2020,Q1,Diabetes mellitus inadequate control,,2020,Q1,1,I,201707.0,20200114.0,20200121,20200121,EXP,GB-MHRA-EYC 00173721,NVSC2020GB009019,NOVARTIS,,71.0,YR,,M,Y,115.21,KG,20200121.0,,HP,GB,GB,2020,Q1,Elderly
172967061,17296706,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2020,Q1,Fatigue,,2020,Q1,1,I,201707.0,20200114.0,20200121,20200121,EXP,GB-MHRA-EYC 00173721,NVSC2020GB009019,NOVARTIS,,71.0,YR,,M,Y,115.21,KG,20200121.0,,HP,GB,GB,2020,Q1,Elderly
172967061,17296706,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2020,Q1,Thirst,,2020,Q1,1,I,201707.0,20200114.0,20200121,20200121,EXP,GB-MHRA-EYC 00173721,NVSC2020GB009019,NOVARTIS,,71.0,YR,,M,Y,115.21,KG,20200121.0,,HP,GB,GB,2020,Q1,Elderly
172967061,17296706,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2020,Q1,Vision blurred,,2020,Q1,1,I,201707.0,20200114.0,20200121,20200121,EXP,GB-MHRA-EYC 00173721,NVSC2020GB009019,NOVARTIS,,71.0,YR,,M,Y,115.21,KG,20200121.0,,HP,GB,GB,2020,Q1,Elderly
172974351,17297435,1,PS,DAPAGLIFLOZIN (8615A),DAPAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Lipodystrophy acquired,,2020,Q1,1,I,201902.0,20200113.0,20200121,20200121,EXP,,ES-ASTRAZENECA-2020SE06068,ASTRAZENECA,,59.0,YR,,F,Y,,,20200121.0,,MD,ES,ES,2020,Q1,Adult
173024621,17302462,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,,10 MILLIGRAM,,,,,,,,10.0,MG,TABLET,,2020,Q1,Arthralgia,,2020,Q1,1,I,200803.0,20200114.0,20200122,20200122,EXP,,US-MYLANLABS-2020M1007146,MYLAN,,52.0,YR,,F,Y,74.0,KG,20200122.0,,HP,US,US,2020,Q1,Adult
173024621,17302462,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,,10 MILLIGRAM,,,,,,,,10.0,MG,TABLET,,2020,Q1,Atrial fibrillation,,2020,Q1,1,I,200803.0,20200114.0,20200122,20200122,EXP,,US-MYLANLABS-2020M1007146,MYLAN,,52.0,YR,,F,Y,74.0,KG,20200122.0,,HP,US,US,2020,Q1,Adult
173024621,17302462,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,,10 MILLIGRAM,,,,,,,,10.0,MG,TABLET,,2020,Q1,Diabetes mellitus,,2020,Q1,1,I,200803.0,20200114.0,20200122,20200122,EXP,,US-MYLANLABS-2020M1007146,MYLAN,,52.0,YR,,F,Y,74.0,KG,20200122.0,,HP,US,US,2020,Q1,Adult
173024621,17302462,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,,10 MILLIGRAM,,,,,,,,10.0,MG,TABLET,,2020,Q1,Glomerular filtration rate decreased,,2020,Q1,1,I,200803.0,20200114.0,20200122,20200122,EXP,,US-MYLANLABS-2020M1007146,MYLAN,,52.0,YR,,F,Y,74.0,KG,20200122.0,,HP,US,US,2020,Q1,Adult
173024621,17302462,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,,10 MILLIGRAM,,,,,,,,10.0,MG,TABLET,,2020,Q1,Immunosuppressant drug level decreased,,2020,Q1,1,I,200803.0,20200114.0,20200122,20200122,EXP,,US-MYLANLABS-2020M1007146,MYLAN,,52.0,YR,,F,Y,74.0,KG,20200122.0,,HP,US,US,2020,Q1,Adult
173024621,17302462,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,,10 MILLIGRAM,,,,,,,,10.0,MG,TABLET,,2020,Q1,Myocardial infarction,,2020,Q1,1,I,200803.0,20200114.0,20200122,20200122,EXP,,US-MYLANLABS-2020M1007146,MYLAN,,52.0,YR,,F,Y,74.0,KG,20200122.0,,HP,US,US,2020,Q1,Adult
173024621,17302462,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,,10 MILLIGRAM,,,,,,,,10.0,MG,TABLET,,2020,Q1,Product storage error,,2020,Q1,1,I,200803.0,20200114.0,20200122,20200122,EXP,,US-MYLANLABS-2020M1007146,MYLAN,,52.0,YR,,F,Y,74.0,KG,20200122.0,,HP,US,US,2020,Q1,Adult
173025851,17302585,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 MG,,,U,,,,,5.0,MG,,,2020,Q1,Acute kidney injury,,2020,Q1,1,I,20180712.0,20200116.0,20200122,20200122,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,NVSC2020GB011214,NOVARTIS,,79.0,YR,,M,Y,,,20200122.0,,HP,COUNTRY NOT SPECIFIED,GB,2020,Q1,Elderly
173025851,17302585,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 MG,,,U,,,,,5.0,MG,,,2020,Q1,Confusional state,,2020,Q1,1,I,20180712.0,20200116.0,20200122,20200122,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,NVSC2020GB011214,NOVARTIS,,79.0,YR,,M,Y,,,20200122.0,,HP,COUNTRY NOT SPECIFIED,GB,2020,Q1,Elderly
173025851,17302585,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 MG,,,U,,,,,5.0,MG,,,2020,Q1,Hyperlactacidaemia,,2020,Q1,1,I,20180712.0,20200116.0,20200122,20200122,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,NVSC2020GB011214,NOVARTIS,,79.0,YR,,M,Y,,,20200122.0,,HP,COUNTRY NOT SPECIFIED,GB,2020,Q1,Elderly
173025851,17302585,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 MG,,,U,,,,,5.0,MG,,,2020,Q1,Infection,,2020,Q1,1,I,20180712.0,20200116.0,20200122,20200122,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,NVSC2020GB011214,NOVARTIS,,79.0,YR,,M,Y,,,20200122.0,,HP,COUNTRY NOT SPECIFIED,GB,2020,Q1,Elderly
173025851,17302585,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 MG,,,U,,,,,5.0,MG,,,2020,Q1,Oedema peripheral,,2020,Q1,1,I,20180712.0,20200116.0,20200122,20200122,EXP,GB-MHRA-MIDB-72AAF05B-E608-4CEE-8681-4A296FB1541D,NVSC2020GB011214,NOVARTIS,,79.0,YR,,M,Y,,,20200122.0,,HP,COUNTRY NOT SPECIFIED,GB,2020,Q1,Elderly
173052252,17305225,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,,,,202293.0,10.0,MG,TABLET,,2020,Q1,Vulvovaginal discomfort,,2020,Q1,2,F,20160725.0,20200312.0,20200123,20200320,EXP,,GB-ASTRAZENECA-2020SE06926,ASTRAZENECA,,62.0,YR,,F,Y,112.0,KG,20200320.0,,,GB,GB,2020,Q1,Adult
173052252,17305225,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,,,,202293.0,10.0,MG,TABLET,,2020,Q1,Vulvovaginal pruritus,,2020,Q1,2,F,20160725.0,20200312.0,20200123,20200320,EXP,,GB-ASTRAZENECA-2020SE06926,ASTRAZENECA,,62.0,YR,,F,Y,112.0,KG,20200320.0,,,GB,GB,2020,Q1,Adult
173081701,17308170,9,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,1 TOTAL,,,U,U,,,,,,TABLET,,2020,Q1,Intentional overdose,,2020,Q1,1,I,20191019.0,20200116.0,20200123,20200123,EXP,,NVSC2020DE010898,NOVARTIS,,78.0,YR,,F,Y,,,20200123.0,,HP,DE,DE,2020,Q1,Elderly
173081701,17308170,9,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,1 TOTAL,,,U,U,,,,,,TABLET,,2020,Q1,Suicide attempt,,2020,Q1,1,I,20191019.0,20200116.0,20200123,20200123,EXP,,NVSC2020DE010898,NOVARTIS,,78.0,YR,,F,Y,,,20200123.0,,HP,DE,DE,2020,Q1,Elderly
173156301,17315630,3,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE W/METFO,,2,,,,,,,,,,,,,,2020,Q1,Drug delivery system malfunction,,2020,Q1,1,I,201905.0,20190715.0,20200124,20200124,EXP,,BR-JNJFOC-20190727320,JOHNSON AND JOHNSON,,72.0,YR,,M,Y,,,20200124.0,,CN,BR,BR,2020,Q1,Elderly
173156301,17315630,3,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE W/METFO,,2,,,,,,,,,,,,,,2020,Q1,Neoplasm,,2020,Q1,1,I,201905.0,20190715.0,20200124,20200124,EXP,,BR-JNJFOC-20190727320,JOHNSON AND JOHNSON,,72.0,YR,,M,Y,,,20200124.0,,CN,BR,BR,2020,Q1,Elderly
173156301,17315630,3,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE W/METFO,,2,,,,,,,,,,,,,,2020,Q1,Product dose omission,,2020,Q1,1,I,201905.0,20190715.0,20200124,20200124,EXP,,BR-JNJFOC-20190727320,JOHNSON AND JOHNSON,,72.0,YR,,M,Y,,,20200124.0,,CN,BR,BR,2020,Q1,Elderly
173159481,17315948,1,PS,DAPAGLIFLOZIN/METFORMIN,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,10/2000/D,,,Y,,,,205649.0,,,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20200115.0,20200124,20200124,EXP,,GR-ASTRAZENECA-2020SE07100,ASTRAZENECA,,51.0,YR,,F,Y,88.0,KG,20200124.0,,HP,GR,GR,2020,Q1,Adult
173159481,17315948,1,PS,DAPAGLIFLOZIN/METFORMIN,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,10/2000/D,,,Y,,,,205649.0,,,TABLET,,2020,Q1,Off label use,,2020,Q1,1,I,,20200115.0,20200124,20200124,EXP,,GR-ASTRAZENECA-2020SE07100,ASTRAZENECA,,51.0,YR,,F,Y,88.0,KG,20200124.0,,HP,GR,GR,2020,Q1,Adult
173182481,17318248,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, 1-0-0",,,,,,,,,,,,2020,Q1,Asthenia,,2020,Q1,1,I,2018.0,20200117.0,20200124,20200124,EXP,,DE-ASTRAZENECA-2020SE09721,ASTRAZENECA,,44.0,YR,,F,Y,83.0,KG,20200124.0,,MD,DE,DE,2020,Q1,Adult
173182481,17318248,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, 1-0-0",,,,,,,,,,,,2020,Q1,Blood glucose increased,,2020,Q1,1,I,2018.0,20200117.0,20200124,20200124,EXP,,DE-ASTRAZENECA-2020SE09721,ASTRAZENECA,,44.0,YR,,F,Y,83.0,KG,20200124.0,,MD,DE,DE,2020,Q1,Adult
173182481,17318248,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, 1-0-0",,,,,,,,,,,,2020,Q1,Fatigue,,2020,Q1,1,I,2018.0,20200117.0,20200124,20200124,EXP,,DE-ASTRAZENECA-2020SE09721,ASTRAZENECA,,44.0,YR,,F,Y,83.0,KG,20200124.0,,MD,DE,DE,2020,Q1,Adult
173182481,17318248,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, 1-0-0",,,,,,,,,,,,2020,Q1,General physical health deterioration,,2020,Q1,1,I,2018.0,20200117.0,20200124,20200124,EXP,,DE-ASTRAZENECA-2020SE09721,ASTRAZENECA,,44.0,YR,,F,Y,83.0,KG,20200124.0,,MD,DE,DE,2020,Q1,Adult
173182481,17318248,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, 1-0-0",,,,,,,,,,,,2020,Q1,Glycosylated haemoglobin increased,,2020,Q1,1,I,2018.0,20200117.0,20200124,20200124,EXP,,DE-ASTRAZENECA-2020SE09721,ASTRAZENECA,,44.0,YR,,F,Y,83.0,KG,20200124.0,,MD,DE,DE,2020,Q1,Adult
173182481,17318248,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, 1-0-0",,,,,,,,,,,,2020,Q1,Pancreatic disorder,,2020,Q1,1,I,2018.0,20200117.0,20200124,20200124,EXP,,DE-ASTRAZENECA-2020SE09721,ASTRAZENECA,,44.0,YR,,F,Y,83.0,KG,20200124.0,,MD,DE,DE,2020,Q1,Adult
173182481,17318248,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, 1-0-0",,,,,,,,,,,,2020,Q1,Weight decreased,,2020,Q1,1,I,2018.0,20200117.0,20200124,20200124,EXP,,DE-ASTRAZENECA-2020SE09721,ASTRAZENECA,,44.0,YR,,F,Y,83.0,KG,20200124.0,,MD,DE,DE,2020,Q1,Adult
173361351,17336135,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Febrile neutropenia,,2020,Q1,1,I,,20200122.0,20200128,20200128,EXP,,PT-MYLANLABS-2020M1009178,MYLAN,"COUTO C., VASCONCELOS G., SA A.J., MESQUITA M. FEBRILE NEUTROPENIA- AN ETIOLOGY OF EXCLUSION. MEDICINA INTERNA - CONGRESSO NACIONAL. 1",58.0,YR,,F,Y,,,20200128.0,,HP,PT,PT,2020,Q1,Adult
173361351,17336135,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Flushing,,2020,Q1,1,I,,20200122.0,20200128,20200128,EXP,,PT-MYLANLABS-2020M1009178,MYLAN,"COUTO C., VASCONCELOS G., SA A.J., MESQUITA M. FEBRILE NEUTROPENIA- AN ETIOLOGY OF EXCLUSION. MEDICINA INTERNA - CONGRESSO NACIONAL. 1",58.0,YR,,F,Y,,,20200128.0,,HP,PT,PT,2020,Q1,Adult
173361351,17336135,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Gingival swelling,,2020,Q1,1,I,,20200122.0,20200128,20200128,EXP,,PT-MYLANLABS-2020M1009178,MYLAN,"COUTO C., VASCONCELOS G., SA A.J., MESQUITA M. FEBRILE NEUTROPENIA- AN ETIOLOGY OF EXCLUSION. MEDICINA INTERNA - CONGRESSO NACIONAL. 1",58.0,YR,,F,Y,,,20200128.0,,HP,PT,PT,2020,Q1,Adult
173361351,17336135,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Headache,,2020,Q1,1,I,,20200122.0,20200128,20200128,EXP,,PT-MYLANLABS-2020M1009178,MYLAN,"COUTO C., VASCONCELOS G., SA A.J., MESQUITA M. FEBRILE NEUTROPENIA- AN ETIOLOGY OF EXCLUSION. MEDICINA INTERNA - CONGRESSO NACIONAL. 1",58.0,YR,,F,Y,,,20200128.0,,HP,PT,PT,2020,Q1,Adult
173361351,17336135,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Leukopenia,,2020,Q1,1,I,,20200122.0,20200128,20200128,EXP,,PT-MYLANLABS-2020M1009178,MYLAN,"COUTO C., VASCONCELOS G., SA A.J., MESQUITA M. FEBRILE NEUTROPENIA- AN ETIOLOGY OF EXCLUSION. MEDICINA INTERNA - CONGRESSO NACIONAL. 1",58.0,YR,,F,Y,,,20200128.0,,HP,PT,PT,2020,Q1,Adult
173361351,17336135,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Mouth ulceration,,2020,Q1,1,I,,20200122.0,20200128,20200128,EXP,,PT-MYLANLABS-2020M1009178,MYLAN,"COUTO C., VASCONCELOS G., SA A.J., MESQUITA M. FEBRILE NEUTROPENIA- AN ETIOLOGY OF EXCLUSION. MEDICINA INTERNA - CONGRESSO NACIONAL. 1",58.0,YR,,F,Y,,,20200128.0,,HP,PT,PT,2020,Q1,Adult
173361351,17336135,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Myalgia,,2020,Q1,1,I,,20200122.0,20200128,20200128,EXP,,PT-MYLANLABS-2020M1009178,MYLAN,"COUTO C., VASCONCELOS G., SA A.J., MESQUITA M. FEBRILE NEUTROPENIA- AN ETIOLOGY OF EXCLUSION. MEDICINA INTERNA - CONGRESSO NACIONAL. 1",58.0,YR,,F,Y,,,20200128.0,,HP,PT,PT,2020,Q1,Adult
173361351,17336135,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Neutropenia,,2020,Q1,1,I,,20200122.0,20200128,20200128,EXP,,PT-MYLANLABS-2020M1009178,MYLAN,"COUTO C., VASCONCELOS G., SA A.J., MESQUITA M. FEBRILE NEUTROPENIA- AN ETIOLOGY OF EXCLUSION. MEDICINA INTERNA - CONGRESSO NACIONAL. 1",58.0,YR,,F,Y,,,20200128.0,,HP,PT,PT,2020,Q1,Adult
173361351,17336135,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Pyrexia,,2020,Q1,1,I,,20200122.0,20200128,20200128,EXP,,PT-MYLANLABS-2020M1009178,MYLAN,"COUTO C., VASCONCELOS G., SA A.J., MESQUITA M. FEBRILE NEUTROPENIA- AN ETIOLOGY OF EXCLUSION. MEDICINA INTERNA - CONGRESSO NACIONAL. 1",58.0,YR,,F,Y,,,20200128.0,,HP,PT,PT,2020,Q1,Adult
173389371,17338937,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,TABLETS,,2020,Q1,Arthralgia,,2020,Q1,1,I,200805.0,20200114.0,20200129,20200129,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-00224,HIKMA,,52.0,YR,,F,Y,74.0,KG,20200128.0,,CN,US,US,2020,Q1,Adult
173389371,17338937,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,TABLETS,,2020,Q1,Atrial fibrillation,,2020,Q1,1,I,200805.0,20200114.0,20200129,20200129,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-00224,HIKMA,,52.0,YR,,F,Y,74.0,KG,20200128.0,,CN,US,US,2020,Q1,Adult
173389371,17338937,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,TABLETS,,2020,Q1,Back pain,,2020,Q1,1,I,200805.0,20200114.0,20200129,20200129,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-00224,HIKMA,,52.0,YR,,F,Y,74.0,KG,20200128.0,,CN,US,US,2020,Q1,Adult
173389371,17338937,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,TABLETS,,2020,Q1,Chest pain,,2020,Q1,1,I,200805.0,20200114.0,20200129,20200129,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-00224,HIKMA,,52.0,YR,,F,Y,74.0,KG,20200128.0,,CN,US,US,2020,Q1,Adult
173389371,17338937,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,TABLETS,,2020,Q1,Contusion,,2020,Q1,1,I,200805.0,20200114.0,20200129,20200129,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-00224,HIKMA,,52.0,YR,,F,Y,74.0,KG,20200128.0,,CN,US,US,2020,Q1,Adult
173389371,17338937,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,TABLETS,,2020,Q1,Diabetes mellitus,,2020,Q1,1,I,200805.0,20200114.0,20200129,20200129,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-00224,HIKMA,,52.0,YR,,F,Y,74.0,KG,20200128.0,,CN,US,US,2020,Q1,Adult
173389371,17338937,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,TABLETS,,2020,Q1,Gingival bleeding,,2020,Q1,1,I,200805.0,20200114.0,20200129,20200129,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-00224,HIKMA,,52.0,YR,,F,Y,74.0,KG,20200128.0,,CN,US,US,2020,Q1,Adult
173389371,17338937,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,TABLETS,,2020,Q1,Glomerular filtration rate decreased,,2020,Q1,1,I,200805.0,20200114.0,20200129,20200129,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-00224,HIKMA,,52.0,YR,,F,Y,74.0,KG,20200128.0,,CN,US,US,2020,Q1,Adult
173389371,17338937,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,TABLETS,,2020,Q1,Gout,,2020,Q1,1,I,200805.0,20200114.0,20200129,20200129,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-00224,HIKMA,,52.0,YR,,F,Y,74.0,KG,20200128.0,,CN,US,US,2020,Q1,Adult
173389371,17338937,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,TABLETS,,2020,Q1,Headache,,2020,Q1,1,I,200805.0,20200114.0,20200129,20200129,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-00224,HIKMA,,52.0,YR,,F,Y,74.0,KG,20200128.0,,CN,US,US,2020,Q1,Adult
173389371,17338937,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,TABLETS,,2020,Q1,Hypoaesthesia,,2020,Q1,1,I,200805.0,20200114.0,20200129,20200129,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-00224,HIKMA,,52.0,YR,,F,Y,74.0,KG,20200128.0,,CN,US,US,2020,Q1,Adult
173389371,17338937,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,TABLETS,,2020,Q1,Insomnia,,2020,Q1,1,I,200805.0,20200114.0,20200129,20200129,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-00224,HIKMA,,52.0,YR,,F,Y,74.0,KG,20200128.0,,CN,US,US,2020,Q1,Adult
173389371,17338937,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,TABLETS,,2020,Q1,Myocardial infarction,,2020,Q1,1,I,200805.0,20200114.0,20200129,20200129,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-00224,HIKMA,,52.0,YR,,F,Y,74.0,KG,20200128.0,,CN,US,US,2020,Q1,Adult
173389371,17338937,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,TABLETS,,2020,Q1,Sinus disorder,,2020,Q1,1,I,200805.0,20200114.0,20200129,20200129,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-00224,HIKMA,,52.0,YR,,F,Y,74.0,KG,20200128.0,,CN,US,US,2020,Q1,Adult
173389371,17338937,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,TABLETS,,2020,Q1,Weight decreased,,2020,Q1,1,I,200805.0,20200114.0,20200129,20200129,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-00224,HIKMA,,52.0,YR,,F,Y,74.0,KG,20200128.0,,CN,US,US,2020,Q1,Adult
173497222,17349722,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q1,Abdominal pain,,2020,Q1,2,F,,20200124.0,20200130,20200205,EXP,,CA-AUROBINDO-AUR-APL-2019-077306,AUROBINDO,,62.0,YR,,M,Y,,,20200205.0,,CN,CA,CA,2020,Q1,Adult
173497222,17349722,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q1,Anaphylactic reaction,,2020,Q1,2,F,,20200124.0,20200130,20200205,EXP,,CA-AUROBINDO-AUR-APL-2019-077306,AUROBINDO,,62.0,YR,,M,Y,,,20200205.0,,CN,CA,CA,2020,Q1,Adult
173497222,17349722,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q1,Blood immunoglobulin E increased,,2020,Q1,2,F,,20200124.0,20200130,20200205,EXP,,CA-AUROBINDO-AUR-APL-2019-077306,AUROBINDO,,62.0,YR,,M,Y,,,20200205.0,,CN,CA,CA,2020,Q1,Adult
173497222,17349722,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q1,Diabetes mellitus inadequate control,,2020,Q1,2,F,,20200124.0,20200130,20200205,EXP,,CA-AUROBINDO-AUR-APL-2019-077306,AUROBINDO,,62.0,YR,,M,Y,,,20200205.0,,CN,CA,CA,2020,Q1,Adult
173497222,17349722,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q1,Diarrhoea,,2020,Q1,2,F,,20200124.0,20200130,20200205,EXP,,CA-AUROBINDO-AUR-APL-2019-077306,AUROBINDO,,62.0,YR,,M,Y,,,20200205.0,,CN,CA,CA,2020,Q1,Adult
173497222,17349722,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q1,Drug hypersensitivity,,2020,Q1,2,F,,20200124.0,20200130,20200205,EXP,,CA-AUROBINDO-AUR-APL-2019-077306,AUROBINDO,,62.0,YR,,M,Y,,,20200205.0,,CN,CA,CA,2020,Q1,Adult
173497222,17349722,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q1,Drug intolerance,,2020,Q1,2,F,,20200124.0,20200130,20200205,EXP,,CA-AUROBINDO-AUR-APL-2019-077306,AUROBINDO,,62.0,YR,,M,Y,,,20200205.0,,CN,CA,CA,2020,Q1,Adult
173497222,17349722,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q1,Dyspnoea,,2020,Q1,2,F,,20200124.0,20200130,20200205,EXP,,CA-AUROBINDO-AUR-APL-2019-077306,AUROBINDO,,62.0,YR,,M,Y,,,20200205.0,,CN,CA,CA,2020,Q1,Adult
173497222,17349722,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q1,Skin test positive,,2020,Q1,2,F,,20200124.0,20200130,20200205,EXP,,CA-AUROBINDO-AUR-APL-2019-077306,AUROBINDO,,62.0,YR,,M,Y,,,20200205.0,,CN,CA,CA,2020,Q1,Adult
173497222,17349722,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q1,Type I hypersensitivity,,2020,Q1,2,F,,20200124.0,20200130,20200205,EXP,,CA-AUROBINDO-AUR-APL-2019-077306,AUROBINDO,,62.0,YR,,M,Y,,,20200205.0,,CN,CA,CA,2020,Q1,Adult
173497222,17349722,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q1,Urticaria,,2020,Q1,2,F,,20200124.0,20200130,20200205,EXP,,CA-AUROBINDO-AUR-APL-2019-077306,AUROBINDO,,62.0,YR,,M,Y,,,20200205.0,,CN,CA,CA,2020,Q1,Adult
173523621,17352362,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,MORNING,,,,,,,,10.0,MG,TABLET,,2020,Q1,Dermatitis,,2020,Q1,1,I,201908.0,20200128.0,20200130,20200130,EXP,,CO-ABBVIE-20K-036-3255871-00,ABBVIE,,61.0,YR,,F,Y,59.0,KG,20200130.0,,CN,CO,CO,2020,Q1,Adult
173523621,17352362,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,MORNING,,,,,,,,10.0,MG,TABLET,,2020,Q1,Hypersensitivity,,2020,Q1,1,I,201908.0,20200128.0,20200130,20200130,EXP,,CO-ABBVIE-20K-036-3255871-00,ABBVIE,,61.0,YR,,F,Y,59.0,KG,20200130.0,,CN,CO,CO,2020,Q1,Adult
173523621,17352362,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,MORNING,,,,,,,,10.0,MG,TABLET,,2020,Q1,Inflammation,,2020,Q1,1,I,201908.0,20200128.0,20200130,20200130,EXP,,CO-ABBVIE-20K-036-3255871-00,ABBVIE,,61.0,YR,,F,Y,59.0,KG,20200130.0,,CN,CO,CO,2020,Q1,Adult
173523621,17352362,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,MORNING,,,,,,,,10.0,MG,TABLET,,2020,Q1,Malaise,,2020,Q1,1,I,201908.0,20200128.0,20200130,20200130,EXP,,CO-ABBVIE-20K-036-3255871-00,ABBVIE,,61.0,YR,,F,Y,59.0,KG,20200130.0,,CN,CO,CO,2020,Q1,Adult
173523621,17352362,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,MORNING,,,,,,,,10.0,MG,TABLET,,2020,Q1,Pruritus,,2020,Q1,1,I,201908.0,20200128.0,20200130,20200130,EXP,,CO-ABBVIE-20K-036-3255871-00,ABBVIE,,61.0,YR,,F,Y,59.0,KG,20200130.0,,CN,CO,CO,2020,Q1,Adult
173523621,17352362,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,MORNING,,,,,,,,10.0,MG,TABLET,,2020,Q1,Tooth extraction,,2020,Q1,1,I,201908.0,20200128.0,20200130,20200130,EXP,,CO-ABBVIE-20K-036-3255871-00,ABBVIE,,61.0,YR,,F,Y,59.0,KG,20200130.0,,CN,CO,CO,2020,Q1,Adult
173523621,17352362,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,MORNING,,,,,,,,10.0,MG,TABLET,,2020,Q1,Tooth fracture,,2020,Q1,1,I,201908.0,20200128.0,20200130,20200130,EXP,,CO-ABBVIE-20K-036-3255871-00,ABBVIE,,61.0,YR,,F,Y,59.0,KG,20200130.0,,CN,CO,CO,2020,Q1,Adult
173523621,17352362,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,MORNING,,,,,,,,10.0,MG,TABLET,,2020,Q1,Toothache,,2020,Q1,1,I,201908.0,20200128.0,20200130,20200130,EXP,,CO-ABBVIE-20K-036-3255871-00,ABBVIE,,61.0,YR,,F,Y,59.0,KG,20200130.0,,CN,CO,CO,2020,Q1,Adult
173566111,17356611,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Transplacental,,,,,,,,,,,,,2020,Q1,Congenital hydrocephalus,,2020,Q1,1,I,,20160223.0,20200131,20200131,EXP,,GB-EMD SERONO-8069769,EMD SERONO INC,,20.0,WK,,,Y,,,20200131.0,,MD,GB,GB,2020,Q1,Youth
173648271,17364827,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Transplacental,10 MILLIGRAM,,,D,,,,,10.0,MG,,,2020,Q1,Congenital hydrocephalus,,2020,Q1,1,I,,20160223.0,20200204,20200204,EXP,GB-MHRA-ADR 23357992,GB-EMCURE PHARMACEUTICALS LTD-2016-EPL-0192,EMCURE,,20.0,WK,,,Y,,,20200204.0,,MD,GB,GB,2020,Q1,Youth
173648271,17364827,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Transplacental,10 MILLIGRAM,,,D,,,,,10.0,MG,,,2020,Q1,Foetal exposure during pregnancy,,2020,Q1,1,I,,20160223.0,20200204,20200204,EXP,GB-MHRA-ADR 23357992,GB-EMCURE PHARMACEUTICALS LTD-2016-EPL-0192,EMCURE,,20.0,WK,,,Y,,,20200204.0,,MD,GB,GB,2020,Q1,Youth
173667401,17366740,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q1,Drug interaction,,2020,Q1,1,I,,20200126.0,20200204,20200204,EXP,,PL-PRINSTON PHARMACEUTICAL INC.-2020PRN00041,PRINSTON PHARMACEUTICAL,"WORON J, SIWEK M, GOROSTOWICZ A. ADVERSE EFFECTS OF INTERACTIONS BETWEEN ANTIDEPRESSANTS AND MEDICATIONS USED IN TREATMENT OF CARDIOVASCULAR DISORDERS.. PSYCHIATR POL. 2019;53(5):977-995",51.0,YR,,F,Y,,,20200204.0,,HP,PL,PL,2020,Q1,Adult
173667401,17366740,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q1,Granulocytopenia,,2020,Q1,1,I,,20200126.0,20200204,20200204,EXP,,PL-PRINSTON PHARMACEUTICAL INC.-2020PRN00041,PRINSTON PHARMACEUTICAL,"WORON J, SIWEK M, GOROSTOWICZ A. ADVERSE EFFECTS OF INTERACTIONS BETWEEN ANTIDEPRESSANTS AND MEDICATIONS USED IN TREATMENT OF CARDIOVASCULAR DISORDERS.. PSYCHIATR POL. 2019;53(5):977-995",51.0,YR,,F,Y,,,20200204.0,,HP,PL,PL,2020,Q1,Adult
173676871,17367687,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Drug interaction,,2020,Q1,1,I,,20200129.0,20200204,20200204,EXP,,PL-MYLANLABS-2020M1011818,MYLAN,,51.0,YR,,F,Y,,,20200204.0,,HP,PL,PL,2020,Q1,Adult
173676871,17367687,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Drug level increased,,2020,Q1,1,I,,20200129.0,20200204,20200204,EXP,,PL-MYLANLABS-2020M1011818,MYLAN,,51.0,YR,,F,Y,,,20200204.0,,HP,PL,PL,2020,Q1,Adult
173676871,17367687,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Granulocytopenia,,2020,Q1,1,I,,20200129.0,20200204,20200204,EXP,,PL-MYLANLABS-2020M1011818,MYLAN,,51.0,YR,,F,Y,,,20200204.0,,HP,PL,PL,2020,Q1,Adult
173713221,17371322,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q1,Bradycardia,,2020,Q1,1,I,,20200127.0,20200205,20200205,EXP,,PL-APNAR-000049,APNAR PHARMA,"WORON J, SIWEK M, GOROSTOWICZ A, ADVERSE EFFECTS OF INTERACTIONS BETWEEN ANTI-DEPRESSANTS AND MEDICATIONS USED IN TREATMENT OF CARDIOVASCULAR DISORDERS, PSYCHIATR. POL. 2019; 53(5): 977-995.",55.0,YR,,F,Y,,,20200205.0,,HP,PL,PL,2020,Q1,Adult
173713221,17371322,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q1,Dizziness,,2020,Q1,1,I,,20200127.0,20200205,20200205,EXP,,PL-APNAR-000049,APNAR PHARMA,"WORON J, SIWEK M, GOROSTOWICZ A, ADVERSE EFFECTS OF INTERACTIONS BETWEEN ANTI-DEPRESSANTS AND MEDICATIONS USED IN TREATMENT OF CARDIOVASCULAR DISORDERS, PSYCHIATR. POL. 2019; 53(5): 977-995.",55.0,YR,,F,Y,,,20200205.0,,HP,PL,PL,2020,Q1,Adult
173713221,17371322,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q1,Drug interaction,,2020,Q1,1,I,,20200127.0,20200205,20200205,EXP,,PL-APNAR-000049,APNAR PHARMA,"WORON J, SIWEK M, GOROSTOWICZ A, ADVERSE EFFECTS OF INTERACTIONS BETWEEN ANTI-DEPRESSANTS AND MEDICATIONS USED IN TREATMENT OF CARDIOVASCULAR DISORDERS, PSYCHIATR. POL. 2019; 53(5): 977-995.",55.0,YR,,F,Y,,,20200205.0,,HP,PL,PL,2020,Q1,Adult
173713221,17371322,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q1,Drug level increased,,2020,Q1,1,I,,20200127.0,20200205,20200205,EXP,,PL-APNAR-000049,APNAR PHARMA,"WORON J, SIWEK M, GOROSTOWICZ A, ADVERSE EFFECTS OF INTERACTIONS BETWEEN ANTI-DEPRESSANTS AND MEDICATIONS USED IN TREATMENT OF CARDIOVASCULAR DISORDERS, PSYCHIATR. POL. 2019; 53(5): 977-995.",55.0,YR,,F,Y,,,20200205.0,,HP,PL,PL,2020,Q1,Adult
173713221,17371322,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q1,Hypotension,,2020,Q1,1,I,,20200127.0,20200205,20200205,EXP,,PL-APNAR-000049,APNAR PHARMA,"WORON J, SIWEK M, GOROSTOWICZ A, ADVERSE EFFECTS OF INTERACTIONS BETWEEN ANTI-DEPRESSANTS AND MEDICATIONS USED IN TREATMENT OF CARDIOVASCULAR DISORDERS, PSYCHIATR. POL. 2019; 53(5): 977-995.",55.0,YR,,F,Y,,,20200205.0,,HP,PL,PL,2020,Q1,Adult
173715021,17371502,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q1,Drug interaction,,2020,Q1,1,I,,20200127.0,20200205,20200205,EXP,,PL-INVENTIA-000355,INVENTIA HEALTHCARE,"WORON J, SIWEK M, GOROSTOWICZ A, ADVERSE EFFECTS OF INTERACTIONS BETWEEN ANTI-DEPRESSANTS AND MEDICATIONS USED IN TREATMENT OF CARDIOVASCULAR DISORDERS, PSYCHIATR. POL. 2019; 53(5): 977-995.",51.0,YR,,F,Y,,,20200205.0,,HP,PL,PL,2020,Q1,Adult
173715021,17371502,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q1,Drug level increased,,2020,Q1,1,I,,20200127.0,20200205,20200205,EXP,,PL-INVENTIA-000355,INVENTIA HEALTHCARE,"WORON J, SIWEK M, GOROSTOWICZ A, ADVERSE EFFECTS OF INTERACTIONS BETWEEN ANTI-DEPRESSANTS AND MEDICATIONS USED IN TREATMENT OF CARDIOVASCULAR DISORDERS, PSYCHIATR. POL. 2019; 53(5): 977-995.",51.0,YR,,F,Y,,,20200205.0,,HP,PL,PL,2020,Q1,Adult
173715021,17371502,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q1,Granulocytopenia,,2020,Q1,1,I,,20200127.0,20200205,20200205,EXP,,PL-INVENTIA-000355,INVENTIA HEALTHCARE,"WORON J, SIWEK M, GOROSTOWICZ A, ADVERSE EFFECTS OF INTERACTIONS BETWEEN ANTI-DEPRESSANTS AND MEDICATIONS USED IN TREATMENT OF CARDIOVASCULAR DISORDERS, PSYCHIATR. POL. 2019; 53(5): 977-995.",51.0,YR,,F,Y,,,20200205.0,,HP,PL,PL,2020,Q1,Adult
173757611,17375761,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q1,Fournier's gangrene,,2020,Q1,1,I,20190602.0,20190806.0,20200206,20200206,EXP,,GB-ASTRAZENECA-2019SF12349,ASTRAZENECA,,56.0,YR,,M,Y,110.0,KG,20200206.0,,PH,GB,GB,2020,Q1,Adult
173757611,17375761,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q1,Groin abscess,,2020,Q1,1,I,20190602.0,20190806.0,20200206,20200206,EXP,,GB-ASTRAZENECA-2019SF12349,ASTRAZENECA,,56.0,YR,,M,Y,110.0,KG,20200206.0,,PH,GB,GB,2020,Q1,Adult
173757611,17375761,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q1,Necrotising fasciitis,,2020,Q1,1,I,20190602.0,20190806.0,20200206,20200206,EXP,,GB-ASTRAZENECA-2019SF12349,ASTRAZENECA,,56.0,YR,,M,Y,110.0,KG,20200206.0,,PH,GB,GB,2020,Q1,Adult
173758351,17375835,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q1,Drug interaction,,2020,Q1,1,I,,20200126.0,20200206,20200206,EXP,,PL-AJANTA PHARMA USA INC.-2079882,AJANTA PHARMA,"WORON J., SIWEK M. AND GOROSTOWICZ A. ADVERSE EFFECTS OF INTERACTIONS BETWEEN ANTIDEPRESSANTS AND MEDICATIONS USED IN TREATMENT OF CARDIOVASCULAR DISORDERS. PSYCHIATR. POL., 53(5), (2019), PP.977-995.",51.0,YR,,F,Y,,,20200206.0,,HP,PL,PL,2020,Q1,Adult
173758351,17375835,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q1,Granulocytopenia,,2020,Q1,1,I,,20200126.0,20200206,20200206,EXP,,PL-AJANTA PHARMA USA INC.-2079882,AJANTA PHARMA,"WORON J., SIWEK M. AND GOROSTOWICZ A. ADVERSE EFFECTS OF INTERACTIONS BETWEEN ANTIDEPRESSANTS AND MEDICATIONS USED IN TREATMENT OF CARDIOVASCULAR DISORDERS. PSYCHIATR. POL., 53(5), (2019), PP.977-995.",51.0,YR,,F,Y,,,20200206.0,,HP,PL,PL,2020,Q1,Adult
173768311,17376831,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,ONGOING = CHECKED,,,,,,,,,,,,2020,Q1,Hypokalaemia,,2020,Q1,1,I,20180611.0,20200201.0,20200206,20200206,EXP,,GR-MYLANLABS-2020M1012987,MYLAN,,51.0,YR,,F,Y,98.0,KG,20200206.0,,MD,GR,GR,2020,Q1,Adult
173894541,17389454,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q1,Escherichia urinary tract infection,,2020,Q1,1,I,20191125.0,20200128.0,20200207,20200207,EXP,,AU-EMD SERONO-9143345,EMD SERONO INC,,69.0,YR,,M,Y,,,20200207.0,,HP,AU,AU,2020,Q1,Elderly
173894541,17389454,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q1,Fall,,2020,Q1,1,I,20191125.0,20200128.0,20200207,20200207,EXP,,AU-EMD SERONO-9143345,EMD SERONO INC,,69.0,YR,,M,Y,,,20200207.0,,HP,AU,AU,2020,Q1,Elderly
173894541,17389454,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q1,Lymphocyte count decreased,,2020,Q1,1,I,20191125.0,20200128.0,20200207,20200207,EXP,,AU-EMD SERONO-9143345,EMD SERONO INC,,69.0,YR,,M,Y,,,20200207.0,,HP,AU,AU,2020,Q1,Elderly
173894541,17389454,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q1,Multiple sclerosis relapse,,2020,Q1,1,I,20191125.0,20200128.0,20200207,20200207,EXP,,AU-EMD SERONO-9143345,EMD SERONO INC,,69.0,YR,,M,Y,,,20200207.0,,HP,AU,AU,2020,Q1,Elderly
173900911,17390091,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q1,Dyspnoea,,2020,Q1,1,I,,20200204.0,20200207,20200207,EXP,,GB-ASTRAZENECA-2020SE17786,ASTRAZENECA,,53.0,YR,,F,Y,95.0,KG,20200207.0,,PH,GB,GB,2020,Q1,Adult
173900911,17390091,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20200204.0,20200207,20200207,EXP,,GB-ASTRAZENECA-2020SE17786,ASTRAZENECA,,53.0,YR,,F,Y,95.0,KG,20200207.0,,PH,GB,GB,2020,Q1,Adult
173902381,17390238,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"UNK, UNKNOWN",,,U,,,,,,,,,2020,Q1,Diabetic ketoacidosis,,2020,Q1,1,I,20200110.0,20200205.0,20200207,20200207,EXP,GB-MHRA-EYC 00216853,GB-ELI_LILLY_AND_COMPANY-GB202002002514,ELI LILLY AND CO,,65.0,YR,,F,Y,,,20200207.0,,CN,GB,GB,2020,Q1,Elderly
173902381,17390238,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"UNK, UNKNOWN",,,U,,,,,,,,,2020,Q1,Pancreatitis acute,,2020,Q1,1,I,20200110.0,20200205.0,20200207,20200207,EXP,GB-MHRA-EYC 00216853,GB-ELI_LILLY_AND_COMPANY-GB202002002514,ELI LILLY AND CO,,65.0,YR,,F,Y,,,20200207.0,,CN,GB,GB,2020,Q1,Elderly
174006421,17400642,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Febrile neutropenia,,2020,Q1,1,I,,20200205.0,20200211,20200211,EXP,PT-EMA-20200204-AUTODUP-30640000,PT-ACCORD-172137,ACCORD,,58.0,YR,,F,Y,,,20200211.0,,HP,PT,PT,2020,Q1,Adult
174006421,17400642,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Flushing,,2020,Q1,1,I,,20200205.0,20200211,20200211,EXP,PT-EMA-20200204-AUTODUP-30640000,PT-ACCORD-172137,ACCORD,,58.0,YR,,F,Y,,,20200211.0,,HP,PT,PT,2020,Q1,Adult
174006421,17400642,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Gingival swelling,,2020,Q1,1,I,,20200205.0,20200211,20200211,EXP,PT-EMA-20200204-AUTODUP-30640000,PT-ACCORD-172137,ACCORD,,58.0,YR,,F,Y,,,20200211.0,,HP,PT,PT,2020,Q1,Adult
174006421,17400642,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Headache,,2020,Q1,1,I,,20200205.0,20200211,20200211,EXP,PT-EMA-20200204-AUTODUP-30640000,PT-ACCORD-172137,ACCORD,,58.0,YR,,F,Y,,,20200211.0,,HP,PT,PT,2020,Q1,Adult
174006421,17400642,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Leukopenia,,2020,Q1,1,I,,20200205.0,20200211,20200211,EXP,PT-EMA-20200204-AUTODUP-30640000,PT-ACCORD-172137,ACCORD,,58.0,YR,,F,Y,,,20200211.0,,HP,PT,PT,2020,Q1,Adult
174006421,17400642,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Mouth ulceration,,2020,Q1,1,I,,20200205.0,20200211,20200211,EXP,PT-EMA-20200204-AUTODUP-30640000,PT-ACCORD-172137,ACCORD,,58.0,YR,,F,Y,,,20200211.0,,HP,PT,PT,2020,Q1,Adult
174006421,17400642,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Myalgia,,2020,Q1,1,I,,20200205.0,20200211,20200211,EXP,PT-EMA-20200204-AUTODUP-30640000,PT-ACCORD-172137,ACCORD,,58.0,YR,,F,Y,,,20200211.0,,HP,PT,PT,2020,Q1,Adult
174006421,17400642,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Neutropenia,,2020,Q1,1,I,,20200205.0,20200211,20200211,EXP,PT-EMA-20200204-AUTODUP-30640000,PT-ACCORD-172137,ACCORD,,58.0,YR,,F,Y,,,20200211.0,,HP,PT,PT,2020,Q1,Adult
174006421,17400642,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q1,Pyrexia,,2020,Q1,1,I,,20200205.0,20200211,20200211,EXP,PT-EMA-20200204-AUTODUP-30640000,PT-ACCORD-172137,ACCORD,,58.0,YR,,F,Y,,,20200211.0,,HP,PT,PT,2020,Q1,Adult
174013431,17401343,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10,,,Y,, UNKNOWN,,202293.0,,,TABLET,,2020,Q1,Diabetic ketoacidosis,,2020,Q1,1,I,20200115.0,20200206.0,20200211,20200211,EXP,,GB-ASTRAZENECA-2020SE19039,ASTRAZENECA,,31.0,YR,,F,Y,,,20200211.0,,MD,GB,GB,2020,Q1,Young Adult
174013431,17401343,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10,,,Y,, UNKNOWN,,202293.0,,,TABLET,,2020,Q1,Hyperglycaemia,,2020,Q1,1,I,20200115.0,20200206.0,20200211,20200211,EXP,,GB-ASTRAZENECA-2020SE19039,ASTRAZENECA,,31.0,YR,,F,Y,,,20200211.0,,MD,GB,GB,2020,Q1,Young Adult
174085122,17408512,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,5480.0,MG,,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Abdominal distension,,2020,Q1,2,F,20200124.0,20200219.0,20200212,20200224,EXP,,GB-ASTRAZENECA-2020SE19286,ASTRAZENECA,,61.0,YR,,F,Y,,,20200224.0,,PH,GB,GB,2020,Q1,Adult
174085122,17408512,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,5480.0,MG,,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Chronic obstructive pulmonary disease,,2020,Q1,2,F,20200124.0,20200219.0,20200212,20200224,EXP,,GB-ASTRAZENECA-2020SE19286,ASTRAZENECA,,61.0,YR,,F,Y,,,20200224.0,,PH,GB,GB,2020,Q1,Adult
174085122,17408512,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,5480.0,MG,,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Coeliac disease,,2020,Q1,2,F,20200124.0,20200219.0,20200212,20200224,EXP,,GB-ASTRAZENECA-2020SE19286,ASTRAZENECA,,61.0,YR,,F,Y,,,20200224.0,,PH,GB,GB,2020,Q1,Adult
174085122,17408512,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,5480.0,MG,,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Diabetes mellitus,,2020,Q1,2,F,20200124.0,20200219.0,20200212,20200224,EXP,,GB-ASTRAZENECA-2020SE19286,ASTRAZENECA,,61.0,YR,,F,Y,,,20200224.0,,PH,GB,GB,2020,Q1,Adult
174085122,17408512,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,5480.0,MG,,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Diarrhoea,,2020,Q1,2,F,20200124.0,20200219.0,20200212,20200224,EXP,,GB-ASTRAZENECA-2020SE19286,ASTRAZENECA,,61.0,YR,,F,Y,,,20200224.0,,PH,GB,GB,2020,Q1,Adult
174085122,17408512,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,5480.0,MG,,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Hypotension,,2020,Q1,2,F,20200124.0,20200219.0,20200212,20200224,EXP,,GB-ASTRAZENECA-2020SE19286,ASTRAZENECA,,61.0,YR,,F,Y,,,20200224.0,,PH,GB,GB,2020,Q1,Adult
174085122,17408512,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,5480.0,MG,,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Hypothermia,,2020,Q1,2,F,20200124.0,20200219.0,20200212,20200224,EXP,,GB-ASTRAZENECA-2020SE19286,ASTRAZENECA,,61.0,YR,,F,Y,,,20200224.0,,PH,GB,GB,2020,Q1,Adult
174085122,17408512,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,5480.0,MG,,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Lactic acidosis,,2020,Q1,2,F,20200124.0,20200219.0,20200212,20200224,EXP,,GB-ASTRAZENECA-2020SE19286,ASTRAZENECA,,61.0,YR,,F,Y,,,20200224.0,,PH,GB,GB,2020,Q1,Adult
174085122,17408512,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,5480.0,MG,,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Multiple organ dysfunction syndrome,,2020,Q1,2,F,20200124.0,20200219.0,20200212,20200224,EXP,,GB-ASTRAZENECA-2020SE19286,ASTRAZENECA,,61.0,YR,,F,Y,,,20200224.0,,PH,GB,GB,2020,Q1,Adult
174085122,17408512,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,5480.0,MG,,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Schizophrenia,,2020,Q1,2,F,20200124.0,20200219.0,20200212,20200224,EXP,,GB-ASTRAZENECA-2020SE19286,ASTRAZENECA,,61.0,YR,,F,Y,,,20200224.0,,PH,GB,GB,2020,Q1,Adult
174131492,17413149,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,,,TABLET,,2020,Q1,Ketoacidosis,,2020,Q1,2,F,20200121.0,20200305.0,20200213,20200310,EXP,,DE-ASTRAZENECA-2020SE18646,ASTRAZENECA,,6417.0,DY,,M,Y,78.0,KG,20200310.0,,MD,DE,DE,2020,Q1,Elderly
174131492,17413149,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,,,TABLET,,2020,Q1,Off label use,,2020,Q1,2,F,20200121.0,20200305.0,20200213,20200310,EXP,,DE-ASTRAZENECA-2020SE18646,ASTRAZENECA,,6417.0,DY,,M,Y,78.0,KG,20200310.0,,MD,DE,DE,2020,Q1,Elderly
174131492,17413149,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,,,TABLET,,2020,Q1,Product use in unapproved indication,,2020,Q1,2,F,20200121.0,20200305.0,20200213,20200310,EXP,,DE-ASTRAZENECA-2020SE18646,ASTRAZENECA,,6417.0,DY,,M,Y,78.0,KG,20200310.0,,MD,DE,DE,2020,Q1,Elderly
174132031,17413203,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,D,,,,202293.0,,,TABLET,,2020,Q1,Acute kidney injury,,2020,Q1,1,I,,20200204.0,20200213,20200213,EXP,,US-ASTRAZENECA-2020SE21156,ASTRAZENECA,,75.0,YR,,F,Y,,,20200213.0,,HP,US,US,2020,Q1,Elderly
174132031,17413203,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,D,,,,202293.0,,,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20200204.0,20200213,20200213,EXP,,US-ASTRAZENECA-2020SE21156,ASTRAZENECA,,75.0,YR,,F,Y,,,20200213.0,,HP,US,US,2020,Q1,Elderly
174134031,17413403,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,U,,,202293.0,,,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20171214.0,20200213,20200213,EXP,,GB-ASTRAZENECA-2017SF28731,ASTRAZENECA,,39.0,YR,,F,Y,,,20200213.0,,MD,GB,GB,2020,Q1,Adult
174134041,17413404,1,PS,METFORMIN/ DAPAGLIFLOZIN,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,1000MG/5MG TWO TIMES A DAY,,,Y,,,,205649.0,,,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20190318.0,20200213,20200213,EXP,,PT-ASTRAZENECA-2019SE44193,ASTRAZENECA,,46.0,YR,,F,Y,,,20200213.0,,HP,PT,PT,2020,Q1,Adult
174134051,17413405,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20180328.0,20200213,20200213,EXP,,GB-ASTRAZENECA-2018SE40319,ASTRAZENECA,,57.0,YR,,F,Y,,,20200213.0,,HP,GB,GB,2020,Q1,Adult
174134051,17413405,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20180328.0,20200213,20200213,EXP,,GB-ASTRAZENECA-2018SE40319,ASTRAZENECA,,57.0,YR,,F,Y,,,20200213.0,,HP,GB,GB,2020,Q1,Adult
174134081,17413408,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,U,,,202293.0,,,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20180523.0,20200213,20200213,EXP,,US-ASTRAZENECA-2018SE68797,ASTRAZENECA,"GAJJAR K, LUTHRA P. EUGLYCEMIC DIABETIC KETOACIDOSIS IN THE SETTING OF SGLT2 INHIBITOR USE AND HYPERTRIGLYCERIDEMIA: A CASE REPORT AND REVIEW OF LITERATURE. CUREUS 2019;11(4):E4384.",28.0,YR,,F,Y,,,20200213.0,,MD,US,US,2020,Q1,Young Adult
174134121,17413412,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,TABLET,,2020,Q1,Ketoacidosis,,2020,Q1,1,I,20160406.0,20160509.0,20200213,20200213,EXP,,GB-ASTRAZENECA-2016SE50483,ASTRAZENECA,,51.0,YR,,F,Y,73.0,KG,20200213.0,,HP,GB,GB,2020,Q1,Adult
174134141,17413414,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,U,,,202293.0,,,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20171122.0,20200213,20200213,EXP,,CA-ASTRAZENECA-2017SF19556,ASTRAZENECA,,53.0,YR,,M,Y,,,20200213.0,,MD,CA,CA,2020,Q1,Adult
174134151,17413415,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,,,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20180623.0,20200213,20200213,EXP,,KW-ASTRAZENECA-2018SE82327,ASTRAZENECA,"HUSSAIN J. A CASE OF SEVERE METABOLIC ACIDOSIS REQUIRING HEMODIALYSIS IN A PATIENT ON DAPAGLIFLOZIN. 23RD ANNUAL HEALTH SCIENCES CENTRE (HSC) POSTER CONFERENCE - KUWAIT UNIVERSITY, HEALTH SCIENCES CENTRE, FACULTY OFMEDICINE",43.0,YR,,M,Y,,,20200213.0,,HP,KW,KW,2020,Q1,Adult
174134181,17413418,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20190409.0,20200213,20200213,EXP,,IT-ASTRAZENECA-2019SE55035,ASTRAZENECA,,47.0,YR,,F,Y,,,20200213.0,,HP,IT,IT,2020,Q1,Adult
174134231,17413423,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,20180220.0,20180308.0,20200213,20200213,EXP,,GB-ASTRAZENECA-2018SE29929,ASTRAZENECA,,74.0,YR,,F,Y,68.0,KG,20200213.0,,MD,GB,GB,2020,Q1,Elderly
174134251,17413425,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Diabetic ketoacidosis,,2020,Q1,1,I,20181012.0,20181031.0,20200213,20200213,EXP,,GB-ASTRAZENECA-2018SF43381,ASTRAZENECA,,60.0,YR,,F,Y,,,20200213.0,,,GB,GB,2020,Q1,Adult
174134271,17413427,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20180414.0,20200213,20200213,EXP,,AU-ASTRAZENECA-2018SE52151,ASTRAZENECA,,54.0,YR,,F,Y,,,20200213.0,,HP,AU,AU,2020,Q1,Adult
174134281,17413428,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,U,,,202293.0,,,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20180523.0,20200213,20200213,EXP,,US-ASTRAZENECA-2018SE68800,ASTRAZENECA,"MARK ALEGRIA R. A CASE REPORT ON EUGLYCEMIC DIABETIC KETOACIDOSIS IN A PATIENT WITH TYPE 2 DIABETES ON DAPAGLIFLOZIN, KETOGENIC DIET AND INTERMITTENT FASTING. 27TH ANNUAL SCIENTIFIC AND CLINICAL CONGRESS OF THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS (AACE) 2018;",35.0,YR,,M,Y,,,20200213.0,,HP,US,US,2020,Q1,Adult
174134291,17413429,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20190306.0,20200213,20200213,EXP,,US-ASTRAZENECA-2019SE37764,ASTRAZENECA,PARKER A. EUGLYCEMIC DIABETIC KETOACIDOSIS (DKA) IN A PATIENT TAKING DAPAGLIFLOZIN AFTER STARTING A KETOGENIC DIET. 2018 MIDYEAR CLINICAL MEETING OF THE AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS (ASHP) 2018;6-137.,48.0,YR,,F,Y,,,20200213.0,,HP,US,US,2020,Q1,Adult
174134311,17413431,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Subcutaneous,5.0MG UNKNOWN,,,Y,U,,,202293.0,5.0,MG,TABLET,,2020,Q1,Depressed level of consciousness,,2020,Q1,1,I,20190127.0,20190212.0,20200213,20200213,EXP,,GB-ASTRAZENECA-2019SE25140,ASTRAZENECA,,64.0,YR,,F,Y,98.4,KG,20200213.0,,,GB,GB,2020,Q1,Adult
174134311,17413431,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Subcutaneous,5.0MG UNKNOWN,,,Y,U,,,202293.0,5.0,MG,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,20190127.0,20190212.0,20200213,20200213,EXP,,GB-ASTRAZENECA-2019SE25140,ASTRAZENECA,,64.0,YR,,F,Y,98.4,KG,20200213.0,,,GB,GB,2020,Q1,Adult
174134331,17413433,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20181224.0,20200213,20200213,EXP,,PT-ASTRAZENECA-2018SF70946,ASTRAZENECA,,51.0,YR,,F,Y,,,20200213.0,,HP,PT,PT,2020,Q1,Adult
174134351,17413435,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20190318.0,20200213,20200213,EXP,,PT-ASTRAZENECA-2019SE44457,ASTRAZENECA,,48.0,YR,,M,Y,,,20200213.0,,HP,PT,PT,2020,Q1,Adult
174134401,17413440,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20190410.0,20200213,20200213,EXP,,TW-ASTRAZENECA-2019SE55136,ASTRAZENECA,,60.0,YR,,F,Y,,,20200213.0,,HP,TW,TW,2020,Q1,Adult
174134401,17413440,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Off label use,,2020,Q1,1,I,,20190410.0,20200213,20200213,EXP,,TW-ASTRAZENECA-2019SE55136,ASTRAZENECA,,60.0,YR,,F,Y,,,20200213.0,,HP,TW,TW,2020,Q1,Adult
174134401,17413440,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Product use in unapproved indication,,2020,Q1,1,I,,20190410.0,20200213,20200213,EXP,,TW-ASTRAZENECA-2019SE55136,ASTRAZENECA,,60.0,YR,,F,Y,,,20200213.0,,HP,TW,TW,2020,Q1,Adult
174134411,17413441,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,10.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,20190128.0,20190402.0,20200213,20200213,EXP,,GB-ASTRAZENECA-2019SE51167,ASTRAZENECA,,64.0,YR,,F,Y,,,20200213.0,,HP,GB,GB,2020,Q1,Adult
174134421,17413442,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,202293.0,10.0,MG,TABLET,,2020,Q1,Dehydration,,2020,Q1,1,I,20150317.0,20160505.0,20200213,20200213,EXP,,QA-ASTRAZENECA-2016SE49357,ASTRAZENECA,,18322.0,DY,,M,Y,70.0,KG,20200213.0,,MD,QA,QA,2020,Q1,Elderly
174134421,17413442,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,202293.0,10.0,MG,TABLET,,2020,Q1,Ketoacidosis,,2020,Q1,1,I,20150317.0,20160505.0,20200213,20200213,EXP,,QA-ASTRAZENECA-2016SE49357,ASTRAZENECA,,18322.0,DY,,M,Y,70.0,KG,20200213.0,,MD,QA,QA,2020,Q1,Elderly
174134461,17413446,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,U,,,202293.0,,,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20180517.0,20200213,20200213,EXP,,GR-ASTRAZENECA-2018SE67407,ASTRAZENECA,,73.0,YR,,M,Y,,,20200213.0,,HP,GR,GR,2020,Q1,Elderly
174134471,17413447,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20180927.0,20200213,20200213,EXP,,PT-ASTRAZENECA-2018SF25493,ASTRAZENECA,,51.0,YR,,F,Y,,,20200213.0,,HP,PT,PT,2020,Q1,Adult
174134531,17413453,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20180625.0,20200213,20200213,EXP,,AU-ASTRAZENECA-2018SE84948,ASTRAZENECA,,66.0,YR,,F,Y,,,20200213.0,,MD,AU,AU,2020,Q1,Elderly
174134591,17413459,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,,,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20180214.0,20200213,20200213,EXP,,GB-ASTRAZENECA-2018SE20923,ASTRAZENECA,,50.0,YR,,F,Y,,,20200213.0,,MD,GB,GB,2020,Q1,Adult
174134601,17413460,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,D,,,,202293.0,10.0,MG,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20180308.0,20200213,20200213,EXP,,GB-ASTRAZENECA-2018SE30007,ASTRAZENECA,,67.0,YR,,F,Y,68.0,KG,20200213.0,,,GB,GB,2020,Q1,Elderly
174134671,17413467,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,202293.0,,,TABLET,,2020,Q1,Diabetic ketoacidosis,,2020,Q1,1,I,20170905.0,20170916.0,20200213,20200213,EXP,,GB-ASTRAZENECA-2017SE94887,ASTRAZENECA,,52.0,YR,,M,Y,55.0,KG,20200213.0,,CN,GB,GB,2020,Q1,Adult
174134701,17413470,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,U,,,202293.0,,,,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20180927.0,20200213,20200213,EXP,,PT-ASTRAZENECA-2018SF25494,ASTRAZENECA,,74.0,YR,,F,Y,,,20200213.0,,HP,PT,PT,2020,Q1,Elderly
174134701,17413470,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,U,,,202293.0,,,,,2020,Q1,Urosepsis,,2020,Q1,1,I,,20180927.0,20200213,20200213,EXP,,PT-ASTRAZENECA-2018SF25494,ASTRAZENECA,,74.0,YR,,F,Y,,,20200213.0,,HP,PT,PT,2020,Q1,Elderly
174134741,17413474,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,U,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20190410.0,20200213,20200213,EXP,,TW-ASTRAZENECA-2019SE55153,ASTRAZENECA,,63.0,YR,,F,Y,,,20200213.0,,HP,TW,TW,2020,Q1,Adult
174134861,17413486,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,,,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20181128.0,20200213,20200213,EXP,,US-ASTRAZENECA-2018SF55949,ASTRAZENECA,,75.0,YR,,M,Y,,,20200213.0,,HP,US,US,2020,Q1,Elderly
174134881,17413488,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,U,,,202293.0,10.0,MG,TABLET,,2020,Q1,Diabetes mellitus inadequate control,,2020,Q1,1,I,20160929.0,20161014.0,20200213,20200213,EXP,,GB-ASTRAZENECA-2016SF09109,ASTRAZENECA,,43.0,YR,,F,Y,,,20200213.0,,MD,GB,GB,2020,Q1,Adult
174134881,17413488,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,U,,,202293.0,10.0,MG,TABLET,,2020,Q1,Diabetic ketoacidosis,,2020,Q1,1,I,20160929.0,20161014.0,20200213,20200213,EXP,,GB-ASTRAZENECA-2016SF09109,ASTRAZENECA,,43.0,YR,,F,Y,,,20200213.0,,MD,GB,GB,2020,Q1,Adult
174134881,17413488,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,U,,,202293.0,10.0,MG,TABLET,,2020,Q1,Urosepsis,,2020,Q1,1,I,20160929.0,20161014.0,20200213,20200213,EXP,,GB-ASTRAZENECA-2016SF09109,ASTRAZENECA,,43.0,YR,,F,Y,,,20200213.0,,MD,GB,GB,2020,Q1,Adult
174138111,17413811,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,,,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20191125.0,20200213,20200213,EXP,,GB-ASTRAZENECA-2019SF69364,ASTRAZENECA,,63.0,YR,,F,Y,,,20200213.0,,,GB,GB,2020,Q1,Adult
174138121,17413812,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20190610.0,20200213,20200213,EXP,,AU-ASTRAZENECA-2019SE86485,ASTRAZENECA,,64.0,YR,,F,Y,,,20200213.0,,HP,AU,AU,2020,Q1,Adult
174138151,17413815,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MG EACH MORNING,,,Y,,,,,,,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20191017.0,20200213,20200213,EXP,,GB-ASTRAZENECA-2019SF47884,ASTRAZENECA,,46.0,YR,,F,Y,,,20200213.0,,,GB,GB,2020,Q1,Adult
174138171,17413817,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,,,,202293.0,10.0,MG,TABLET,,2020,Q1,Diabetic ketoacidosis,,2020,Q1,1,I,2018.0,20191021.0,20200213,20200213,EXP,,ES-ASTRAZENECA-2019SF50994,ASTRAZENECA,,58.0,YR,,M,Y,,,20200213.0,,HP,ES,ES,2020,Q1,Adult
174138201,17413820,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,N,,,,,10.0,MG,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,20190125.0,20190814.0,20200213,20200213,EXP,,DE-ASTRAZENECA-2019SF16938,ASTRAZENECA,,33.0,YR,,F,Y,120.0,KG,20200213.0,,MD,DE,DE,2020,Q1,Young Adult
174138211,17413821,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20190914.0,20200213,20200213,EXP,,KR-ASTRAZENECA-2019SF31785,ASTRAZENECA,,76.0,YR,,F,Y,,,20200213.0,,HP,KR,KR,2020,Q1,Elderly
174138231,17413823,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,,,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20191024.0,20200213,20200213,EXP,,GB-ASTRAZENECA-2019SF52577,ASTRAZENECA,TOAL M. EUGLYCAEMIC DIABETIC KETOACIDOSIS IN TYPE 2 DIABETES: A RARE COMPLICATION OF SGLT-2 INHIBITORS. 52ND ANNUAL MEETING AND EXPOSITION OF THE AMERICAN SOCIETY OF NEPHROLOGY (ASN): KIDNEY WEEK 2019;SA-PO386.,81.0,YR,,F,Y,,,20200213.0,,HP,GB,GB,2020,Q1,Elderly
174138241,17413824,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,20190527.0,20190624.0,20200213,20200213,EXP,,GB-ASTRAZENECA-2019SE90993,ASTRAZENECA,,60.0,YR,,F,Y,82.0,KG,20200213.0,,,GB,GB,2020,Q1,Adult
174138271,17413827,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,3655.0,MG,Y,,,,202293.0,5.0,MG,TABLET,QD,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,2018.0,20190502.0,20200213,20200213,EXP,,IT-ASTRAZENECA-2019SE67532,ASTRAZENECA,,50.0,YR,,F,Y,,,20200213.0,,HP,IT,IT,2020,Q1,Adult
174138301,17413830,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20191024.0,20200213,20200213,EXP,,GB-ASTRAZENECA-2019SF52077,ASTRAZENECA,,51.0,YR,,F,Y,83.0,KG,20200213.0,,HP,GB,GB,2020,Q1,Adult
174138301,17413830,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20191024.0,20200213,20200213,EXP,,GB-ASTRAZENECA-2019SF52077,ASTRAZENECA,,51.0,YR,,F,Y,83.0,KG,20200213.0,,HP,GB,GB,2020,Q1,Adult
174138321,17413832,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,U,,,202293.0,,,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20190519.0,20200213,20200213,EXP,,US-ASTRAZENECA-2019SE76441,ASTRAZENECA,,51.0,YR,,F,Y,,,20200213.0,,HP,US,US,2020,Q1,Adult
174138351,17413835,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,202293.0,,,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20190412.0,20200213,20200213,EXP,,US-ASTRAZENECA-2019SE57612,ASTRAZENECA,,52.0,YR,,F,Y,,,20200213.0,,MD,US,US,2020,Q1,Adult
174138381,17413838,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,,,,202293.0,10.0,MG,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,20191103.0,20191121.0,20200213,20200213,EXP,,IE-ASTRAZENECA-2019SF67360,ASTRAZENECA,,58.0,YR,,F,Y,66.0,KG,20200213.0,,PH,IE,IE,2020,Q1,Adult
174138381,17413838,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,,,,202293.0,10.0,MG,TABLET,,2020,Q1,Fournier's gangrene,,2020,Q1,1,I,20191103.0,20191121.0,20200213,20200213,EXP,,IE-ASTRAZENECA-2019SF67360,ASTRAZENECA,,58.0,YR,,F,Y,66.0,KG,20200213.0,,PH,IE,IE,2020,Q1,Adult
174138411,17413841,1,PS,DAPAGLIFLOZIN/METFORMIN XR,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,"10/2000 MG ONCE DAILY (DURATION UNKNOWN),",,,Y,,,,205649.0,,,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20190514.0,20200213,20200213,EXP,,US-ASTRAZENECA-2019SE72545,ASTRAZENECA,,55.0,YR,,F,Y,,,20200213.0,,HP,US,US,2020,Q1,Adult
174138421,17413842,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,U,,,202293.0,,,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20190418.0,20200213,20200213,EXP,,AU-ASTRAZENECA-2019SE59742,ASTRAZENECA,,44.0,YR,,M,Y,,,20200213.0,,HP,AU,AU,2020,Q1,Adult
174138431,17413843,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20190618.0,20200213,20200213,EXP,,GR-ASTRAZENECA-2019SE90883,ASTRAZENECA,,77.0,YR,,M,Y,,,20200213.0,,MD,GR,GR,2020,Q1,Elderly
174138471,17413847,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,,10.0,MG,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,20191105.0,20191203.0,20200213,20200213,EXP,,GB-ASTRAZENECA-2019SF74017,ASTRAZENECA,,53.0,YR,,F,Y,,,20200213.0,,,GB,GB,2020,Q1,Adult
174138511,17413851,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,2.0,DF,TABLET,QD,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20190801.0,20200213,20200213,EXP,,TR-ASTRAZENECA-2019SF11094,ASTRAZENECA,ARAC E. PROLONGED DIABETIC KETOACIDOSIS ASSOCIATED WITH DAPAGLIFLOZIN: A CASE REPORT. 1ST INTERNATIONAL AHI MEDICAL AND HEALTH SCIENCE CONGRESS (IAMHC) - ANNAJAH NATIONAL UNIVERSITY (DENIZLI; TURKEY) 2019;,54.0,YR,,F,Y,,,20200213.0,,HP,TR,TR,2020,Q1,Adult
174138571,17413857,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,3655.0,MG,U,,,,202293.0,5.0,MG,TABLET,QD,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,20191125.0,20191203.0,20200213,20200213,EXP,,DE-ASTRAZENECA-2019SF74047,ASTRAZENECA,,62.0,YR,,M,Y,93.0,KG,20200213.0,,MD,DE,DE,2020,Q1,Adult
174160091,17416009,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20181031.0,20200213,20200213,EXP,,TR-ASTRAZENECA-2018SF42909,ASTRAZENECA,,72.0,YR,,F,Y,,,20200213.0,,HP,TR,TR,2020,Q1,Elderly
174195402,17419540,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY; MORNING,,,,, UNKNOWN,,,10.0,MG,,QD,2020,Q1,Abdominal distension,,2020,Q1,2,F,20200124.0,20200220.0,20200214,20200228,EXP,GB-MHRA-EYC 00217369,GB-TEVA-2020-GB-1185716,TEVA,,61.0,YR,,F,Y,,,20200228.0,,PH,GB,GB,2020,Q1,Adult
174195402,17419540,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY; MORNING,,,,, UNKNOWN,,,10.0,MG,,QD,2020,Q1,Chronic obstructive pulmonary disease,,2020,Q1,2,F,20200124.0,20200220.0,20200214,20200228,EXP,GB-MHRA-EYC 00217369,GB-TEVA-2020-GB-1185716,TEVA,,61.0,YR,,F,Y,,,20200228.0,,PH,GB,GB,2020,Q1,Adult
174195402,17419540,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY; MORNING,,,,, UNKNOWN,,,10.0,MG,,QD,2020,Q1,Coeliac disease,,2020,Q1,2,F,20200124.0,20200220.0,20200214,20200228,EXP,GB-MHRA-EYC 00217369,GB-TEVA-2020-GB-1185716,TEVA,,61.0,YR,,F,Y,,,20200228.0,,PH,GB,GB,2020,Q1,Adult
174195402,17419540,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY; MORNING,,,,, UNKNOWN,,,10.0,MG,,QD,2020,Q1,Diabetes mellitus,,2020,Q1,2,F,20200124.0,20200220.0,20200214,20200228,EXP,GB-MHRA-EYC 00217369,GB-TEVA-2020-GB-1185716,TEVA,,61.0,YR,,F,Y,,,20200228.0,,PH,GB,GB,2020,Q1,Adult
174195402,17419540,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY; MORNING,,,,, UNKNOWN,,,10.0,MG,,QD,2020,Q1,Diarrhoea,,2020,Q1,2,F,20200124.0,20200220.0,20200214,20200228,EXP,GB-MHRA-EYC 00217369,GB-TEVA-2020-GB-1185716,TEVA,,61.0,YR,,F,Y,,,20200228.0,,PH,GB,GB,2020,Q1,Adult
174195402,17419540,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY; MORNING,,,,, UNKNOWN,,,10.0,MG,,QD,2020,Q1,Hypotension,,2020,Q1,2,F,20200124.0,20200220.0,20200214,20200228,EXP,GB-MHRA-EYC 00217369,GB-TEVA-2020-GB-1185716,TEVA,,61.0,YR,,F,Y,,,20200228.0,,PH,GB,GB,2020,Q1,Adult
174195402,17419540,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY; MORNING,,,,, UNKNOWN,,,10.0,MG,,QD,2020,Q1,Hypothermia,,2020,Q1,2,F,20200124.0,20200220.0,20200214,20200228,EXP,GB-MHRA-EYC 00217369,GB-TEVA-2020-GB-1185716,TEVA,,61.0,YR,,F,Y,,,20200228.0,,PH,GB,GB,2020,Q1,Adult
174195402,17419540,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY; MORNING,,,,, UNKNOWN,,,10.0,MG,,QD,2020,Q1,Lactic acidosis,,2020,Q1,2,F,20200124.0,20200220.0,20200214,20200228,EXP,GB-MHRA-EYC 00217369,GB-TEVA-2020-GB-1185716,TEVA,,61.0,YR,,F,Y,,,20200228.0,,PH,GB,GB,2020,Q1,Adult
174195402,17419540,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY; MORNING,,,,, UNKNOWN,,,10.0,MG,,QD,2020,Q1,Multiple organ dysfunction syndrome,,2020,Q1,2,F,20200124.0,20200220.0,20200214,20200228,EXP,GB-MHRA-EYC 00217369,GB-TEVA-2020-GB-1185716,TEVA,,61.0,YR,,F,Y,,,20200228.0,,PH,GB,GB,2020,Q1,Adult
174195402,17419540,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY; MORNING,,,,, UNKNOWN,,,10.0,MG,,QD,2020,Q1,Schizophrenia,,2020,Q1,2,F,20200124.0,20200220.0,20200214,20200228,EXP,GB-MHRA-EYC 00217369,GB-TEVA-2020-GB-1185716,TEVA,,61.0,YR,,F,Y,,,20200228.0,,PH,GB,GB,2020,Q1,Adult
174231332,17423133,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY (MORNING)",,,D,,,,,10.0,MG,,QD,2020,Q1,Abdominal distension,,2020,Q1,2,F,20200124.0,20200215.0,20200216,20200224,EXP,,GB-AUROBINDO-AUR-APL-2020-007358,AUROBINDO,,61.0,YR,,F,Y,,,20200224.0,,PH,GB,GB,2020,Q1,Adult
174231332,17423133,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY (MORNING)",,,D,,,,,10.0,MG,,QD,2020,Q1,Chronic obstructive pulmonary disease,,2020,Q1,2,F,20200124.0,20200215.0,20200216,20200224,EXP,,GB-AUROBINDO-AUR-APL-2020-007358,AUROBINDO,,61.0,YR,,F,Y,,,20200224.0,,PH,GB,GB,2020,Q1,Adult
174231332,17423133,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY (MORNING)",,,D,,,,,10.0,MG,,QD,2020,Q1,Coeliac disease,,2020,Q1,2,F,20200124.0,20200215.0,20200216,20200224,EXP,,GB-AUROBINDO-AUR-APL-2020-007358,AUROBINDO,,61.0,YR,,F,Y,,,20200224.0,,PH,GB,GB,2020,Q1,Adult
174231332,17423133,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY (MORNING)",,,D,,,,,10.0,MG,,QD,2020,Q1,Diabetes mellitus,,2020,Q1,2,F,20200124.0,20200215.0,20200216,20200224,EXP,,GB-AUROBINDO-AUR-APL-2020-007358,AUROBINDO,,61.0,YR,,F,Y,,,20200224.0,,PH,GB,GB,2020,Q1,Adult
174231332,17423133,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY (MORNING)",,,D,,,,,10.0,MG,,QD,2020,Q1,Diarrhoea,,2020,Q1,2,F,20200124.0,20200215.0,20200216,20200224,EXP,,GB-AUROBINDO-AUR-APL-2020-007358,AUROBINDO,,61.0,YR,,F,Y,,,20200224.0,,PH,GB,GB,2020,Q1,Adult
174231332,17423133,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY (MORNING)",,,D,,,,,10.0,MG,,QD,2020,Q1,Hypotension,,2020,Q1,2,F,20200124.0,20200215.0,20200216,20200224,EXP,,GB-AUROBINDO-AUR-APL-2020-007358,AUROBINDO,,61.0,YR,,F,Y,,,20200224.0,,PH,GB,GB,2020,Q1,Adult
174231332,17423133,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY (MORNING)",,,D,,,,,10.0,MG,,QD,2020,Q1,Hypothermia,,2020,Q1,2,F,20200124.0,20200215.0,20200216,20200224,EXP,,GB-AUROBINDO-AUR-APL-2020-007358,AUROBINDO,,61.0,YR,,F,Y,,,20200224.0,,PH,GB,GB,2020,Q1,Adult
174231332,17423133,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY (MORNING)",,,D,,,,,10.0,MG,,QD,2020,Q1,Lactic acidosis,,2020,Q1,2,F,20200124.0,20200215.0,20200216,20200224,EXP,,GB-AUROBINDO-AUR-APL-2020-007358,AUROBINDO,,61.0,YR,,F,Y,,,20200224.0,,PH,GB,GB,2020,Q1,Adult
174231332,17423133,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY (MORNING)",,,D,,,,,10.0,MG,,QD,2020,Q1,Multiple organ dysfunction syndrome,,2020,Q1,2,F,20200124.0,20200215.0,20200216,20200224,EXP,,GB-AUROBINDO-AUR-APL-2020-007358,AUROBINDO,,61.0,YR,,F,Y,,,20200224.0,,PH,GB,GB,2020,Q1,Adult
174231332,17423133,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY (MORNING)",,,D,,,,,10.0,MG,,QD,2020,Q1,Schizophrenia,,2020,Q1,2,F,20200124.0,20200215.0,20200216,20200224,EXP,,GB-AUROBINDO-AUR-APL-2020-007358,AUROBINDO,,61.0,YR,,F,Y,,,20200224.0,,PH,GB,GB,2020,Q1,Adult
174232001,17423200,5,I,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q1,Contusion,,2020,Q1,1,I,20181009.0,20181023.0,20200216,20200216,EXP,,CO-ABBVIE-18K-036-3122763-00,ABBVIE,,68.0,YR,,F,Y,75.0,KG,20200216.0,,HP,CO,CO,2020,Q1,Elderly
174232001,17423200,5,I,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q1,Depressed mood,,2020,Q1,1,I,20181009.0,20181023.0,20200216,20200216,EXP,,CO-ABBVIE-18K-036-3122763-00,ABBVIE,,68.0,YR,,F,Y,75.0,KG,20200216.0,,HP,CO,CO,2020,Q1,Elderly
174232001,17423200,5,I,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q1,Diarrhoea,,2020,Q1,1,I,20181009.0,20181023.0,20200216,20200216,EXP,,CO-ABBVIE-18K-036-3122763-00,ABBVIE,,68.0,YR,,F,Y,75.0,KG,20200216.0,,HP,CO,CO,2020,Q1,Elderly
174232001,17423200,5,I,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q1,Drug interaction,,2020,Q1,1,I,20181009.0,20181023.0,20200216,20200216,EXP,,CO-ABBVIE-18K-036-3122763-00,ABBVIE,,68.0,YR,,F,Y,75.0,KG,20200216.0,,HP,CO,CO,2020,Q1,Elderly
174232001,17423200,5,I,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q1,Incorrect dose administered,,2020,Q1,1,I,20181009.0,20181023.0,20200216,20200216,EXP,,CO-ABBVIE-18K-036-3122763-00,ABBVIE,,68.0,YR,,F,Y,75.0,KG,20200216.0,,HP,CO,CO,2020,Q1,Elderly
174232001,17423200,5,I,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q1,Nail disorder,,2020,Q1,1,I,20181009.0,20181023.0,20200216,20200216,EXP,,CO-ABBVIE-18K-036-3122763-00,ABBVIE,,68.0,YR,,F,Y,75.0,KG,20200216.0,,HP,CO,CO,2020,Q1,Elderly
174232001,17423200,5,I,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q1,Off label use,,2020,Q1,1,I,20181009.0,20181023.0,20200216,20200216,EXP,,CO-ABBVIE-18K-036-3122763-00,ABBVIE,,68.0,YR,,F,Y,75.0,KG,20200216.0,,HP,CO,CO,2020,Q1,Elderly
174232001,17423200,5,I,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q1,Pain in extremity,,2020,Q1,1,I,20181009.0,20181023.0,20200216,20200216,EXP,,CO-ABBVIE-18K-036-3122763-00,ABBVIE,,68.0,YR,,F,Y,75.0,KG,20200216.0,,HP,CO,CO,2020,Q1,Elderly
174232001,17423200,5,I,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q1,Petechiae,,2020,Q1,1,I,20181009.0,20181023.0,20200216,20200216,EXP,,CO-ABBVIE-18K-036-3122763-00,ABBVIE,,68.0,YR,,F,Y,75.0,KG,20200216.0,,HP,CO,CO,2020,Q1,Elderly
174232001,17423200,5,I,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q1,Rash,,2020,Q1,1,I,20181009.0,20181023.0,20200216,20200216,EXP,,CO-ABBVIE-18K-036-3122763-00,ABBVIE,,68.0,YR,,F,Y,75.0,KG,20200216.0,,HP,CO,CO,2020,Q1,Elderly
174232001,17423200,5,I,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q1,Urinary tract infection,,2020,Q1,1,I,20181009.0,20181023.0,20200216,20200216,EXP,,CO-ABBVIE-18K-036-3122763-00,ABBVIE,,68.0,YR,,F,Y,75.0,KG,20200216.0,,HP,CO,CO,2020,Q1,Elderly
174232001,17423200,5,I,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2020,Q1,Vomiting,,2020,Q1,1,I,20181009.0,20181023.0,20200216,20200216,EXP,,CO-ABBVIE-18K-036-3122763-00,ABBVIE,,68.0,YR,,F,Y,75.0,KG,20200216.0,,HP,CO,CO,2020,Q1,Elderly
174255081,17425508,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,U, -,,202293.0,10.0,MG,TABLET,,2020,Q1,Drug interaction,,2020,Q1,1,I,20180918.0,20200212.0,20200217,20200217,EXP,,GB-ASTRAZENECA-2020SE22401,ASTRAZENECA,,61.0,YR,,F,Y,56.7,KG,20200217.0,,,GB,GB,2020,Q1,Adult
174255081,17425508,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,U, -,,202293.0,10.0,MG,TABLET,,2020,Q1,Lactic acidosis,,2020,Q1,1,I,20180918.0,20200212.0,20200217,20200217,EXP,,GB-ASTRAZENECA-2020SE22401,ASTRAZENECA,,61.0,YR,,F,Y,56.7,KG,20200217.0,,,GB,GB,2020,Q1,Adult
174260881,17426088,15,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"1 DOSAGE FORM, QD",186.042,DF,,,,,,1.0,DF,,QD,2020,Q1,Palpitations,,2020,Q1,1,I,20191203.0,20200210.0,20200217,20200217,EXP,GB-MHRA-TPP3132931C2911612YC1575536474789,GB-MYLANLABS-2020M1015862,MYLAN,,57.0,YR,,F,Y,159.0,KG,20200217.0,,HP,GB,GB,2020,Q1,Adult
174285173,17428517,2,SS,DAPAGLIFLOZIN/DAPAGLIFLOZIN,DAPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2020,Q1,Abdominal distension,,2020,Q1,3,F,20200124.0,20200220.0,20200218,20200228,EXP,GB-MHRA-EYC 00217369,GB-EMD SERONO-E2B_90074912,EMD SERONO INC,,61.0,YR,,F,Y,,,20200228.0,,PH,GB,GB,2020,Q1,Adult
174285173,17428517,2,SS,DAPAGLIFLOZIN/DAPAGLIFLOZIN,DAPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2020,Q1,Chronic obstructive pulmonary disease,,2020,Q1,3,F,20200124.0,20200220.0,20200218,20200228,EXP,GB-MHRA-EYC 00217369,GB-EMD SERONO-E2B_90074912,EMD SERONO INC,,61.0,YR,,F,Y,,,20200228.0,,PH,GB,GB,2020,Q1,Adult
174285173,17428517,2,SS,DAPAGLIFLOZIN/DAPAGLIFLOZIN,DAPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2020,Q1,Coeliac disease,,2020,Q1,3,F,20200124.0,20200220.0,20200218,20200228,EXP,GB-MHRA-EYC 00217369,GB-EMD SERONO-E2B_90074912,EMD SERONO INC,,61.0,YR,,F,Y,,,20200228.0,,PH,GB,GB,2020,Q1,Adult
174285173,17428517,2,SS,DAPAGLIFLOZIN/DAPAGLIFLOZIN,DAPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2020,Q1,Diabetes mellitus,,2020,Q1,3,F,20200124.0,20200220.0,20200218,20200228,EXP,GB-MHRA-EYC 00217369,GB-EMD SERONO-E2B_90074912,EMD SERONO INC,,61.0,YR,,F,Y,,,20200228.0,,PH,GB,GB,2020,Q1,Adult
174285173,17428517,2,SS,DAPAGLIFLOZIN/DAPAGLIFLOZIN,DAPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2020,Q1,Diarrhoea,,2020,Q1,3,F,20200124.0,20200220.0,20200218,20200228,EXP,GB-MHRA-EYC 00217369,GB-EMD SERONO-E2B_90074912,EMD SERONO INC,,61.0,YR,,F,Y,,,20200228.0,,PH,GB,GB,2020,Q1,Adult
174285173,17428517,2,SS,DAPAGLIFLOZIN/DAPAGLIFLOZIN,DAPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2020,Q1,Hypotension,,2020,Q1,3,F,20200124.0,20200220.0,20200218,20200228,EXP,GB-MHRA-EYC 00217369,GB-EMD SERONO-E2B_90074912,EMD SERONO INC,,61.0,YR,,F,Y,,,20200228.0,,PH,GB,GB,2020,Q1,Adult
174285173,17428517,2,SS,DAPAGLIFLOZIN/DAPAGLIFLOZIN,DAPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2020,Q1,Hypothermia,,2020,Q1,3,F,20200124.0,20200220.0,20200218,20200228,EXP,GB-MHRA-EYC 00217369,GB-EMD SERONO-E2B_90074912,EMD SERONO INC,,61.0,YR,,F,Y,,,20200228.0,,PH,GB,GB,2020,Q1,Adult
174285173,17428517,2,SS,DAPAGLIFLOZIN/DAPAGLIFLOZIN,DAPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2020,Q1,Lactic acidosis,,2020,Q1,3,F,20200124.0,20200220.0,20200218,20200228,EXP,GB-MHRA-EYC 00217369,GB-EMD SERONO-E2B_90074912,EMD SERONO INC,,61.0,YR,,F,Y,,,20200228.0,,PH,GB,GB,2020,Q1,Adult
174285173,17428517,2,SS,DAPAGLIFLOZIN/DAPAGLIFLOZIN,DAPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2020,Q1,Multiple organ dysfunction syndrome,,2020,Q1,3,F,20200124.0,20200220.0,20200218,20200228,EXP,GB-MHRA-EYC 00217369,GB-EMD SERONO-E2B_90074912,EMD SERONO INC,,61.0,YR,,F,Y,,,20200228.0,,PH,GB,GB,2020,Q1,Adult
174285173,17428517,2,SS,DAPAGLIFLOZIN/DAPAGLIFLOZIN,DAPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2020,Q1,Schizophrenia,,2020,Q1,3,F,20200124.0,20200220.0,20200218,20200228,EXP,GB-MHRA-EYC 00217369,GB-EMD SERONO-E2B_90074912,EMD SERONO INC,,61.0,YR,,F,Y,,,20200228.0,,PH,GB,GB,2020,Q1,Adult
174293231,17429323,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Diabetic ketoacidosis,,2020,Q1,1,I,,20200209.0,20200218,20200218,EXP,,AU-ASTRAZENECA-2020SE22770,ASTRAZENECA,,61.0,YR,,M,Y,,,20200218.0,,HP,AU,AU,2020,Q1,Adult
174328852,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q1,Arthralgia,,2020,Q1,2,F,2019.0,20200212.0,20200219,20200220,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200220.0,,CN,US,US,2020,Q1,Elderly
174328852,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q1,Atrial fibrillation,,2020,Q1,2,F,2019.0,20200212.0,20200219,20200220,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200220.0,,CN,US,US,2020,Q1,Elderly
174328852,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q1,Blood cholesterol increased,,2020,Q1,2,F,2019.0,20200212.0,20200219,20200220,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200220.0,,CN,US,US,2020,Q1,Elderly
174328852,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q1,Cardiac pacemaker insertion,,2020,Q1,2,F,2019.0,20200212.0,20200219,20200220,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200220.0,,CN,US,US,2020,Q1,Elderly
174328852,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q1,Chronic obstructive pulmonary disease,,2020,Q1,2,F,2019.0,20200212.0,20200219,20200220,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200220.0,,CN,US,US,2020,Q1,Elderly
174328852,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q1,Diabetic neuropathy,,2020,Q1,2,F,2019.0,20200212.0,20200219,20200220,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200220.0,,CN,US,US,2020,Q1,Elderly
174328852,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q1,Flushing,,2020,Q1,2,F,2019.0,20200212.0,20200219,20200220,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200220.0,,CN,US,US,2020,Q1,Elderly
174328852,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q1,Gastrooesophageal reflux disease,,2020,Q1,2,F,2019.0,20200212.0,20200219,20200220,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200220.0,,CN,US,US,2020,Q1,Elderly
174328852,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q1,Hypertension,,2020,Q1,2,F,2019.0,20200212.0,20200219,20200220,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200220.0,,CN,US,US,2020,Q1,Elderly
174328852,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q1,Infection,,2020,Q1,2,F,2019.0,20200212.0,20200219,20200220,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200220.0,,CN,US,US,2020,Q1,Elderly
174328852,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q1,Mobility decreased,,2020,Q1,2,F,2019.0,20200212.0,20200219,20200220,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200220.0,,CN,US,US,2020,Q1,Elderly
174328852,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q1,Pain,,2020,Q1,2,F,2019.0,20200212.0,20200219,20200220,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200220.0,,CN,US,US,2020,Q1,Elderly
174328852,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q1,Pyrexia,,2020,Q1,2,F,2019.0,20200212.0,20200219,20200220,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200220.0,,CN,US,US,2020,Q1,Elderly
174328852,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q1,Sleep apnoea syndrome,,2020,Q1,2,F,2019.0,20200212.0,20200219,20200220,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200220.0,,CN,US,US,2020,Q1,Elderly
174328852,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q1,Systemic inflammatory response syndrome,,2020,Q1,2,F,2019.0,20200212.0,20200219,20200220,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200220.0,,CN,US,US,2020,Q1,Elderly
174328852,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q1,Tachycardia,,2020,Q1,2,F,2019.0,20200212.0,20200219,20200220,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200220.0,,CN,US,US,2020,Q1,Elderly
174328852,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q1,Type 1 diabetes mellitus,,2020,Q1,2,F,2019.0,20200212.0,20200219,20200220,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200220.0,,CN,US,US,2020,Q1,Elderly
174328852,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q1,Viral infection,,2020,Q1,2,F,2019.0,20200212.0,20200219,20200220,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200220.0,,CN,US,US,2020,Q1,Elderly
174335191,17433519,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MG,,,U,, -,,,10.0,MG,TABLET,,2020,Q1,Drug interaction,,2020,Q1,1,I,20180918.0,20200213.0,20200219,20200219,EXP,GB-MHRA-EYC 00217500,GB-TEVA-2020-GB-1187520,TEVA,,61.0,YR,,F,Y,56.69,KG,20200219.0,,CN,GB,GB,2020,Q1,Adult
174335191,17433519,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MG,,,U,, -,,,10.0,MG,TABLET,,2020,Q1,Lactic acidosis,,2020,Q1,1,I,20180918.0,20200213.0,20200219,20200219,EXP,GB-MHRA-EYC 00217500,GB-TEVA-2020-GB-1187520,TEVA,,61.0,YR,,F,Y,56.69,KG,20200219.0,,CN,GB,GB,2020,Q1,Adult
174351681,17435168,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,TABLET,QD,2020,Q1,Diabetic ketoacidosis,,2020,Q1,1,I,20200126.0,20200211.0,20200219,20200219,EXP,,GB-ASTRAZENECA-2020SE21672,ASTRAZENECA,,53.0,YR,,F,Y,,,20200219.0,,PH,GB,GB,2020,Q1,Adult
174370891,17437089,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2020,Q1,Immune-mediated hepatitis,,2020,Q1,1,I,,20200211.0,20200219,20200219,EXP,,CA-TEVA-2020-CA-1185668,TEVA,,65.0,YR,,M,Y,,,20200219.0,,MD,CA,CA,2020,Q1,Elderly
174375421,17437542,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,Y,,,,,10.0,MG,,QD,2020,Q1,Diabetes mellitus inadequate control,,2020,Q1,1,I,2019.0,20200207.0,20200219,20200219,EXP,,PL-BAUSCH-BL-2020-004341,BAUSCH AND LOMB,"I K, UNKNOWN. WHEN DIABETES AND TUBERCULOSIS GO HAND IN HAND. DIABETOLOGIA PO DYPLOMIE. 2019;1:1-8.",62.0,YR,,M,Y,81.0,KG,20200219.0,,HP,PL,PL,2020,Q1,Adult
174375421,17437542,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,Y,,,,,10.0,MG,,QD,2020,Q1,Hyperglycaemia,,2020,Q1,1,I,2019.0,20200207.0,20200219,20200219,EXP,,PL-BAUSCH-BL-2020-004341,BAUSCH AND LOMB,"I K, UNKNOWN. WHEN DIABETES AND TUBERCULOSIS GO HAND IN HAND. DIABETOLOGIA PO DYPLOMIE. 2019;1:1-8.",62.0,YR,,M,Y,81.0,KG,20200219.0,,HP,PL,PL,2020,Q1,Adult
174375421,17437542,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,Y,,,,,10.0,MG,,QD,2020,Q1,Tuberculosis,,2020,Q1,1,I,2019.0,20200207.0,20200219,20200219,EXP,,PL-BAUSCH-BL-2020-004341,BAUSCH AND LOMB,"I K, UNKNOWN. WHEN DIABETES AND TUBERCULOSIS GO HAND IN HAND. DIABETOLOGIA PO DYPLOMIE. 2019;1:1-8.",62.0,YR,,M,Y,81.0,KG,20200219.0,,HP,PL,PL,2020,Q1,Adult
174378881,17437888,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,106.041664,DF,,,,,,1.0,DF,,QD,2020,Q1,Confusional state,,2020,Q1,1,I,20200129.0,20200213.0,20200219,20200219,EXP,GB-MHRA-TPP26641640C957746YC1580286106588,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-12-008551",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,78.0,KG,20200220.0,,MD,GB,GB,2020,Q1,Elderly
174378881,17437888,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,106.041664,DF,,,,,,1.0,DF,,QD,2020,Q1,Feeling abnormal,,2020,Q1,1,I,20200129.0,20200213.0,20200219,20200219,EXP,GB-MHRA-TPP26641640C957746YC1580286106588,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-12-008551",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,78.0,KG,20200220.0,,MD,GB,GB,2020,Q1,Elderly
174378881,17437888,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,106.041664,DF,,,,,,1.0,DF,,QD,2020,Q1,Skin discolouration,,2020,Q1,1,I,20200129.0,20200213.0,20200219,20200219,EXP,GB-MHRA-TPP26641640C957746YC1580286106588,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-12-008551",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,78.0,KG,20200220.0,,MD,GB,GB,2020,Q1,Elderly
174378881,17437888,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,106.041664,DF,,,,,,1.0,DF,,QD,2020,Q1,Visual impairment,,2020,Q1,1,I,20200129.0,20200213.0,20200219,20200219,EXP,GB-MHRA-TPP26641640C957746YC1580286106588,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-12-008551",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,78.0,KG,20200220.0,,MD,GB,GB,2020,Q1,Elderly
174386281,17438628,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,TABLET,,2020,Q1,Drug interaction,,2020,Q1,1,I,20180918.0,20200210.0,20200220,20200220,EXP,GB-MHRA-ADR 24472272,GB-EMCURE PHARMACEUTICALS LTD-2020-EPL-0175,EMCURE,,61.0,YR,,F,Y,56.69,KG,20200220.0,,CN,GB,GB,2020,Q1,Adult
174386281,17438628,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,TABLET,,2020,Q1,Lactic acidosis,,2020,Q1,1,I,20180918.0,20200210.0,20200220,20200220,EXP,GB-MHRA-ADR 24472272,GB-EMCURE PHARMACEUTICALS LTD-2020-EPL-0175,EMCURE,,61.0,YR,,F,Y,56.69,KG,20200220.0,,CN,GB,GB,2020,Q1,Adult
174419261,17441926,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,TABLET,,2020,Q1,Drug interaction,,2020,Q1,1,I,20180918.0,20200210.0,20200220,20200220,EXP,GB-MHRA-EYC 00217500,GB-BAUSCH-BL-2020-004613,BAUSCH AND LOMB,,61.0,YR,,F,Y,56.69,KG,20200220.0,,CN,GB,GB,2020,Q1,Adult
174419261,17441926,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,TABLET,,2020,Q1,Lactic acidosis,,2020,Q1,1,I,20180918.0,20200210.0,20200220,20200220,EXP,GB-MHRA-EYC 00217500,GB-BAUSCH-BL-2020-004613,BAUSCH AND LOMB,,61.0,YR,,F,Y,56.69,KG,20200220.0,,CN,GB,GB,2020,Q1,Adult
174463731,17446373,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2020,Q1,Drug interaction,,2020,Q1,1,I,20180918.0,20200213.0,20200221,20200221,EXP,GB-MHRA-EYC 00217500,GB-EMD SERONO-E2B_90075028,EMD SERONO INC,,61.0,YR,,F,Y,57.0,KG,20200221.0,,CN,GB,GB,2020,Q1,Adult
174463731,17446373,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2020,Q1,Lactic acidosis,,2020,Q1,1,I,20180918.0,20200213.0,20200221,20200221,EXP,GB-MHRA-EYC 00217500,GB-EMD SERONO-E2B_90075028,EMD SERONO INC,,61.0,YR,,F,Y,57.0,KG,20200221.0,,CN,GB,GB,2020,Q1,Adult
174519941,17451994,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20200214.0,20200224,20200224,EXP,,GB-ASTRAZENECA-2020SE23667,ASTRAZENECA,,57.0,YR,,F,Y,,,20200224.0,,HP,GB,GB,2020,Q1,Adult
174660051,17466005,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,4730.417,MG,N,, UNKNOWN,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Scrotal abscess,,2020,Q1,1,I,20200209.0,20200221.0,20200227,20200227,EXP,,GB-ASTRAZENECA-2020SE26200,ASTRAZENECA,,53.0,YR,,M,Y,75.0,KG,20200227.0,,PH,GB,GB,2020,Q1,Adult
174660851,17466085,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,,,,202293.0,10.0,MG,TABLET,,2020,Q1,Joint swelling,,2020,Q1,1,I,20200206.0,20200219.0,20200227,20200227,EXP,,GB-ASTRAZENECA-2020SE24986,ASTRAZENECA,,66.0,YR,,F,Y,82.0,KG,20200227.0,,MD,GB,GB,2020,Q1,Elderly
174660851,17466085,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,,,,202293.0,10.0,MG,TABLET,,2020,Q1,Palpitations,,2020,Q1,1,I,20200206.0,20200219.0,20200227,20200227,EXP,,GB-ASTRAZENECA-2020SE24986,ASTRAZENECA,,66.0,YR,,F,Y,82.0,KG,20200227.0,,MD,GB,GB,2020,Q1,Elderly
174695121,17469512,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,MORNING,,,N,,,,,10.0,MG,,QD,2020,Q1,Abdominal distension,,2020,Q1,1,I,20200124.0,20200217.0,20200227,20200227,EXP,GB-MHRA-EYC 00217369,GB-BAUSCH-BL-2020-005267,BAUSCH AND LOMB,,61.0,YR,,F,Y,,,20200227.0,,PH,GB,GB,2020,Q1,Adult
174695121,17469512,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,MORNING,,,N,,,,,10.0,MG,,QD,2020,Q1,Chronic obstructive pulmonary disease,,2020,Q1,1,I,20200124.0,20200217.0,20200227,20200227,EXP,GB-MHRA-EYC 00217369,GB-BAUSCH-BL-2020-005267,BAUSCH AND LOMB,,61.0,YR,,F,Y,,,20200227.0,,PH,GB,GB,2020,Q1,Adult
174695121,17469512,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,MORNING,,,N,,,,,10.0,MG,,QD,2020,Q1,Coeliac disease,,2020,Q1,1,I,20200124.0,20200217.0,20200227,20200227,EXP,GB-MHRA-EYC 00217369,GB-BAUSCH-BL-2020-005267,BAUSCH AND LOMB,,61.0,YR,,F,Y,,,20200227.0,,PH,GB,GB,2020,Q1,Adult
174695121,17469512,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,MORNING,,,N,,,,,10.0,MG,,QD,2020,Q1,Diabetes mellitus,,2020,Q1,1,I,20200124.0,20200217.0,20200227,20200227,EXP,GB-MHRA-EYC 00217369,GB-BAUSCH-BL-2020-005267,BAUSCH AND LOMB,,61.0,YR,,F,Y,,,20200227.0,,PH,GB,GB,2020,Q1,Adult
174695121,17469512,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,MORNING,,,N,,,,,10.0,MG,,QD,2020,Q1,Diarrhoea,,2020,Q1,1,I,20200124.0,20200217.0,20200227,20200227,EXP,GB-MHRA-EYC 00217369,GB-BAUSCH-BL-2020-005267,BAUSCH AND LOMB,,61.0,YR,,F,Y,,,20200227.0,,PH,GB,GB,2020,Q1,Adult
174695121,17469512,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,MORNING,,,N,,,,,10.0,MG,,QD,2020,Q1,Hypotension,,2020,Q1,1,I,20200124.0,20200217.0,20200227,20200227,EXP,GB-MHRA-EYC 00217369,GB-BAUSCH-BL-2020-005267,BAUSCH AND LOMB,,61.0,YR,,F,Y,,,20200227.0,,PH,GB,GB,2020,Q1,Adult
174695121,17469512,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,MORNING,,,N,,,,,10.0,MG,,QD,2020,Q1,Hypothermia,,2020,Q1,1,I,20200124.0,20200217.0,20200227,20200227,EXP,GB-MHRA-EYC 00217369,GB-BAUSCH-BL-2020-005267,BAUSCH AND LOMB,,61.0,YR,,F,Y,,,20200227.0,,PH,GB,GB,2020,Q1,Adult
174695121,17469512,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,MORNING,,,N,,,,,10.0,MG,,QD,2020,Q1,Lactic acidosis,,2020,Q1,1,I,20200124.0,20200217.0,20200227,20200227,EXP,GB-MHRA-EYC 00217369,GB-BAUSCH-BL-2020-005267,BAUSCH AND LOMB,,61.0,YR,,F,Y,,,20200227.0,,PH,GB,GB,2020,Q1,Adult
174695121,17469512,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,MORNING,,,N,,,,,10.0,MG,,QD,2020,Q1,Multiple organ dysfunction syndrome,,2020,Q1,1,I,20200124.0,20200217.0,20200227,20200227,EXP,GB-MHRA-EYC 00217369,GB-BAUSCH-BL-2020-005267,BAUSCH AND LOMB,,61.0,YR,,F,Y,,,20200227.0,,PH,GB,GB,2020,Q1,Adult
174695121,17469512,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,MORNING,,,N,,,,,10.0,MG,,QD,2020,Q1,Schizophrenia,,2020,Q1,1,I,20200124.0,20200217.0,20200227,20200227,EXP,GB-MHRA-EYC 00217369,GB-BAUSCH-BL-2020-005267,BAUSCH AND LOMB,,61.0,YR,,F,Y,,,20200227.0,,PH,GB,GB,2020,Q1,Adult
174719992,17471999,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY IN THE MORNING,3650.0,MG,,,,,,10.0,MG,,,2020,Q1,Abdominal distension,,2020,Q1,2,F,20200124.0,20200305.0,20200228,20200318,EXP,GB-MHRA-ADR 24471535,GB-EMCURE PHARMACEUTICALS LTD-2020-EPL-000228,EMCURE,,61.0,YR,,F,Y,,,20200318.0,,PH,GB,GB,2020,Q1,Adult
174719992,17471999,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY IN THE MORNING,3650.0,MG,,,,,,10.0,MG,,,2020,Q1,Diarrhoea,,2020,Q1,2,F,20200124.0,20200305.0,20200228,20200318,EXP,GB-MHRA-ADR 24471535,GB-EMCURE PHARMACEUTICALS LTD-2020-EPL-000228,EMCURE,,61.0,YR,,F,Y,,,20200318.0,,PH,GB,GB,2020,Q1,Adult
174719992,17471999,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY IN THE MORNING,3650.0,MG,,,,,,10.0,MG,,,2020,Q1,Hypotension,,2020,Q1,2,F,20200124.0,20200305.0,20200228,20200318,EXP,GB-MHRA-ADR 24471535,GB-EMCURE PHARMACEUTICALS LTD-2020-EPL-000228,EMCURE,,61.0,YR,,F,Y,,,20200318.0,,PH,GB,GB,2020,Q1,Adult
174719992,17471999,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY IN THE MORNING,3650.0,MG,,,,,,10.0,MG,,,2020,Q1,Hypothermia,,2020,Q1,2,F,20200124.0,20200305.0,20200228,20200318,EXP,GB-MHRA-ADR 24471535,GB-EMCURE PHARMACEUTICALS LTD-2020-EPL-000228,EMCURE,,61.0,YR,,F,Y,,,20200318.0,,PH,GB,GB,2020,Q1,Adult
174719992,17471999,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY IN THE MORNING,3650.0,MG,,,,,,10.0,MG,,,2020,Q1,Lactic acidosis,,2020,Q1,2,F,20200124.0,20200305.0,20200228,20200318,EXP,GB-MHRA-ADR 24471535,GB-EMCURE PHARMACEUTICALS LTD-2020-EPL-000228,EMCURE,,61.0,YR,,F,Y,,,20200318.0,,PH,GB,GB,2020,Q1,Adult
174719992,17471999,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY IN THE MORNING,3650.0,MG,,,,,,10.0,MG,,,2020,Q1,Multiple organ dysfunction syndrome,,2020,Q1,2,F,20200124.0,20200305.0,20200228,20200318,EXP,GB-MHRA-ADR 24471535,GB-EMCURE PHARMACEUTICALS LTD-2020-EPL-000228,EMCURE,,61.0,YR,,F,Y,,,20200318.0,,PH,GB,GB,2020,Q1,Adult
174746711,17474671,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2020,Q1,Drug interaction,,2020,Q1,1,I,,20200221.0,20200228,20200228,EXP,,PL-MYLANLABS-2020M1022630,MYLAN,,51.0,YR,,F,Y,,,20200228.0,,HP,PL,PL,2020,Q1,Adult
174746711,17474671,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2020,Q1,Granulocytopenia,,2020,Q1,1,I,,20200221.0,20200228,20200228,EXP,,PL-MYLANLABS-2020M1022630,MYLAN,,51.0,YR,,F,Y,,,20200228.0,,HP,PL,PL,2020,Q1,Adult
174748431,17474843,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2020,Q1,Diabetes mellitus inadequate control,,2020,Q1,1,I,,20200220.0,20200228,20200228,EXP,,PL-EMD SERONO-E2B_90075332,EMD SERONO INC,KORZENIEWSKA-DYL I. WHEN DIABETES AND TUBERCULOSIS GO HAND IN HAND. DIABETOLOGIA PO DYPLOMIE. 2019;1:1-8.,62.0,YR,,M,Y,81.0,KG,20200228.0,,HP,PL,PL,2020,Q1,Adult
174748431,17474843,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2020,Q1,Tuberculosis,,2020,Q1,1,I,,20200220.0,20200228,20200228,EXP,,PL-EMD SERONO-E2B_90075332,EMD SERONO INC,KORZENIEWSKA-DYL I. WHEN DIABETES AND TUBERCULOSIS GO HAND IN HAND. DIABETOLOGIA PO DYPLOMIE. 2019;1:1-8.,62.0,YR,,M,Y,81.0,KG,20200228.0,,HP,PL,PL,2020,Q1,Adult
174786221,17478622,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1220.0,MG,,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Pancreatitis acute,,2020,Q1,1,I,201809.0,20200220.0,20200228,20200228,EXP,,US-ASTRAZENECA-2020SE26367,ASTRAZENECA,BRIM P.,50.0,YR,,M,Y,,,20200228.0,,HP,US,US,2020,Q1,Adult
174789131,17478913,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q1,Diabetic ketoacidosis,,2020,Q1,1,I,20180824.0,20191108.0,20200228,20200228,EXP,,GB-JNJFOC-20191114475,JOHNSON AND JOHNSON,,67.0,YR,,M,Y,127.5,KG,20200228.0,,HP,GB,GB,2020,Q1,Elderly
174789131,17478913,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q1,Sepsis,,2020,Q1,1,I,20180824.0,20191108.0,20200228,20200228,EXP,,GB-JNJFOC-20191114475,JOHNSON AND JOHNSON,,67.0,YR,,M,Y,127.5,KG,20200228.0,,HP,GB,GB,2020,Q1,Elderly
174814093,17481409,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q1,Blood pressure increased,,2020,Q1,3,F,,20200320.0,20200302,20200324,EXP,,RU-EMD SERONO-9148635,EMD SERONO INC,"PRIVACY P, PRIVACY P, PRIVACY P. COMPLEX NEUROMETABOLIC THERAPY POTENTIAL FOR COMORBID PATIENTS WITH CHRONIC CEREBRAL ISCHEMIA. NERVOUS DISEASES. 2019;4:16-19. DOI:10.24411/2226- 0757-2019-12131",65.0,YR,,F,Y,78.0,KG,20200324.0,,MD,RU,RU,2020,Q1,Elderly
174814093,17481409,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q1,Chest discomfort,,2020,Q1,3,F,,20200320.0,20200302,20200324,EXP,,RU-EMD SERONO-9148635,EMD SERONO INC,"PRIVACY P, PRIVACY P, PRIVACY P. COMPLEX NEUROMETABOLIC THERAPY POTENTIAL FOR COMORBID PATIENTS WITH CHRONIC CEREBRAL ISCHEMIA. NERVOUS DISEASES. 2019;4:16-19. DOI:10.24411/2226- 0757-2019-12131",65.0,YR,,F,Y,78.0,KG,20200324.0,,MD,RU,RU,2020,Q1,Elderly
174814093,17481409,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q1,Dyspnoea,,2020,Q1,3,F,,20200320.0,20200302,20200324,EXP,,RU-EMD SERONO-9148635,EMD SERONO INC,"PRIVACY P, PRIVACY P, PRIVACY P. COMPLEX NEUROMETABOLIC THERAPY POTENTIAL FOR COMORBID PATIENTS WITH CHRONIC CEREBRAL ISCHEMIA. NERVOUS DISEASES. 2019;4:16-19. DOI:10.24411/2226- 0757-2019-12131",65.0,YR,,F,Y,78.0,KG,20200324.0,,MD,RU,RU,2020,Q1,Elderly
174860142,17486014,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,U,, UNKNOWN,,,10.0,MG,,QD,2020,Q1,Diabetes mellitus inadequate control,,2020,Q1,2,F,,20200305.0,20200303,20200317,EXP,PL-EMA-DD-20200214-GONUGUNTLA_N1-134423,PL-LUPIN PHARMACEUTICALS INC.-2020-01113,LUPIN,,62.0,YR,,M,Y,81.0,KG,20200317.0,,CN,GB,PL,2020,Q1,Adult
174860142,17486014,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,U,, UNKNOWN,,,10.0,MG,,QD,2020,Q1,Pulmonary tuberculosis,,2020,Q1,2,F,,20200305.0,20200303,20200317,EXP,PL-EMA-DD-20200214-GONUGUNTLA_N1-134423,PL-LUPIN PHARMACEUTICALS INC.-2020-01113,LUPIN,,62.0,YR,,M,Y,81.0,KG,20200317.0,,CN,GB,PL,2020,Q1,Adult
175022621,17502262,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20200225.0,20200305,20200305,EXP,,GB-ASTRAZENECA-2020SE27961,ASTRAZENECA,,69.0,YR,,M,Y,,,20200305.0,,HP,GB,GB,2020,Q1,Elderly
175022631,17502263,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,,10.0,MG,TABLET,,2020,Q1,Diabetic ketoacidosis,,2020,Q1,1,I,20200109.0,20200302.0,20200305,20200305,EXP,,GB-ASTRAZENECA-2020SE30646,ASTRAZENECA,,65.0,YR,,F,Y,,,20200305.0,,,GB,GB,2020,Q1,Elderly
175032641,17503264,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2020,Q1,Immune-mediated hepatitis,,2020,Q1,1,I,,20200228.0,20200305,20200305,EXP,,CA-CELGENEUS-CAN-20200300168,CELGENE,,65.0,YR,,M,Y,,,20200305.0,,MD,CA,CA,2020,Q1,Elderly
175082981,17508298,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q1,Bradycardia,,2020,Q1,1,I,,20200221.0,20200306,20200306,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-239576,RANBAXY,,55.0,YR,,F,Y,,,20200306.0,,HP,PL,PL,2020,Q1,Adult
175082981,17508298,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q1,Dizziness,,2020,Q1,1,I,,20200221.0,20200306,20200306,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-239576,RANBAXY,,55.0,YR,,F,Y,,,20200306.0,,HP,PL,PL,2020,Q1,Adult
175082981,17508298,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q1,Drug interaction,,2020,Q1,1,I,,20200221.0,20200306,20200306,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-239576,RANBAXY,,55.0,YR,,F,Y,,,20200306.0,,HP,PL,PL,2020,Q1,Adult
175082981,17508298,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q1,Drug level increased,,2020,Q1,1,I,,20200221.0,20200306,20200306,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-239576,RANBAXY,,55.0,YR,,F,Y,,,20200306.0,,HP,PL,PL,2020,Q1,Adult
175082981,17508298,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q1,Hypotension,,2020,Q1,1,I,,20200221.0,20200306,20200306,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-239576,RANBAXY,,55.0,YR,,F,Y,,,20200306.0,,HP,PL,PL,2020,Q1,Adult
175091181,17509118,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Drug interaction,,2020,Q1,1,I,,20200228.0,20200306,20200306,EXP,,GB-ASTRAZENECA-2020SE30799,ASTRAZENECA,,76.0,YR,,M,Y,101.0,KG,20200306.0,,,GB,GB,2020,Q1,Elderly
175091181,17509118,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,International normalised ratio increased,,2020,Q1,1,I,,20200228.0,20200306,20200306,EXP,,GB-ASTRAZENECA-2020SE30799,ASTRAZENECA,,76.0,YR,,M,Y,101.0,KG,20200306.0,,,GB,GB,2020,Q1,Elderly
175104221,17510422,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2020,Q1,Drug interaction,,2020,Q1,1,I,,20200221.0,20200306,20200306,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-239582,RANBAXY,,51.0,YR,,F,Y,,,20200306.0,,HP,PL,PL,2020,Q1,Adult
175104221,17510422,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2020,Q1,Drug level increased,,2020,Q1,1,I,,20200221.0,20200306,20200306,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-239582,RANBAXY,,51.0,YR,,F,Y,,,20200306.0,,HP,PL,PL,2020,Q1,Adult
175104221,17510422,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2020,Q1,Granulocytopenia,,2020,Q1,1,I,,20200221.0,20200306,20200306,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-239582,RANBAXY,,51.0,YR,,F,Y,,,20200306.0,,HP,PL,PL,2020,Q1,Adult
175113981,17511398,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, 1 DAY",,,,,,,,,,,,2020,Q1,Drug interaction,,2020,Q1,1,I,,20200226.0,20200306,20200306,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-016835,BRISTOL MYERS SQUIBB,,76.0,YR,,M,Y,101.0,KG,20200306.0,,MD,GB,GB,2020,Q1,Elderly
175113981,17511398,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, 1 DAY",,,,,,,,,,,,2020,Q1,International normalised ratio increased,,2020,Q1,1,I,,20200226.0,20200306,20200306,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-016835,BRISTOL MYERS SQUIBB,,76.0,YR,,M,Y,101.0,KG,20200306.0,,MD,GB,GB,2020,Q1,Elderly
175159912,17515991,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,MORNING,,,N,,,,,10.0,MG,,QD,2020,Q1,Abdominal distension,,2020,Q1,2,F,20200124.0,20200307.0,20200309,20200316,EXP,GB-MHRA-EYC 00217369,GB-MYLANLABS-2020M1025526,MYLAN,,61.0,YR,,F,Y,,,20200316.0,,PH,GB,GB,2020,Q1,Adult
175159912,17515991,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,MORNING,,,N,,,,,10.0,MG,,QD,2020,Q1,Chronic obstructive pulmonary disease,,2020,Q1,2,F,20200124.0,20200307.0,20200309,20200316,EXP,GB-MHRA-EYC 00217369,GB-MYLANLABS-2020M1025526,MYLAN,,61.0,YR,,F,Y,,,20200316.0,,PH,GB,GB,2020,Q1,Adult
175159912,17515991,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,MORNING,,,N,,,,,10.0,MG,,QD,2020,Q1,Coeliac disease,,2020,Q1,2,F,20200124.0,20200307.0,20200309,20200316,EXP,GB-MHRA-EYC 00217369,GB-MYLANLABS-2020M1025526,MYLAN,,61.0,YR,,F,Y,,,20200316.0,,PH,GB,GB,2020,Q1,Adult
175159912,17515991,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,MORNING,,,N,,,,,10.0,MG,,QD,2020,Q1,Diabetes mellitus,,2020,Q1,2,F,20200124.0,20200307.0,20200309,20200316,EXP,GB-MHRA-EYC 00217369,GB-MYLANLABS-2020M1025526,MYLAN,,61.0,YR,,F,Y,,,20200316.0,,PH,GB,GB,2020,Q1,Adult
175159912,17515991,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,MORNING,,,N,,,,,10.0,MG,,QD,2020,Q1,Diarrhoea,,2020,Q1,2,F,20200124.0,20200307.0,20200309,20200316,EXP,GB-MHRA-EYC 00217369,GB-MYLANLABS-2020M1025526,MYLAN,,61.0,YR,,F,Y,,,20200316.0,,PH,GB,GB,2020,Q1,Adult
175159912,17515991,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,MORNING,,,N,,,,,10.0,MG,,QD,2020,Q1,Hypotension,,2020,Q1,2,F,20200124.0,20200307.0,20200309,20200316,EXP,GB-MHRA-EYC 00217369,GB-MYLANLABS-2020M1025526,MYLAN,,61.0,YR,,F,Y,,,20200316.0,,PH,GB,GB,2020,Q1,Adult
175159912,17515991,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,MORNING,,,N,,,,,10.0,MG,,QD,2020,Q1,Hypothermia,,2020,Q1,2,F,20200124.0,20200307.0,20200309,20200316,EXP,GB-MHRA-EYC 00217369,GB-MYLANLABS-2020M1025526,MYLAN,,61.0,YR,,F,Y,,,20200316.0,,PH,GB,GB,2020,Q1,Adult
175159912,17515991,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,MORNING,,,N,,,,,10.0,MG,,QD,2020,Q1,Lactic acidosis,,2020,Q1,2,F,20200124.0,20200307.0,20200309,20200316,EXP,GB-MHRA-EYC 00217369,GB-MYLANLABS-2020M1025526,MYLAN,,61.0,YR,,F,Y,,,20200316.0,,PH,GB,GB,2020,Q1,Adult
175159912,17515991,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,MORNING,,,N,,,,,10.0,MG,,QD,2020,Q1,Multiple organ dysfunction syndrome,,2020,Q1,2,F,20200124.0,20200307.0,20200309,20200316,EXP,GB-MHRA-EYC 00217369,GB-MYLANLABS-2020M1025526,MYLAN,,61.0,YR,,F,Y,,,20200316.0,,PH,GB,GB,2020,Q1,Adult
175159912,17515991,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,MORNING,,,N,,,,,10.0,MG,,QD,2020,Q1,Schizophrenia,,2020,Q1,2,F,20200124.0,20200307.0,20200309,20200316,EXP,GB-MHRA-EYC 00217369,GB-MYLANLABS-2020M1025526,MYLAN,,61.0,YR,,F,Y,,,20200316.0,,PH,GB,GB,2020,Q1,Adult
175171371,17517137,1,PS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,1220.0,MG,,, UNKNOWN,,,10.0,MG,TABLET,QD,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,20200214.0,20200302.0,20200309,20200309,EXP,,NL-ASTRAZENECA-2020SE30626,ASTRAZENECA,,39.0,YR,,F,Y,,,20200309.0,,MD,NL,NL,2020,Q1,Adult
175171531,17517153,1,PS,DAPAGLFLZIE (DAPAGLIFLOZIN),DAPAGLIFLOZIN,1,Oral,,690.0,MG,,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Ketoacidosis,,2020,Q1,1,I,20200218.0,20200303.0,20200309,20200309,EXP,,NL-ASTRAZENECA-2020SE31966,ASTRAZENECA,,59.0,YR,,F,Y,75.0,KG,20200309.0,,MD,NL,NL,2020,Q1,Adult
175194461,17519446,3,C,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2020,Q1,Acute myocardial infarction,,2020,Q1,1,I,20200105.0,20200302.0,20200310,20200310,EXP,GB-MHRA-EYC 00216076,GB-TEVA-2020-GB-1195673,TEVA,,55.0,YR,,M,Y,,,20200310.0,,PH,GB,GB,2020,Q1,Adult
175194461,17519446,3,C,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2020,Q1,Loss of consciousness,,2020,Q1,1,I,20200105.0,20200302.0,20200310,20200310,EXP,GB-MHRA-EYC 00216076,GB-TEVA-2020-GB-1195673,TEVA,,55.0,YR,,M,Y,,,20200310.0,,PH,GB,GB,2020,Q1,Adult
175194501,17519450,3,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,D,,,,,10.0,MG,,QD,2020,Q1,Acute myocardial infarction,,2020,Q1,1,I,20200105.0,20200227.0,20200310,20200310,EXP,,GB-AUROBINDO-AUR-APL-2020-011508,AUROBINDO,,55.0,YR,,M,Y,,,20200310.0,,PH,GB,GB,2020,Q1,Adult
175194501,17519450,3,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,D,,,,,10.0,MG,,QD,2020,Q1,Loss of consciousness,,2020,Q1,1,I,20200105.0,20200227.0,20200310,20200310,EXP,,GB-AUROBINDO-AUR-APL-2020-011508,AUROBINDO,,55.0,YR,,M,Y,,,20200310.0,,PH,GB,GB,2020,Q1,Adult
175195971,17519597,16,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"1 DF, QD",186.042,DF,U,,,,,1.0,DF,,QD,2020,Q1,Palpitations,,2020,Q1,1,I,20191203.0,20200306.0,20200309,20200309,EXP,GB-MHRA-TPP3132931C2911612YC1575536474789,NVSC2020GB065044,NOVARTIS,,57.0,YR,,F,Y,159.0,KG,20200309.0,,HP,GB,GB,2020,Q1,Adult
175213681,17521368,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,,10.0,MG,TABLET,,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,,20200304.0,20200310,20200310,EXP,,GB-ASTRAZENECA-2020SE32876,ASTRAZENECA,,66.0,YR,,F,Y,,,20200310.0,,PH,GB,GB,2020,Q1,Elderly
175213691,17521369,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,TABLET,QD,2020,Q1,Euglycaemic diabetic ketoacidosis,,2020,Q1,1,I,20200121.0,20200304.0,20200310,20200310,EXP,,GB-ASTRAZENECA-2020SE32947,ASTRAZENECA,,58.0,YR,,F,Y,63.0,KG,20200310.0,,PH,GB,GB,2020,Q1,Adult
175234611,17523461,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"UNK UNK, QD",29.0,DF,,,,,,,,TABLET,QD,2020,Q1,Cholestasis,,2020,Q1,1,I,20200116.0,20200304.0,20200310,20200310,EXP,GB-MHRA-TPP48274730C6769893YC1582113327863,GB-TAKEDA-2020TEU002563,TAKEDA,,60.0,YR,,M,Y,78.0,KG,20200310.0,,HP,GB,GB,2020,Q1,Adult
175234611,17523461,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"UNK UNK, QD",29.0,DF,,,,,,,,TABLET,QD,2020,Q1,Liver function test abnormal,,2020,Q1,1,I,20200116.0,20200304.0,20200310,20200310,EXP,GB-MHRA-TPP48274730C6769893YC1582113327863,GB-TAKEDA-2020TEU002563,TAKEDA,,60.0,YR,,M,Y,78.0,KG,20200310.0,,HP,GB,GB,2020,Q1,Adult
175259461,17525946,2,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,"10 MG, DAILY",,,Y,,,,,10.0,MG,,QD,2020,Q1,Diabetic ketoacidosis,,2020,Q1,1,I,20200124.0,20200305.0,20200310,20200310,EXP,GB-MHRA-EYC 00219110,GB-ELI_LILLY_AND_COMPANY-GB202003003120,ELI LILLY AND CO,,78.0,YR,,F,Y,64.41,KG,20200310.0,,HP,GB,GB,2020,Q1,Elderly
175294841,17529484,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,D,,,,,10.0,MG,TABLET,,2020,Q1,Drug interaction,,2020,Q1,1,I,20180918.0,20200305.0,20200311,20200311,EXP,GB-MHRA-EYC 00217500,GB-MYLANLABS-2020M1026206,MYLAN,,61.0,YR,,F,Y,56.69,KG,20200311.0,,CN,GB,GB,2020,Q1,Adult
175294841,17529484,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,D,,,,,10.0,MG,TABLET,,2020,Q1,Lactic acidosis,,2020,Q1,1,I,20180918.0,20200305.0,20200311,20200311,EXP,GB-MHRA-EYC 00217500,GB-MYLANLABS-2020M1026206,MYLAN,,61.0,YR,,F,Y,56.69,KG,20200311.0,,CN,GB,GB,2020,Q1,Adult
175364161,17536416,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2020,Q1,Bradycardia,,2020,Q1,1,I,,20200302.0,20200313,20200313,EXP,,PL-AUROBINDO-AUR-APL-2020-012367,AUROBINDO,,55.0,YR,,F,Y,,,20200313.0,,HP,PL,PL,2020,Q1,Adult
175364161,17536416,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2020,Q1,Dizziness,,2020,Q1,1,I,,20200302.0,20200313,20200313,EXP,,PL-AUROBINDO-AUR-APL-2020-012367,AUROBINDO,,55.0,YR,,F,Y,,,20200313.0,,HP,PL,PL,2020,Q1,Adult
175364161,17536416,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2020,Q1,Drug interaction,,2020,Q1,1,I,,20200302.0,20200313,20200313,EXP,,PL-AUROBINDO-AUR-APL-2020-012367,AUROBINDO,,55.0,YR,,F,Y,,,20200313.0,,HP,PL,PL,2020,Q1,Adult
175364161,17536416,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2020,Q1,Hypotension,,2020,Q1,1,I,,20200302.0,20200313,20200313,EXP,,PL-AUROBINDO-AUR-APL-2020-012367,AUROBINDO,,55.0,YR,,F,Y,,,20200313.0,,HP,PL,PL,2020,Q1,Adult
175364161,17536416,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2020,Q1,Toxicity to various agents,,2020,Q1,1,I,,20200302.0,20200313,20200313,EXP,,PL-AUROBINDO-AUR-APL-2020-012367,AUROBINDO,,55.0,YR,,F,Y,,,20200313.0,,HP,PL,PL,2020,Q1,Adult
175380921,17538092,3,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, DAILY",,,,,,,,10.0,MG,,,2020,Q1,Acute myocardial infarction,,2020,Q1,1,I,20200105.0,20200311.0,20200313,20200313,EXP,GB-MHRA-EYC 00216076,GB-PFIZER INC-2020107671,PFIZER,,55.0,YR,,M,Y,,,20200313.0,,PH,GB,GB,2020,Q1,Adult
175380921,17538092,3,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MG, DAILY",,,,,,,,10.0,MG,,,2020,Q1,Loss of consciousness,,2020,Q1,1,I,20200105.0,20200311.0,20200313,20200313,EXP,GB-MHRA-EYC 00216076,GB-PFIZER INC-2020107671,PFIZER,,55.0,YR,,M,Y,,,20200313.0,,PH,GB,GB,2020,Q1,Adult
175393121,17539312,3,C,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,10.0,MG,,,2020,Q1,Acute myocardial infarction,,2020,Q1,1,I,20200105.0,20200303.0,20200313,20200313,EXP,GB-MHRA-EYC 00216076,GB-TORRENT-00023078,TORRENT,,55.0,YR,A,M,Y,,,20200313.0,,PH,GB,GB,2020,Q1,Adult
175393121,17539312,3,C,DAPAGLIFLOZIN PROPANEDIOL.,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,10.0,MG,,,2020,Q1,Loss of consciousness,,2020,Q1,1,I,20200105.0,20200303.0,20200313,20200313,EXP,GB-MHRA-EYC 00216076,GB-TORRENT-00023078,TORRENT,,55.0,YR,A,M,Y,,,20200313.0,,PH,GB,GB,2020,Q1,Adult
175434212,17543421,2,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE;METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,DAILY DOSE: 2 DF DOSAGE FORM EVERY DAYS 2 SEPARATED DOSES?5MG/1000MG,,,Y,,,,,2.0,DF,,BID,2020,Q1,Acute kidney injury,,2020,Q1,2,F,20200122.0,20200323.0,20200316,20200326,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-12-014462",BOEHRINGER INGELHEIM,,73.0,YR,,M,Y,80.0,KG,20200326.0,,MD,DE,DE,2020,Q1,Elderly
175434212,17543421,2,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE;METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,DAILY DOSE: 2 DF DOSAGE FORM EVERY DAYS 2 SEPARATED DOSES?5MG/1000MG,,,Y,,,,,2.0,DF,,BID,2020,Q1,Duplicate therapy error,,2020,Q1,2,F,20200122.0,20200323.0,20200316,20200326,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-12-014462",BOEHRINGER INGELHEIM,,73.0,YR,,M,Y,80.0,KG,20200326.0,,MD,DE,DE,2020,Q1,Elderly
175434212,17543421,2,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE;METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,DAILY DOSE: 2 DF DOSAGE FORM EVERY DAYS 2 SEPARATED DOSES?5MG/1000MG,,,Y,,,,,2.0,DF,,BID,2020,Q1,Ketoacidosis,,2020,Q1,2,F,20200122.0,20200323.0,20200316,20200326,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-12-014462",BOEHRINGER INGELHEIM,,73.0,YR,,M,Y,80.0,KG,20200326.0,,MD,DE,DE,2020,Q1,Elderly
175434212,17543421,2,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE;METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,DAILY DOSE: 2 DF DOSAGE FORM EVERY DAYS 2 SEPARATED DOSES?5MG/1000MG,,,Y,,,,,2.0,DF,,BID,2020,Q1,Lactic acidosis,,2020,Q1,2,F,20200122.0,20200323.0,20200316,20200326,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-12-014462",BOEHRINGER INGELHEIM,,73.0,YR,,M,Y,80.0,KG,20200326.0,,MD,DE,DE,2020,Q1,Elderly
175434212,17543421,2,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE;METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,DAILY DOSE: 2 DF DOSAGE FORM EVERY DAYS 2 SEPARATED DOSES?5MG/1000MG,,,Y,,,,,2.0,DF,,BID,2020,Q1,Polyuria,,2020,Q1,2,F,20200122.0,20200323.0,20200316,20200326,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-12-014462",BOEHRINGER INGELHEIM,,73.0,YR,,M,Y,80.0,KG,20200326.0,,MD,DE,DE,2020,Q1,Elderly
175434212,17543421,2,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE;METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,DAILY DOSE: 2 DF DOSAGE FORM EVERY DAYS 2 SEPARATED DOSES?5MG/1000MG,,,Y,,,,,2.0,DF,,BID,2020,Q1,Product prescribing error,,2020,Q1,2,F,20200122.0,20200323.0,20200316,20200326,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-12-014462",BOEHRINGER INGELHEIM,,73.0,YR,,M,Y,80.0,KG,20200326.0,,MD,DE,DE,2020,Q1,Elderly
175469632,17546963,2,C,DAPA [DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE],,2,,MORE THAN ONE YEAR OD,,,,, UNKNOWN,,,,,,,2020,Q1,Myocardial infarction,,2020,Q1,2,F,20200126.0,20200318.0,20200316,20200327,EXP,,PK-NOVOPROD-718224,NOVO NORDISK,,60.0,YR,,F,Y,80.0,KG,20200327.0,,CN,PK,PK,2020,Q1,Adult
175504871,17550487,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,,10.0,MG,TABLET,,2020,Q1,Diabetic ketoacidosis,,2020,Q1,1,I,,20200311.0,20200317,20200317,EXP,,GB-ASTRAZENECA-2020SE37129,ASTRAZENECA,,50.0,YR,,F,Y,,,20200317.0,,HP,GB,GB,2020,Q1,Adult
175508891,17550889,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,Y,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Pancreatitis acute,,2020,Q1,1,I,,20200312.0,20200317,20200317,EXP,,US-ASTRAZENECA-2020SE37489,ASTRAZENECA,,51.0,YR,,M,Y,,,20200317.0,,HP,US,US,2020,Q1,Adult
175508891,17550889,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MG,,,Y,Y,,,202293.0,,,TABLET,,2020,Q1,Pancreatitis acute,,2020,Q1,1,I,,20200312.0,20200317,20200317,EXP,,US-ASTRAZENECA-2020SE37489,ASTRAZENECA,,51.0,YR,,M,Y,,,20200317.0,,HP,US,US,2020,Q1,Adult
175524192,17552419,1,PS,DAPAGLIFLOZIN - METFORMIN,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,DAILY DOSE: 2 DF DOSAGE FORM EVERY DAYS 2 SEPARATED DOSES,,,Y,,,,205649.0,,,TABLET,,2020,Q1,Acute kidney injury,,2020,Q1,2,F,20200122.0,20200324.0,20200317,20200327,EXP,,DE-ASTRAZENECA-2020SE37636,ASTRAZENECA,,73.0,YR,,M,Y,80.0,KG,20200327.0,,MD,DE,DE,2020,Q1,Elderly
175524192,17552419,1,PS,DAPAGLIFLOZIN - METFORMIN,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,DAILY DOSE: 2 DF DOSAGE FORM EVERY DAYS 2 SEPARATED DOSES,,,Y,,,,205649.0,,,TABLET,,2020,Q1,Duplicate therapy error,,2020,Q1,2,F,20200122.0,20200324.0,20200317,20200327,EXP,,DE-ASTRAZENECA-2020SE37636,ASTRAZENECA,,73.0,YR,,M,Y,80.0,KG,20200327.0,,MD,DE,DE,2020,Q1,Elderly
175524192,17552419,1,PS,DAPAGLIFLOZIN - METFORMIN,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,DAILY DOSE: 2 DF DOSAGE FORM EVERY DAYS 2 SEPARATED DOSES,,,Y,,,,205649.0,,,TABLET,,2020,Q1,Ketoacidosis,,2020,Q1,2,F,20200122.0,20200324.0,20200317,20200327,EXP,,DE-ASTRAZENECA-2020SE37636,ASTRAZENECA,,73.0,YR,,M,Y,80.0,KG,20200327.0,,MD,DE,DE,2020,Q1,Elderly
175524192,17552419,1,PS,DAPAGLIFLOZIN - METFORMIN,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,DAILY DOSE: 2 DF DOSAGE FORM EVERY DAYS 2 SEPARATED DOSES,,,Y,,,,205649.0,,,TABLET,,2020,Q1,Lactic acidosis,,2020,Q1,2,F,20200122.0,20200324.0,20200317,20200327,EXP,,DE-ASTRAZENECA-2020SE37636,ASTRAZENECA,,73.0,YR,,M,Y,80.0,KG,20200327.0,,MD,DE,DE,2020,Q1,Elderly
175524192,17552419,1,PS,DAPAGLIFLOZIN - METFORMIN,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,DAILY DOSE: 2 DF DOSAGE FORM EVERY DAYS 2 SEPARATED DOSES,,,Y,,,,205649.0,,,TABLET,,2020,Q1,Polyuria,,2020,Q1,2,F,20200122.0,20200324.0,20200317,20200327,EXP,,DE-ASTRAZENECA-2020SE37636,ASTRAZENECA,,73.0,YR,,M,Y,80.0,KG,20200327.0,,MD,DE,DE,2020,Q1,Elderly
175524192,17552419,1,PS,DAPAGLIFLOZIN - METFORMIN,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,DAILY DOSE: 2 DF DOSAGE FORM EVERY DAYS 2 SEPARATED DOSES,,,Y,,,,205649.0,,,TABLET,,2020,Q1,Product prescribing error,,2020,Q1,2,F,20200122.0,20200324.0,20200317,20200327,EXP,,DE-ASTRAZENECA-2020SE37636,ASTRAZENECA,,73.0,YR,,M,Y,80.0,KG,20200327.0,,MD,DE,DE,2020,Q1,Elderly
175541551,17554155,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,1 DOSAGE FORMS,,,,, UNKNOWN,,,1.0,DF,,,2020,Q1,Visual acuity reduced,,2020,Q1,1,I,,20200312.0,20200318,20200318,EXP,GB-MHRA-TPP23417663C955200YC1582798187752,GB-TEVA-2020-GB-1205246,TEVA,,84.0,YR,,M,Y,85.0,KG,20200318.0,,MD,GB,GB,2020,Q1,Elderly
175573311,17557331,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,,,TABLET,,2020,Q1,Diabetic ketoacidosis,,2020,Q1,1,I,,20200313.0,20200318,20200318,EXP,,US-ASTRAZENECA-2020SE37786,ASTRAZENECA,,48.0,YR,,M,Y,,,20200318.0,,HP,US,US,2020,Q1,Adult
175573311,17557331,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,,,TABLET,,2020,Q1,Pancreatitis acute,,2020,Q1,1,I,,20200313.0,20200318,20200318,EXP,,US-ASTRAZENECA-2020SE37786,ASTRAZENECA,,48.0,YR,,M,Y,,,20200318.0,,HP,US,US,2020,Q1,Adult
175581211,17558121,2,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,UNK,,,U,U, UNK,,,,,,,2020,Q1,Diverticulum intestinal,,2020,Q1,1,I,,20200309.0,20200318,20200318,EXP,,CA-NOVOPROD-717744,NOVO NORDISK,,58.0,YR,,F,Y,,,20200318.0,,CN,CA,CA,2020,Q1,Adult
175581211,17558121,2,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,UNK,,,U,U, UNK,,,,,,,2020,Q1,Nephrolithiasis,,2020,Q1,1,I,,20200309.0,20200318,20200318,EXP,,CA-NOVOPROD-717744,NOVO NORDISK,,58.0,YR,,F,Y,,,20200318.0,,CN,CA,CA,2020,Q1,Adult
175584331,17558433,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"1 DOSAGE FORM, ONCE A DAY",,,U,,,,,1.0,DF,,QD,2020,Q1,Visual acuity reduced,,2020,Q1,1,I,,20200310.0,20200319,20200319,EXP,,GB-AUROBINDO-AUR-APL-2020-014039,AUROBINDO,,84.0,YR,,M,Y,85.0,KG,20200319.0,,MD,GB,GB,2020,Q1,Elderly
175604431,17560443,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,,10.0,MG,TABLET,,2020,Q1,Diabetic ketoacidosis,,2020,Q1,1,I,20200226.0,20200313.0,20200319,20200319,EXP,,GB-ASTRAZENECA-2020SE38544,ASTRAZENECA,,69.0,YR,,F,Y,90.0,KG,20200319.0,,,GB,GB,2020,Q1,Elderly
175643071,17564307,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,,QD,2020,Q1,Visual acuity reduced,,2020,Q1,1,I,,20200313.0,20200320,20200320,EXP,GB-MHRA-TPP23417663C955200YC1582798187752,GB-SA-2020SA066511,SANOFI AVENTIS,,84.0,YR,E,M,Y,85.0,KG,20200320.0,,MD,GB,GB,2020,Q1,Elderly
175649081,17564908,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Diabetic ketoacidosis,,2020,Q1,1,I,,20200316.0,20200320,20200320,EXP,,GB-ASTRAZENECA-2020SE38079,ASTRAZENECA,,60.0,YR,,,Y,,,20200320.0,,,GB,GB,2020,Q1,Adult
175649081,17564908,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Diarrhoea,,2020,Q1,1,I,,20200316.0,20200320,20200320,EXP,,GB-ASTRAZENECA-2020SE38079,ASTRAZENECA,,60.0,YR,,,Y,,,20200320.0,,,GB,GB,2020,Q1,Adult
175649081,17564908,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Vomiting,,2020,Q1,1,I,,20200316.0,20200320,20200320,EXP,,GB-ASTRAZENECA-2020SE38079,ASTRAZENECA,,60.0,YR,,,Y,,,20200320.0,,,GB,GB,2020,Q1,Adult
175717661,17571766,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,5.0,MG,TABLET,BID,2020,Q1,Diabetic ketoacidosis,,2020,Q1,1,I,,20200316.0,20200323,20200323,EXP,,PT-ASTRAZENECA-2020SE39557,ASTRAZENECA,,60.0,YR,,F,Y,,,20200323.0,,MD,PT,PT,2020,Q1,Adult
175731611,17573161,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,,, UNKNOWN,,,,,,,2020,Q1,Hyperglycaemia,,2020,Q1,1,I,20200206.0,20200310.0,20200323,20200323,EXP,,PK-NOVOPROD-718933,NOVO NORDISK,,71.0,YR,,M,Y,82.0,KG,20200323.0,,CN,PK,PK,2020,Q1,Elderly
175731611,17573161,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,,, UNKNOWN,,,,,,,2020,Q1,Hypertension,,2020,Q1,1,I,20200206.0,20200310.0,20200323,20200323,EXP,,PK-NOVOPROD-718933,NOVO NORDISK,,71.0,YR,,M,Y,82.0,KG,20200323.0,,CN,PK,PK,2020,Q1,Elderly
175732511,17573251,3,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2020,Q1,Acute myocardial infarction,,2020,Q1,1,I,20200105.0,20200316.0,20200323,20200323,EXP,GB-MHRA-EYC 00216076,GB-MYLANLABS-2020M1030125,MYLAN,,55.0,YR,,M,Y,,,20200323.0,,PH,GB,GB,2020,Q1,Adult
175732511,17573251,3,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2020,Q1,Loss of consciousness,,2020,Q1,1,I,20200105.0,20200316.0,20200323,20200323,EXP,GB-MHRA-EYC 00216076,GB-MYLANLABS-2020M1030125,MYLAN,,55.0,YR,,M,Y,,,20200323.0,,PH,GB,GB,2020,Q1,Adult
175766661,17576666,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2020,Q1,Drug interaction,,2020,Q1,1,I,,20200316.0,20200324,20200324,EXP,GB-MHRA-EYC 00218740,GB-MYLANLABS-2020M1030052,MYLAN,,76.0,YR,,M,Y,101.0,KG,20200324.0,,MD,GB,GB,2020,Q1,Elderly
175766661,17576666,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2020,Q1,International normalised ratio increased,,2020,Q1,1,I,,20200316.0,20200324,20200324,EXP,GB-MHRA-EYC 00218740,GB-MYLANLABS-2020M1030052,MYLAN,,76.0,YR,,M,Y,101.0,KG,20200324.0,,MD,GB,GB,2020,Q1,Elderly
175848241,17584824,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,,10.0,MG,TABLET,,2020,Q1,Diabetic ketoacidosis,,2020,Q1,1,I,20200305.0,20200320.0,20200326,20200326,EXP,,GB-ASTRAZENECA-2020SE40634,ASTRAZENECA,,35.0,YR,,M,Y,65.0,KG,20200326.0,,MD,GB,GB,2020,Q1,Adult
175920571,17592057,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,50.0,MG,U,, LF2750,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Diabetic ketosis,,2020,Q1,1,I,20200311.0,20200318.0,20200327,20200327,EXP,,CN-ASTRAZENECA-2020SE42042,ASTRAZENECA,,64.0,YR,,F,Y,56.0,KG,20200327.0,,HP,CN,CN,2020,Q1,Adult
175920571,17592057,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,50.0,MG,U,, LF2750,,202293.0,10.0,MG,TABLET,QD,2020,Q1,Diabetic ketosis,,2020,Q1,1,I,20200311.0,20200318.0,20200327,20200327,EXP,,CN-ASTRAZENECA-2020SE42042,ASTRAZENECA,,64.0,YR,,F,Y,56.0,KG,20200327.0,,HP,CN,CN,2020,Q1,Adult
176003001,17600300,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"1 DOSAGE FORM, QD",,,,,,,,1.0,DF,,QD,2020,Q1,Visual acuity reduced,,2020,Q1,1,I,,20200320.0,20200330,20200330,EXP,GB-MHRA-TPP23417663C955200YC1582798187752,GB-MYLANLABS-2020M1032573,MYLAN,,84.0,YR,,M,Y,85.0,KG,20200330.0,,MD,GB,GB,2020,Q1,Elderly
176016171,17601617,5,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,,,,,,,,,,2020,Q1,Eye movement disorder,,2020,Q1,1,I,,20200320.0,20200330,20200330,EXP,GB-MHRA-EYC 00220148,GB-NOVOPROD-719864,NOVO NORDISK,,47.0,YR,,F,Y,105.68,KG,20200330.0,,CN,GB,GB,2020,Q1,Adult
176016171,17601617,5,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,,,,,,,,,,2020,Q1,Fatigue,,2020,Q1,1,I,,20200320.0,20200330,20200330,EXP,GB-MHRA-EYC 00220148,GB-NOVOPROD-719864,NOVO NORDISK,,47.0,YR,,F,Y,105.68,KG,20200330.0,,CN,GB,GB,2020,Q1,Adult
121336523,12133652,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Transplacental,MATERNAL DOSE: 10 MG,,,,,,,,,,,,2020,Q2,Congenital hydrocephalus,,2020,Q2,3,F,,20200420.0,20160301,20200429,EXP,GB-MHRA-ADR 23357992,PHHY2016GB024615,NOVARTIS,,20.0,WK,,,Y,,,20200429.0,,HP,COUNTRY NOT SPECIFIED,GB,2020,Q2,Youth
121336523,12133652,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Transplacental,MATERNAL DOSE: 10 MG,,,,,,,,,,,,2020,Q2,Foetal exposure during pregnancy,,2020,Q2,3,F,,20200420.0,20160301,20200429,EXP,GB-MHRA-ADR 23357992,PHHY2016GB024615,NOVARTIS,,20.0,WK,,,Y,,,20200429.0,,HP,COUNTRY NOT SPECIFIED,GB,2020,Q2,Youth
121618053,12161805,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Transplacental,"10 MILLIGRAMS, UNK",,,,,,,,10.0,MG,,,2020,Q2,Congenital hydrocephalus,,2020,Q2,3,F,,20200611.0,20160309,20200625,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2016RR-112871,RANBAXY,,20.0,WK,,,Y,,,20200625.0,,HP,NL,GB,2020,Q2,Youth
146161935,14616193,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,,5.0,MG,,BID,2020,Q2,General physical health deterioration,,2020,Q2,5,F,20180213.0,20200330.0,20180309,20200401,EXP,,ES-ROCHE-2082970,ROCHE,,65.0,YR,,M,Y,93.0,KG,20200401.0,,MD,ES,ES,2020,Q2,Elderly
148713102,14871310,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,2200.0,MG,,,,,,10.0,MG,TABLET,QD,2020,Q2,Hyperkalaemia,,2020,Q2,2,F,20171230.0,20200417.0,20180509,20200424,EXP,,CA-ASTRAZENECA-2018SE58670,ASTRAZENECA,,24432.0,DY,,F,Y,,,20200424.0,,MD,CA,CA,2020,Q2,Elderly
148713102,14871310,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,2200.0,MG,,,,,,10.0,MG,TABLET,QD,2020,Q2,Hyperkalaemia,,2020,Q2,2,F,20171230.0,20200417.0,20180509,20200424,EXP,,CA-ASTRAZENECA-2018SE58670,ASTRAZENECA,,24432.0,DY,,F,Y,,,20200424.0,,MD,CA,CA,2020,Q2,Elderly
153245585,15324558,1,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,QD,2020,Q2,Decreased vibratory sense,,2020,Q2,5,F,2016.0,20200217.0,20180828,20200520,EXP,DE-EMA-DD-20180608-ISHAEVHP-143511,DE-TORRENT-00009642,TORRENT,,61.0,YR,A,F,Y,97.0,KG,20200520.0,,HP,DE,DE,2020,Q2,Adult
153245585,15324558,1,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,QD,2020,Q2,Diabetes mellitus inadequate control,,2020,Q2,5,F,2016.0,20200217.0,20180828,20200520,EXP,DE-EMA-DD-20180608-ISHAEVHP-143511,DE-TORRENT-00009642,TORRENT,,61.0,YR,A,F,Y,97.0,KG,20200520.0,,HP,DE,DE,2020,Q2,Adult
153245585,15324558,1,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,QD,2020,Q2,Gastrointestinal disorder,,2020,Q2,5,F,2016.0,20200217.0,20180828,20200520,EXP,DE-EMA-DD-20180608-ISHAEVHP-143511,DE-TORRENT-00009642,TORRENT,,61.0,YR,A,F,Y,97.0,KG,20200520.0,,HP,DE,DE,2020,Q2,Adult
153245585,15324558,1,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,QD,2020,Q2,Limb discomfort,,2020,Q2,5,F,2016.0,20200217.0,20180828,20200520,EXP,DE-EMA-DD-20180608-ISHAEVHP-143511,DE-TORRENT-00009642,TORRENT,,61.0,YR,A,F,Y,97.0,KG,20200520.0,,HP,DE,DE,2020,Q2,Adult
153245585,15324558,1,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,QD,2020,Q2,Neuropathy peripheral,,2020,Q2,5,F,2016.0,20200217.0,20180828,20200520,EXP,DE-EMA-DD-20180608-ISHAEVHP-143511,DE-TORRENT-00009642,TORRENT,,61.0,YR,A,F,Y,97.0,KG,20200520.0,,HP,DE,DE,2020,Q2,Adult
153245585,15324558,1,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,QD,2020,Q2,Pain in extremity,,2020,Q2,5,F,2016.0,20200217.0,20180828,20200520,EXP,DE-EMA-DD-20180608-ISHAEVHP-143511,DE-TORRENT-00009642,TORRENT,,61.0,YR,A,F,Y,97.0,KG,20200520.0,,HP,DE,DE,2020,Q2,Adult
153245585,15324558,1,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,QD,2020,Q2,Sensory disturbance,,2020,Q2,5,F,2016.0,20200217.0,20180828,20200520,EXP,DE-EMA-DD-20180608-ISHAEVHP-143511,DE-TORRENT-00009642,TORRENT,,61.0,YR,A,F,Y,97.0,KG,20200520.0,,HP,DE,DE,2020,Q2,Adult
153245585,15324558,1,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,QD,2020,Q2,Sleep disorder,,2020,Q2,5,F,2016.0,20200217.0,20180828,20200520,EXP,DE-EMA-DD-20180608-ISHAEVHP-143511,DE-TORRENT-00009642,TORRENT,,61.0,YR,A,F,Y,97.0,KG,20200520.0,,HP,DE,DE,2020,Q2,Adult
153245585,15324558,1,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,QD,2020,Q2,Temperature perception test abnormal,,2020,Q2,5,F,2016.0,20200217.0,20180828,20200520,EXP,DE-EMA-DD-20180608-ISHAEVHP-143511,DE-TORRENT-00009642,TORRENT,,61.0,YR,A,F,Y,97.0,KG,20200520.0,,HP,DE,DE,2020,Q2,Adult
153245585,15324558,1,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,QD,2020,Q2,Visual impairment,,2020,Q2,5,F,2016.0,20200217.0,20180828,20200520,EXP,DE-EMA-DD-20180608-ISHAEVHP-143511,DE-TORRENT-00009642,TORRENT,,61.0,YR,A,F,Y,97.0,KG,20200520.0,,HP,DE,DE,2020,Q2,Adult
155183719,15518371,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q2,Decreased vibratory sense,,2020,Q2,9,F,2016.0,20200615.0,20181017,20200622,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20200622.0,,HP,DE,DE,2020,Q2,Adult
155183719,15518371,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q2,Diabetes mellitus inadequate control,,2020,Q2,9,F,2016.0,20200615.0,20181017,20200622,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20200622.0,,HP,DE,DE,2020,Q2,Adult
155183719,15518371,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q2,Gastrointestinal disorder,,2020,Q2,9,F,2016.0,20200615.0,20181017,20200622,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20200622.0,,HP,DE,DE,2020,Q2,Adult
155183719,15518371,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q2,Limb discomfort,,2020,Q2,9,F,2016.0,20200615.0,20181017,20200622,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20200622.0,,HP,DE,DE,2020,Q2,Adult
155183719,15518371,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q2,Neuropathy peripheral,,2020,Q2,9,F,2016.0,20200615.0,20181017,20200622,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20200622.0,,HP,DE,DE,2020,Q2,Adult
155183719,15518371,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q2,Pain in extremity,,2020,Q2,9,F,2016.0,20200615.0,20181017,20200622,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20200622.0,,HP,DE,DE,2020,Q2,Adult
155183719,15518371,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q2,Sensory disturbance,,2020,Q2,9,F,2016.0,20200615.0,20181017,20200622,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20200622.0,,HP,DE,DE,2020,Q2,Adult
155183719,15518371,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q2,Sleep disorder,,2020,Q2,9,F,2016.0,20200615.0,20181017,20200622,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20200622.0,,HP,DE,DE,2020,Q2,Adult
155183719,15518371,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q2,Temperature perception test abnormal,,2020,Q2,9,F,2016.0,20200615.0,20181017,20200622,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20200622.0,,HP,DE,DE,2020,Q2,Adult
155183719,15518371,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q2,Visual impairment,,2020,Q2,9,F,2016.0,20200615.0,20181017,20200622,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20200622.0,,HP,DE,DE,2020,Q2,Adult
155183719,15518371,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q2,Decreased vibratory sense,,2020,Q2,9,F,2016.0,20200615.0,20181017,20200622,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20200622.0,,HP,DE,DE,2020,Q2,Adult
155183719,15518371,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q2,Diabetes mellitus inadequate control,,2020,Q2,9,F,2016.0,20200615.0,20181017,20200622,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20200622.0,,HP,DE,DE,2020,Q2,Adult
155183719,15518371,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q2,Gastrointestinal disorder,,2020,Q2,9,F,2016.0,20200615.0,20181017,20200622,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20200622.0,,HP,DE,DE,2020,Q2,Adult
155183719,15518371,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q2,Limb discomfort,,2020,Q2,9,F,2016.0,20200615.0,20181017,20200622,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20200622.0,,HP,DE,DE,2020,Q2,Adult
155183719,15518371,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q2,Neuropathy peripheral,,2020,Q2,9,F,2016.0,20200615.0,20181017,20200622,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20200622.0,,HP,DE,DE,2020,Q2,Adult
155183719,15518371,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q2,Pain in extremity,,2020,Q2,9,F,2016.0,20200615.0,20181017,20200622,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20200622.0,,HP,DE,DE,2020,Q2,Adult
155183719,15518371,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q2,Sensory disturbance,,2020,Q2,9,F,2016.0,20200615.0,20181017,20200622,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20200622.0,,HP,DE,DE,2020,Q2,Adult
155183719,15518371,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q2,Sleep disorder,,2020,Q2,9,F,2016.0,20200615.0,20181017,20200622,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20200622.0,,HP,DE,DE,2020,Q2,Adult
155183719,15518371,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q2,Temperature perception test abnormal,,2020,Q2,9,F,2016.0,20200615.0,20181017,20200622,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20200622.0,,HP,DE,DE,2020,Q2,Adult
155183719,15518371,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q2,Visual impairment,,2020,Q2,9,F,2016.0,20200615.0,20181017,20200622,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20200622.0,,HP,DE,DE,2020,Q2,Adult
155183719,15518371,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10 MILLIGRAM,,,Y,U,,,,10.0,MG,TABLET,,2020,Q2,Decreased vibratory sense,,2020,Q2,9,F,2016.0,20200615.0,20181017,20200622,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20200622.0,,HP,DE,DE,2020,Q2,Adult
155183719,15518371,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10 MILLIGRAM,,,Y,U,,,,10.0,MG,TABLET,,2020,Q2,Diabetes mellitus inadequate control,,2020,Q2,9,F,2016.0,20200615.0,20181017,20200622,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20200622.0,,HP,DE,DE,2020,Q2,Adult
155183719,15518371,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10 MILLIGRAM,,,Y,U,,,,10.0,MG,TABLET,,2020,Q2,Gastrointestinal disorder,,2020,Q2,9,F,2016.0,20200615.0,20181017,20200622,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20200622.0,,HP,DE,DE,2020,Q2,Adult
155183719,15518371,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10 MILLIGRAM,,,Y,U,,,,10.0,MG,TABLET,,2020,Q2,Limb discomfort,,2020,Q2,9,F,2016.0,20200615.0,20181017,20200622,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20200622.0,,HP,DE,DE,2020,Q2,Adult
155183719,15518371,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10 MILLIGRAM,,,Y,U,,,,10.0,MG,TABLET,,2020,Q2,Neuropathy peripheral,,2020,Q2,9,F,2016.0,20200615.0,20181017,20200622,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20200622.0,,HP,DE,DE,2020,Q2,Adult
155183719,15518371,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10 MILLIGRAM,,,Y,U,,,,10.0,MG,TABLET,,2020,Q2,Pain in extremity,,2020,Q2,9,F,2016.0,20200615.0,20181017,20200622,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20200622.0,,HP,DE,DE,2020,Q2,Adult
155183719,15518371,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10 MILLIGRAM,,,Y,U,,,,10.0,MG,TABLET,,2020,Q2,Sensory disturbance,,2020,Q2,9,F,2016.0,20200615.0,20181017,20200622,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20200622.0,,HP,DE,DE,2020,Q2,Adult
155183719,15518371,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10 MILLIGRAM,,,Y,U,,,,10.0,MG,TABLET,,2020,Q2,Sleep disorder,,2020,Q2,9,F,2016.0,20200615.0,20181017,20200622,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20200622.0,,HP,DE,DE,2020,Q2,Adult
155183719,15518371,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10 MILLIGRAM,,,Y,U,,,,10.0,MG,TABLET,,2020,Q2,Temperature perception test abnormal,,2020,Q2,9,F,2016.0,20200615.0,20181017,20200622,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20200622.0,,HP,DE,DE,2020,Q2,Adult
155183719,15518371,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10 MILLIGRAM,,,Y,U,,,,10.0,MG,TABLET,,2020,Q2,Visual impairment,,2020,Q2,9,F,2016.0,20200615.0,20181017,20200622,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017;11 (3):6-7,61.0,YR,,F,Y,97.0,KG,20200622.0,,HP,DE,DE,2020,Q2,Adult
155996362,15599636,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"5 MG, QD",,,,,,,,5.0,MG,,QD,2020,Q2,Metastases to liver,,2020,Q2,2,F,201702.0,20200603.0,20181108,20200612,EXP,,US-NOVOPROD-630528,NOVO NORDISK,,67.0,YR,,M,Y,118.37,KG,20200612.0,,LW,US,US,2020,Q2,Elderly
155996362,15599636,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"5 MG, QD",,,,,,,,5.0,MG,,QD,2020,Q2,Metastases to lung,,2020,Q2,2,F,201702.0,20200603.0,20181108,20200612,EXP,,US-NOVOPROD-630528,NOVO NORDISK,,67.0,YR,,M,Y,118.37,KG,20200612.0,,LW,US,US,2020,Q2,Elderly
155996362,15599636,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"5 MG, QD",,,,,,,,5.0,MG,,QD,2020,Q2,Pancreatic carcinoma metastatic,,2020,Q2,2,F,201702.0,20200603.0,20181108,20200612,EXP,,US-NOVOPROD-630528,NOVO NORDISK,,67.0,YR,,M,Y,118.37,KG,20200612.0,,LW,US,US,2020,Q2,Elderly
157420082,15742008,33,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2020,Q2,Sepsis,,2020,Q2,2,F,20181013.0,20200529.0,20181219,20200603,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-096858,BRISTOL MYERS SQUIBB,,78.0,YR,,M,Y,79.5,KG,20200603.0,,HP,ES,ES,2020,Q2,Elderly
157420082,15742008,33,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2020,Q2,Urinary tract infection,,2020,Q2,2,F,20181013.0,20200529.0,20181219,20200603,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-096858,BRISTOL MYERS SQUIBB,,78.0,YR,,M,Y,79.5,KG,20200603.0,,HP,ES,ES,2020,Q2,Elderly
158452123,15845212,10,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,FORMULATION UNKNOWN,QD,2020,Q2,Influenza,,2020,Q2,3,F,201811.0,20200406.0,20190119,20200409,EXP,,CO-ASTELLAS-2019US002216,ASTELLAS,,32.0,YR,,F,Y,,,20200409.0,,CN,CO,CO,2020,Q2,Young Adult
158452123,15845212,10,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,FORMULATION UNKNOWN,QD,2020,Q2,Respiratory alkalosis,,2020,Q2,3,F,201811.0,20200406.0,20190119,20200409,EXP,,CO-ASTELLAS-2019US002216,ASTELLAS,,32.0,YR,,F,Y,,,20200409.0,,CN,CO,CO,2020,Q2,Young Adult
158452123,15845212,10,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,FORMULATION UNKNOWN,QD,2020,Q2,Tachycardia,,2020,Q2,3,F,201811.0,20200406.0,20190119,20200409,EXP,,CO-ASTELLAS-2019US002216,ASTELLAS,,32.0,YR,,F,Y,,,20200409.0,,CN,CO,CO,2020,Q2,Young Adult
158452123,15845212,10,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,FORMULATION UNKNOWN,QD,2020,Q2,Tremor,,2020,Q2,3,F,201811.0,20200406.0,20190119,20200409,EXP,,CO-ASTELLAS-2019US002216,ASTELLAS,,32.0,YR,,F,Y,,,20200409.0,,CN,CO,CO,2020,Q2,Young Adult
160271416,16027141,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q2,Cellulitis,,2020,Q2,6,F,20181225.0,20200420.0,20190303,20200423,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-019559,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,130.0,KG,20200423.0,,HP,DE,DE,2020,Q2,Adult
160271416,16027141,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q2,Lymphangitis,,2020,Q2,6,F,20181225.0,20200420.0,20190303,20200423,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-019559,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,130.0,KG,20200423.0,,HP,DE,DE,2020,Q2,Adult
160271416,16027141,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q2,Necrosis,,2020,Q2,6,F,20181225.0,20200420.0,20190303,20200423,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-019559,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,130.0,KG,20200423.0,,HP,DE,DE,2020,Q2,Adult
160271416,16027141,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q2,Soft tissue infection,,2020,Q2,6,F,20181225.0,20200420.0,20190303,20200423,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-019559,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,130.0,KG,20200423.0,,HP,DE,DE,2020,Q2,Adult
161112527,16111252,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Acidosis,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Acute kidney injury,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Blood glucose increased,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Cardiac failure,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Dehydration,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Diabetic ketoacidosis,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Diabetic metabolic decompensation,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Drug ineffective,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Drug interaction,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Eating disorder,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Fatigue,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Food refusal,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Hypernatraemia,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Metabolic acidosis,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Off label use,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Urine ketone body present,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,5,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Acidosis,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,5,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Acute kidney injury,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,5,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Blood glucose increased,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,5,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Cardiac failure,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,5,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Dehydration,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,5,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Diabetic ketoacidosis,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,5,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Diabetic metabolic decompensation,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,5,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Drug ineffective,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,5,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Drug interaction,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,5,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Eating disorder,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,5,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Fatigue,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,5,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Food refusal,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,5,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Hypernatraemia,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,5,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Metabolic acidosis,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,5,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Off label use,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,5,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Urine ketone body present,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,6,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Acidosis,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,6,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Acute kidney injury,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,6,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Blood glucose increased,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,6,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Cardiac failure,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,6,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Dehydration,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,6,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Diabetic ketoacidosis,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,6,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Diabetic metabolic decompensation,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,6,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Drug ineffective,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,6,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Drug interaction,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,6,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Eating disorder,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,6,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Fatigue,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,6,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Food refusal,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,6,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Hypernatraemia,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,6,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Metabolic acidosis,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,6,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Off label use,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161112527,16111252,6,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Urine ketone body present,,2020,Q2,7,F,,20200403.0,20190325,20200412,EXP,,PT-AUROBINDO-AUR-APL-2019-015293,AUROBINDO,,69.0,YR,,F,Y,,,20200413.0,,HP,PT,PT,2020,Q2,Elderly
161403715,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2020,Q2,Acidosis,,2020,Q2,5,F,,20200601.0,20190401,20200604,EXP,,PHHY2019PT072916,NOVARTIS,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT2 INHIBITORS BEING TAKEN INTO ACCOUNT. PORTUGUESE DIABETES JOURNAL. 2019;14(1)",69.0,YR,,F,Y,,,20200604.0,,HP,PT,PT,2020,Q2,Elderly
161403715,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2020,Q2,Acute kidney injury,,2020,Q2,5,F,,20200601.0,20190401,20200604,EXP,,PHHY2019PT072916,NOVARTIS,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT2 INHIBITORS BEING TAKEN INTO ACCOUNT. PORTUGUESE DIABETES JOURNAL. 2019;14(1)",69.0,YR,,F,Y,,,20200604.0,,HP,PT,PT,2020,Q2,Elderly
161403715,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2020,Q2,Cardiac failure,,2020,Q2,5,F,,20200601.0,20190401,20200604,EXP,,PHHY2019PT072916,NOVARTIS,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT2 INHIBITORS BEING TAKEN INTO ACCOUNT. PORTUGUESE DIABETES JOURNAL. 2019;14(1)",69.0,YR,,F,Y,,,20200604.0,,HP,PT,PT,2020,Q2,Elderly
161403715,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2020,Q2,Dehydration,,2020,Q2,5,F,,20200601.0,20190401,20200604,EXP,,PHHY2019PT072916,NOVARTIS,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT2 INHIBITORS BEING TAKEN INTO ACCOUNT. PORTUGUESE DIABETES JOURNAL. 2019;14(1)",69.0,YR,,F,Y,,,20200604.0,,HP,PT,PT,2020,Q2,Elderly
161403715,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2020,Q2,Diabetic ketoacidosis,,2020,Q2,5,F,,20200601.0,20190401,20200604,EXP,,PHHY2019PT072916,NOVARTIS,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT2 INHIBITORS BEING TAKEN INTO ACCOUNT. PORTUGUESE DIABETES JOURNAL. 2019;14(1)",69.0,YR,,F,Y,,,20200604.0,,HP,PT,PT,2020,Q2,Elderly
161403715,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2020,Q2,Diabetic metabolic decompensation,,2020,Q2,5,F,,20200601.0,20190401,20200604,EXP,,PHHY2019PT072916,NOVARTIS,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT2 INHIBITORS BEING TAKEN INTO ACCOUNT. PORTUGUESE DIABETES JOURNAL. 2019;14(1)",69.0,YR,,F,Y,,,20200604.0,,HP,PT,PT,2020,Q2,Elderly
161403715,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2020,Q2,Drug ineffective,,2020,Q2,5,F,,20200601.0,20190401,20200604,EXP,,PHHY2019PT072916,NOVARTIS,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT2 INHIBITORS BEING TAKEN INTO ACCOUNT. PORTUGUESE DIABETES JOURNAL. 2019;14(1)",69.0,YR,,F,Y,,,20200604.0,,HP,PT,PT,2020,Q2,Elderly
161403715,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2020,Q2,Drug interaction,,2020,Q2,5,F,,20200601.0,20190401,20200604,EXP,,PHHY2019PT072916,NOVARTIS,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT2 INHIBITORS BEING TAKEN INTO ACCOUNT. PORTUGUESE DIABETES JOURNAL. 2019;14(1)",69.0,YR,,F,Y,,,20200604.0,,HP,PT,PT,2020,Q2,Elderly
161403715,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2020,Q2,Eating disorder,,2020,Q2,5,F,,20200601.0,20190401,20200604,EXP,,PHHY2019PT072916,NOVARTIS,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT2 INHIBITORS BEING TAKEN INTO ACCOUNT. PORTUGUESE DIABETES JOURNAL. 2019;14(1)",69.0,YR,,F,Y,,,20200604.0,,HP,PT,PT,2020,Q2,Elderly
161403715,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2020,Q2,Fatigue,,2020,Q2,5,F,,20200601.0,20190401,20200604,EXP,,PHHY2019PT072916,NOVARTIS,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT2 INHIBITORS BEING TAKEN INTO ACCOUNT. PORTUGUESE DIABETES JOURNAL. 2019;14(1)",69.0,YR,,F,Y,,,20200604.0,,HP,PT,PT,2020,Q2,Elderly
161403715,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2020,Q2,Food refusal,,2020,Q2,5,F,,20200601.0,20190401,20200604,EXP,,PHHY2019PT072916,NOVARTIS,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT2 INHIBITORS BEING TAKEN INTO ACCOUNT. PORTUGUESE DIABETES JOURNAL. 2019;14(1)",69.0,YR,,F,Y,,,20200604.0,,HP,PT,PT,2020,Q2,Elderly
161403715,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2020,Q2,Hypernatraemia,,2020,Q2,5,F,,20200601.0,20190401,20200604,EXP,,PHHY2019PT072916,NOVARTIS,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT2 INHIBITORS BEING TAKEN INTO ACCOUNT. PORTUGUESE DIABETES JOURNAL. 2019;14(1)",69.0,YR,,F,Y,,,20200604.0,,HP,PT,PT,2020,Q2,Elderly
161403715,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2020,Q2,Metabolic acidosis,,2020,Q2,5,F,,20200601.0,20190401,20200604,EXP,,PHHY2019PT072916,NOVARTIS,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT2 INHIBITORS BEING TAKEN INTO ACCOUNT. PORTUGUESE DIABETES JOURNAL. 2019;14(1)",69.0,YR,,F,Y,,,20200604.0,,HP,PT,PT,2020,Q2,Elderly
161403715,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2020,Q2,Off label use,,2020,Q2,5,F,,20200601.0,20190401,20200604,EXP,,PHHY2019PT072916,NOVARTIS,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT2 INHIBITORS BEING TAKEN INTO ACCOUNT. PORTUGUESE DIABETES JOURNAL. 2019;14(1)",69.0,YR,,F,Y,,,20200604.0,,HP,PT,PT,2020,Q2,Elderly
161403715,16140371,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2020,Q2,Urine ketone body present,,2020,Q2,5,F,,20200601.0,20190401,20200604,EXP,,PHHY2019PT072916,NOVARTIS,"FONSECA L, OLIVEIRA A, SANTOS T, SILVA F, FERREIRA T, VILAVERDE J ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT2 INHIBITORS BEING TAKEN INTO ACCOUNT. PORTUGUESE DIABETES JOURNAL. 2019;14(1)",69.0,YR,,F,Y,,,20200604.0,,HP,PT,PT,2020,Q2,Elderly
162547233,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2020,Q2,Acute coronary syndrome,,2020,Q2,3,F,,20200330.0,20190430,20200402,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20200402.0,,MD,CA,CA,2020,Q2,Adult
162547233,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2020,Q2,Angina unstable,,2020,Q2,3,F,,20200330.0,20190430,20200402,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20200402.0,,MD,CA,CA,2020,Q2,Adult
162547233,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2020,Q2,Blood cholesterol increased,,2020,Q2,3,F,,20200330.0,20190430,20200402,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20200402.0,,MD,CA,CA,2020,Q2,Adult
162547233,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2020,Q2,Blood creatine phosphokinase increased,,2020,Q2,3,F,,20200330.0,20190430,20200402,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20200402.0,,MD,CA,CA,2020,Q2,Adult
162547233,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2020,Q2,Blood parathyroid hormone increased,,2020,Q2,3,F,,20200330.0,20190430,20200402,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20200402.0,,MD,CA,CA,2020,Q2,Adult
162547233,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2020,Q2,Blood triglycerides increased,,2020,Q2,3,F,,20200330.0,20190430,20200402,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20200402.0,,MD,CA,CA,2020,Q2,Adult
162547233,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2020,Q2,Coronary artery stenosis,,2020,Q2,3,F,,20200330.0,20190430,20200402,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20200402.0,,MD,CA,CA,2020,Q2,Adult
162547233,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2020,Q2,High density lipoprotein decreased,,2020,Q2,3,F,,20200330.0,20190430,20200402,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20200402.0,,MD,CA,CA,2020,Q2,Adult
162547233,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2020,Q2,Low density lipoprotein increased,,2020,Q2,3,F,,20200330.0,20190430,20200402,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20200402.0,,MD,CA,CA,2020,Q2,Adult
162547233,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2020,Q2,Muscular weakness,,2020,Q2,3,F,,20200330.0,20190430,20200402,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20200402.0,,MD,CA,CA,2020,Q2,Adult
162547233,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2020,Q2,Myalgia,,2020,Q2,3,F,,20200330.0,20190430,20200402,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20200402.0,,MD,CA,CA,2020,Q2,Adult
162547233,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2020,Q2,Myopathy,,2020,Q2,3,F,,20200330.0,20190430,20200402,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20200402.0,,MD,CA,CA,2020,Q2,Adult
162547233,16254723,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2020,Q2,Total cholesterol/HDL ratio increased,,2020,Q2,3,F,,20200330.0,20190430,20200402,EXP,,CA-TEVA-2019-CA-1041766,TEVA,,56.0,YR,,M,Y,82.0,KG,20200402.0,,MD,CA,CA,2020,Q2,Adult
164375423,16437542,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,,2020,Q2,Acute kidney injury,,2020,Q2,3,F,,20200413.0,20190615,20200418,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-ACCORD-132960,ACCORD,,69.0,YR,E,F,Y,,,20200418.0,,MD,PT,PT,2020,Q2,Elderly
164375423,16437542,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,,2020,Q2,Cardiac failure,,2020,Q2,3,F,,20200413.0,20190615,20200418,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-ACCORD-132960,ACCORD,,69.0,YR,E,F,Y,,,20200418.0,,MD,PT,PT,2020,Q2,Elderly
164375423,16437542,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,,2020,Q2,Dehydration,,2020,Q2,3,F,,20200413.0,20190615,20200418,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-ACCORD-132960,ACCORD,,69.0,YR,E,F,Y,,,20200418.0,,MD,PT,PT,2020,Q2,Elderly
164375423,16437542,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,,2020,Q2,Diabetic ketoacidosis,,2020,Q2,3,F,,20200413.0,20190615,20200418,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-ACCORD-132960,ACCORD,,69.0,YR,E,F,Y,,,20200418.0,,MD,PT,PT,2020,Q2,Elderly
164375423,16437542,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,,2020,Q2,Diabetic metabolic decompensation,,2020,Q2,3,F,,20200413.0,20190615,20200418,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-ACCORD-132960,ACCORD,,69.0,YR,E,F,Y,,,20200418.0,,MD,PT,PT,2020,Q2,Elderly
164375423,16437542,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,,2020,Q2,Drug ineffective,,2020,Q2,3,F,,20200413.0,20190615,20200418,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-ACCORD-132960,ACCORD,,69.0,YR,E,F,Y,,,20200418.0,,MD,PT,PT,2020,Q2,Elderly
164375423,16437542,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,,2020,Q2,Drug interaction,,2020,Q2,3,F,,20200413.0,20190615,20200418,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-ACCORD-132960,ACCORD,,69.0,YR,E,F,Y,,,20200418.0,,MD,PT,PT,2020,Q2,Elderly
164375423,16437542,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,,2020,Q2,Fatigue,,2020,Q2,3,F,,20200413.0,20190615,20200418,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-ACCORD-132960,ACCORD,,69.0,YR,E,F,Y,,,20200418.0,,MD,PT,PT,2020,Q2,Elderly
164375423,16437542,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,,2020,Q2,Food refusal,,2020,Q2,3,F,,20200413.0,20190615,20200418,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-ACCORD-132960,ACCORD,,69.0,YR,E,F,Y,,,20200418.0,,MD,PT,PT,2020,Q2,Elderly
164375423,16437542,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,,2020,Q2,Hypernatraemia,,2020,Q2,3,F,,20200413.0,20190615,20200418,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-ACCORD-132960,ACCORD,,69.0,YR,E,F,Y,,,20200418.0,,MD,PT,PT,2020,Q2,Elderly
164375423,16437542,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,,2020,Q2,Metabolic acidosis,,2020,Q2,3,F,,20200413.0,20190615,20200418,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-ACCORD-132960,ACCORD,,69.0,YR,E,F,Y,,,20200418.0,,MD,PT,PT,2020,Q2,Elderly
164375423,16437542,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,,2020,Q2,Urine ketone body present,,2020,Q2,3,F,,20200413.0,20190615,20200418,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-ACCORD-132960,ACCORD,,69.0,YR,E,F,Y,,,20200418.0,,MD,PT,PT,2020,Q2,Elderly
166138642,16613864,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q2,Diarrhoea,,2020,Q2,2,F,20170908.0,20200331.0,20190723,20200406,EXP,,GB-ASTRAZENECA-2019SF03828,ASTRAZENECA,,53.0,YR,,F,Y,134.0,KG,20200407.0,,,GB,GB,2020,Q2,Adult
166138642,16613864,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q2,Irritable bowel syndrome,,2020,Q2,2,F,20170908.0,20200331.0,20190723,20200406,EXP,,GB-ASTRAZENECA-2019SF03828,ASTRAZENECA,,53.0,YR,,F,Y,134.0,KG,20200407.0,,,GB,GB,2020,Q2,Adult
166427203,16642720,8,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,,,2020,Q2,Acute kidney injury,,2020,Q2,3,F,,20200420.0,20190729,20200424,EXP,,PHHY2019GB170606,NOVARTIS,,39.0,YR,,M,Y,,,20200424.0,,HP,GB,GB,2020,Q2,Adult
166427203,16642720,8,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,,,2020,Q2,Euglycaemic diabetic ketoacidosis,,2020,Q2,3,F,,20200420.0,20190729,20200424,EXP,,PHHY2019GB170606,NOVARTIS,,39.0,YR,,M,Y,,,20200424.0,,HP,GB,GB,2020,Q2,Adult
166427203,16642720,8,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,,,2020,Q2,Hypotension,,2020,Q2,3,F,,20200420.0,20190729,20200424,EXP,,PHHY2019GB170606,NOVARTIS,,39.0,YR,,M,Y,,,20200424.0,,HP,GB,GB,2020,Q2,Adult
166427203,16642720,8,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,,,2020,Q2,Intentional overdose,,2020,Q2,3,F,,20200420.0,20190729,20200424,EXP,,PHHY2019GB170606,NOVARTIS,,39.0,YR,,M,Y,,,20200424.0,,HP,GB,GB,2020,Q2,Adult
167678296,16767829,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Acidosis,,2020,Q2,6,F,,20200425.0,20190903,20200430,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20200430.0,,HP,PT,PT,2020,Q2,Elderly
167678296,16767829,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Acute kidney injury,,2020,Q2,6,F,,20200425.0,20190903,20200430,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20200430.0,,HP,PT,PT,2020,Q2,Elderly
167678296,16767829,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Cardiac failure,,2020,Q2,6,F,,20200425.0,20190903,20200430,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20200430.0,,HP,PT,PT,2020,Q2,Elderly
167678296,16767829,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Dehydration,,2020,Q2,6,F,,20200425.0,20190903,20200430,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20200430.0,,HP,PT,PT,2020,Q2,Elderly
167678296,16767829,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Diabetic ketoacidosis,,2020,Q2,6,F,,20200425.0,20190903,20200430,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20200430.0,,HP,PT,PT,2020,Q2,Elderly
167678296,16767829,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Diabetic metabolic decompensation,,2020,Q2,6,F,,20200425.0,20190903,20200430,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20200430.0,,HP,PT,PT,2020,Q2,Elderly
167678296,16767829,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Drug ineffective,,2020,Q2,6,F,,20200425.0,20190903,20200430,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20200430.0,,HP,PT,PT,2020,Q2,Elderly
167678296,16767829,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Drug interaction,,2020,Q2,6,F,,20200425.0,20190903,20200430,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20200430.0,,HP,PT,PT,2020,Q2,Elderly
167678296,16767829,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Eating disorder,,2020,Q2,6,F,,20200425.0,20190903,20200430,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20200430.0,,HP,PT,PT,2020,Q2,Elderly
167678296,16767829,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Fatigue,,2020,Q2,6,F,,20200425.0,20190903,20200430,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20200430.0,,HP,PT,PT,2020,Q2,Elderly
167678296,16767829,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Food refusal,,2020,Q2,6,F,,20200425.0,20190903,20200430,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20200430.0,,HP,PT,PT,2020,Q2,Elderly
167678296,16767829,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Hypernatraemia,,2020,Q2,6,F,,20200425.0,20190903,20200430,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20200430.0,,HP,PT,PT,2020,Q2,Elderly
167678296,16767829,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Intentional product misuse,,2020,Q2,6,F,,20200425.0,20190903,20200430,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20200430.0,,HP,PT,PT,2020,Q2,Elderly
167678296,16767829,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Metabolic acidosis,,2020,Q2,6,F,,20200425.0,20190903,20200430,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20200430.0,,HP,PT,PT,2020,Q2,Elderly
167678296,16767829,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Off label use,,2020,Q2,6,F,,20200425.0,20190903,20200430,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20200430.0,,HP,PT,PT,2020,Q2,Elderly
167678296,16767829,3,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Urine ketone body present,,2020,Q2,6,F,,20200425.0,20190903,20200430,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20200430.0,,HP,PT,PT,2020,Q2,Elderly
167678296,16767829,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Acidosis,,2020,Q2,6,F,,20200425.0,20190903,20200430,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20200430.0,,HP,PT,PT,2020,Q2,Elderly
167678296,16767829,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Acute kidney injury,,2020,Q2,6,F,,20200425.0,20190903,20200430,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20200430.0,,HP,PT,PT,2020,Q2,Elderly
167678296,16767829,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Cardiac failure,,2020,Q2,6,F,,20200425.0,20190903,20200430,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20200430.0,,HP,PT,PT,2020,Q2,Elderly
167678296,16767829,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Dehydration,,2020,Q2,6,F,,20200425.0,20190903,20200430,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20200430.0,,HP,PT,PT,2020,Q2,Elderly
167678296,16767829,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Diabetic ketoacidosis,,2020,Q2,6,F,,20200425.0,20190903,20200430,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20200430.0,,HP,PT,PT,2020,Q2,Elderly
167678296,16767829,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Diabetic metabolic decompensation,,2020,Q2,6,F,,20200425.0,20190903,20200430,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20200430.0,,HP,PT,PT,2020,Q2,Elderly
167678296,16767829,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Drug ineffective,,2020,Q2,6,F,,20200425.0,20190903,20200430,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20200430.0,,HP,PT,PT,2020,Q2,Elderly
167678296,16767829,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Drug interaction,,2020,Q2,6,F,,20200425.0,20190903,20200430,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20200430.0,,HP,PT,PT,2020,Q2,Elderly
167678296,16767829,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Eating disorder,,2020,Q2,6,F,,20200425.0,20190903,20200430,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20200430.0,,HP,PT,PT,2020,Q2,Elderly
167678296,16767829,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Fatigue,,2020,Q2,6,F,,20200425.0,20190903,20200430,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20200430.0,,HP,PT,PT,2020,Q2,Elderly
167678296,16767829,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Food refusal,,2020,Q2,6,F,,20200425.0,20190903,20200430,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20200430.0,,HP,PT,PT,2020,Q2,Elderly
167678296,16767829,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Hypernatraemia,,2020,Q2,6,F,,20200425.0,20190903,20200430,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20200430.0,,HP,PT,PT,2020,Q2,Elderly
167678296,16767829,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Intentional product misuse,,2020,Q2,6,F,,20200425.0,20190903,20200430,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20200430.0,,HP,PT,PT,2020,Q2,Elderly
167678296,16767829,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Metabolic acidosis,,2020,Q2,6,F,,20200425.0,20190903,20200430,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20200430.0,,HP,PT,PT,2020,Q2,Elderly
167678296,16767829,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Off label use,,2020,Q2,6,F,,20200425.0,20190903,20200430,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20200430.0,,HP,PT,PT,2020,Q2,Elderly
167678296,16767829,4,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,,,TABLET,,2020,Q2,Urine ketone body present,,2020,Q2,6,F,,20200425.0,20190903,20200430,EXP,,PT-MYLANLABS-2019M1081772,MYLAN,"FONSECA L., OLIVEIRA A., SANTOS T., S?LVA F., FERREIRA T., VILAVERDE J., ET AL.. DIABETIC KETOACIDOSIS: A REALITY OF SGLT-2 INHIBITORS BEING TAKEN INTO ACCOUNT.. PORTUGUESE DIABETES JOURNAL. 2019;14(1):1-2",69.0,YR,,F,Y,,,20200430.0,,HP,PT,PT,2020,Q2,Elderly
168337724,16833772,12,SS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",7880.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Diabetic ketoacidosis,,2020,Q2,4,F,20190824.0,20200429.0,20190920,20200430,EXP,,PHHY2019NL215353,NOVARTIS,,54.0,YR,,F,Y,84.5,KG,20200430.0,,HP,COUNTRY NOT SPECIFIED,NL,2020,Q2,Adult
168337724,16833772,13,SS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",7880.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Diabetic ketoacidosis,,2020,Q2,4,F,20190824.0,20200429.0,20190920,20200430,EXP,,PHHY2019NL215353,NOVARTIS,,54.0,YR,,F,Y,84.5,KG,20200430.0,,HP,COUNTRY NOT SPECIFIED,NL,2020,Q2,Adult
169431193,16943119,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2020,Q2,Abdominal discomfort,,2020,Q2,3,F,20190815.0,20200611.0,20191021,20200619,EXP,,GB-NOVOPROD-684930,NOVO NORDISK,,60.0,YR,,M,Y,115.8,KG,20200619.0,,MD,GB,GB,2020,Q2,Adult
169431193,16943119,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2020,Q2,Abdominal distension,,2020,Q2,3,F,20190815.0,20200611.0,20191021,20200619,EXP,,GB-NOVOPROD-684930,NOVO NORDISK,,60.0,YR,,M,Y,115.8,KG,20200619.0,,MD,GB,GB,2020,Q2,Adult
169431193,16943119,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2020,Q2,Constipation,,2020,Q2,3,F,20190815.0,20200611.0,20191021,20200619,EXP,,GB-NOVOPROD-684930,NOVO NORDISK,,60.0,YR,,M,Y,115.8,KG,20200619.0,,MD,GB,GB,2020,Q2,Adult
169431193,16943119,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2020,Q2,Diarrhoea,,2020,Q2,3,F,20190815.0,20200611.0,20191021,20200619,EXP,,GB-NOVOPROD-684930,NOVO NORDISK,,60.0,YR,,M,Y,115.8,KG,20200619.0,,MD,GB,GB,2020,Q2,Adult
169431193,16943119,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2020,Q2,Hypoglycaemia,,2020,Q2,3,F,20190815.0,20200611.0,20191021,20200619,EXP,,GB-NOVOPROD-684930,NOVO NORDISK,,60.0,YR,,M,Y,115.8,KG,20200619.0,,MD,GB,GB,2020,Q2,Adult
169431193,16943119,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2020,Q2,Malaise,,2020,Q2,3,F,20190815.0,20200611.0,20191021,20200619,EXP,,GB-NOVOPROD-684930,NOVO NORDISK,,60.0,YR,,M,Y,115.8,KG,20200619.0,,MD,GB,GB,2020,Q2,Adult
170949339,17094933,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2020,Q2,Febrile neutropenia,,2020,Q2,9,F,,20200615.0,20191130,20200622,EXP,,PT-AUROBINDO-AUR-APL-2019-075818,AUROBINDO,,58.0,YR,,F,Y,,,20200622.0,,HP,PT,PT,2020,Q2,Adult
170949339,17094933,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2020,Q2,Flushing,,2020,Q2,9,F,,20200615.0,20191130,20200622,EXP,,PT-AUROBINDO-AUR-APL-2019-075818,AUROBINDO,,58.0,YR,,F,Y,,,20200622.0,,HP,PT,PT,2020,Q2,Adult
170949339,17094933,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2020,Q2,Gingival oedema,,2020,Q2,9,F,,20200615.0,20191130,20200622,EXP,,PT-AUROBINDO-AUR-APL-2019-075818,AUROBINDO,,58.0,YR,,F,Y,,,20200622.0,,HP,PT,PT,2020,Q2,Adult
170949339,17094933,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2020,Q2,Gingival swelling,,2020,Q2,9,F,,20200615.0,20191130,20200622,EXP,,PT-AUROBINDO-AUR-APL-2019-075818,AUROBINDO,,58.0,YR,,F,Y,,,20200622.0,,HP,PT,PT,2020,Q2,Adult
170949339,17094933,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2020,Q2,Headache,,2020,Q2,9,F,,20200615.0,20191130,20200622,EXP,,PT-AUROBINDO-AUR-APL-2019-075818,AUROBINDO,,58.0,YR,,F,Y,,,20200622.0,,HP,PT,PT,2020,Q2,Adult
170949339,17094933,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2020,Q2,Iatrogenic injury,,2020,Q2,9,F,,20200615.0,20191130,20200622,EXP,,PT-AUROBINDO-AUR-APL-2019-075818,AUROBINDO,,58.0,YR,,F,Y,,,20200622.0,,HP,PT,PT,2020,Q2,Adult
170949339,17094933,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2020,Q2,Leukopenia,,2020,Q2,9,F,,20200615.0,20191130,20200622,EXP,,PT-AUROBINDO-AUR-APL-2019-075818,AUROBINDO,,58.0,YR,,F,Y,,,20200622.0,,HP,PT,PT,2020,Q2,Adult
170949339,17094933,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2020,Q2,Lymphocyte morphology abnormal,,2020,Q2,9,F,,20200615.0,20191130,20200622,EXP,,PT-AUROBINDO-AUR-APL-2019-075818,AUROBINDO,,58.0,YR,,F,Y,,,20200622.0,,HP,PT,PT,2020,Q2,Adult
170949339,17094933,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2020,Q2,Mouth ulceration,,2020,Q2,9,F,,20200615.0,20191130,20200622,EXP,,PT-AUROBINDO-AUR-APL-2019-075818,AUROBINDO,,58.0,YR,,F,Y,,,20200622.0,,HP,PT,PT,2020,Q2,Adult
170949339,17094933,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2020,Q2,Myalgia,,2020,Q2,9,F,,20200615.0,20191130,20200622,EXP,,PT-AUROBINDO-AUR-APL-2019-075818,AUROBINDO,,58.0,YR,,F,Y,,,20200622.0,,HP,PT,PT,2020,Q2,Adult
170949339,17094933,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2020,Q2,Neutropenia,,2020,Q2,9,F,,20200615.0,20191130,20200622,EXP,,PT-AUROBINDO-AUR-APL-2019-075818,AUROBINDO,,58.0,YR,,F,Y,,,20200622.0,,HP,PT,PT,2020,Q2,Adult
170949339,17094933,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2020,Q2,Pyrexia,,2020,Q2,9,F,,20200615.0,20191130,20200622,EXP,,PT-AUROBINDO-AUR-APL-2019-075818,AUROBINDO,,58.0,YR,,F,Y,,,20200622.0,,HP,PT,PT,2020,Q2,Adult
1710513315,17105133,10,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,TABLETS,,2020,Q2,Hypoglycaemia,Hypoglycaemia,2020,Q2,15,F,20191118.0,20200505.0,20191203,20200508,PER,,GB-EISAI MEDICAL RESEARCH-EC-2019-066343,EISAI,,70.0,YR,E,M,Y,81.0,KG,20200508.0,,MD,GB,GB,2020,Q2,Elderly
171277252,17127725,15,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,U,,,,,,,,2020,Q2,Depression,,2020,Q2,2,F,20170330.0,20170504.0,20191209,20200601,EXP,,US-UCBSA-2017005054,UCB,,53.0,YR,,M,Y,93.0,KG,20200601.0,,CN,US,US,2020,Q2,Adult
171277252,17127725,15,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,U,,,,,,,,2020,Q2,Fatigue,,2020,Q2,2,F,20170330.0,20170504.0,20191209,20200601,EXP,,US-UCBSA-2017005054,UCB,,53.0,YR,,M,Y,93.0,KG,20200601.0,,CN,US,US,2020,Q2,Adult
171277252,17127725,15,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,U,,,,,,,,2020,Q2,Myocardial infarction,,2020,Q2,2,F,20170330.0,20170504.0,20191209,20200601,EXP,,US-UCBSA-2017005054,UCB,,53.0,YR,,M,Y,93.0,KG,20200601.0,,CN,US,US,2020,Q2,Adult
171277252,17127725,15,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,U,,,,,,,,2020,Q2,Somnolence,,2020,Q2,2,F,20170330.0,20170504.0,20191209,20200601,EXP,,US-UCBSA-2017005054,UCB,,53.0,YR,,M,Y,93.0,KG,20200601.0,,CN,US,US,2020,Q2,Adult
171296714,17129671,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2020,Q2,Febrile neutropenia,,2020,Q2,4,F,,20200622.0,20191209,20200630,EXP,,PT-MYLANLABS-2019M1119018,MYLAN,,58.0,YR,,F,Y,,,20200630.0,,MD,PT,PT,2020,Q2,Adult
171296714,17129671,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2020,Q2,Flushing,,2020,Q2,4,F,,20200622.0,20191209,20200630,EXP,,PT-MYLANLABS-2019M1119018,MYLAN,,58.0,YR,,F,Y,,,20200630.0,,MD,PT,PT,2020,Q2,Adult
171296714,17129671,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2020,Q2,Gingival oedema,,2020,Q2,4,F,,20200622.0,20191209,20200630,EXP,,PT-MYLANLABS-2019M1119018,MYLAN,,58.0,YR,,F,Y,,,20200630.0,,MD,PT,PT,2020,Q2,Adult
171296714,17129671,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2020,Q2,Gingival swelling,,2020,Q2,4,F,,20200622.0,20191209,20200630,EXP,,PT-MYLANLABS-2019M1119018,MYLAN,,58.0,YR,,F,Y,,,20200630.0,,MD,PT,PT,2020,Q2,Adult
171296714,17129671,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2020,Q2,Headache,,2020,Q2,4,F,,20200622.0,20191209,20200630,EXP,,PT-MYLANLABS-2019M1119018,MYLAN,,58.0,YR,,F,Y,,,20200630.0,,MD,PT,PT,2020,Q2,Adult
171296714,17129671,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2020,Q2,Iatrogenic injury,,2020,Q2,4,F,,20200622.0,20191209,20200630,EXP,,PT-MYLANLABS-2019M1119018,MYLAN,,58.0,YR,,F,Y,,,20200630.0,,MD,PT,PT,2020,Q2,Adult
171296714,17129671,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2020,Q2,Leukopenia,,2020,Q2,4,F,,20200622.0,20191209,20200630,EXP,,PT-MYLANLABS-2019M1119018,MYLAN,,58.0,YR,,F,Y,,,20200630.0,,MD,PT,PT,2020,Q2,Adult
171296714,17129671,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2020,Q2,Lymphocyte morphology abnormal,,2020,Q2,4,F,,20200622.0,20191209,20200630,EXP,,PT-MYLANLABS-2019M1119018,MYLAN,,58.0,YR,,F,Y,,,20200630.0,,MD,PT,PT,2020,Q2,Adult
171296714,17129671,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2020,Q2,Mouth ulceration,,2020,Q2,4,F,,20200622.0,20191209,20200630,EXP,,PT-MYLANLABS-2019M1119018,MYLAN,,58.0,YR,,F,Y,,,20200630.0,,MD,PT,PT,2020,Q2,Adult
171296714,17129671,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2020,Q2,Myalgia,,2020,Q2,4,F,,20200622.0,20191209,20200630,EXP,,PT-MYLANLABS-2019M1119018,MYLAN,,58.0,YR,,F,Y,,,20200630.0,,MD,PT,PT,2020,Q2,Adult
171296714,17129671,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2020,Q2,Neutropenia,,2020,Q2,4,F,,20200622.0,20191209,20200630,EXP,,PT-MYLANLABS-2019M1119018,MYLAN,,58.0,YR,,F,Y,,,20200630.0,,MD,PT,PT,2020,Q2,Adult
171296714,17129671,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2020,Q2,Pyrexia,,2020,Q2,4,F,,20200622.0,20191209,20200630,EXP,,PT-MYLANLABS-2019M1119018,MYLAN,,58.0,YR,,F,Y,,,20200630.0,,MD,PT,PT,2020,Q2,Adult
171508722,17150872,11,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,,,,,,,,,10.0,MG,,QD,2020,Q2,Creatinine renal clearance decreased,,2020,Q2,2,F,,20200601.0,20191213,20200603,EXP,,CA-ROCHE-2491088,ROCHE,,55.0,YR,,F,Y,,,20200603.0,,CN,CA,CA,2020,Q2,Adult
171508722,17150872,11,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,,,,,,,,,10.0,MG,,QD,2020,Q2,Death,,2020,Q2,2,F,,20200601.0,20191213,20200603,EXP,,CA-ROCHE-2491088,ROCHE,,55.0,YR,,F,Y,,,20200603.0,,CN,CA,CA,2020,Q2,Adult
171508722,17150872,11,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,,,,,,,,,10.0,MG,,QD,2020,Q2,Diabetes mellitus inadequate control,,2020,Q2,2,F,,20200601.0,20191213,20200603,EXP,,CA-ROCHE-2491088,ROCHE,,55.0,YR,,F,Y,,,20200603.0,,CN,CA,CA,2020,Q2,Adult
171508722,17150872,11,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,,,,,,,,,10.0,MG,,QD,2020,Q2,Injection site pain,,2020,Q2,2,F,,20200601.0,20191213,20200603,EXP,,CA-ROCHE-2491088,ROCHE,,55.0,YR,,F,Y,,,20200603.0,,CN,CA,CA,2020,Q2,Adult
171508722,17150872,11,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,,,,,,,,,10.0,MG,,QD,2020,Q2,Pancreatitis,,2020,Q2,2,F,,20200601.0,20191213,20200603,EXP,,CA-ROCHE-2491088,ROCHE,,55.0,YR,,F,Y,,,20200603.0,,CN,CA,CA,2020,Q2,Adult
171508722,17150872,11,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,,,,,,,,,10.0,MG,,QD,2020,Q2,Product use issue,,2020,Q2,2,F,,20200601.0,20191213,20200603,EXP,,CA-ROCHE-2491088,ROCHE,,55.0,YR,,F,Y,,,20200603.0,,CN,CA,CA,2020,Q2,Adult
172178872,17217887,5,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,,,2020,Q2,Blood glucose increased,,2020,Q2,2,F,,20200610.0,20191231,20200617,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20200617.0,,CN,CA,CA,2020,Q2,Elderly
172178872,17217887,5,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,,,2020,Q2,Diarrhoea,,2020,Q2,2,F,,20200610.0,20191231,20200617,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20200617.0,,CN,CA,CA,2020,Q2,Elderly
172178872,17217887,5,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,,,2020,Q2,Dyspepsia,,2020,Q2,2,F,,20200610.0,20191231,20200617,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20200617.0,,CN,CA,CA,2020,Q2,Elderly
172178872,17217887,5,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,,,2020,Q2,Fatigue,,2020,Q2,2,F,,20200610.0,20191231,20200617,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20200617.0,,CN,CA,CA,2020,Q2,Elderly
172178872,17217887,5,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,,,2020,Q2,Feeding disorder,,2020,Q2,2,F,,20200610.0,20191231,20200617,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20200617.0,,CN,CA,CA,2020,Q2,Elderly
172178872,17217887,5,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,,,2020,Q2,Flatulence,,2020,Q2,2,F,,20200610.0,20191231,20200617,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20200617.0,,CN,CA,CA,2020,Q2,Elderly
172178872,17217887,5,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,,,2020,Q2,Heart rate irregular,,2020,Q2,2,F,,20200610.0,20191231,20200617,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20200617.0,,CN,CA,CA,2020,Q2,Elderly
172178872,17217887,5,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,,,2020,Q2,Herpes zoster,,2020,Q2,2,F,,20200610.0,20191231,20200617,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20200617.0,,CN,CA,CA,2020,Q2,Elderly
172178872,17217887,5,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,,,2020,Q2,Hyperhidrosis,,2020,Q2,2,F,,20200610.0,20191231,20200617,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20200617.0,,CN,CA,CA,2020,Q2,Elderly
172178872,17217887,5,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,,,2020,Q2,Nausea,,2020,Q2,2,F,,20200610.0,20191231,20200617,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20200617.0,,CN,CA,CA,2020,Q2,Elderly
172178872,17217887,5,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,,,2020,Q2,Pruritus,,2020,Q2,2,F,,20200610.0,20191231,20200617,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20200617.0,,CN,CA,CA,2020,Q2,Elderly
172178872,17217887,5,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,,,2020,Q2,Retching,,2020,Q2,2,F,,20200610.0,20191231,20200617,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20200617.0,,CN,CA,CA,2020,Q2,Elderly
172178872,17217887,5,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,,,2020,Q2,Syncope,,2020,Q2,2,F,,20200610.0,20191231,20200617,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20200617.0,,CN,CA,CA,2020,Q2,Elderly
172178872,17217887,5,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,5 MILLIGRAM,,,U,,,,,5.0,MG,,,2020,Q2,Vomiting,,2020,Q2,2,F,,20200610.0,20191231,20200617,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20200617.0,,CN,CA,CA,2020,Q2,Elderly
172178872,17217887,6,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2020,Q2,Blood glucose increased,,2020,Q2,2,F,,20200610.0,20191231,20200617,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20200617.0,,CN,CA,CA,2020,Q2,Elderly
172178872,17217887,6,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2020,Q2,Diarrhoea,,2020,Q2,2,F,,20200610.0,20191231,20200617,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20200617.0,,CN,CA,CA,2020,Q2,Elderly
172178872,17217887,6,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2020,Q2,Dyspepsia,,2020,Q2,2,F,,20200610.0,20191231,20200617,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20200617.0,,CN,CA,CA,2020,Q2,Elderly
172178872,17217887,6,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2020,Q2,Fatigue,,2020,Q2,2,F,,20200610.0,20191231,20200617,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20200617.0,,CN,CA,CA,2020,Q2,Elderly
172178872,17217887,6,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2020,Q2,Feeding disorder,,2020,Q2,2,F,,20200610.0,20191231,20200617,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20200617.0,,CN,CA,CA,2020,Q2,Elderly
172178872,17217887,6,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2020,Q2,Flatulence,,2020,Q2,2,F,,20200610.0,20191231,20200617,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20200617.0,,CN,CA,CA,2020,Q2,Elderly
172178872,17217887,6,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2020,Q2,Heart rate irregular,,2020,Q2,2,F,,20200610.0,20191231,20200617,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20200617.0,,CN,CA,CA,2020,Q2,Elderly
172178872,17217887,6,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2020,Q2,Herpes zoster,,2020,Q2,2,F,,20200610.0,20191231,20200617,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20200617.0,,CN,CA,CA,2020,Q2,Elderly
172178872,17217887,6,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2020,Q2,Hyperhidrosis,,2020,Q2,2,F,,20200610.0,20191231,20200617,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20200617.0,,CN,CA,CA,2020,Q2,Elderly
172178872,17217887,6,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2020,Q2,Nausea,,2020,Q2,2,F,,20200610.0,20191231,20200617,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20200617.0,,CN,CA,CA,2020,Q2,Elderly
172178872,17217887,6,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2020,Q2,Pruritus,,2020,Q2,2,F,,20200610.0,20191231,20200617,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20200617.0,,CN,CA,CA,2020,Q2,Elderly
172178872,17217887,6,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2020,Q2,Retching,,2020,Q2,2,F,,20200610.0,20191231,20200617,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20200617.0,,CN,CA,CA,2020,Q2,Elderly
172178872,17217887,6,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2020,Q2,Syncope,,2020,Q2,2,F,,20200610.0,20191231,20200617,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20200617.0,,CN,CA,CA,2020,Q2,Elderly
172178872,17217887,6,C,Dapagliflozin propanediol monohydrate,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2020,Q2,Vomiting,,2020,Q2,2,F,,20200610.0,20191231,20200617,EXP,,CA-AUROBINDO-AUR-APL-2019-108091,AUROBINDO,,69.0,YR,,M,Y,,,20200617.0,,CN,CA,CA,2020,Q2,Elderly
172453848,17245384,14,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,2.5 MILLIGRAM,,,U,,,,,2.5,MG,,,2020,Q2,Myocarditis,,2020,Q2,8,F,20191225.0,20200615.0,20200108,20200616,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-124057,BRISTOL MYERS SQUIBB,,58.0,YR,,M,Y,79.0,KG,20200616.0,,HP,JP,JP,2020,Q2,Adult
172766133,17276613,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2020,Q2,Diabetes mellitus inadequate control,,2020,Q2,3,F,2019.0,20200421.0,20200116,20200423,EXP,,NVSC2020PL006489,NOVARTIS,,62.0,YR,,M,Y,81.0,KG,20200423.0,,HP,PL,PL,2020,Q2,Adult
172766133,17276613,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2020,Q2,Hyperglycaemia,,2020,Q2,3,F,2019.0,20200421.0,20200116,20200423,EXP,,NVSC2020PL006489,NOVARTIS,,62.0,YR,,M,Y,81.0,KG,20200423.0,,HP,PL,PL,2020,Q2,Adult
172766133,17276613,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2020,Q2,Tuberculosis,,2020,Q2,3,F,2019.0,20200421.0,20200116,20200423,EXP,,NVSC2020PL006489,NOVARTIS,,62.0,YR,,M,Y,81.0,KG,20200423.0,,HP,PL,PL,2020,Q2,Adult
173389372,17338937,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,TABLETS,,2020,Q2,Arthralgia,,2020,Q2,2,F,200805.0,20200114.0,20200129,20200520,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-00224,HIKMA,,52.0,YR,,F,Y,74.0,KG,20200520.0,,CN,US,US,2020,Q2,Adult
173389372,17338937,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,TABLETS,,2020,Q2,Atrial fibrillation,,2020,Q2,2,F,200805.0,20200114.0,20200129,20200520,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-00224,HIKMA,,52.0,YR,,F,Y,74.0,KG,20200520.0,,CN,US,US,2020,Q2,Adult
173389372,17338937,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,TABLETS,,2020,Q2,Back pain,,2020,Q2,2,F,200805.0,20200114.0,20200129,20200520,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-00224,HIKMA,,52.0,YR,,F,Y,74.0,KG,20200520.0,,CN,US,US,2020,Q2,Adult
173389372,17338937,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,TABLETS,,2020,Q2,Chest pain,,2020,Q2,2,F,200805.0,20200114.0,20200129,20200520,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-00224,HIKMA,,52.0,YR,,F,Y,74.0,KG,20200520.0,,CN,US,US,2020,Q2,Adult
173389372,17338937,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,TABLETS,,2020,Q2,Contusion,,2020,Q2,2,F,200805.0,20200114.0,20200129,20200520,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-00224,HIKMA,,52.0,YR,,F,Y,74.0,KG,20200520.0,,CN,US,US,2020,Q2,Adult
173389372,17338937,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,TABLETS,,2020,Q2,Diabetes mellitus,,2020,Q2,2,F,200805.0,20200114.0,20200129,20200520,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-00224,HIKMA,,52.0,YR,,F,Y,74.0,KG,20200520.0,,CN,US,US,2020,Q2,Adult
173389372,17338937,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,TABLETS,,2020,Q2,Gingival bleeding,,2020,Q2,2,F,200805.0,20200114.0,20200129,20200520,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-00224,HIKMA,,52.0,YR,,F,Y,74.0,KG,20200520.0,,CN,US,US,2020,Q2,Adult
173389372,17338937,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,TABLETS,,2020,Q2,Glomerular filtration rate decreased,,2020,Q2,2,F,200805.0,20200114.0,20200129,20200520,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-00224,HIKMA,,52.0,YR,,F,Y,74.0,KG,20200520.0,,CN,US,US,2020,Q2,Adult
173389372,17338937,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,TABLETS,,2020,Q2,Gout,,2020,Q2,2,F,200805.0,20200114.0,20200129,20200520,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-00224,HIKMA,,52.0,YR,,F,Y,74.0,KG,20200520.0,,CN,US,US,2020,Q2,Adult
173389372,17338937,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,TABLETS,,2020,Q2,Headache,,2020,Q2,2,F,200805.0,20200114.0,20200129,20200520,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-00224,HIKMA,,52.0,YR,,F,Y,74.0,KG,20200520.0,,CN,US,US,2020,Q2,Adult
173389372,17338937,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,TABLETS,,2020,Q2,Hypoaesthesia,,2020,Q2,2,F,200805.0,20200114.0,20200129,20200520,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-00224,HIKMA,,52.0,YR,,F,Y,74.0,KG,20200520.0,,CN,US,US,2020,Q2,Adult
173389372,17338937,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,TABLETS,,2020,Q2,Insomnia,,2020,Q2,2,F,200805.0,20200114.0,20200129,20200520,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-00224,HIKMA,,52.0,YR,,F,Y,74.0,KG,20200520.0,,CN,US,US,2020,Q2,Adult
173389372,17338937,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,TABLETS,,2020,Q2,Myocardial infarction,,2020,Q2,2,F,200805.0,20200114.0,20200129,20200520,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-00224,HIKMA,,52.0,YR,,F,Y,74.0,KG,20200520.0,,CN,US,US,2020,Q2,Adult
173389372,17338937,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,TABLETS,,2020,Q2,Sinus disorder,,2020,Q2,2,F,200805.0,20200114.0,20200129,20200520,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-00224,HIKMA,,52.0,YR,,F,Y,74.0,KG,20200520.0,,CN,US,US,2020,Q2,Adult
173389372,17338937,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,TABLETS,,2020,Q2,Weight decreased,,2020,Q2,2,F,200805.0,20200114.0,20200129,20200520,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-00224,HIKMA,,52.0,YR,,F,Y,74.0,KG,20200520.0,,CN,US,US,2020,Q2,Adult
173648272,17364827,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Transplacental,10 MILLIGRAM,,,D,,,,,10.0,MG,,,2020,Q2,Congenital hydrocephalus,,2020,Q2,2,F,,20200605.0,20200204,20200616,EXP,GB-MHRA-ADR 23357992,GB-EMCURE PHARMACEUTICALS LTD-2016-EPL-0192,EMCURE,,20.0,WK,,,Y,,,20200616.0,,MD,GB,GB,2020,Q2,Youth
173648272,17364827,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Transplacental,10 MILLIGRAM,,,D,,,,,10.0,MG,,,2020,Q2,Foetal exposure during pregnancy,,2020,Q2,2,F,,20200605.0,20200204,20200616,EXP,GB-MHRA-ADR 23357992,GB-EMCURE PHARMACEUTICALS LTD-2016-EPL-0192,EMCURE,,20.0,WK,,,Y,,,20200616.0,,MD,GB,GB,2020,Q2,Youth
174138212,17413821,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,202293.0,10.0,MG,TABLET,QD,2020,Q2,Euglycaemic diabetic ketoacidosis,,2020,Q2,2,F,,20200612.0,20200213,20200618,EXP,,KR-ASTRAZENECA-2019SF31785,ASTRAZENECA,,76.0,YR,,F,Y,,,20200618.0,,HP,KR,KR,2020,Q2,Elderly
174138212,17413821,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,202293.0,10.0,MG,TABLET,QD,2020,Q2,Hypernatraemia,,2020,Q2,2,F,,20200612.0,20200213,20200618,EXP,,KR-ASTRAZENECA-2019SF31785,ASTRAZENECA,,76.0,YR,,F,Y,,,20200618.0,,HP,KR,KR,2020,Q2,Elderly
174138212,17413821,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,202293.0,10.0,MG,TABLET,QD,2020,Q2,Hypokalaemia,,2020,Q2,2,F,,20200612.0,20200213,20200618,EXP,,KR-ASTRAZENECA-2019SF31785,ASTRAZENECA,,76.0,YR,,F,Y,,,20200618.0,,HP,KR,KR,2020,Q2,Elderly
174138212,17413821,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,202293.0,10.0,MG,TABLET,QD,2020,Q2,Hypovolaemia,,2020,Q2,2,F,,20200612.0,20200213,20200618,EXP,,KR-ASTRAZENECA-2019SF31785,ASTRAZENECA,,76.0,YR,,F,Y,,,20200618.0,,HP,KR,KR,2020,Q2,Elderly
174138212,17413821,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,202293.0,10.0,MG,TABLET,QD,2020,Q2,Euglycaemic diabetic ketoacidosis,,2020,Q2,2,F,,20200612.0,20200213,20200618,EXP,,KR-ASTRAZENECA-2019SF31785,ASTRAZENECA,,76.0,YR,,F,Y,,,20200618.0,,HP,KR,KR,2020,Q2,Elderly
174138212,17413821,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,202293.0,10.0,MG,TABLET,QD,2020,Q2,Hypernatraemia,,2020,Q2,2,F,,20200612.0,20200213,20200618,EXP,,KR-ASTRAZENECA-2019SF31785,ASTRAZENECA,,76.0,YR,,F,Y,,,20200618.0,,HP,KR,KR,2020,Q2,Elderly
174138212,17413821,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,202293.0,10.0,MG,TABLET,QD,2020,Q2,Hypokalaemia,,2020,Q2,2,F,,20200612.0,20200213,20200618,EXP,,KR-ASTRAZENECA-2019SF31785,ASTRAZENECA,,76.0,YR,,F,Y,,,20200618.0,,HP,KR,KR,2020,Q2,Elderly
174138212,17413821,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,202293.0,10.0,MG,TABLET,QD,2020,Q2,Hypovolaemia,,2020,Q2,2,F,,20200612.0,20200213,20200618,EXP,,KR-ASTRAZENECA-2019SF31785,ASTRAZENECA,,76.0,YR,,F,Y,,,20200618.0,,HP,KR,KR,2020,Q2,Elderly
174253732,17425373,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2020,Q2,Colon cancer stage III,,2020,Q2,2,F,20180604.0,20200522.0,20200217,20200604,EXP,,US-MYLANLABS-2020M1016394,MYLAN,,73.0,YR,,M,Y,127.0,KG,20200604.0,,LW,US,US,2020,Q2,Elderly
174328854,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q2,Arthralgia,,2020,Q2,4,F,2019.0,20200428.0,20200219,20200505,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200505.0,,CN,US,US,2020,Q2,Elderly
174328854,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q2,Atrial fibrillation,,2020,Q2,4,F,2019.0,20200428.0,20200219,20200505,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200505.0,,CN,US,US,2020,Q2,Elderly
174328854,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q2,Blood cholesterol increased,,2020,Q2,4,F,2019.0,20200428.0,20200219,20200505,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200505.0,,CN,US,US,2020,Q2,Elderly
174328854,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q2,Chest pain,,2020,Q2,4,F,2019.0,20200428.0,20200219,20200505,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200505.0,,CN,US,US,2020,Q2,Elderly
174328854,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q2,Chronic obstructive pulmonary disease,,2020,Q2,4,F,2019.0,20200428.0,20200219,20200505,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200505.0,,CN,US,US,2020,Q2,Elderly
174328854,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q2,Diabetic neuropathy,,2020,Q2,4,F,2019.0,20200428.0,20200219,20200505,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200505.0,,CN,US,US,2020,Q2,Elderly
174328854,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q2,Flushing,,2020,Q2,4,F,2019.0,20200428.0,20200219,20200505,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200505.0,,CN,US,US,2020,Q2,Elderly
174328854,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q2,Gastrooesophageal reflux disease,,2020,Q2,4,F,2019.0,20200428.0,20200219,20200505,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200505.0,,CN,US,US,2020,Q2,Elderly
174328854,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q2,Heart rate irregular,,2020,Q2,4,F,2019.0,20200428.0,20200219,20200505,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200505.0,,CN,US,US,2020,Q2,Elderly
174328854,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q2,Hypertension,,2020,Q2,4,F,2019.0,20200428.0,20200219,20200505,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200505.0,,CN,US,US,2020,Q2,Elderly
174328854,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q2,Infection,,2020,Q2,4,F,2019.0,20200428.0,20200219,20200505,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200505.0,,CN,US,US,2020,Q2,Elderly
174328854,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q2,Mobility decreased,,2020,Q2,4,F,2019.0,20200428.0,20200219,20200505,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200505.0,,CN,US,US,2020,Q2,Elderly
174328854,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q2,Pain,,2020,Q2,4,F,2019.0,20200428.0,20200219,20200505,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200505.0,,CN,US,US,2020,Q2,Elderly
174328854,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q2,Pyrexia,,2020,Q2,4,F,2019.0,20200428.0,20200219,20200505,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200505.0,,CN,US,US,2020,Q2,Elderly
174328854,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q2,Sleep apnoea syndrome,,2020,Q2,4,F,2019.0,20200428.0,20200219,20200505,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200505.0,,CN,US,US,2020,Q2,Elderly
174328854,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q2,Systemic inflammatory response syndrome,,2020,Q2,4,F,2019.0,20200428.0,20200219,20200505,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200505.0,,CN,US,US,2020,Q2,Elderly
174328854,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q2,Tachycardia,,2020,Q2,4,F,2019.0,20200428.0,20200219,20200505,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200505.0,,CN,US,US,2020,Q2,Elderly
174328854,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q2,Type 1 diabetes mellitus,,2020,Q2,4,F,2019.0,20200428.0,20200219,20200505,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200505.0,,CN,US,US,2020,Q2,Elderly
174328854,17432885,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,QD,2020,Q2,Viral infection,,2020,Q2,4,F,2019.0,20200428.0,20200219,20200505,EXP,,US-ABBVIE-19K-163-3169422-00,ABBVIE,,68.0,YR,,M,Y,122.13,KG,20200505.0,,CN,US,US,2020,Q2,Elderly
175259462,17525946,2,SS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,"10 MG, DAILY",,,Y,,,,,10.0,MG,,QD,2020,Q2,Diabetic ketoacidosis,,2020,Q2,2,F,20200124.0,20200615.0,20200310,20200618,EXP,GB-MHRA-EYC 00219110,GB-ELI_LILLY_AND_COMPANY-GB202003003120,ELI LILLY AND CO,,78.0,YR,,F,Y,64.41,KG,20200618.0,,HP,GB,GB,2020,Q2,Elderly
175467542,17546754,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2020,Q2,Abnormal loss of weight,,2020,Q2,2,F,20190624.0,20200326.0,20200316,20200406,EXP,,GB-NOVOPROD-710766,NOVO NORDISK,,61.0,YR,,M,Y,99.0,KG,20200406.0,,MD,GB,GB,2020,Q2,Adult
175467542,17546754,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2020,Q2,Lethargy,,2020,Q2,2,F,20190624.0,20200326.0,20200316,20200406,EXP,,GB-NOVOPROD-710766,NOVO NORDISK,,61.0,YR,,M,Y,99.0,KG,20200406.0,,MD,GB,GB,2020,Q2,Adult
175467542,17546754,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2020,Q2,Nausea,,2020,Q2,2,F,20190624.0,20200326.0,20200316,20200406,EXP,,GB-NOVOPROD-710766,NOVO NORDISK,,61.0,YR,,M,Y,99.0,KG,20200406.0,,MD,GB,GB,2020,Q2,Adult
175467542,17546754,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2020,Q2,Vomiting,,2020,Q2,2,F,20190624.0,20200326.0,20200316,20200406,EXP,,GB-NOVOPROD-710766,NOVO NORDISK,,61.0,YR,,M,Y,99.0,KG,20200406.0,,MD,GB,GB,2020,Q2,Adult
175532462,17553246,16,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Abscess,,2020,Q2,2,F,20160228.0,20200519.0,20200318,20200527,EXP,,US-ASTRAZENECA-2020SE36893,ASTRAZENECA,,19954.0,DY,,F,Y,98.0,KG,20200527.0,,,US,US,2020,Q2,Elderly
175532462,17553246,16,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Abscess limb,,2020,Q2,2,F,20160228.0,20200519.0,20200318,20200527,EXP,,US-ASTRAZENECA-2020SE36893,ASTRAZENECA,,19954.0,DY,,F,Y,98.0,KG,20200527.0,,,US,US,2020,Q2,Elderly
175532462,17553246,16,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Cellulitis,,2020,Q2,2,F,20160228.0,20200519.0,20200318,20200527,EXP,,US-ASTRAZENECA-2020SE36893,ASTRAZENECA,,19954.0,DY,,F,Y,98.0,KG,20200527.0,,,US,US,2020,Q2,Elderly
175532462,17553246,16,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Fournier's gangrene,,2020,Q2,2,F,20160228.0,20200519.0,20200318,20200527,EXP,,US-ASTRAZENECA-2020SE36893,ASTRAZENECA,,19954.0,DY,,F,Y,98.0,KG,20200527.0,,,US,US,2020,Q2,Elderly
175532462,17553246,16,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Leukocytosis,,2020,Q2,2,F,20160228.0,20200519.0,20200318,20200527,EXP,,US-ASTRAZENECA-2020SE36893,ASTRAZENECA,,19954.0,DY,,F,Y,98.0,KG,20200527.0,,,US,US,2020,Q2,Elderly
175532462,17553246,16,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Necrotising fasciitis,,2020,Q2,2,F,20160228.0,20200519.0,20200318,20200527,EXP,,US-ASTRAZENECA-2020SE36893,ASTRAZENECA,,19954.0,DY,,F,Y,98.0,KG,20200527.0,,,US,US,2020,Q2,Elderly
175532462,17553246,16,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Perineal abscess,,2020,Q2,2,F,20160228.0,20200519.0,20200318,20200527,EXP,,US-ASTRAZENECA-2020SE36893,ASTRAZENECA,,19954.0,DY,,F,Y,98.0,KG,20200527.0,,,US,US,2020,Q2,Elderly
175532462,17553246,16,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Perineal cellulitis,,2020,Q2,2,F,20160228.0,20200519.0,20200318,20200527,EXP,,US-ASTRAZENECA-2020SE36893,ASTRAZENECA,,19954.0,DY,,F,Y,98.0,KG,20200527.0,,,US,US,2020,Q2,Elderly
175532462,17553246,16,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Perirectal abscess,,2020,Q2,2,F,20160228.0,20200519.0,20200318,20200527,EXP,,US-ASTRAZENECA-2020SE36893,ASTRAZENECA,,19954.0,DY,,F,Y,98.0,KG,20200527.0,,,US,US,2020,Q2,Elderly
175532462,17553246,16,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Sepsis,,2020,Q2,2,F,20160228.0,20200519.0,20200318,20200527,EXP,,US-ASTRAZENECA-2020SE36893,ASTRAZENECA,,19954.0,DY,,F,Y,98.0,KG,20200527.0,,,US,US,2020,Q2,Elderly
175532462,17553246,16,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Vulval abscess,,2020,Q2,2,F,20160228.0,20200519.0,20200318,20200527,EXP,,US-ASTRAZENECA-2020SE36893,ASTRAZENECA,,19954.0,DY,,F,Y,98.0,KG,20200527.0,,,US,US,2020,Q2,Elderly
175584332,17558433,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"1 DOSAGE FORM, ONCE A DAY",,,U,,,,,1.0,DF,,QD,2020,Q2,Visual acuity reduced,,2020,Q2,2,F,,20200415.0,20200319,20200423,EXP,,GB-AUROBINDO-AUR-APL-2020-014039,AUROBINDO,,84.0,YR,,M,Y,85.0,KG,20200424.0,,MD,GB,GB,2020,Q2,Elderly
175731612,17573161,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,,, UNKNOWN,,,,,,,2020,Q2,Hyperglycaemia,,2020,Q2,2,F,20200206.0,20200407.0,20200323,20200416,EXP,,PK-NOVOPROD-718933,NOVO NORDISK,,71.0,YR,,M,Y,82.0,KG,20200416.0,,CN,PK,PK,2020,Q2,Elderly
176164091,17616409,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,TABLET,QD,2020,Q2,Euglycaemic diabetic ketoacidosis,,2020,Q2,1,I,,20200324.0,20200402,20200402,EXP,,GB-ASTRAZENECA-2020SE41950,ASTRAZENECA,,62.0,YR,,M,Y,,,20200402.0,,,GB,GB,2020,Q2,Adult
176210851,17621085,5,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,,,,,,,,,2020,Q2,Drug ineffective,,2020,Q2,1,I,,20200331.0,20200403,20200403,EXP,,NVSC2020CA090179,NOVARTIS,,35.0,YR,,M,Y,,,20200403.0,,HP,CA,CA,2020,Q2,Adult
176210851,17621085,5,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,,,,,,,,,2020,Q2,Musculoskeletal discomfort,,2020,Q2,1,I,,20200331.0,20200403,20200403,EXP,,NVSC2020CA090179,NOVARTIS,,35.0,YR,,M,Y,,,20200403.0,,HP,CA,CA,2020,Q2,Adult
176210851,17621085,5,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,,,,,,,,,2020,Q2,Product prescribing error,,2020,Q2,1,I,,20200331.0,20200403,20200403,EXP,,NVSC2020CA090179,NOVARTIS,,35.0,YR,,M,Y,,,20200403.0,,HP,CA,CA,2020,Q2,Adult
176210851,17621085,5,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,,,,,,,,,2020,Q2,Psoriasis,,2020,Q2,1,I,,20200331.0,20200403,20200403,EXP,,NVSC2020CA090179,NOVARTIS,,35.0,YR,,M,Y,,,20200403.0,,HP,CA,CA,2020,Q2,Adult
176210851,17621085,5,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,U,,,,,,,,,2020,Q2,Psoriatic arthropathy,,2020,Q2,1,I,,20200331.0,20200403,20200403,EXP,,NVSC2020CA090179,NOVARTIS,,35.0,YR,,M,Y,,,20200403.0,,HP,CA,CA,2020,Q2,Adult
176265301,17626530,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q2,Abdominal pain upper,,2020,Q2,1,I,20200131.0,20200327.0,20200404,20200404,EXP,GB-MHRA-EYC 00220725,GB-NOVOPROD-721319,NOVO NORDISK,,72.0,YR,,M,Y,73.0,KG,20200405.0,,MD,GB,GB,2020,Q2,Elderly
176265301,17626530,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q2,Abnormal loss of weight,,2020,Q2,1,I,20200131.0,20200327.0,20200404,20200404,EXP,GB-MHRA-EYC 00220725,GB-NOVOPROD-721319,NOVO NORDISK,,72.0,YR,,M,Y,73.0,KG,20200405.0,,MD,GB,GB,2020,Q2,Elderly
176265301,17626530,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q2,Decreased appetite,,2020,Q2,1,I,20200131.0,20200327.0,20200404,20200404,EXP,GB-MHRA-EYC 00220725,GB-NOVOPROD-721319,NOVO NORDISK,,72.0,YR,,M,Y,73.0,KG,20200405.0,,MD,GB,GB,2020,Q2,Elderly
176265301,17626530,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q2,Vomiting,,2020,Q2,1,I,20200131.0,20200327.0,20200404,20200404,EXP,GB-MHRA-EYC 00220725,GB-NOVOPROD-721319,NOVO NORDISK,,72.0,YR,,M,Y,73.0,KG,20200405.0,,MD,GB,GB,2020,Q2,Elderly
176308021,17630802,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q2,Diabetic ketoacidosis,,2020,Q2,1,I,20200314.0,20200331.0,20200406,20200406,EXP,,GB-ASTRAZENECA-2020SE45141,ASTRAZENECA,,65.0,YR,,F,Y,88.5,KG,20200406.0,,,GB,GB,2020,Q2,Elderly
176321311,17632131,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MILLIGRAM, TWO TIMES A DAY",,,U,U,,,,5.0,MG,TABLET,BID,2020,Q2,Diabetic ketoacidosis,,2020,Q2,1,I,,20200330.0,20200406,20200406,EXP,,PT-AUROBINDO-AUR-APL-2020-016498,AUROBINDO,,60.0,YR,,F,Y,,,20200406.0,,MD,PT,PT,2020,Q2,Adult
176417131,17641713,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,2920.0,MG,N,,,,202293.0,10.0,MG,TABLET,QD,2020,Q2,Fixed eruption,,2020,Q2,1,I,20200317.0,20200331.0,20200408,20200408,EXP,,CN-ASTRAZENECA-2020SE47021,ASTRAZENECA,,47.0,YR,,M,Y,72.0,KG,20200408.0,,HP,CN,CN,2020,Q2,Adult
176417131,17641713,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,2920.0,MG,N,,,,202293.0,10.0,MG,TABLET,QD,2020,Q2,Toothache,,2020,Q2,1,I,20200317.0,20200331.0,20200408,20200408,EXP,,CN-ASTRAZENECA-2020SE47021,ASTRAZENECA,,47.0,YR,,M,Y,72.0,KG,20200408.0,,HP,CN,CN,2020,Q2,Adult
176561462,17656146,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,TABLET,QD,2020,Q2,Acute kidney injury,,2020,Q2,2,F,,20200408.0,20200410,20200414,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-EMD SERONO-E2B_90067976,EMD SERONO INC,FONSECA L. UMA REALIDADE DOS INIBIDORES DE SGLT-2 A TER EM CONTA. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):79.,69.0,YR,,F,Y,,,20200414.0,,HP,PT,PT,2020,Q2,Elderly
176561462,17656146,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,TABLET,QD,2020,Q2,Cardiac failure,,2020,Q2,2,F,,20200408.0,20200410,20200414,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-EMD SERONO-E2B_90067976,EMD SERONO INC,FONSECA L. UMA REALIDADE DOS INIBIDORES DE SGLT-2 A TER EM CONTA. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):79.,69.0,YR,,F,Y,,,20200414.0,,HP,PT,PT,2020,Q2,Elderly
176561462,17656146,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,TABLET,QD,2020,Q2,Dehydration,,2020,Q2,2,F,,20200408.0,20200410,20200414,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-EMD SERONO-E2B_90067976,EMD SERONO INC,FONSECA L. UMA REALIDADE DOS INIBIDORES DE SGLT-2 A TER EM CONTA. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):79.,69.0,YR,,F,Y,,,20200414.0,,HP,PT,PT,2020,Q2,Elderly
176561462,17656146,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,TABLET,QD,2020,Q2,Diabetic ketoacidosis,,2020,Q2,2,F,,20200408.0,20200410,20200414,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-EMD SERONO-E2B_90067976,EMD SERONO INC,FONSECA L. UMA REALIDADE DOS INIBIDORES DE SGLT-2 A TER EM CONTA. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):79.,69.0,YR,,F,Y,,,20200414.0,,HP,PT,PT,2020,Q2,Elderly
176561462,17656146,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,TABLET,QD,2020,Q2,Diabetic metabolic decompensation,,2020,Q2,2,F,,20200408.0,20200410,20200414,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-EMD SERONO-E2B_90067976,EMD SERONO INC,FONSECA L. UMA REALIDADE DOS INIBIDORES DE SGLT-2 A TER EM CONTA. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):79.,69.0,YR,,F,Y,,,20200414.0,,HP,PT,PT,2020,Q2,Elderly
176561462,17656146,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,TABLET,QD,2020,Q2,Drug ineffective,,2020,Q2,2,F,,20200408.0,20200410,20200414,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-EMD SERONO-E2B_90067976,EMD SERONO INC,FONSECA L. UMA REALIDADE DOS INIBIDORES DE SGLT-2 A TER EM CONTA. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):79.,69.0,YR,,F,Y,,,20200414.0,,HP,PT,PT,2020,Q2,Elderly
176561462,17656146,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,TABLET,QD,2020,Q2,Drug interaction,,2020,Q2,2,F,,20200408.0,20200410,20200414,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-EMD SERONO-E2B_90067976,EMD SERONO INC,FONSECA L. UMA REALIDADE DOS INIBIDORES DE SGLT-2 A TER EM CONTA. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):79.,69.0,YR,,F,Y,,,20200414.0,,HP,PT,PT,2020,Q2,Elderly
176561462,17656146,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,TABLET,QD,2020,Q2,Fatigue,,2020,Q2,2,F,,20200408.0,20200410,20200414,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-EMD SERONO-E2B_90067976,EMD SERONO INC,FONSECA L. UMA REALIDADE DOS INIBIDORES DE SGLT-2 A TER EM CONTA. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):79.,69.0,YR,,F,Y,,,20200414.0,,HP,PT,PT,2020,Q2,Elderly
176561462,17656146,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,TABLET,QD,2020,Q2,Food refusal,,2020,Q2,2,F,,20200408.0,20200410,20200414,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-EMD SERONO-E2B_90067976,EMD SERONO INC,FONSECA L. UMA REALIDADE DOS INIBIDORES DE SGLT-2 A TER EM CONTA. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):79.,69.0,YR,,F,Y,,,20200414.0,,HP,PT,PT,2020,Q2,Elderly
176561462,17656146,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,TABLET,QD,2020,Q2,Hypernatraemia,,2020,Q2,2,F,,20200408.0,20200410,20200414,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-EMD SERONO-E2B_90067976,EMD SERONO INC,FONSECA L. UMA REALIDADE DOS INIBIDORES DE SGLT-2 A TER EM CONTA. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):79.,69.0,YR,,F,Y,,,20200414.0,,HP,PT,PT,2020,Q2,Elderly
176561462,17656146,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,TABLET,QD,2020,Q2,Metabolic acidosis,,2020,Q2,2,F,,20200408.0,20200410,20200414,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-EMD SERONO-E2B_90067976,EMD SERONO INC,FONSECA L. UMA REALIDADE DOS INIBIDORES DE SGLT-2 A TER EM CONTA. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):79.,69.0,YR,,F,Y,,,20200414.0,,HP,PT,PT,2020,Q2,Elderly
176561462,17656146,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,TABLET,QD,2020,Q2,Off label use,,2020,Q2,2,F,,20200408.0,20200410,20200414,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-EMD SERONO-E2B_90067976,EMD SERONO INC,FONSECA L. UMA REALIDADE DOS INIBIDORES DE SGLT-2 A TER EM CONTA. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):79.,69.0,YR,,F,Y,,,20200414.0,,HP,PT,PT,2020,Q2,Elderly
176561462,17656146,2,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,TABLET,QD,2020,Q2,Urine ketone body present,,2020,Q2,2,F,,20200408.0,20200410,20200414,EXP,PT-EMA-DD-20190508-KUMARSINGH_A-133720,PT-EMD SERONO-E2B_90067976,EMD SERONO INC,FONSECA L. UMA REALIDADE DOS INIBIDORES DE SGLT-2 A TER EM CONTA. REVISTA PORTUGUESA DE DIABETES. 2019;14(1):79.,69.0,YR,,F,Y,,,20200414.0,,HP,PT,PT,2020,Q2,Elderly
176562961,17656296,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q2,Diabetic ketosis,,2020,Q2,1,I,20200225.0,20200402.0,20200410,20200410,EXP,,GB-ASTRAZENECA-2020SE46278,ASTRAZENECA,,50.0,YR,,F,Y,,,20200410.0,,,GB,GB,2020,Q2,Adult
176670011,17667001,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,TABLET,QD,2020,Q2,Arthralgia,,2020,Q2,1,I,200805.0,20190711.0,20200414,20200414,PER,,US-ASTELLAS-2019US028633,ASTELLAS,,52.0,YR,,F,Y,,,20200414.0,,CN,US,US,2020,Q2,Adult
176670011,17667001,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,TABLET,QD,2020,Q2,Atrial fibrillation,,2020,Q2,1,I,200805.0,20190711.0,20200414,20200414,PER,,US-ASTELLAS-2019US028633,ASTELLAS,,52.0,YR,,F,Y,,,20200414.0,,CN,US,US,2020,Q2,Adult
176670011,17667001,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,TABLET,QD,2020,Q2,Diabetes mellitus,,2020,Q2,1,I,200805.0,20190711.0,20200414,20200414,PER,,US-ASTELLAS-2019US028633,ASTELLAS,,52.0,YR,,F,Y,,,20200414.0,,CN,US,US,2020,Q2,Adult
176670011,17667001,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,TABLET,QD,2020,Q2,Glomerular filtration rate decreased,,2020,Q2,1,I,200805.0,20190711.0,20200414,20200414,PER,,US-ASTELLAS-2019US028633,ASTELLAS,,52.0,YR,,F,Y,,,20200414.0,,CN,US,US,2020,Q2,Adult
176670011,17667001,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,TABLET,QD,2020,Q2,Immunosuppressant drug level decreased,,2020,Q2,1,I,200805.0,20190711.0,20200414,20200414,PER,,US-ASTELLAS-2019US028633,ASTELLAS,,52.0,YR,,F,Y,,,20200414.0,,CN,US,US,2020,Q2,Adult
176670011,17667001,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,TABLET,QD,2020,Q2,Myocardial infarction,,2020,Q2,1,I,200805.0,20190711.0,20200414,20200414,PER,,US-ASTELLAS-2019US028633,ASTELLAS,,52.0,YR,,F,Y,,,20200414.0,,CN,US,US,2020,Q2,Adult
176670011,17667001,16,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,TABLET,QD,2020,Q2,Product storage error,,2020,Q2,1,I,200805.0,20190711.0,20200414,20200414,PER,,US-ASTELLAS-2019US028633,ASTELLAS,,52.0,YR,,F,Y,,,20200414.0,,CN,US,US,2020,Q2,Adult
176791991,17679199,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,TABLET,QD,2020,Q2,Diabetic ketoacidosis,,2020,Q2,1,I,20200328.0,20200413.0,20200417,20200417,EXP,,GB-ASTRAZENECA-2020SE50248,ASTRAZENECA,,59.0,YR,,M,Y,,,20200417.0,,PH,GB,GB,2020,Q2,Adult
176807431,17680743,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MILLIGRAM, BID",,,U,U,,,,5.0,MG,TABLET,BID,2020,Q2,Diabetic ketoacidosis,,2020,Q2,1,I,,20200414.0,20200417,20200417,EXP,,PT-MYLANLABS-2020M1038925,MYLAN,"MENDONCA F, SILVA M. M, SOUTO S, FREITAS P, CARVALHO D.. P078 - DIABETIC KETOACIDOSIS AFTER BARIATRIC SURGERY: ABOUT A CLINICAL CASE.. REVISTA PORTUGUESA DE DIABETES. 2020;15(1):86-93",60.0,YR,,F,Y,,,20200417.0,,MD,PT,PT,2020,Q2,Adult
176815535,17681553,5,C,"DAPAGLIFLOZIN, METFORMIN",,2,Unknown,"0.5 DF, QD",,,,,,,,0.5,DF,,QD,2020,Q2,Blood cholesterol increased,,2020,Q2,5,F,20200116.0,20200604.0,20200417,20200609,EXP,,NVSC2020IN015550,NOVARTIS,,48.0,YR,,M,Y,107.0,KG,20200609.0,,CN,COUNTRY NOT SPECIFIED,IN,2020,Q2,Adult
176815535,17681553,5,C,"DAPAGLIFLOZIN, METFORMIN",,2,Unknown,"0.5 DF, QD",,,,,,,,0.5,DF,,QD,2020,Q2,Blood triglycerides increased,,2020,Q2,5,F,20200116.0,20200604.0,20200417,20200609,EXP,,NVSC2020IN015550,NOVARTIS,,48.0,YR,,M,Y,107.0,KG,20200609.0,,CN,COUNTRY NOT SPECIFIED,IN,2020,Q2,Adult
176815535,17681553,5,C,"DAPAGLIFLOZIN, METFORMIN",,2,Unknown,"0.5 DF, QD",,,,,,,,0.5,DF,,QD,2020,Q2,Discomfort,,2020,Q2,5,F,20200116.0,20200604.0,20200417,20200609,EXP,,NVSC2020IN015550,NOVARTIS,,48.0,YR,,M,Y,107.0,KG,20200609.0,,CN,COUNTRY NOT SPECIFIED,IN,2020,Q2,Adult
176815535,17681553,5,C,"DAPAGLIFLOZIN, METFORMIN",,2,Unknown,"0.5 DF, QD",,,,,,,,0.5,DF,,QD,2020,Q2,Glycosylated haemoglobin increased,,2020,Q2,5,F,20200116.0,20200604.0,20200417,20200609,EXP,,NVSC2020IN015550,NOVARTIS,,48.0,YR,,M,Y,107.0,KG,20200609.0,,CN,COUNTRY NOT SPECIFIED,IN,2020,Q2,Adult
176815535,17681553,5,C,"DAPAGLIFLOZIN, METFORMIN",,2,Unknown,"0.5 DF, QD",,,,,,,,0.5,DF,,QD,2020,Q2,Hyperglycaemia,,2020,Q2,5,F,20200116.0,20200604.0,20200417,20200609,EXP,,NVSC2020IN015550,NOVARTIS,,48.0,YR,,M,Y,107.0,KG,20200609.0,,CN,COUNTRY NOT SPECIFIED,IN,2020,Q2,Adult
176815535,17681553,5,C,"DAPAGLIFLOZIN, METFORMIN",,2,Unknown,"0.5 DF, QD",,,,,,,,0.5,DF,,QD,2020,Q2,Pain in extremity,,2020,Q2,5,F,20200116.0,20200604.0,20200417,20200609,EXP,,NVSC2020IN015550,NOVARTIS,,48.0,YR,,M,Y,107.0,KG,20200609.0,,CN,COUNTRY NOT SPECIFIED,IN,2020,Q2,Adult
176815535,17681553,5,C,"DAPAGLIFLOZIN, METFORMIN",,2,Unknown,"0.5 DF, QD",,,,,,,,0.5,DF,,QD,2020,Q2,Weight decreased,,2020,Q2,5,F,20200116.0,20200604.0,20200417,20200609,EXP,,NVSC2020IN015550,NOVARTIS,,48.0,YR,,M,Y,107.0,KG,20200609.0,,CN,COUNTRY NOT SPECIFIED,IN,2020,Q2,Adult
176815535,17681553,5,C,"DAPAGLIFLOZIN, METFORMIN",,2,Unknown,"0.5 DF, QD",,,,,,,,0.5,DF,,QD,2020,Q2,Weight increased,,2020,Q2,5,F,20200116.0,20200604.0,20200417,20200609,EXP,,NVSC2020IN015550,NOVARTIS,,48.0,YR,,M,Y,107.0,KG,20200609.0,,CN,COUNTRY NOT SPECIFIED,IN,2020,Q2,Adult
176826661,17682666,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,85.0,MG,U,,,,202293.0,5.0,MG,TABLET,QD,2020,Q2,Dyspepsia,,2020,Q2,1,I,20200326.0,20200414.0,20200419,20200419,EXP,,GB-ASTRAZENECA-2020SE50660,ASTRAZENECA,,33.0,YR,,F,Y,128.0,KG,20200419.0,,MD,GB,GB,2020,Q2,Young Adult
176882141,17688214,1,PS,DAPAGLIFLOZIN-METFORMIN,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,,,,Y,,,,205649.0,,,TABLET,,2020,Q2,Euglycaemic diabetic ketoacidosis,,2020,Q2,1,I,,20200412.0,20200421,20200421,EXP,,US-ASTRAZENECA-2020SE50714,ASTRAZENECA,,57.0,YR,,F,Y,,,20200421.0,,HP,US,US,2020,Q2,Adult
176975471,17697547,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,TABLET,QD,2020,Q2,Ketoacidosis,,2020,Q2,1,I,20200408.0,20200417.0,20200423,20200423,EXP,,DE-ASTRAZENECA-2020SE52276,ASTRAZENECA,,67.0,YR,,M,Y,108.0,KG,20200423.0,,MD,DE,DE,2020,Q2,Elderly
177040711,17704071,2,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,,,,,2020,Q2,Decreased appetite,,2020,Q2,1,I,20191114.0,20200414.0,20200424,20200424,EXP,GB-MHRA-EYC 00221203,GB-ELI_LILLY_AND_COMPANY-GB202004005249,ELI LILLY AND CO,,69.0,YR,,M,Y,80.0,KG,20200424.0,,MD,GB,GB,2020,Q2,Elderly
177040711,17704071,2,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,,,,,2020,Q2,Hypoglycaemia,,2020,Q2,1,I,20191114.0,20200414.0,20200424,20200424,EXP,GB-MHRA-EYC 00221203,GB-ELI_LILLY_AND_COMPANY-GB202004005249,ELI LILLY AND CO,,69.0,YR,,M,Y,80.0,KG,20200424.0,,MD,GB,GB,2020,Q2,Elderly
177040711,17704071,2,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,U,,,,,,,,,2020,Q2,Syncope,,2020,Q2,1,I,20191114.0,20200414.0,20200424,20200424,EXP,GB-MHRA-EYC 00221203,GB-ELI_LILLY_AND_COMPANY-GB202004005249,ELI LILLY AND CO,,69.0,YR,,M,Y,80.0,KG,20200424.0,,MD,GB,GB,2020,Q2,Elderly
177118472,17711847,6,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2020,Q2,Cerebrovascular accident,,2020,Q2,2,F,20200417.0,20200615.0,20200427,20200623,EXP,,IE-MYLANLABS-2020M1040893,MYLAN,,60.0,YR,,M,Y,,,20200623.0,,MD,IE,IE,2020,Q2,Adult
177118472,17711847,6,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2020,Q2,Myocardial infarction,,2020,Q2,2,F,20200417.0,20200615.0,20200427,20200623,EXP,,IE-MYLANLABS-2020M1040893,MYLAN,,60.0,YR,,M,Y,,,20200623.0,,MD,IE,IE,2020,Q2,Adult
177169091,17716909,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,U,,,,,10.0,MG,,QD,2020,Q2,Ketoacidosis,,2020,Q2,1,I,20200408.0,20200422.0,20200428,20200428,EXP,DE-BFARM-20004692,DE-009507513-2004DEU006732,MERCK,,67.0,YR,,M,Y,108.0,KG,20200428.0,,MD,DE,DE,2020,Q2,Elderly
177173731,17717373,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,5.0,MG,TABLET,QD,2020,Q2,Decreased appetite,,2020,Q2,1,I,,20200421.0,20200428,20200428,EXP,,CN-ASTRAZENECA-2020SE56152,ASTRAZENECA,,63.0,YR,,M,Y,,,20200428.0,,MD,CN,CN,2020,Q2,Adult
177173731,17717373,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,5.0,MG,TABLET,QD,2020,Q2,Ketoacidosis,,2020,Q2,1,I,,20200421.0,20200428,20200428,EXP,,CN-ASTRAZENECA-2020SE56152,ASTRAZENECA,,63.0,YR,,M,Y,,,20200428.0,,MD,CN,CN,2020,Q2,Adult
177173731,17717373,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,5.0,MG,TABLET,QD,2020,Q2,Nausea,,2020,Q2,1,I,,20200421.0,20200428,20200428,EXP,,CN-ASTRAZENECA-2020SE56152,ASTRAZENECA,,63.0,YR,,M,Y,,,20200428.0,,MD,CN,CN,2020,Q2,Adult
177173731,17717373,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,5.0,MG,TABLET,QD,2020,Q2,Vomiting,,2020,Q2,1,I,,20200421.0,20200428,20200428,EXP,,CN-ASTRAZENECA-2020SE56152,ASTRAZENECA,,63.0,YR,,M,Y,,,20200428.0,,MD,CN,CN,2020,Q2,Adult
177176881,17717688,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,, JJ2181,,202293.0,10.0,MG,TABLET,QD,2020,Q2,Ketoacidosis,,2020,Q2,1,I,20181124.0,20200421.0,20200428,20200428,EXP,,CN-ASTRAZENECA-2020SE56123,ASTRAZENECA,,48.0,YR,,F,Y,,,20200428.0,,MD,CN,CN,2020,Q2,Adult
177176881,17717688,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,, JJ2181,,202293.0,10.0,MG,TABLET,QD,2020,Q2,Nausea,,2020,Q2,1,I,20181124.0,20200421.0,20200428,20200428,EXP,,CN-ASTRAZENECA-2020SE56123,ASTRAZENECA,,48.0,YR,,F,Y,,,20200428.0,,MD,CN,CN,2020,Q2,Adult
177176881,17717688,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,, JJ2181,,202293.0,10.0,MG,TABLET,QD,2020,Q2,Vomiting,,2020,Q2,1,I,20181124.0,20200421.0,20200428,20200428,EXP,,CN-ASTRAZENECA-2020SE56123,ASTRAZENECA,,48.0,YR,,F,Y,,,20200428.0,,MD,CN,CN,2020,Q2,Adult
177222571,17722257,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Transplacental,UNK,,,D,,,,,,,,,2020,Q2,Congenital hydrocephalus,,2020,Q2,1,I,,20200427.0,20200429,20200429,EXP,,NVSC2020GB113629,NOVARTIS,,20.0,WK,,,Y,,,20200429.0,,HP,GB,GB,2020,Q2,Youth
177308763,17730876,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,D,,,,,10.0,MG,,QD,2020,Q2,Abdominal distension,,2020,Q2,3,F,20200124.0,20200518.0,20200430,20200522,EXP,GB-MHRA-EYC 00217369,NVSC2020GB116158,NOVARTIS,,61.0,YR,,F,Y,,,20200522.0,,HP,GB,GB,2020,Q2,Adult
177308763,17730876,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,D,,,,,10.0,MG,,QD,2020,Q2,Chronic obstructive pulmonary disease,,2020,Q2,3,F,20200124.0,20200518.0,20200430,20200522,EXP,GB-MHRA-EYC 00217369,NVSC2020GB116158,NOVARTIS,,61.0,YR,,F,Y,,,20200522.0,,HP,GB,GB,2020,Q2,Adult
177308763,17730876,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,D,,,,,10.0,MG,,QD,2020,Q2,Diarrhoea,,2020,Q2,3,F,20200124.0,20200518.0,20200430,20200522,EXP,GB-MHRA-EYC 00217369,NVSC2020GB116158,NOVARTIS,,61.0,YR,,F,Y,,,20200522.0,,HP,GB,GB,2020,Q2,Adult
177308763,17730876,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,D,,,,,10.0,MG,,QD,2020,Q2,Hypotension,,2020,Q2,3,F,20200124.0,20200518.0,20200430,20200522,EXP,GB-MHRA-EYC 00217369,NVSC2020GB116158,NOVARTIS,,61.0,YR,,F,Y,,,20200522.0,,HP,GB,GB,2020,Q2,Adult
177308763,17730876,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,D,,,,,10.0,MG,,QD,2020,Q2,Hypothermia,,2020,Q2,3,F,20200124.0,20200518.0,20200430,20200522,EXP,GB-MHRA-EYC 00217369,NVSC2020GB116158,NOVARTIS,,61.0,YR,,F,Y,,,20200522.0,,HP,GB,GB,2020,Q2,Adult
177308763,17730876,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,D,,,,,10.0,MG,,QD,2020,Q2,Lactic acidosis,,2020,Q2,3,F,20200124.0,20200518.0,20200430,20200522,EXP,GB-MHRA-EYC 00217369,NVSC2020GB116158,NOVARTIS,,61.0,YR,,F,Y,,,20200522.0,,HP,GB,GB,2020,Q2,Adult
177308763,17730876,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,D,,,,,10.0,MG,,QD,2020,Q2,Multiple organ dysfunction syndrome,,2020,Q2,3,F,20200124.0,20200518.0,20200430,20200522,EXP,GB-MHRA-EYC 00217369,NVSC2020GB116158,NOVARTIS,,61.0,YR,,F,Y,,,20200522.0,,HP,GB,GB,2020,Q2,Adult
177348471,17734847,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,5 MG DAILY EVERY MORNING,,,Y,, LA3403,,,,,TABLET,,2020,Q2,Chest discomfort,,2020,Q2,1,I,20200316.0,20200424.0,20200501,20200501,EXP,,CN-ASTRAZENECA-2020SE56929,ASTRAZENECA,,17898.0,DY,,F,Y,38.0,KG,20200501.0,,HP,CN,CN,2020,Q2,Elderly
177348471,17734847,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,5 MG DAILY EVERY MORNING,,,Y,, LA3403,,,,,TABLET,,2020,Q2,Diabetic ketoacidosis,,2020,Q2,1,I,20200316.0,20200424.0,20200501,20200501,EXP,,CN-ASTRAZENECA-2020SE56929,ASTRAZENECA,,17898.0,DY,,F,Y,38.0,KG,20200501.0,,HP,CN,CN,2020,Q2,Elderly
177526001,17752600,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,TABLET,,2020,Q2,Glucose urine present,,2020,Q2,1,I,,20200428.0,20200506,20200506,EXP,,CN-ASTRAZENECA-2020SE58599,ASTRAZENECA,,63.0,YR,,M,Y,,,20200506.0,,MD,CN,CN,2020,Q2,Adult
177526001,17752600,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,TABLET,,2020,Q2,Ketoacidosis,,2020,Q2,1,I,,20200428.0,20200506,20200506,EXP,,CN-ASTRAZENECA-2020SE58599,ASTRAZENECA,,63.0,YR,,M,Y,,,20200506.0,,MD,CN,CN,2020,Q2,Adult
177526001,17752600,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,TABLET,,2020,Q2,Urine ketone body,,2020,Q2,1,I,,20200428.0,20200506,20200506,EXP,,CN-ASTRAZENECA-2020SE58599,ASTRAZENECA,,63.0,YR,,M,Y,,,20200506.0,,MD,CN,CN,2020,Q2,Adult
177851211,17785121,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,202293.0,10.0,MG,TABLET,QD,2020,Q2,Diabetic neuropathic ulcer,,2020,Q2,1,I,2018.0,20200506.0,20200514,20200514,EXP,,GB-ASTRAZENECA-2020SE60525,ASTRAZENECA,,61.0,YR,,M,Y,,,20200514.0,,,GB,GB,2020,Q2,Adult
177851211,17785121,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,202293.0,10.0,MG,TABLET,QD,2020,Q2,Ischaemia,,2020,Q2,1,I,2018.0,20200506.0,20200514,20200514,EXP,,GB-ASTRAZENECA-2020SE60525,ASTRAZENECA,,61.0,YR,,M,Y,,,20200514.0,,,GB,GB,2020,Q2,Adult
177851211,17785121,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,202293.0,10.0,MG,TABLET,QD,2020,Q2,Necrosis,,2020,Q2,1,I,2018.0,20200506.0,20200514,20200514,EXP,,GB-ASTRAZENECA-2020SE60525,ASTRAZENECA,,61.0,YR,,M,Y,,,20200514.0,,,GB,GB,2020,Q2,Adult
177986341,17798634,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MG STOPPED 2 DAYS PRIOR THE CABG SURGERY,,,D,,,,202293.0,,,TABLET,,2020,Q2,Euglycaemic diabetic ketoacidosis,,2020,Q2,1,I,,20200508.0,20200518,20200518,EXP,,US-ASTRAZENECA-2020SE62528,ASTRAZENECA,,51.0,YR,,M,Y,,,20200518.0,,HP,US,US,2020,Q2,Adult
178131161,17813116,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,,QD,2020,Q2,Visual acuity reduced,,2020,Q2,1,I,,20200518.0,20200521,20200521,EXP,GB-MHRA-TPP23417663C955200YC1582798187752,NVSC2020GB136669,NOVARTIS,,84.0,YR,,M,Y,85.0,KG,20200521.0,,HP,GB,GB,2020,Q2,Elderly
178168051,17816805,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Abdominal discomfort,,2020,Q2,1,I,,20200519.0,20200522,20200522,EXP,,CA-PFIZER INC-2020202843,PFIZER,,55.0,YR,,M,Y,,,20200522.0,,HP,CA,CA,2020,Q2,Adult
178168051,17816805,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Arthralgia,,2020,Q2,1,I,,20200519.0,20200522,20200522,EXP,,CA-PFIZER INC-2020202843,PFIZER,,55.0,YR,,M,Y,,,20200522.0,,HP,CA,CA,2020,Q2,Adult
178168051,17816805,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Arthritis,,2020,Q2,1,I,,20200519.0,20200522,20200522,EXP,,CA-PFIZER INC-2020202843,PFIZER,,55.0,YR,,M,Y,,,20200522.0,,HP,CA,CA,2020,Q2,Adult
178168051,17816805,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Blood glucose abnormal,,2020,Q2,1,I,,20200519.0,20200522,20200522,EXP,,CA-PFIZER INC-2020202843,PFIZER,,55.0,YR,,M,Y,,,20200522.0,,HP,CA,CA,2020,Q2,Adult
178168051,17816805,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Cataract,,2020,Q2,1,I,,20200519.0,20200522,20200522,EXP,,CA-PFIZER INC-2020202843,PFIZER,,55.0,YR,,M,Y,,,20200522.0,,HP,CA,CA,2020,Q2,Adult
178168051,17816805,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Dizziness,,2020,Q2,1,I,,20200519.0,20200522,20200522,EXP,,CA-PFIZER INC-2020202843,PFIZER,,55.0,YR,,M,Y,,,20200522.0,,HP,CA,CA,2020,Q2,Adult
178168051,17816805,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Ear discomfort,,2020,Q2,1,I,,20200519.0,20200522,20200522,EXP,,CA-PFIZER INC-2020202843,PFIZER,,55.0,YR,,M,Y,,,20200522.0,,HP,CA,CA,2020,Q2,Adult
178168051,17816805,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Erythema,,2020,Q2,1,I,,20200519.0,20200522,20200522,EXP,,CA-PFIZER INC-2020202843,PFIZER,,55.0,YR,,M,Y,,,20200522.0,,HP,CA,CA,2020,Q2,Adult
178168051,17816805,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Fatigue,,2020,Q2,1,I,,20200519.0,20200522,20200522,EXP,,CA-PFIZER INC-2020202843,PFIZER,,55.0,YR,,M,Y,,,20200522.0,,HP,CA,CA,2020,Q2,Adult
178168051,17816805,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Headache,,2020,Q2,1,I,,20200519.0,20200522,20200522,EXP,,CA-PFIZER INC-2020202843,PFIZER,,55.0,YR,,M,Y,,,20200522.0,,HP,CA,CA,2020,Q2,Adult
178168051,17816805,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Hypotension,,2020,Q2,1,I,,20200519.0,20200522,20200522,EXP,,CA-PFIZER INC-2020202843,PFIZER,,55.0,YR,,M,Y,,,20200522.0,,HP,CA,CA,2020,Q2,Adult
178168051,17816805,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Inappropriate schedule of product administration,,2020,Q2,1,I,,20200519.0,20200522,20200522,EXP,,CA-PFIZER INC-2020202843,PFIZER,,55.0,YR,,M,Y,,,20200522.0,,HP,CA,CA,2020,Q2,Adult
178168051,17816805,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Joint stiffness,,2020,Q2,1,I,,20200519.0,20200522,20200522,EXP,,CA-PFIZER INC-2020202843,PFIZER,,55.0,YR,,M,Y,,,20200522.0,,HP,CA,CA,2020,Q2,Adult
178168051,17816805,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Muscle spasms,,2020,Q2,1,I,,20200519.0,20200522,20200522,EXP,,CA-PFIZER INC-2020202843,PFIZER,,55.0,YR,,M,Y,,,20200522.0,,HP,CA,CA,2020,Q2,Adult
178168051,17816805,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Nausea,,2020,Q2,1,I,,20200519.0,20200522,20200522,EXP,,CA-PFIZER INC-2020202843,PFIZER,,55.0,YR,,M,Y,,,20200522.0,,HP,CA,CA,2020,Q2,Adult
178168051,17816805,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Rheumatoid arthritis,,2020,Q2,1,I,,20200519.0,20200522,20200522,EXP,,CA-PFIZER INC-2020202843,PFIZER,,55.0,YR,,M,Y,,,20200522.0,,HP,CA,CA,2020,Q2,Adult
178168051,17816805,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Vomiting,,2020,Q2,1,I,,20200519.0,20200522,20200522,EXP,,CA-PFIZER INC-2020202843,PFIZER,,55.0,YR,,M,Y,,,20200522.0,,HP,CA,CA,2020,Q2,Adult
178206911,17820691,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Abdominal discomfort,,2020,Q2,1,I,,20200520.0,20200525,20200525,EXP,,CA-PFIZER INC-2020202532,PFIZER,,55.0,YR,,M,Y,,,20200525.0,,HP,CA,CA,2020,Q2,Adult
178206911,17820691,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Arthralgia,,2020,Q2,1,I,,20200520.0,20200525,20200525,EXP,,CA-PFIZER INC-2020202532,PFIZER,,55.0,YR,,M,Y,,,20200525.0,,HP,CA,CA,2020,Q2,Adult
178206911,17820691,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Arthritis,,2020,Q2,1,I,,20200520.0,20200525,20200525,EXP,,CA-PFIZER INC-2020202532,PFIZER,,55.0,YR,,M,Y,,,20200525.0,,HP,CA,CA,2020,Q2,Adult
178206911,17820691,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Blood glucose abnormal,,2020,Q2,1,I,,20200520.0,20200525,20200525,EXP,,CA-PFIZER INC-2020202532,PFIZER,,55.0,YR,,M,Y,,,20200525.0,,HP,CA,CA,2020,Q2,Adult
178206911,17820691,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Cataract,,2020,Q2,1,I,,20200520.0,20200525,20200525,EXP,,CA-PFIZER INC-2020202532,PFIZER,,55.0,YR,,M,Y,,,20200525.0,,HP,CA,CA,2020,Q2,Adult
178206911,17820691,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Cholelithiasis,,2020,Q2,1,I,,20200520.0,20200525,20200525,EXP,,CA-PFIZER INC-2020202532,PFIZER,,55.0,YR,,M,Y,,,20200525.0,,HP,CA,CA,2020,Q2,Adult
178206911,17820691,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Dizziness,,2020,Q2,1,I,,20200520.0,20200525,20200525,EXP,,CA-PFIZER INC-2020202532,PFIZER,,55.0,YR,,M,Y,,,20200525.0,,HP,CA,CA,2020,Q2,Adult
178206911,17820691,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Ear discomfort,,2020,Q2,1,I,,20200520.0,20200525,20200525,EXP,,CA-PFIZER INC-2020202532,PFIZER,,55.0,YR,,M,Y,,,20200525.0,,HP,CA,CA,2020,Q2,Adult
178206911,17820691,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Erythema,,2020,Q2,1,I,,20200520.0,20200525,20200525,EXP,,CA-PFIZER INC-2020202532,PFIZER,,55.0,YR,,M,Y,,,20200525.0,,HP,CA,CA,2020,Q2,Adult
178206911,17820691,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Facial neuralgia,,2020,Q2,1,I,,20200520.0,20200525,20200525,EXP,,CA-PFIZER INC-2020202532,PFIZER,,55.0,YR,,M,Y,,,20200525.0,,HP,CA,CA,2020,Q2,Adult
178206911,17820691,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Fatigue,,2020,Q2,1,I,,20200520.0,20200525,20200525,EXP,,CA-PFIZER INC-2020202532,PFIZER,,55.0,YR,,M,Y,,,20200525.0,,HP,CA,CA,2020,Q2,Adult
178206911,17820691,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Groin pain,,2020,Q2,1,I,,20200520.0,20200525,20200525,EXP,,CA-PFIZER INC-2020202532,PFIZER,,55.0,YR,,M,Y,,,20200525.0,,HP,CA,CA,2020,Q2,Adult
178206911,17820691,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Headache,,2020,Q2,1,I,,20200520.0,20200525,20200525,EXP,,CA-PFIZER INC-2020202532,PFIZER,,55.0,YR,,M,Y,,,20200525.0,,HP,CA,CA,2020,Q2,Adult
178206911,17820691,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Hypotension,,2020,Q2,1,I,,20200520.0,20200525,20200525,EXP,,CA-PFIZER INC-2020202532,PFIZER,,55.0,YR,,M,Y,,,20200525.0,,HP,CA,CA,2020,Q2,Adult
178206911,17820691,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Inappropriate schedule of product administration,,2020,Q2,1,I,,20200520.0,20200525,20200525,EXP,,CA-PFIZER INC-2020202532,PFIZER,,55.0,YR,,M,Y,,,20200525.0,,HP,CA,CA,2020,Q2,Adult
178206911,17820691,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Joint stiffness,,2020,Q2,1,I,,20200520.0,20200525,20200525,EXP,,CA-PFIZER INC-2020202532,PFIZER,,55.0,YR,,M,Y,,,20200525.0,,HP,CA,CA,2020,Q2,Adult
178206911,17820691,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Labyrinthitis,,2020,Q2,1,I,,20200520.0,20200525,20200525,EXP,,CA-PFIZER INC-2020202532,PFIZER,,55.0,YR,,M,Y,,,20200525.0,,HP,CA,CA,2020,Q2,Adult
178206911,17820691,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Muscle spasms,,2020,Q2,1,I,,20200520.0,20200525,20200525,EXP,,CA-PFIZER INC-2020202532,PFIZER,,55.0,YR,,M,Y,,,20200525.0,,HP,CA,CA,2020,Q2,Adult
178206911,17820691,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Nausea,,2020,Q2,1,I,,20200520.0,20200525,20200525,EXP,,CA-PFIZER INC-2020202532,PFIZER,,55.0,YR,,M,Y,,,20200525.0,,HP,CA,CA,2020,Q2,Adult
178206911,17820691,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Rheumatoid arthritis,,2020,Q2,1,I,,20200520.0,20200525,20200525,EXP,,CA-PFIZER INC-2020202532,PFIZER,,55.0,YR,,M,Y,,,20200525.0,,HP,CA,CA,2020,Q2,Adult
178206911,17820691,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Visual impairment,,2020,Q2,1,I,,20200520.0,20200525,20200525,EXP,,CA-PFIZER INC-2020202532,PFIZER,,55.0,YR,,M,Y,,,20200525.0,,HP,CA,CA,2020,Q2,Adult
178206911,17820691,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, 1X/DAY",,,,,,,,5.0,MG,,QD,2020,Q2,Vomiting,,2020,Q2,1,I,,20200520.0,20200525,20200525,EXP,,CA-PFIZER INC-2020202532,PFIZER,,55.0,YR,,M,Y,,,20200525.0,,HP,CA,CA,2020,Q2,Adult
178244211,17824421,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,TABLET,QD,2020,Q2,Decreased vibratory sense,,2020,Q2,1,I,2016.0,20180306.0,20200526,20200526,EXP,,DE-EMD SERONO-E2B_90030980,EMD SERONO INC,"HOLLENRIEDER V, UNKNOWN, UNKNOWN, UNKNOWN. BEINSCHMERZEN WEGER GUTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11 (3):6-7.",61.0,YR,,F,Y,97.0,KG,20200526.0,,MD,DE,DE,2020,Q2,Adult
178244211,17824421,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,TABLET,QD,2020,Q2,Diabetes mellitus inadequate control,,2020,Q2,1,I,2016.0,20180306.0,20200526,20200526,EXP,,DE-EMD SERONO-E2B_90030980,EMD SERONO INC,"HOLLENRIEDER V, UNKNOWN, UNKNOWN, UNKNOWN. BEINSCHMERZEN WEGER GUTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11 (3):6-7.",61.0,YR,,F,Y,97.0,KG,20200526.0,,MD,DE,DE,2020,Q2,Adult
178244211,17824421,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,TABLET,QD,2020,Q2,Gastrointestinal disorder,,2020,Q2,1,I,2016.0,20180306.0,20200526,20200526,EXP,,DE-EMD SERONO-E2B_90030980,EMD SERONO INC,"HOLLENRIEDER V, UNKNOWN, UNKNOWN, UNKNOWN. BEINSCHMERZEN WEGER GUTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11 (3):6-7.",61.0,YR,,F,Y,97.0,KG,20200526.0,,MD,DE,DE,2020,Q2,Adult
178244211,17824421,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,TABLET,QD,2020,Q2,Limb discomfort,,2020,Q2,1,I,2016.0,20180306.0,20200526,20200526,EXP,,DE-EMD SERONO-E2B_90030980,EMD SERONO INC,"HOLLENRIEDER V, UNKNOWN, UNKNOWN, UNKNOWN. BEINSCHMERZEN WEGER GUTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11 (3):6-7.",61.0,YR,,F,Y,97.0,KG,20200526.0,,MD,DE,DE,2020,Q2,Adult
178244211,17824421,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,TABLET,QD,2020,Q2,Neuropathy peripheral,,2020,Q2,1,I,2016.0,20180306.0,20200526,20200526,EXP,,DE-EMD SERONO-E2B_90030980,EMD SERONO INC,"HOLLENRIEDER V, UNKNOWN, UNKNOWN, UNKNOWN. BEINSCHMERZEN WEGER GUTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11 (3):6-7.",61.0,YR,,F,Y,97.0,KG,20200526.0,,MD,DE,DE,2020,Q2,Adult
178244211,17824421,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,TABLET,QD,2020,Q2,Pain in extremity,,2020,Q2,1,I,2016.0,20180306.0,20200526,20200526,EXP,,DE-EMD SERONO-E2B_90030980,EMD SERONO INC,"HOLLENRIEDER V, UNKNOWN, UNKNOWN, UNKNOWN. BEINSCHMERZEN WEGER GUTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11 (3):6-7.",61.0,YR,,F,Y,97.0,KG,20200526.0,,MD,DE,DE,2020,Q2,Adult
178244211,17824421,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,TABLET,QD,2020,Q2,Sensory disturbance,,2020,Q2,1,I,2016.0,20180306.0,20200526,20200526,EXP,,DE-EMD SERONO-E2B_90030980,EMD SERONO INC,"HOLLENRIEDER V, UNKNOWN, UNKNOWN, UNKNOWN. BEINSCHMERZEN WEGER GUTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11 (3):6-7.",61.0,YR,,F,Y,97.0,KG,20200526.0,,MD,DE,DE,2020,Q2,Adult
178244211,17824421,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,TABLET,QD,2020,Q2,Sleep disorder,,2020,Q2,1,I,2016.0,20180306.0,20200526,20200526,EXP,,DE-EMD SERONO-E2B_90030980,EMD SERONO INC,"HOLLENRIEDER V, UNKNOWN, UNKNOWN, UNKNOWN. BEINSCHMERZEN WEGER GUTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11 (3):6-7.",61.0,YR,,F,Y,97.0,KG,20200526.0,,MD,DE,DE,2020,Q2,Adult
178244211,17824421,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,TABLET,QD,2020,Q2,Temperature perception test abnormal,,2020,Q2,1,I,2016.0,20180306.0,20200526,20200526,EXP,,DE-EMD SERONO-E2B_90030980,EMD SERONO INC,"HOLLENRIEDER V, UNKNOWN, UNKNOWN, UNKNOWN. BEINSCHMERZEN WEGER GUTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11 (3):6-7.",61.0,YR,,F,Y,97.0,KG,20200526.0,,MD,DE,DE,2020,Q2,Adult
178244211,17824421,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,TABLET,QD,2020,Q2,Visual impairment,,2020,Q2,1,I,2016.0,20180306.0,20200526,20200526,EXP,,DE-EMD SERONO-E2B_90030980,EMD SERONO INC,"HOLLENRIEDER V, UNKNOWN, UNKNOWN, UNKNOWN. BEINSCHMERZEN WEGER GUTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11 (3):6-7.",61.0,YR,,F,Y,97.0,KG,20200526.0,,MD,DE,DE,2020,Q2,Adult
178244211,17824421,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DOSE REDUCED,,,Y,,,,,,,TABLET,,2020,Q2,Decreased vibratory sense,,2020,Q2,1,I,2016.0,20180306.0,20200526,20200526,EXP,,DE-EMD SERONO-E2B_90030980,EMD SERONO INC,"HOLLENRIEDER V, UNKNOWN, UNKNOWN, UNKNOWN. BEINSCHMERZEN WEGER GUTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11 (3):6-7.",61.0,YR,,F,Y,97.0,KG,20200526.0,,MD,DE,DE,2020,Q2,Adult
178244211,17824421,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DOSE REDUCED,,,Y,,,,,,,TABLET,,2020,Q2,Diabetes mellitus inadequate control,,2020,Q2,1,I,2016.0,20180306.0,20200526,20200526,EXP,,DE-EMD SERONO-E2B_90030980,EMD SERONO INC,"HOLLENRIEDER V, UNKNOWN, UNKNOWN, UNKNOWN. BEINSCHMERZEN WEGER GUTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11 (3):6-7.",61.0,YR,,F,Y,97.0,KG,20200526.0,,MD,DE,DE,2020,Q2,Adult
178244211,17824421,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DOSE REDUCED,,,Y,,,,,,,TABLET,,2020,Q2,Gastrointestinal disorder,,2020,Q2,1,I,2016.0,20180306.0,20200526,20200526,EXP,,DE-EMD SERONO-E2B_90030980,EMD SERONO INC,"HOLLENRIEDER V, UNKNOWN, UNKNOWN, UNKNOWN. BEINSCHMERZEN WEGER GUTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11 (3):6-7.",61.0,YR,,F,Y,97.0,KG,20200526.0,,MD,DE,DE,2020,Q2,Adult
178244211,17824421,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DOSE REDUCED,,,Y,,,,,,,TABLET,,2020,Q2,Limb discomfort,,2020,Q2,1,I,2016.0,20180306.0,20200526,20200526,EXP,,DE-EMD SERONO-E2B_90030980,EMD SERONO INC,"HOLLENRIEDER V, UNKNOWN, UNKNOWN, UNKNOWN. BEINSCHMERZEN WEGER GUTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11 (3):6-7.",61.0,YR,,F,Y,97.0,KG,20200526.0,,MD,DE,DE,2020,Q2,Adult
178244211,17824421,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DOSE REDUCED,,,Y,,,,,,,TABLET,,2020,Q2,Neuropathy peripheral,,2020,Q2,1,I,2016.0,20180306.0,20200526,20200526,EXP,,DE-EMD SERONO-E2B_90030980,EMD SERONO INC,"HOLLENRIEDER V, UNKNOWN, UNKNOWN, UNKNOWN. BEINSCHMERZEN WEGER GUTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11 (3):6-7.",61.0,YR,,F,Y,97.0,KG,20200526.0,,MD,DE,DE,2020,Q2,Adult
178244211,17824421,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DOSE REDUCED,,,Y,,,,,,,TABLET,,2020,Q2,Pain in extremity,,2020,Q2,1,I,2016.0,20180306.0,20200526,20200526,EXP,,DE-EMD SERONO-E2B_90030980,EMD SERONO INC,"HOLLENRIEDER V, UNKNOWN, UNKNOWN, UNKNOWN. BEINSCHMERZEN WEGER GUTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11 (3):6-7.",61.0,YR,,F,Y,97.0,KG,20200526.0,,MD,DE,DE,2020,Q2,Adult
178244211,17824421,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DOSE REDUCED,,,Y,,,,,,,TABLET,,2020,Q2,Sensory disturbance,,2020,Q2,1,I,2016.0,20180306.0,20200526,20200526,EXP,,DE-EMD SERONO-E2B_90030980,EMD SERONO INC,"HOLLENRIEDER V, UNKNOWN, UNKNOWN, UNKNOWN. BEINSCHMERZEN WEGER GUTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11 (3):6-7.",61.0,YR,,F,Y,97.0,KG,20200526.0,,MD,DE,DE,2020,Q2,Adult
178244211,17824421,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DOSE REDUCED,,,Y,,,,,,,TABLET,,2020,Q2,Sleep disorder,,2020,Q2,1,I,2016.0,20180306.0,20200526,20200526,EXP,,DE-EMD SERONO-E2B_90030980,EMD SERONO INC,"HOLLENRIEDER V, UNKNOWN, UNKNOWN, UNKNOWN. BEINSCHMERZEN WEGER GUTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11 (3):6-7.",61.0,YR,,F,Y,97.0,KG,20200526.0,,MD,DE,DE,2020,Q2,Adult
178244211,17824421,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DOSE REDUCED,,,Y,,,,,,,TABLET,,2020,Q2,Temperature perception test abnormal,,2020,Q2,1,I,2016.0,20180306.0,20200526,20200526,EXP,,DE-EMD SERONO-E2B_90030980,EMD SERONO INC,"HOLLENRIEDER V, UNKNOWN, UNKNOWN, UNKNOWN. BEINSCHMERZEN WEGER GUTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11 (3):6-7.",61.0,YR,,F,Y,97.0,KG,20200526.0,,MD,DE,DE,2020,Q2,Adult
178244211,17824421,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,DOSE REDUCED,,,Y,,,,,,,TABLET,,2020,Q2,Visual impairment,,2020,Q2,1,I,2016.0,20180306.0,20200526,20200526,EXP,,DE-EMD SERONO-E2B_90030980,EMD SERONO INC,"HOLLENRIEDER V, UNKNOWN, UNKNOWN, UNKNOWN. BEINSCHMERZEN WEGER GUTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11 (3):6-7.",61.0,YR,,F,Y,97.0,KG,20200526.0,,MD,DE,DE,2020,Q2,Adult
178272021,17827202,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,,,,,,,,,10.0,MG,,QD,2020,Q2,Creatinine renal clearance decreased,,2020,Q2,1,I,,20200519.0,20200527,20200527,EXP,,CA-ROCHE-2604344,ROCHE,,56.0,YR,,F,Y,,,20200527.0,,CN,CA,CA,2020,Q2,Adult
178272021,17827202,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,,,,,,,,,10.0,MG,,QD,2020,Q2,Diabetes mellitus inadequate control,,2020,Q2,1,I,,20200519.0,20200527,20200527,EXP,,CA-ROCHE-2604344,ROCHE,,56.0,YR,,F,Y,,,20200527.0,,CN,CA,CA,2020,Q2,Adult
178272021,17827202,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,,,,,,,,,10.0,MG,,QD,2020,Q2,Injection site pain,,2020,Q2,1,I,,20200519.0,20200527,20200527,EXP,,CA-ROCHE-2604344,ROCHE,,56.0,YR,,F,Y,,,20200527.0,,CN,CA,CA,2020,Q2,Adult
178272021,17827202,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,,,,,,,,,10.0,MG,,QD,2020,Q2,Pancreatitis,,2020,Q2,1,I,,20200519.0,20200527,20200527,EXP,,CA-ROCHE-2604344,ROCHE,,56.0,YR,,F,Y,,,20200527.0,,CN,CA,CA,2020,Q2,Adult
178272021,17827202,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,,,,,,,,,10.0,MG,,QD,2020,Q2,Product use issue,,2020,Q2,1,I,,20200519.0,20200527,20200527,EXP,,CA-ROCHE-2604344,ROCHE,,56.0,YR,,F,Y,,,20200527.0,,CN,CA,CA,2020,Q2,Adult
178390801,17839080,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,D,,,,,10.0,MG,TABLET,,2020,Q2,Blood thyroid stimulating hormone decreased,,2020,Q2,1,I,20200501.0,20200520.0,20200529,20200529,EXP,,ES-AUROBINDO-AUR-APL-2020-026220,AUROBINDO,,78.0,YR,,M,Y,,,20200529.0,,MD,ES,ES,2020,Q2,Elderly
178390801,17839080,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,D,,,,,10.0,MG,TABLET,,2020,Q2,Muscular weakness,,2020,Q2,1,I,20200501.0,20200520.0,20200529,20200529,EXP,,ES-AUROBINDO-AUR-APL-2020-026220,AUROBINDO,,78.0,YR,,M,Y,,,20200529.0,,MD,ES,ES,2020,Q2,Elderly
178417951,17841795,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, Q12H",,,U,U,,,,5.0,MG,TABLET,Q12H,2020,Q2,Diabetic ketoacidosis,,2020,Q2,1,I,,20200528.0,20200529,20200529,EXP,,NVSC2020PT148649,NOVARTIS,,60.0,YR,,F,Y,,,20200529.0,,HP,PT,PT,2020,Q2,Adult
178433932,17843393,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1640.0,MG,Y,,,,,5.0,MG,TABLET,QD,2020,Q2,Accidental overdose,,2020,Q2,2,F,20200506.0,20200527.0,20200530,20200604,EXP,,US-ASTRAZENECA-2020SE64941,ASTRAZENECA,,18.0,YR,,F,Y,74.1,KG,20200604.0,,MD,US,US,2020,Q2,Youth
178433932,17843393,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1640.0,MG,Y,,,,,5.0,MG,TABLET,QD,2020,Q2,Accidental overdose,,2020,Q2,2,F,20200506.0,20200527.0,20200530,20200604,EXP,,US-ASTRAZENECA-2020SE64941,ASTRAZENECA,,18.0,YR,,F,Y,74.1,KG,20200604.0,,MD,US,US,2020,Q2,Youth
178433932,17843393,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1640.0,MG,Y,,,,,5.0,MG,TABLET,QD,2020,Q2,Accidental overdose,,2020,Q2,2,F,20200506.0,20200527.0,20200530,20200604,EXP,,US-ASTRAZENECA-2020SE64941,ASTRAZENECA,,18.0,YR,,F,Y,74.1,KG,20200604.0,,MD,US,US,2020,Q2,Youth
178433932,17843393,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1640.0,MG,Y,,,,,5.0,MG,TABLET,QD,2020,Q2,Accidental overdose,,2020,Q2,2,F,20200506.0,20200527.0,20200530,20200604,EXP,,US-ASTRAZENECA-2020SE64941,ASTRAZENECA,,18.0,YR,,F,Y,74.1,KG,20200604.0,,MD,US,US,2020,Q2,Youth
178433932,17843393,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1640.0,MG,Y,,,,,5.0,MG,TABLET,QD,2020,Q2,Accidental overdose,,2020,Q2,2,F,20200506.0,20200527.0,20200530,20200604,EXP,,US-ASTRAZENECA-2020SE64941,ASTRAZENECA,,18.0,YR,,F,Y,74.1,KG,20200604.0,,MD,US,US,2020,Q2,Youth
178433932,17843393,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1640.0,MG,Y,,,,,5.0,MG,TABLET,QD,2020,Q2,Accidental overdose,,2020,Q2,2,F,20200506.0,20200527.0,20200530,20200604,EXP,,US-ASTRAZENECA-2020SE64941,ASTRAZENECA,,18.0,YR,,F,Y,74.1,KG,20200604.0,,MD,US,US,2020,Q2,Youth
178436851,17843685,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,5.0,MG,,QD,2020,Q2,General physical health deterioration,,2020,Q2,1,I,2020.0,20200528.0,20200531,20200531,EXP,,DE-ASTRAZENECA-2020SE69475,ASTRAZENECA,,74.0,YR,,F,Y,85.0,KG,20200601.0,,MD,DE,DE,2020,Q2,Elderly
178436851,17843685,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,5.0,MG,,QD,2020,Q2,Ketoacidosis,,2020,Q2,1,I,2020.0,20200528.0,20200531,20200531,EXP,,DE-ASTRAZENECA-2020SE69475,ASTRAZENECA,,74.0,YR,,F,Y,85.0,KG,20200601.0,,MD,DE,DE,2020,Q2,Elderly
178436851,17843685,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,5.0,MG,,QD,2020,Q2,Vomiting,,2020,Q2,1,I,2020.0,20200528.0,20200531,20200531,EXP,,DE-ASTRAZENECA-2020SE69475,ASTRAZENECA,,74.0,YR,,F,Y,85.0,KG,20200601.0,,MD,DE,DE,2020,Q2,Elderly
178504501,17850450,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,40.0,MG,U,, LB2648,,,10.0,MG,TABLET,QD,2020,Q2,Ketoacidosis,,2020,Q2,1,I,20200401.0,20200524.0,20200602,20200602,EXP,,CN-ASTRAZENECA-2020SE69911,ASTRAZENECA,,31412.0,DY,,F,Y,60.0,KG,20200602.0,,HP,CN,CN,2020,Q2,Elderly
178516991,17851699,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,45.0,MG,Y,,,,202293.0,5.0,MG,TABLET,QD,2020,Q2,Diabetes mellitus inadequate control,,2020,Q2,1,I,20200509.0,20200526.0,20200602,20200602,EXP,,GB-ASTRAZENECA-2020SE68642,ASTRAZENECA,,56.0,YR,,M,Y,75.0,KG,20200602.0,,,GB,GB,2020,Q2,Adult
178516991,17851699,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,45.0,MG,Y,,,,202293.0,5.0,MG,TABLET,QD,2020,Q2,Fournier's gangrene,,2020,Q2,1,I,20200509.0,20200526.0,20200602,20200602,EXP,,GB-ASTRAZENECA-2020SE68642,ASTRAZENECA,,56.0,YR,,M,Y,75.0,KG,20200602.0,,,GB,GB,2020,Q2,Adult
178516991,17851699,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,45.0,MG,Y,,,,202293.0,5.0,MG,TABLET,QD,2020,Q2,Sepsis,,2020,Q2,1,I,20200509.0,20200526.0,20200602,20200602,EXP,,GB-ASTRAZENECA-2020SE68642,ASTRAZENECA,,56.0,YR,,M,Y,75.0,KG,20200602.0,,,GB,GB,2020,Q2,Adult
178650651,17865065,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,, 2003069,,202293.0,,,TABLET,,2020,Q2,Eyelid oedema,,2020,Q2,1,I,20200521.0,20200528.0,20200605,20200605,EXP,,CN-ASTRAZENECA-2020SE71142,ASTRAZENECA,,43.0,YR,,M,Y,86.0,KG,20200605.0,,HP,CN,CN,2020,Q2,Adult
178650651,17865065,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,, 2003069,,202293.0,,,TABLET,,2020,Q2,Pruritus,,2020,Q2,1,I,20200521.0,20200528.0,20200605,20200605,EXP,,CN-ASTRAZENECA-2020SE71142,ASTRAZENECA,,43.0,YR,,M,Y,86.0,KG,20200605.0,,HP,CN,CN,2020,Q2,Adult
178650651,17865065,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,, 2003069,,202293.0,,,TABLET,,2020,Q2,Rash,,2020,Q2,1,I,20200521.0,20200528.0,20200605,20200605,EXP,,CN-ASTRAZENECA-2020SE71142,ASTRAZENECA,,43.0,YR,,M,Y,86.0,KG,20200605.0,,HP,CN,CN,2020,Q2,Adult
178703174,17870317,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",200.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Anal incontinence,,2020,Q2,4,F,20200502.0,20200617.0,20200608,20200619,EXP,,CA-PFIZER INC-2020221646,PFIZER,,75.0,YR,,M,Y,,,20200619.0,,HP,CA,CA,2020,Q2,Elderly
178703174,17870317,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",200.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Fall,,2020,Q2,4,F,20200502.0,20200617.0,20200608,20200619,EXP,,CA-PFIZER INC-2020221646,PFIZER,,75.0,YR,,M,Y,,,20200619.0,,HP,CA,CA,2020,Q2,Elderly
178703174,17870317,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",200.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Fatigue,,2020,Q2,4,F,20200502.0,20200617.0,20200608,20200619,EXP,,CA-PFIZER INC-2020221646,PFIZER,,75.0,YR,,M,Y,,,20200619.0,,HP,CA,CA,2020,Q2,Elderly
178703174,17870317,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",200.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Haemarthrosis,,2020,Q2,4,F,20200502.0,20200617.0,20200608,20200619,EXP,,CA-PFIZER INC-2020221646,PFIZER,,75.0,YR,,M,Y,,,20200619.0,,HP,CA,CA,2020,Q2,Elderly
178703174,17870317,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",200.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Hypotension,,2020,Q2,4,F,20200502.0,20200617.0,20200608,20200619,EXP,,CA-PFIZER INC-2020221646,PFIZER,,75.0,YR,,M,Y,,,20200619.0,,HP,CA,CA,2020,Q2,Elderly
178703174,17870317,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",200.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Loss of consciousness,,2020,Q2,4,F,20200502.0,20200617.0,20200608,20200619,EXP,,CA-PFIZER INC-2020221646,PFIZER,,75.0,YR,,M,Y,,,20200619.0,,HP,CA,CA,2020,Q2,Elderly
178703174,17870317,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",200.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Musculoskeletal pain,,2020,Q2,4,F,20200502.0,20200617.0,20200608,20200619,EXP,,CA-PFIZER INC-2020221646,PFIZER,,75.0,YR,,M,Y,,,20200619.0,,HP,CA,CA,2020,Q2,Elderly
178703174,17870317,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",200.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Pleural effusion,,2020,Q2,4,F,20200502.0,20200617.0,20200608,20200619,EXP,,CA-PFIZER INC-2020221646,PFIZER,,75.0,YR,,M,Y,,,20200619.0,,HP,CA,CA,2020,Q2,Elderly
178703174,17870317,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",200.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Renal cyst,,2020,Q2,4,F,20200502.0,20200617.0,20200608,20200619,EXP,,CA-PFIZER INC-2020221646,PFIZER,,75.0,YR,,M,Y,,,20200619.0,,HP,CA,CA,2020,Q2,Elderly
178703174,17870317,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",200.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Seizure,,2020,Q2,4,F,20200502.0,20200617.0,20200608,20200619,EXP,,CA-PFIZER INC-2020221646,PFIZER,,75.0,YR,,M,Y,,,20200619.0,,HP,CA,CA,2020,Q2,Elderly
178703174,17870317,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",200.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Syncope,,2020,Q2,4,F,20200502.0,20200617.0,20200608,20200619,EXP,,CA-PFIZER INC-2020221646,PFIZER,,75.0,YR,,M,Y,,,20200619.0,,HP,CA,CA,2020,Q2,Elderly
178703174,17870317,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",200.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Anal incontinence,,2020,Q2,4,F,20200502.0,20200617.0,20200608,20200619,EXP,,CA-PFIZER INC-2020221646,PFIZER,,75.0,YR,,M,Y,,,20200619.0,,HP,CA,CA,2020,Q2,Elderly
178703174,17870317,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",200.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Fall,,2020,Q2,4,F,20200502.0,20200617.0,20200608,20200619,EXP,,CA-PFIZER INC-2020221646,PFIZER,,75.0,YR,,M,Y,,,20200619.0,,HP,CA,CA,2020,Q2,Elderly
178703174,17870317,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",200.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Fatigue,,2020,Q2,4,F,20200502.0,20200617.0,20200608,20200619,EXP,,CA-PFIZER INC-2020221646,PFIZER,,75.0,YR,,M,Y,,,20200619.0,,HP,CA,CA,2020,Q2,Elderly
178703174,17870317,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",200.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Haemarthrosis,,2020,Q2,4,F,20200502.0,20200617.0,20200608,20200619,EXP,,CA-PFIZER INC-2020221646,PFIZER,,75.0,YR,,M,Y,,,20200619.0,,HP,CA,CA,2020,Q2,Elderly
178703174,17870317,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",200.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Hypotension,,2020,Q2,4,F,20200502.0,20200617.0,20200608,20200619,EXP,,CA-PFIZER INC-2020221646,PFIZER,,75.0,YR,,M,Y,,,20200619.0,,HP,CA,CA,2020,Q2,Elderly
178703174,17870317,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",200.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Loss of consciousness,,2020,Q2,4,F,20200502.0,20200617.0,20200608,20200619,EXP,,CA-PFIZER INC-2020221646,PFIZER,,75.0,YR,,M,Y,,,20200619.0,,HP,CA,CA,2020,Q2,Elderly
178703174,17870317,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",200.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Musculoskeletal pain,,2020,Q2,4,F,20200502.0,20200617.0,20200608,20200619,EXP,,CA-PFIZER INC-2020221646,PFIZER,,75.0,YR,,M,Y,,,20200619.0,,HP,CA,CA,2020,Q2,Elderly
178703174,17870317,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",200.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Pleural effusion,,2020,Q2,4,F,20200502.0,20200617.0,20200608,20200619,EXP,,CA-PFIZER INC-2020221646,PFIZER,,75.0,YR,,M,Y,,,20200619.0,,HP,CA,CA,2020,Q2,Elderly
178703174,17870317,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",200.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Renal cyst,,2020,Q2,4,F,20200502.0,20200617.0,20200608,20200619,EXP,,CA-PFIZER INC-2020221646,PFIZER,,75.0,YR,,M,Y,,,20200619.0,,HP,CA,CA,2020,Q2,Elderly
178703174,17870317,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",200.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Seizure,,2020,Q2,4,F,20200502.0,20200617.0,20200608,20200619,EXP,,CA-PFIZER INC-2020221646,PFIZER,,75.0,YR,,M,Y,,,20200619.0,,HP,CA,CA,2020,Q2,Elderly
178703174,17870317,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",200.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q2,Syncope,,2020,Q2,4,F,20200502.0,20200617.0,20200608,20200619,EXP,,CA-PFIZER INC-2020221646,PFIZER,,75.0,YR,,M,Y,,,20200619.0,,HP,CA,CA,2020,Q2,Elderly
178703733,17870373,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q2,Asthenia,,2020,Q2,3,F,20200522.0,20200611.0,20200608,20200622,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202005009493,ELI LILLY AND CO,,57.0,YR,,M,Y,51.0,KG,20200622.0,,CN,CN,CN,2020,Q2,Adult
178703733,17870373,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q2,Decreased appetite,,2020,Q2,3,F,20200522.0,20200611.0,20200608,20200622,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202005009493,ELI LILLY AND CO,,57.0,YR,,M,Y,51.0,KG,20200622.0,,CN,CN,CN,2020,Q2,Adult
178703733,17870373,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q2,Diarrhoea,,2020,Q2,3,F,20200522.0,20200611.0,20200608,20200622,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202005009493,ELI LILLY AND CO,,57.0,YR,,M,Y,51.0,KG,20200622.0,,CN,CN,CN,2020,Q2,Adult
178703733,17870373,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q2,Mood swings,,2020,Q2,3,F,20200522.0,20200611.0,20200608,20200622,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202005009493,ELI LILLY AND CO,,57.0,YR,,M,Y,51.0,KG,20200622.0,,CN,CN,CN,2020,Q2,Adult
178703733,17870373,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q2,Nausea,,2020,Q2,3,F,20200522.0,20200611.0,20200608,20200622,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202005009493,ELI LILLY AND CO,,57.0,YR,,M,Y,51.0,KG,20200622.0,,CN,CN,CN,2020,Q2,Adult
178703733,17870373,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q2,Vomiting,,2020,Q2,3,F,20200522.0,20200611.0,20200608,20200622,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202005009493,ELI LILLY AND CO,,57.0,YR,,M,Y,51.0,KG,20200622.0,,CN,CN,CN,2020,Q2,Adult
178703733,17870373,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q2,Weight decreased,,2020,Q2,3,F,20200522.0,20200611.0,20200608,20200622,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202005009493,ELI LILLY AND CO,,57.0,YR,,M,Y,51.0,KG,20200622.0,,CN,CN,CN,2020,Q2,Adult
178709611,17870961,4,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DF, QD (1-0-0-0, TABLETTEN)",,,U,,,,,1.0,DF,TABLET,QD,2020,Q2,Abdominal pain upper,,2020,Q2,1,I,,20200603.0,20200608,20200608,EXP,,NVSC2020DE156507,NOVARTIS,,70.0,YR,,M,Y,,,20200608.0,,HP,DE,DE,2020,Q2,Elderly
178709611,17870961,4,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DF, QD (1-0-0-0, TABLETTEN)",,,U,,,,,1.0,DF,TABLET,QD,2020,Q2,Anaemia,,2020,Q2,1,I,,20200603.0,20200608,20200608,EXP,,NVSC2020DE156507,NOVARTIS,,70.0,YR,,M,Y,,,20200608.0,,HP,DE,DE,2020,Q2,Elderly
178709611,17870961,4,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DF, QD (1-0-0-0, TABLETTEN)",,,U,,,,,1.0,DF,TABLET,QD,2020,Q2,Dry mouth,,2020,Q2,1,I,,20200603.0,20200608,20200608,EXP,,NVSC2020DE156507,NOVARTIS,,70.0,YR,,M,Y,,,20200608.0,,HP,DE,DE,2020,Q2,Elderly
178709611,17870961,4,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DF, QD (1-0-0-0, TABLETTEN)",,,U,,,,,1.0,DF,TABLET,QD,2020,Q2,Fatigue,,2020,Q2,1,I,,20200603.0,20200608,20200608,EXP,,NVSC2020DE156507,NOVARTIS,,70.0,YR,,M,Y,,,20200608.0,,HP,DE,DE,2020,Q2,Elderly
178709611,17870961,4,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DF, QD (1-0-0-0, TABLETTEN)",,,U,,,,,1.0,DF,TABLET,QD,2020,Q2,General physical health deterioration,,2020,Q2,1,I,,20200603.0,20200608,20200608,EXP,,NVSC2020DE156507,NOVARTIS,,70.0,YR,,M,Y,,,20200608.0,,HP,DE,DE,2020,Q2,Elderly
178709611,17870961,4,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"1 DF, QD (1-0-0-0, TABLETTEN)",,,U,,,,,1.0,DF,TABLET,QD,2020,Q2,Night sweats,,2020,Q2,1,I,,20200603.0,20200608,20200608,EXP,,NVSC2020DE156507,NOVARTIS,,70.0,YR,,M,Y,,,20200608.0,,HP,DE,DE,2020,Q2,Elderly
178724051,17872405,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",30.0,MG,Y,U, 2003069,,,10.0,MG,,QD,2020,Q2,Eyelid oedema,,2020,Q2,1,I,20200521.0,20200528.0,20200608,20200608,EXP,,CN-NOVOPROD-731403,NOVO NORDISK,,43.0,YR,,M,Y,86.0,KG,20200608.0,,HP,CN,CN,2020,Q2,Adult
178724051,17872405,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",30.0,MG,Y,U, 2003069,,,10.0,MG,,QD,2020,Q2,Pruritus,,2020,Q2,1,I,20200521.0,20200528.0,20200608,20200608,EXP,,CN-NOVOPROD-731403,NOVO NORDISK,,43.0,YR,,M,Y,86.0,KG,20200608.0,,HP,CN,CN,2020,Q2,Adult
178724051,17872405,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",30.0,MG,Y,U, 2003069,,,10.0,MG,,QD,2020,Q2,Rash,,2020,Q2,1,I,20200521.0,20200528.0,20200608,20200608,EXP,,CN-NOVOPROD-731403,NOVO NORDISK,,43.0,YR,,M,Y,86.0,KG,20200608.0,,HP,CN,CN,2020,Q2,Adult
178838191,17883819,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1820.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q2,Otitis externa,,2020,Q2,1,I,,20200609.0,20200611,20200611,EXP,,GB-ASTRAZENECA-2020SE74424,ASTRAZENECA,,65.0,YR,,M,Y,71.0,KG,20200611.0,,,GB,GB,2020,Q2,Elderly
178855831,17885583,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"1 DOSAGE FORM, QD",,,,, UNK,,,1.0,DF,,QD,2020,Q2,Visual acuity reduced,,2020,Q2,1,I,,20200605.0,20200611,20200611,EXP,,GB-SYNTHON BV-IN51PV20_53761,SYNTHON,,84.0,YR,,M,Y,85.0,KG,20200611.0,,MD,NL,GB,2020,Q2,Elderly
178901441,17890144,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,10.0,MG,TABLET,QD,2020,Q2,Diabetic ketoacidosis,,2020,Q2,1,I,,20200604.0,20200612,20200612,EXP,,GB-ASTRAZENECA-2020SE73097,ASTRAZENECA,,58.0,YR,,F,Y,85.0,KG,20200612.0,,HP,GB,GB,2020,Q2,Adult
178957751,17895775,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Cerebral small vessel ischaemic disease,,2020,Q2,1,I,20200301.0,20200605.0,20200615,20200615,PER,,GB-AMGEN-GBRSP2020090966,AMGEN,,65.0,YR,E,F,Y,,,20200615.0,,HP,GB,GB,2020,Q2,Elderly
178957751,17895775,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q2,Hypoaesthesia,,2020,Q2,1,I,20200301.0,20200605.0,20200615,20200615,PER,,GB-AMGEN-GBRSP2020090966,AMGEN,,65.0,YR,E,F,Y,,,20200615.0,,HP,GB,GB,2020,Q2,Elderly
179093021,17909302,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,2975.0,MG,U,,,,202293.0,5.0,MG,TABLET,QD,2020,Q2,Necrotising fasciitis,,2020,Q2,1,I,,20200609.0,20200617,20200617,EXP,,GB-ASTRAZENECA-2020SE74415,ASTRAZENECA,,64.0,YR,,M,Y,128.0,KG,20200617.0,,MD,GB,GB,2020,Q2,Adult
179100711,17910071,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,TABLET,QD,2020,Q2,Acute kidney injury,,2020,Q2,1,I,,20200608.0,20200617,20200617,EXP,,US-ASTRAZENECA-2020SE76801,ASTRAZENECA,,59.0,YR,,M,Y,111.4,KG,20200617.0,,HP,KR,KR,2020,Q2,Adult
179100711,17910071,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,TABLET,QD,2020,Q2,Blood pressure increased,,2020,Q2,1,I,,20200608.0,20200617,20200617,EXP,,US-ASTRAZENECA-2020SE76801,ASTRAZENECA,,59.0,YR,,M,Y,111.4,KG,20200617.0,,HP,KR,KR,2020,Q2,Adult
179100711,17910071,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,TABLET,QD,2020,Q2,Dehydration,,2020,Q2,1,I,,20200608.0,20200617,20200617,EXP,,US-ASTRAZENECA-2020SE76801,ASTRAZENECA,,59.0,YR,,M,Y,111.4,KG,20200617.0,,HP,KR,KR,2020,Q2,Adult
179100711,17910071,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,TABLET,QD,2020,Q2,Hepatic steatosis,,2020,Q2,1,I,,20200608.0,20200617,20200617,EXP,,US-ASTRAZENECA-2020SE76801,ASTRAZENECA,,59.0,YR,,M,Y,111.4,KG,20200617.0,,HP,KR,KR,2020,Q2,Adult
179100711,17910071,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,TABLET,QD,2020,Q2,Hyperglycaemic hyperosmolar nonketotic syndrome,,2020,Q2,1,I,,20200608.0,20200617,20200617,EXP,,US-ASTRAZENECA-2020SE76801,ASTRAZENECA,,59.0,YR,,M,Y,111.4,KG,20200617.0,,HP,KR,KR,2020,Q2,Adult
179100711,17910071,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,TABLET,QD,2020,Q2,Hyperlipidaemia,,2020,Q2,1,I,,20200608.0,20200617,20200617,EXP,,US-ASTRAZENECA-2020SE76801,ASTRAZENECA,,59.0,YR,,M,Y,111.4,KG,20200617.0,,HP,KR,KR,2020,Q2,Adult
179100711,17910071,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,TABLET,QD,2020,Q2,Left ventricular hypertrophy,,2020,Q2,1,I,,20200608.0,20200617,20200617,EXP,,US-ASTRAZENECA-2020SE76801,ASTRAZENECA,,59.0,YR,,M,Y,111.4,KG,20200617.0,,HP,KR,KR,2020,Q2,Adult
179117341,17911734,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,,10.0,MG,TABLET,,2020,Q2,Diabetic ketoacidosis,,2020,Q2,1,I,20200428.0,20200612.0,20200618,20200618,EXP,,GB-ASTRAZENECA-2020SE75911,ASTRAZENECA,,41.0,YR,,M,Y,93.4,KG,20200618.0,,HP,GB,GB,2020,Q2,Adult
179133081,17913308,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,U,,,,,,,,,2020,Q2,Diabetes mellitus inadequate control,,2020,Q2,1,I,,20200609.0,20200618,20200618,EXP,,ID-EMD SERONO-9168550,EMD SERONO INC,"WIDYSANTO J, LUKITO A. EFFECT OF HYPERGLICEMIA ON THE T WAVE INVERSION. JOURNAL OF ARRHYTHMIA. 2019 DEC 01;35 (1):505.",55.0,YR,,F,Y,,,20200618.0,,HP,ID,ID,2020,Q2,Adult
179133081,17913308,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,U,,,,,,,,,2020,Q2,Electrocardiogram T wave inversion,,2020,Q2,1,I,,20200609.0,20200618,20200618,EXP,,ID-EMD SERONO-9168550,EMD SERONO INC,"WIDYSANTO J, LUKITO A. EFFECT OF HYPERGLICEMIA ON THE T WAVE INVERSION. JOURNAL OF ARRHYTHMIA. 2019 DEC 01;35 (1):505.",55.0,YR,,F,Y,,,20200618.0,,HP,ID,ID,2020,Q2,Adult
179133081,17913308,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,U,,,,,,,,,2020,Q2,Treatment noncompliance,,2020,Q2,1,I,,20200609.0,20200618,20200618,EXP,,ID-EMD SERONO-9168550,EMD SERONO INC,"WIDYSANTO J, LUKITO A. EFFECT OF HYPERGLICEMIA ON THE T WAVE INVERSION. JOURNAL OF ARRHYTHMIA. 2019 DEC 01;35 (1):505.",55.0,YR,,F,Y,,,20200618.0,,HP,ID,ID,2020,Q2,Adult
179137211,17913721,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,,QD,2020,Q2,Visual acuity reduced,,2020,Q2,1,I,,20200615.0,20200618,20200618,EXP,GB-EMA-DD-20200414-GANGAL_S-165038,NVSC2020GB169297,NOVARTIS,,84.0,YR,,M,Y,85.0,KG,20200618.0,,HP,GB,GB,2020,Q2,Elderly
179140431,17914043,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2020,Q2,Anaemia,,2020,Q2,1,I,,20200611.0,20200619,20200619,EXP,,DE-AUROBINDO-AUR-APL-2020-029568,AUROBINDO,,66.0,YR,,F,Y,80.0,KG,20200619.0,,MD,DE,DE,2020,Q2,Elderly
179140431,17914043,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2020,Q2,Dyspnoea,,2020,Q2,1,I,,20200611.0,20200619,20200619,EXP,,DE-AUROBINDO-AUR-APL-2020-029568,AUROBINDO,,66.0,YR,,F,Y,80.0,KG,20200619.0,,MD,DE,DE,2020,Q2,Elderly
179140431,17914043,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2020,Q2,Dyspnoea exertional,,2020,Q2,1,I,,20200611.0,20200619,20200619,EXP,,DE-AUROBINDO-AUR-APL-2020-029568,AUROBINDO,,66.0,YR,,F,Y,80.0,KG,20200619.0,,MD,DE,DE,2020,Q2,Elderly
179140431,17914043,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2020,Q2,General physical health deterioration,,2020,Q2,1,I,,20200611.0,20200619,20200619,EXP,,DE-AUROBINDO-AUR-APL-2020-029568,AUROBINDO,,66.0,YR,,F,Y,80.0,KG,20200619.0,,MD,DE,DE,2020,Q2,Elderly
179140431,17914043,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2020,Q2,Oedema peripheral,,2020,Q2,1,I,,20200611.0,20200619,20200619,EXP,,DE-AUROBINDO-AUR-APL-2020-029568,AUROBINDO,,66.0,YR,,F,Y,80.0,KG,20200619.0,,MD,DE,DE,2020,Q2,Elderly
179140431,17914043,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2020,Q2,Pallor,,2020,Q2,1,I,,20200611.0,20200619,20200619,EXP,,DE-AUROBINDO-AUR-APL-2020-029568,AUROBINDO,,66.0,YR,,F,Y,80.0,KG,20200619.0,,MD,DE,DE,2020,Q2,Elderly
179140431,17914043,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2020,Q2,Weight increased,,2020,Q2,1,I,,20200611.0,20200619,20200619,EXP,,DE-AUROBINDO-AUR-APL-2020-029568,AUROBINDO,,66.0,YR,,F,Y,80.0,KG,20200619.0,,MD,DE,DE,2020,Q2,Elderly
179167291,17916729,2,SS,METFORMIN;DAPAGLIFLOZIN,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,,,,,,,,,2020,Q2,Diabetic ketoacidosis,,2020,Q2,1,I,20200506.0,20200615.0,20200619,20200619,EXP,PT-INFARMED-T202006-63,PT-BAUSCH-BL-2020-017243,BAUSCH AND LOMB,,79.0,YR,,F,Y,45.0,KG,20200619.0,,PH,PT,PT,2020,Q2,Elderly
179177901,17917790,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0",,,,,,,,,,,,2020,Q2,Anaemia,,2020,Q2,1,I,,20200611.0,20200619,20200619,EXP,DE-BFARM-20006543,DE-ACCORD-185646,ACCORD,,66.0,YR,E,F,Y,80.0,KG,20200619.0,,MD,DE,DE,2020,Q2,Elderly
179177901,17917790,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0",,,,,,,,,,,,2020,Q2,Dyspnoea,,2020,Q2,1,I,,20200611.0,20200619,20200619,EXP,DE-BFARM-20006543,DE-ACCORD-185646,ACCORD,,66.0,YR,E,F,Y,80.0,KG,20200619.0,,MD,DE,DE,2020,Q2,Elderly
179177901,17917790,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0",,,,,,,,,,,,2020,Q2,Dyspnoea exertional,,2020,Q2,1,I,,20200611.0,20200619,20200619,EXP,DE-BFARM-20006543,DE-ACCORD-185646,ACCORD,,66.0,YR,E,F,Y,80.0,KG,20200619.0,,MD,DE,DE,2020,Q2,Elderly
179177901,17917790,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0",,,,,,,,,,,,2020,Q2,General physical health deterioration,,2020,Q2,1,I,,20200611.0,20200619,20200619,EXP,DE-BFARM-20006543,DE-ACCORD-185646,ACCORD,,66.0,YR,E,F,Y,80.0,KG,20200619.0,,MD,DE,DE,2020,Q2,Elderly
179177901,17917790,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0",,,,,,,,,,,,2020,Q2,Oedema peripheral,,2020,Q2,1,I,,20200611.0,20200619,20200619,EXP,DE-BFARM-20006543,DE-ACCORD-185646,ACCORD,,66.0,YR,E,F,Y,80.0,KG,20200619.0,,MD,DE,DE,2020,Q2,Elderly
179177901,17917790,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0",,,,,,,,,,,,2020,Q2,Pallor,,2020,Q2,1,I,,20200611.0,20200619,20200619,EXP,DE-BFARM-20006543,DE-ACCORD-185646,ACCORD,,66.0,YR,E,F,Y,80.0,KG,20200619.0,,MD,DE,DE,2020,Q2,Elderly
179177901,17917790,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0",,,,,,,,,,,,2020,Q2,Weight increased,,2020,Q2,1,I,,20200611.0,20200619,20200619,EXP,DE-BFARM-20006543,DE-ACCORD-185646,ACCORD,,66.0,YR,E,F,Y,80.0,KG,20200619.0,,MD,DE,DE,2020,Q2,Elderly
179180931,17918093,2,SS,DAPAGLIFLOZIN W/METFORMIN,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,UNK,,,U,U,,,,,,,,2020,Q2,Diabetic ketoacidosis,,2020,Q2,1,I,20200506.0,20200617.0,20200619,20200619,EXP,PT-INFARMED-T202006-63,PT-MYLANLABS-2020M1057925,MYLAN,,79.0,YR,,F,Y,45.0,KG,20200619.0,,PH,PT,PT,2020,Q2,Elderly
179261811,17926181,2,SS,DAPAGLIFLOZIN;METFORMIN;SAXAGLIPTIN,DAPAGLIFLOZIN\METFORMIN HYDROCHLORIDE\SAXAGLIPTIN HYDROCHLORIDE,1,Oral,UNK,,,U,U,,,,,,,,2020,Q2,Diabetic ketoacidosis,,2020,Q2,1,I,20200506.0,20200615.0,20200623,20200623,EXP,,PT-AUROBINDO-AUR-APL-2020-029888,AUROBINDO,,79.0,YR,,F,Y,45.0,KG,20200623.0,,PH,PT,PT,2020,Q2,Elderly
179265791,17926579,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q2,Hypertriglyceridaemia,,2020,Q2,1,I,,20190409.0,20200623,20200623,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2019R1-205840,RANBAXY,"KIM DS, O^HAYER PJ, RUBENFIRE M, BROOK RD. HYPERTRIGLYCERIDAEMIA-INDUCED PANCREATITIS PROMPTED BY ACUTE CORTICOSTEROID TREATMENT: CAUTION FOR CLINICIANS. INTERN MED J. 2019;49(3):411-412",41.0,YR,,F,Y,,,20200623.0,,HP,US,US,2020,Q2,Adult
179265791,17926579,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q2,Pancreatitis acute,,2020,Q2,1,I,,20190409.0,20200623,20200623,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2019R1-205840,RANBAXY,"KIM DS, O^HAYER PJ, RUBENFIRE M, BROOK RD. HYPERTRIGLYCERIDAEMIA-INDUCED PANCREATITIS PROMPTED BY ACUTE CORTICOSTEROID TREATMENT: CAUTION FOR CLINICIANS. INTERN MED J. 2019;49(3):411-412",41.0,YR,,F,Y,,,20200623.0,,HP,US,US,2020,Q2,Adult
179279702,17927970,2,SS,DAPAGLIFLOZIN W/METFORMIN,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,,,,,,,,,2020,Q2,Diabetic ketoacidosis,,2020,Q2,2,F,20200506.0,20200622.0,20200623,20200624,EXP,PT-INFARMED-T202006-63,PT-EMD SERONO-E2B_90078272,EMD SERONO INC,,79.0,YR,,F,Y,45.0,KG,20200624.0,,PH,PT,PT,2020,Q2,Elderly
179310241,17931024,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0",,,U,,,,,10.0,MG,,,2020,Q2,Anaemia,,2020,Q2,1,I,,20200616.0,20200623,20200623,EXP,DE-ADRED-05065-01,DE-TORRENT-00017845,TORRENT,,66.0,YR,E,F,Y,80.0,KG,20200623.0,,MD,DE,DE,2020,Q2,Elderly
179310241,17931024,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0",,,U,,,,,10.0,MG,,,2020,Q2,Dyspnoea,,2020,Q2,1,I,,20200616.0,20200623,20200623,EXP,DE-ADRED-05065-01,DE-TORRENT-00017845,TORRENT,,66.0,YR,E,F,Y,80.0,KG,20200623.0,,MD,DE,DE,2020,Q2,Elderly
179310241,17931024,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0",,,U,,,,,10.0,MG,,,2020,Q2,Dyspnoea exertional,,2020,Q2,1,I,,20200616.0,20200623,20200623,EXP,DE-ADRED-05065-01,DE-TORRENT-00017845,TORRENT,,66.0,YR,E,F,Y,80.0,KG,20200623.0,,MD,DE,DE,2020,Q2,Elderly
179310241,17931024,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0",,,U,,,,,10.0,MG,,,2020,Q2,General physical health deterioration,,2020,Q2,1,I,,20200616.0,20200623,20200623,EXP,DE-ADRED-05065-01,DE-TORRENT-00017845,TORRENT,,66.0,YR,E,F,Y,80.0,KG,20200623.0,,MD,DE,DE,2020,Q2,Elderly
179310241,17931024,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0",,,U,,,,,10.0,MG,,,2020,Q2,Oedema peripheral,,2020,Q2,1,I,,20200616.0,20200623,20200623,EXP,DE-ADRED-05065-01,DE-TORRENT-00017845,TORRENT,,66.0,YR,E,F,Y,80.0,KG,20200623.0,,MD,DE,DE,2020,Q2,Elderly
179310241,17931024,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0",,,U,,,,,10.0,MG,,,2020,Q2,Pallor,,2020,Q2,1,I,,20200616.0,20200623,20200623,EXP,DE-ADRED-05065-01,DE-TORRENT-00017845,TORRENT,,66.0,YR,E,F,Y,80.0,KG,20200623.0,,MD,DE,DE,2020,Q2,Elderly
179310241,17931024,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0",,,U,,,,,10.0,MG,,,2020,Q2,Weight increased,,2020,Q2,1,I,,20200616.0,20200623,20200623,EXP,DE-ADRED-05065-01,DE-TORRENT-00017845,TORRENT,,66.0,YR,E,F,Y,80.0,KG,20200623.0,,MD,DE,DE,2020,Q2,Elderly
179318891,17931889,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q2,Abnormal loss of weight,,2020,Q2,1,I,,20200610.0,20200624,20200624,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-250869,RANBAXY,,69.0,YR,,F,Y,,,20200624.0,,HP,JP,JP,2020,Q2,Elderly
179318891,17931889,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q2,Dehydration,,2020,Q2,1,I,,20200610.0,20200624,20200624,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-250869,RANBAXY,,69.0,YR,,F,Y,,,20200624.0,,HP,JP,JP,2020,Q2,Elderly
179318891,17931889,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q2,Drug ineffective,,2020,Q2,1,I,,20200610.0,20200624,20200624,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-250869,RANBAXY,,69.0,YR,,F,Y,,,20200624.0,,HP,JP,JP,2020,Q2,Elderly
179318891,17931889,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q2,Dyspnoea,,2020,Q2,1,I,,20200610.0,20200624,20200624,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-250869,RANBAXY,,69.0,YR,,F,Y,,,20200624.0,,HP,JP,JP,2020,Q2,Elderly
179318891,17931889,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q2,Feeling cold,,2020,Q2,1,I,,20200610.0,20200624,20200624,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-250869,RANBAXY,,69.0,YR,,F,Y,,,20200624.0,,HP,JP,JP,2020,Q2,Elderly
179318891,17931889,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q2,Pneumonia bacterial,,2020,Q2,1,I,,20200610.0,20200624,20200624,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-250869,RANBAXY,,69.0,YR,,F,Y,,,20200624.0,,HP,JP,JP,2020,Q2,Elderly
179371211,17937121,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY;  1-0-0-0,,,,,,,,10.0,MG,,QD,2020,Q2,Anaemia,,2020,Q2,1,I,,20200616.0,20200624,20200624,EXP,,DE-TEVA-2020-DE-1790599,TEVA,,66.0,YR,,F,Y,80.0,KG,20200624.0,,MD,DE,DE,2020,Q2,Elderly
179371211,17937121,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY;  1-0-0-0,,,,,,,,10.0,MG,,QD,2020,Q2,Dyspnoea,,2020,Q2,1,I,,20200616.0,20200624,20200624,EXP,,DE-TEVA-2020-DE-1790599,TEVA,,66.0,YR,,F,Y,80.0,KG,20200624.0,,MD,DE,DE,2020,Q2,Elderly
179371211,17937121,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY;  1-0-0-0,,,,,,,,10.0,MG,,QD,2020,Q2,Dyspnoea exertional,,2020,Q2,1,I,,20200616.0,20200624,20200624,EXP,,DE-TEVA-2020-DE-1790599,TEVA,,66.0,YR,,F,Y,80.0,KG,20200624.0,,MD,DE,DE,2020,Q2,Elderly
179371211,17937121,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY;  1-0-0-0,,,,,,,,10.0,MG,,QD,2020,Q2,General physical health deterioration,,2020,Q2,1,I,,20200616.0,20200624,20200624,EXP,,DE-TEVA-2020-DE-1790599,TEVA,,66.0,YR,,F,Y,80.0,KG,20200624.0,,MD,DE,DE,2020,Q2,Elderly
179371211,17937121,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY;  1-0-0-0,,,,,,,,10.0,MG,,QD,2020,Q2,Oedema peripheral,,2020,Q2,1,I,,20200616.0,20200624,20200624,EXP,,DE-TEVA-2020-DE-1790599,TEVA,,66.0,YR,,F,Y,80.0,KG,20200624.0,,MD,DE,DE,2020,Q2,Elderly
179371211,17937121,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY;  1-0-0-0,,,,,,,,10.0,MG,,QD,2020,Q2,Pallor,,2020,Q2,1,I,,20200616.0,20200624,20200624,EXP,,DE-TEVA-2020-DE-1790599,TEVA,,66.0,YR,,F,Y,80.0,KG,20200624.0,,MD,DE,DE,2020,Q2,Elderly
179371211,17937121,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY;  1-0-0-0,,,,,,,,10.0,MG,,QD,2020,Q2,Weight increased,,2020,Q2,1,I,,20200616.0,20200624,20200624,EXP,,DE-TEVA-2020-DE-1790599,TEVA,,66.0,YR,,F,Y,80.0,KG,20200624.0,,MD,DE,DE,2020,Q2,Elderly
179397701,17939770,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0",,,,,,,,10.0,MG,,QD,2020,Q2,Anaemia,,2020,Q2,1,I,,20200615.0,20200624,20200624,EXP,,DE-MYLANLABS-2020M1057728,MYLAN,,66.0,YR,,F,Y,80.0,KG,20200624.0,,MD,DE,DE,2020,Q2,Elderly
179397701,17939770,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0",,,,,,,,10.0,MG,,QD,2020,Q2,Dyspnoea,,2020,Q2,1,I,,20200615.0,20200624,20200624,EXP,,DE-MYLANLABS-2020M1057728,MYLAN,,66.0,YR,,F,Y,80.0,KG,20200624.0,,MD,DE,DE,2020,Q2,Elderly
179397701,17939770,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0",,,,,,,,10.0,MG,,QD,2020,Q2,Dyspnoea exertional,,2020,Q2,1,I,,20200615.0,20200624,20200624,EXP,,DE-MYLANLABS-2020M1057728,MYLAN,,66.0,YR,,F,Y,80.0,KG,20200624.0,,MD,DE,DE,2020,Q2,Elderly
179397701,17939770,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0",,,,,,,,10.0,MG,,QD,2020,Q2,General physical health deterioration,,2020,Q2,1,I,,20200615.0,20200624,20200624,EXP,,DE-MYLANLABS-2020M1057728,MYLAN,,66.0,YR,,F,Y,80.0,KG,20200624.0,,MD,DE,DE,2020,Q2,Elderly
179397701,17939770,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0",,,,,,,,10.0,MG,,QD,2020,Q2,Oedema peripheral,,2020,Q2,1,I,,20200615.0,20200624,20200624,EXP,,DE-MYLANLABS-2020M1057728,MYLAN,,66.0,YR,,F,Y,80.0,KG,20200624.0,,MD,DE,DE,2020,Q2,Elderly
179397701,17939770,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0",,,,,,,,10.0,MG,,QD,2020,Q2,Pallor,,2020,Q2,1,I,,20200615.0,20200624,20200624,EXP,,DE-MYLANLABS-2020M1057728,MYLAN,,66.0,YR,,F,Y,80.0,KG,20200624.0,,MD,DE,DE,2020,Q2,Elderly
179397701,17939770,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, 1-0-0-0",,,,,,,,10.0,MG,,QD,2020,Q2,Weight increased,,2020,Q2,1,I,,20200615.0,20200624,20200624,EXP,,DE-MYLANLABS-2020M1057728,MYLAN,,66.0,YR,,F,Y,80.0,KG,20200624.0,,MD,DE,DE,2020,Q2,Elderly
179425421,17942542,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,85.0,MG,Y,,,,202293.0,5.0,MG,TABLET,QD,2020,Q2,Benign prostatic hyperplasia,,2020,Q2,1,I,20200511.0,20200622.0,20200624,20200624,EXP,,GB-ASTRAZENECA-2020SE79528,ASTRAZENECA,,73.0,YR,,M,Y,85.0,KG,20200625.0,,,GB,GB,2020,Q2,Elderly
179425421,17942542,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,85.0,MG,Y,,,,202293.0,5.0,MG,TABLET,QD,2020,Q2,Urinary retention,,2020,Q2,1,I,20200511.0,20200622.0,20200624,20200624,EXP,,GB-ASTRAZENECA-2020SE79528,ASTRAZENECA,,73.0,YR,,M,Y,85.0,KG,20200625.0,,,GB,GB,2020,Q2,Elderly
179425421,17942542,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,85.0,MG,Y,,,,202293.0,5.0,MG,TABLET,QD,2020,Q2,Urine flow decreased,,2020,Q2,1,I,20200511.0,20200622.0,20200624,20200624,EXP,,GB-ASTRAZENECA-2020SE79528,ASTRAZENECA,,73.0,YR,,M,Y,85.0,KG,20200625.0,,,GB,GB,2020,Q2,Elderly
179441891,17944189,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,5.0,MG,TABLET,QD,2020,Q2,Otitis externa,,2020,Q2,1,I,,20200617.0,20200625,20200625,EXP,,GB-ASTRAZENECA-2020SE78096,ASTRAZENECA,,72.0,YR,,M,Y,120.0,KG,20200625.0,,,GB,GB,2020,Q2,Elderly
179456891,17945689,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5/1000, UNKNOWN TAKING SINCE MONTHS",,,D,,,,202293.0,,,TABLET,,2020,Q2,Ketoacidosis,,2020,Q2,1,I,20200501.0,20200622.0,20200625,20200625,EXP,,DE-ASTRAZENECA-2020SE79374,ASTRAZENECA,,55.0,YR,,F,Y,,,20200625.0,,,DE,DE,2020,Q2,Adult
179461101,17946110,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q2,Electrocardiogram T wave inversion,,2020,Q2,1,I,,20200608.0,20200625,20200625,EXP,,"ID-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-028934",BOEHRINGER INGELHEIM,"WIDYSANTO J, LUKITO A. EFFECT OF HYPERGLYCEMIAON THE T WAVE INVERSION. JOURNAL OF ARRHYTHMIA. 2019;35:19-01099.",55.0,YR,,F,Y,,,20200625.0,,MD,ID,ID,2020,Q2,Adult
179461101,17946110,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2020,Q2,Hyperglycaemia,,2020,Q2,1,I,,20200608.0,20200625,20200625,EXP,,"ID-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-028934",BOEHRINGER INGELHEIM,"WIDYSANTO J, LUKITO A. EFFECT OF HYPERGLYCEMIAON THE T WAVE INVERSION. JOURNAL OF ARRHYTHMIA. 2019;35:19-01099.",55.0,YR,,F,Y,,,20200625.0,,MD,ID,ID,2020,Q2,Adult
179510351,17951035,2,SS,METFORMINA + DAPAGLIFLOZINA,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,, UNKNOWN,,,,,,,2020,Q2,Diabetic ketoacidosis,,2020,Q2,1,I,20200506.0,20200618.0,20200626,20200626,EXP,PT-INFARMED-T202006-63,PT-TEVA-2020-PT-1791343,TEVA,,79.0,YR,,F,Y,45.0,KG,20200626.0,,PH,PT,PT,2020,Q2,Elderly
179533701,17953370,1,PS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,,,,Y,,,,,10.0,MG,TABLET,QD,2020,Q2,Diabetic ketoacidosis,,2020,Q2,1,I,20200607.0,20200622.0,20200628,20200628,EXP,,GB-ASTRAZENECA-2020SE79399,ASTRAZENECA,,50.0,YR,,M,Y,,,20200628.0,,PH,GB,GB,2020,Q2,Adult
179533701,17953370,1,PS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,,,,Y,,,,,10.0,MG,TABLET,QD,2020,Q2,Malaise,,2020,Q2,1,I,20200607.0,20200622.0,20200628,20200628,EXP,,GB-ASTRAZENECA-2020SE79399,ASTRAZENECA,,50.0,YR,,M,Y,,,20200628.0,,PH,GB,GB,2020,Q2,Adult
136135822,13613582,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,TABLET,,2020,Q3,Fall,,2020,Q3,2,F,20170505.0,20170601.0,20170605,20200910,EXP,,GB-ASTRAZENECA-2017SE55677,ASTRAZENECA,,63.0,YR,,F,Y,94.7,KG,20200910.0,,MD,GB,GB,2020,Q3,Adult
136135822,13613582,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,TABLET,,2020,Q3,Jaw fracture,,2020,Q3,2,F,20170505.0,20170601.0,20170605,20200910,EXP,,GB-ASTRAZENECA-2017SE55677,ASTRAZENECA,,63.0,YR,,F,Y,94.7,KG,20200910.0,,MD,GB,GB,2020,Q3,Adult
145991233,14599123,14,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,,,,D,,,,,10.0,MG,,QD,2020,Q3,Haematuria,,2020,Q3,3,F,20180222.0,20180504.0,20180305,20180516,EXP,,KR-JNJFOC-20180300435,PHARMACYCLICS,,53.0,YR,A,M,Y,,,20180516.0,,MD,KR,KR,2020,Q3,Adult
145991233,14599123,14,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,,,,D,,,,,10.0,MG,,QD,2020,Q3,Headache,,2020,Q3,3,F,20180222.0,20180504.0,20180305,20180516,EXP,,KR-JNJFOC-20180300435,PHARMACYCLICS,,53.0,YR,A,M,Y,,,20180516.0,,MD,KR,KR,2020,Q3,Adult
1483540310,14835403,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q3,Decreased vibratory sense,,2020,Q3,10,F,2016.0,20200919.0,20180502,20200925,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017?7:22,61.0,YR,,F,Y,97.0,KG,20200925.0,,MD,DE,DE,2020,Q3,Adult
1483540310,14835403,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q3,Diabetes mellitus inadequate control,,2020,Q3,10,F,2016.0,20200919.0,20180502,20200925,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017?7:22,61.0,YR,,F,Y,97.0,KG,20200925.0,,MD,DE,DE,2020,Q3,Adult
1483540310,14835403,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q3,Gastrointestinal disorder,,2020,Q3,10,F,2016.0,20200919.0,20180502,20200925,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017?7:22,61.0,YR,,F,Y,97.0,KG,20200925.0,,MD,DE,DE,2020,Q3,Adult
1483540310,14835403,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q3,Limb discomfort,,2020,Q3,10,F,2016.0,20200919.0,20180502,20200925,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017?7:22,61.0,YR,,F,Y,97.0,KG,20200925.0,,MD,DE,DE,2020,Q3,Adult
1483540310,14835403,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q3,Neuropathy peripheral,,2020,Q3,10,F,2016.0,20200919.0,20180502,20200925,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017?7:22,61.0,YR,,F,Y,97.0,KG,20200925.0,,MD,DE,DE,2020,Q3,Adult
1483540310,14835403,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q3,Pain in extremity,,2020,Q3,10,F,2016.0,20200919.0,20180502,20200925,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017?7:22,61.0,YR,,F,Y,97.0,KG,20200925.0,,MD,DE,DE,2020,Q3,Adult
1483540310,14835403,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q3,Sensory disturbance,,2020,Q3,10,F,2016.0,20200919.0,20180502,20200925,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017?7:22,61.0,YR,,F,Y,97.0,KG,20200925.0,,MD,DE,DE,2020,Q3,Adult
1483540310,14835403,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q3,Sleep disorder,,2020,Q3,10,F,2016.0,20200919.0,20180502,20200925,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017?7:22,61.0,YR,,F,Y,97.0,KG,20200925.0,,MD,DE,DE,2020,Q3,Adult
1483540310,14835403,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q3,Temperature perception test abnormal,,2020,Q3,10,F,2016.0,20200919.0,20180502,20200925,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017?7:22,61.0,YR,,F,Y,97.0,KG,20200925.0,,MD,DE,DE,2020,Q3,Adult
1483540310,14835403,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q3,Visual impairment,,2020,Q3,10,F,2016.0,20200919.0,20180502,20200925,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017?7:22,61.0,YR,,F,Y,97.0,KG,20200925.0,,MD,DE,DE,2020,Q3,Adult
1483540310,14835403,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q3,Decreased vibratory sense,,2020,Q3,10,F,2016.0,20200919.0,20180502,20200925,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017?7:22,61.0,YR,,F,Y,97.0,KG,20200925.0,,MD,DE,DE,2020,Q3,Adult
1483540310,14835403,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q3,Diabetes mellitus inadequate control,,2020,Q3,10,F,2016.0,20200919.0,20180502,20200925,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017?7:22,61.0,YR,,F,Y,97.0,KG,20200925.0,,MD,DE,DE,2020,Q3,Adult
1483540310,14835403,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q3,Gastrointestinal disorder,,2020,Q3,10,F,2016.0,20200919.0,20180502,20200925,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017?7:22,61.0,YR,,F,Y,97.0,KG,20200925.0,,MD,DE,DE,2020,Q3,Adult
1483540310,14835403,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q3,Limb discomfort,,2020,Q3,10,F,2016.0,20200919.0,20180502,20200925,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017?7:22,61.0,YR,,F,Y,97.0,KG,20200925.0,,MD,DE,DE,2020,Q3,Adult
1483540310,14835403,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q3,Neuropathy peripheral,,2020,Q3,10,F,2016.0,20200919.0,20180502,20200925,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017?7:22,61.0,YR,,F,Y,97.0,KG,20200925.0,,MD,DE,DE,2020,Q3,Adult
1483540310,14835403,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q3,Pain in extremity,,2020,Q3,10,F,2016.0,20200919.0,20180502,20200925,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017?7:22,61.0,YR,,F,Y,97.0,KG,20200925.0,,MD,DE,DE,2020,Q3,Adult
1483540310,14835403,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q3,Sensory disturbance,,2020,Q3,10,F,2016.0,20200919.0,20180502,20200925,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017?7:22,61.0,YR,,F,Y,97.0,KG,20200925.0,,MD,DE,DE,2020,Q3,Adult
1483540310,14835403,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q3,Sleep disorder,,2020,Q3,10,F,2016.0,20200919.0,20180502,20200925,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017?7:22,61.0,YR,,F,Y,97.0,KG,20200925.0,,MD,DE,DE,2020,Q3,Adult
1483540310,14835403,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q3,Temperature perception test abnormal,,2020,Q3,10,F,2016.0,20200919.0,20180502,20200925,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017?7:22,61.0,YR,,F,Y,97.0,KG,20200925.0,,MD,DE,DE,2020,Q3,Adult
1483540310,14835403,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q3,Visual impairment,,2020,Q3,10,F,2016.0,20200919.0,20180502,20200925,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017?7:22,61.0,YR,,F,Y,97.0,KG,20200925.0,,MD,DE,DE,2020,Q3,Adult
149840094,14984009,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2020,Q3,Immune-mediated hepatitis,,2020,Q3,4,F,20180528.0,20180731.0,20180607,20180808,EXP,,CA-CELGENEUS-CAN-20180510957,CELGENE,,65.0,YR,,M,Y,,,20180808.0,,MD,CA,CA,2020,Q3,Elderly
153245586,15324558,1,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,QD,2020,Q3,Decreased vibratory sense,,2020,Q3,6,F,2016.0,20200724.0,20180828,20200804,EXP,DE-EMA-DD-20180608-ISHAEVHP-143511,DE-TORRENT-00009642,TORRENT,,61.0,YR,A,F,Y,97.0,KG,20200804.0,,HP,DE,DE,2020,Q3,Adult
153245586,15324558,1,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,QD,2020,Q3,Diabetes mellitus inadequate control,,2020,Q3,6,F,2016.0,20200724.0,20180828,20200804,EXP,DE-EMA-DD-20180608-ISHAEVHP-143511,DE-TORRENT-00009642,TORRENT,,61.0,YR,A,F,Y,97.0,KG,20200804.0,,HP,DE,DE,2020,Q3,Adult
153245586,15324558,1,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,QD,2020,Q3,Gastrointestinal disorder,,2020,Q3,6,F,2016.0,20200724.0,20180828,20200804,EXP,DE-EMA-DD-20180608-ISHAEVHP-143511,DE-TORRENT-00009642,TORRENT,,61.0,YR,A,F,Y,97.0,KG,20200804.0,,HP,DE,DE,2020,Q3,Adult
153245586,15324558,1,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,QD,2020,Q3,Limb discomfort,,2020,Q3,6,F,2016.0,20200724.0,20180828,20200804,EXP,DE-EMA-DD-20180608-ISHAEVHP-143511,DE-TORRENT-00009642,TORRENT,,61.0,YR,A,F,Y,97.0,KG,20200804.0,,HP,DE,DE,2020,Q3,Adult
153245586,15324558,1,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,QD,2020,Q3,Neuropathy peripheral,,2020,Q3,6,F,2016.0,20200724.0,20180828,20200804,EXP,DE-EMA-DD-20180608-ISHAEVHP-143511,DE-TORRENT-00009642,TORRENT,,61.0,YR,A,F,Y,97.0,KG,20200804.0,,HP,DE,DE,2020,Q3,Adult
153245586,15324558,1,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,QD,2020,Q3,Pain in extremity,,2020,Q3,6,F,2016.0,20200724.0,20180828,20200804,EXP,DE-EMA-DD-20180608-ISHAEVHP-143511,DE-TORRENT-00009642,TORRENT,,61.0,YR,A,F,Y,97.0,KG,20200804.0,,HP,DE,DE,2020,Q3,Adult
153245586,15324558,1,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,QD,2020,Q3,Sensory disturbance,,2020,Q3,6,F,2016.0,20200724.0,20180828,20200804,EXP,DE-EMA-DD-20180608-ISHAEVHP-143511,DE-TORRENT-00009642,TORRENT,,61.0,YR,A,F,Y,97.0,KG,20200804.0,,HP,DE,DE,2020,Q3,Adult
153245586,15324558,1,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,QD,2020,Q3,Sleep disorder,,2020,Q3,6,F,2016.0,20200724.0,20180828,20200804,EXP,DE-EMA-DD-20180608-ISHAEVHP-143511,DE-TORRENT-00009642,TORRENT,,61.0,YR,A,F,Y,97.0,KG,20200804.0,,HP,DE,DE,2020,Q3,Adult
153245586,15324558,1,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,QD,2020,Q3,Temperature perception test abnormal,,2020,Q3,6,F,2016.0,20200724.0,20180828,20200804,EXP,DE-EMA-DD-20180608-ISHAEVHP-143511,DE-TORRENT-00009642,TORRENT,,61.0,YR,A,F,Y,97.0,KG,20200804.0,,HP,DE,DE,2020,Q3,Adult
153245586,15324558,1,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,QD,2020,Q3,Visual impairment,,2020,Q3,6,F,2016.0,20200724.0,20180828,20200804,EXP,DE-EMA-DD-20180608-ISHAEVHP-143511,DE-TORRENT-00009642,TORRENT,,61.0,YR,A,F,Y,97.0,KG,20200804.0,,HP,DE,DE,2020,Q3,Adult
154126753,15412675,16,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2020,Q3,Anaemia,,2020,Q3,3,F,20180719.0,20200730.0,20180921,20200805,EXP,DE-NOVPHSZ-PHHY2018DE103416,PHHY2018DE103416,NOVARTIS,,56.0,YR,,M,Y,,,20200805.0,,MD,DE,DE,2020,Q3,Adult
154126753,15412675,16,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,U,,,,10.0,MG,,QD,2020,Q3,General physical health deterioration,,2020,Q3,3,F,20180719.0,20200730.0,20180921,20200805,EXP,DE-NOVPHSZ-PHHY2018DE103416,PHHY2018DE103416,NOVARTIS,,56.0,YR,,M,Y,,,20200805.0,,MD,DE,DE,2020,Q3,Adult
1551837111,15518371,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q3,Decreased vibratory sense,,2020,Q3,11,F,2016.0,20200904.0,20181017,20200911,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017?11 (3):6?7,61.0,YR,,F,Y,97.0,KG,20200911.0,,HP,DE,DE,2020,Q3,Adult
1551837111,15518371,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q3,Diabetes mellitus inadequate control,,2020,Q3,11,F,2016.0,20200904.0,20181017,20200911,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017?11 (3):6?7,61.0,YR,,F,Y,97.0,KG,20200911.0,,HP,DE,DE,2020,Q3,Adult
1551837111,15518371,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q3,Gastrointestinal disorder,,2020,Q3,11,F,2016.0,20200904.0,20181017,20200911,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017?11 (3):6?7,61.0,YR,,F,Y,97.0,KG,20200911.0,,HP,DE,DE,2020,Q3,Adult
1551837111,15518371,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q3,Limb discomfort,,2020,Q3,11,F,2016.0,20200904.0,20181017,20200911,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017?11 (3):6?7,61.0,YR,,F,Y,97.0,KG,20200911.0,,HP,DE,DE,2020,Q3,Adult
1551837111,15518371,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q3,Neuropathy peripheral,,2020,Q3,11,F,2016.0,20200904.0,20181017,20200911,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017?11 (3):6?7,61.0,YR,,F,Y,97.0,KG,20200911.0,,HP,DE,DE,2020,Q3,Adult
1551837111,15518371,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q3,Pain in extremity,,2020,Q3,11,F,2016.0,20200904.0,20181017,20200911,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017?11 (3):6?7,61.0,YR,,F,Y,97.0,KG,20200911.0,,HP,DE,DE,2020,Q3,Adult
1551837111,15518371,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q3,Sensory disturbance,,2020,Q3,11,F,2016.0,20200904.0,20181017,20200911,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017?11 (3):6?7,61.0,YR,,F,Y,97.0,KG,20200911.0,,HP,DE,DE,2020,Q3,Adult
1551837111,15518371,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q3,Sleep disorder,,2020,Q3,11,F,2016.0,20200904.0,20181017,20200911,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017?11 (3):6?7,61.0,YR,,F,Y,97.0,KG,20200911.0,,HP,DE,DE,2020,Q3,Adult
1551837111,15518371,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q3,Temperature perception test abnormal,,2020,Q3,11,F,2016.0,20200904.0,20181017,20200911,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017?11 (3):6?7,61.0,YR,,F,Y,97.0,KG,20200911.0,,HP,DE,DE,2020,Q3,Adult
1551837111,15518371,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q3,Visual impairment,,2020,Q3,11,F,2016.0,20200904.0,20181017,20200911,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017?11 (3):6?7,61.0,YR,,F,Y,97.0,KG,20200911.0,,HP,DE,DE,2020,Q3,Adult
1551837111,15518371,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q3,Decreased vibratory sense,,2020,Q3,11,F,2016.0,20200904.0,20181017,20200911,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017?11 (3):6?7,61.0,YR,,F,Y,97.0,KG,20200911.0,,HP,DE,DE,2020,Q3,Adult
1551837111,15518371,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q3,Diabetes mellitus inadequate control,,2020,Q3,11,F,2016.0,20200904.0,20181017,20200911,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017?11 (3):6?7,61.0,YR,,F,Y,97.0,KG,20200911.0,,HP,DE,DE,2020,Q3,Adult
1551837111,15518371,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q3,Gastrointestinal disorder,,2020,Q3,11,F,2016.0,20200904.0,20181017,20200911,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017?11 (3):6?7,61.0,YR,,F,Y,97.0,KG,20200911.0,,HP,DE,DE,2020,Q3,Adult
1551837111,15518371,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q3,Limb discomfort,,2020,Q3,11,F,2016.0,20200904.0,20181017,20200911,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017?11 (3):6?7,61.0,YR,,F,Y,97.0,KG,20200911.0,,HP,DE,DE,2020,Q3,Adult
1551837111,15518371,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q3,Neuropathy peripheral,,2020,Q3,11,F,2016.0,20200904.0,20181017,20200911,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017?11 (3):6?7,61.0,YR,,F,Y,97.0,KG,20200911.0,,HP,DE,DE,2020,Q3,Adult
1551837111,15518371,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q3,Pain in extremity,,2020,Q3,11,F,2016.0,20200904.0,20181017,20200911,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017?11 (3):6?7,61.0,YR,,F,Y,97.0,KG,20200911.0,,HP,DE,DE,2020,Q3,Adult
1551837111,15518371,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q3,Sensory disturbance,,2020,Q3,11,F,2016.0,20200904.0,20181017,20200911,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017?11 (3):6?7,61.0,YR,,F,Y,97.0,KG,20200911.0,,HP,DE,DE,2020,Q3,Adult
1551837111,15518371,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q3,Sleep disorder,,2020,Q3,11,F,2016.0,20200904.0,20181017,20200911,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017?11 (3):6?7,61.0,YR,,F,Y,97.0,KG,20200911.0,,HP,DE,DE,2020,Q3,Adult
1551837111,15518371,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q3,Temperature perception test abnormal,,2020,Q3,11,F,2016.0,20200904.0,20181017,20200911,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017?11 (3):6?7,61.0,YR,,F,Y,97.0,KG,20200911.0,,HP,DE,DE,2020,Q3,Adult
1551837111,15518371,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q3,Visual impairment,,2020,Q3,11,F,2016.0,20200904.0,20181017,20200911,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017?11 (3):6?7,61.0,YR,,F,Y,97.0,KG,20200911.0,,HP,DE,DE,2020,Q3,Adult
1551837111,15518371,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,Y,U,,,,10.0,MG,TABLET,,2020,Q3,Decreased vibratory sense,,2020,Q3,11,F,2016.0,20200904.0,20181017,20200911,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017?11 (3):6?7,61.0,YR,,F,Y,97.0,KG,20200911.0,,HP,DE,DE,2020,Q3,Adult
1551837111,15518371,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,Y,U,,,,10.0,MG,TABLET,,2020,Q3,Diabetes mellitus inadequate control,,2020,Q3,11,F,2016.0,20200904.0,20181017,20200911,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017?11 (3):6?7,61.0,YR,,F,Y,97.0,KG,20200911.0,,HP,DE,DE,2020,Q3,Adult
1551837111,15518371,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,Y,U,,,,10.0,MG,TABLET,,2020,Q3,Gastrointestinal disorder,,2020,Q3,11,F,2016.0,20200904.0,20181017,20200911,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017?11 (3):6?7,61.0,YR,,F,Y,97.0,KG,20200911.0,,HP,DE,DE,2020,Q3,Adult
1551837111,15518371,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,Y,U,,,,10.0,MG,TABLET,,2020,Q3,Limb discomfort,,2020,Q3,11,F,2016.0,20200904.0,20181017,20200911,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017?11 (3):6?7,61.0,YR,,F,Y,97.0,KG,20200911.0,,HP,DE,DE,2020,Q3,Adult
1551837111,15518371,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,Y,U,,,,10.0,MG,TABLET,,2020,Q3,Neuropathy peripheral,,2020,Q3,11,F,2016.0,20200904.0,20181017,20200911,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017?11 (3):6?7,61.0,YR,,F,Y,97.0,KG,20200911.0,,HP,DE,DE,2020,Q3,Adult
1551837111,15518371,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,Y,U,,,,10.0,MG,TABLET,,2020,Q3,Pain in extremity,,2020,Q3,11,F,2016.0,20200904.0,20181017,20200911,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017?11 (3):6?7,61.0,YR,,F,Y,97.0,KG,20200911.0,,HP,DE,DE,2020,Q3,Adult
1551837111,15518371,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,Y,U,,,,10.0,MG,TABLET,,2020,Q3,Sensory disturbance,,2020,Q3,11,F,2016.0,20200904.0,20181017,20200911,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017?11 (3):6?7,61.0,YR,,F,Y,97.0,KG,20200911.0,,HP,DE,DE,2020,Q3,Adult
1551837111,15518371,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,Y,U,,,,10.0,MG,TABLET,,2020,Q3,Sleep disorder,,2020,Q3,11,F,2016.0,20200904.0,20181017,20200911,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017?11 (3):6?7,61.0,YR,,F,Y,97.0,KG,20200911.0,,HP,DE,DE,2020,Q3,Adult
1551837111,15518371,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,Y,U,,,,10.0,MG,TABLET,,2020,Q3,Temperature perception test abnormal,,2020,Q3,11,F,2016.0,20200904.0,20181017,20200911,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017?11 (3):6?7,61.0,YR,,F,Y,97.0,KG,20200911.0,,HP,DE,DE,2020,Q3,Adult
1551837111,15518371,7,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,Y,U,,,,10.0,MG,TABLET,,2020,Q3,Visual impairment,,2020,Q3,11,F,2016.0,20200904.0,20181017,20200911,EXP,,DE-MYLANLABS-2018M1077615,MYLAN,HOLLENRIEDER V... BEINSCHMERZEN WEGER GUTTER COMPLIANCE.. INFO DIABETOLOGIE. 2017?11 (3):6?7,61.0,YR,,F,Y,97.0,KG,20200911.0,,HP,DE,DE,2020,Q3,Adult
157420083,15742008,33,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2020,Q3,Sepsis,,2020,Q3,3,F,20181013.0,20200905.0,20181219,20200911,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-096858,BRISTOL MYERS SQUIBB,,78.0,YR,,M,Y,79.5,KG,20200911.0,,HP,ES,ES,2020,Q3,Elderly
157420083,15742008,33,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2020,Q3,Urinary tract infection,,2020,Q3,3,F,20181013.0,20200905.0,20181219,20200911,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-096858,BRISTOL MYERS SQUIBB,,78.0,YR,,M,Y,79.5,KG,20200911.0,,HP,ES,ES,2020,Q3,Elderly
158554663,15855466,18,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2020,Q3,Blood creatine phosphokinase increased,,2020,Q3,3,F,2009.0,20200828.0,20190122,20200905,EXP,,PHHY2019AU008305,NOVARTIS,,29.0,YR,,M,Y,,,20200905.0,,HP,AU,AU,2020,Q3,Young Adult
158554663,15855466,18,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2020,Q3,Body mass index increased,,2020,Q3,3,F,2009.0,20200828.0,20190122,20200905,EXP,,PHHY2019AU008305,NOVARTIS,,29.0,YR,,M,Y,,,20200905.0,,HP,AU,AU,2020,Q3,Young Adult
158554663,15855466,18,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2020,Q3,Cardiac dysfunction,,2020,Q3,3,F,2009.0,20200828.0,20190122,20200905,EXP,,PHHY2019AU008305,NOVARTIS,,29.0,YR,,M,Y,,,20200905.0,,HP,AU,AU,2020,Q3,Young Adult
158554663,15855466,18,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2020,Q3,Cardiomyopathy,,2020,Q3,3,F,2009.0,20200828.0,20190122,20200905,EXP,,PHHY2019AU008305,NOVARTIS,,29.0,YR,,M,Y,,,20200905.0,,HP,AU,AU,2020,Q3,Young Adult
158554663,15855466,18,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2020,Q3,Drug ineffective,,2020,Q3,3,F,2009.0,20200828.0,20190122,20200905,EXP,,PHHY2019AU008305,NOVARTIS,,29.0,YR,,M,Y,,,20200905.0,,HP,AU,AU,2020,Q3,Young Adult
158554663,15855466,18,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2020,Q3,Dyslipidaemia,,2020,Q3,3,F,2009.0,20200828.0,20190122,20200905,EXP,,PHHY2019AU008305,NOVARTIS,,29.0,YR,,M,Y,,,20200905.0,,HP,AU,AU,2020,Q3,Young Adult
158554663,15855466,18,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2020,Q3,Ejection fraction decreased,,2020,Q3,3,F,2009.0,20200828.0,20190122,20200905,EXP,,PHHY2019AU008305,NOVARTIS,,29.0,YR,,M,Y,,,20200905.0,,HP,AU,AU,2020,Q3,Young Adult
158554663,15855466,18,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2020,Q3,Left ventricular dysfunction,,2020,Q3,3,F,2009.0,20200828.0,20190122,20200905,EXP,,PHHY2019AU008305,NOVARTIS,,29.0,YR,,M,Y,,,20200905.0,,HP,AU,AU,2020,Q3,Young Adult
158554663,15855466,18,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2020,Q3,Seizure,,2020,Q3,3,F,2009.0,20200828.0,20190122,20200905,EXP,,PHHY2019AU008305,NOVARTIS,,29.0,YR,,M,Y,,,20200905.0,,HP,AU,AU,2020,Q3,Young Adult
158554663,15855466,18,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2020,Q3,Type 2 diabetes mellitus,,2020,Q3,3,F,2009.0,20200828.0,20190122,20200905,EXP,,PHHY2019AU008305,NOVARTIS,,29.0,YR,,M,Y,,,20200905.0,,HP,AU,AU,2020,Q3,Young Adult
158554663,15855466,18,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2020,Q3,Weight increased,,2020,Q3,3,F,2009.0,20200828.0,20190122,20200905,EXP,,PHHY2019AU008305,NOVARTIS,,29.0,YR,,M,Y,,,20200905.0,,HP,AU,AU,2020,Q3,Young Adult
161433636,16143363,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,D,,,,,5.0,MG,TABLET,QD,2020,Q3,Renal mass,,2020,Q3,6,F,20190325.0,20190605.0,20190401,20190610,EXP,,BR-JNJFOC-20190342024,JANSSEN,,61.0,YR,A,F,Y,98.4,KG,20190610.0,,MD,BR,BR,2020,Q3,Adult
162066043,16206604,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MILLIGRAM, ONCE A DAY",,,Y,U,,,,5.0,MG,,QD,2020,Q3,Blood glucose increased,,2020,Q3,3,F,,20200916.0,20190417,20200923,EXP,,PT-AUROBINDO-AUR-APL-2019-020144,AUROBINDO,,52.0,YR,,F,Y,,,20200923.0,,HP,PT,PT,2020,Q3,Adult
162066043,16206604,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MILLIGRAM, ONCE A DAY",,,Y,U,,,,5.0,MG,,QD,2020,Q3,Body mass index increased,,2020,Q3,3,F,,20200916.0,20190417,20200923,EXP,,PT-AUROBINDO-AUR-APL-2019-020144,AUROBINDO,,52.0,YR,,F,Y,,,20200923.0,,HP,PT,PT,2020,Q3,Adult
162066043,16206604,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MILLIGRAM, ONCE A DAY",,,Y,U,,,,5.0,MG,,QD,2020,Q3,Drug ineffective,,2020,Q3,3,F,,20200916.0,20190417,20200923,EXP,,PT-AUROBINDO-AUR-APL-2019-020144,AUROBINDO,,52.0,YR,,F,Y,,,20200923.0,,HP,PT,PT,2020,Q3,Adult
162066043,16206604,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MILLIGRAM, ONCE A DAY",,,Y,U,,,,5.0,MG,,QD,2020,Q3,Glycosylated haemoglobin increased,,2020,Q3,3,F,,20200916.0,20190417,20200923,EXP,,PT-AUROBINDO-AUR-APL-2019-020144,AUROBINDO,,52.0,YR,,F,Y,,,20200923.0,,HP,PT,PT,2020,Q3,Adult
162066043,16206604,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MILLIGRAM, ONCE A DAY",,,Y,U,,,,5.0,MG,,QD,2020,Q3,Hypoglycaemia,,2020,Q3,3,F,,20200916.0,20190417,20200923,EXP,,PT-AUROBINDO-AUR-APL-2019-020144,AUROBINDO,,52.0,YR,,F,Y,,,20200923.0,,HP,PT,PT,2020,Q3,Adult
162066043,16206604,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MILLIGRAM, ONCE A DAY",,,Y,U,,,,5.0,MG,,QD,2020,Q3,Latent autoimmune diabetes in adults,,2020,Q3,3,F,,20200916.0,20190417,20200923,EXP,,PT-AUROBINDO-AUR-APL-2019-020144,AUROBINDO,,52.0,YR,,F,Y,,,20200923.0,,HP,PT,PT,2020,Q3,Adult
162066043,16206604,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MILLIGRAM, ONCE A DAY",,,Y,U,,,,5.0,MG,,QD,2020,Q3,Postprandial hypoglycaemia,,2020,Q3,3,F,,20200916.0,20190417,20200923,EXP,,PT-AUROBINDO-AUR-APL-2019-020144,AUROBINDO,,52.0,YR,,F,Y,,,20200923.0,,HP,PT,PT,2020,Q3,Adult
167012272,16701227,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,TABLET,,2020,Q3,Hypoglycaemia,,2020,Q3,2,F,20190423.0,20191003.0,20190814,20191011,EXP,,SG-ASTRAZENECA-2019SE63442,ASTRAZENECA,,70.0,YR,,M,Y,61.3,KG,20191011.0,,MD,SG,SG,2020,Q3,Elderly
168743624,16874362,12,SS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,7220.0,MG,Y,,,,,10.0,MG,TABLET,QD,2020,Q3,Diabetic ketoacidosis,,2020,Q3,4,F,20190824.0,20200705.0,20191001,20200714,EXP,,NL-BAUSCH-BL-2019-054808,BAUSCH AND LOMB,,19763.0,DY,,F,Y,84.5,KG,20200714.0,,MD,NL,NL,2020,Q3,Elderly
168743624,16874362,13,SS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,7220.0,MG,Y,,,,,10.0,MG,TABLET,QD,2020,Q3,Diabetic ketoacidosis,,2020,Q3,4,F,20190824.0,20200705.0,20191001,20200714,EXP,,NL-BAUSCH-BL-2019-054808,BAUSCH AND LOMB,,19763.0,DY,,F,Y,84.5,KG,20200714.0,,MD,NL,NL,2020,Q3,Elderly
169060091,16906009,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Cellulitis,,2020,Q3,1,I,20190412.0,20190524.0,20191010,20191010,EXP,,US-JNJFOC-20190543199,JOHNSON AND JOHNSON,,67.0,YR,,M,Y,122.4,KG,20191011.0,,MD,US,US,2020,Q3,Elderly
169704493,16970449,9,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,"5 MG, 1X/DAY, DAPAGLIFLOZIN PROPYLENE GLYCOLATE HYDRATE",,,,,,,,5.0,MG,,QD,2020,Q3,Bacteraemia,,2020,Q3,3,F,20191012.0,20191115.0,20191029,20191122,EXP,,JP-PFIZER INC-2019446126,PFIZER,,82.0,YR,,M,Y,59.9,KG,20191122.0,,MD,JP,JP,2020,Q3,Elderly
1712797116,17127971,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,5.0,MG,TABLETS,,2020,Q3,Hypoglycaemia,,2020,Q3,16,F,20191201.0,20200901.0,20191209,20200904,PER,,BR-EISAI MEDICAL RESEARCH-EC-2019-066649,EISAI,,63.0,YR,A,F,Y,56.8,KG,20200904.0,,MD,BR,BR,2020,Q3,Adult
171687102,17168710,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Pneumonia,,2020,Q3,2,F,20190407.0,20191206.0,20191218,20200910,EXP,,GB-ROCHE-2494850,ROCHE,,76.0,YR,,F,Y,,,20200911.0,,MD,GB,GB,2020,Q3,Elderly
172090597,17209059,7,SS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",7220.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q3,Diabetic ketoacidosis,,2020,Q3,7,F,20190824.0,20200707.0,20191227,20200715,EXP,,NL-MYLANLABS-2019M1128221,MYLAN,,54.0,YR,,F,Y,84.5,KG,20200715.0,,HP,NL,NL,2020,Q3,Adult
172090597,17209059,7,SS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",7220.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q3,Ketoacidosis,,2020,Q3,7,F,20190824.0,20200707.0,20191227,20200715,EXP,,NL-MYLANLABS-2019M1128221,MYLAN,,54.0,YR,,F,Y,84.5,KG,20200715.0,,HP,NL,NL,2020,Q3,Adult
172090597,17209059,8,SS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",7220.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q3,Diabetic ketoacidosis,,2020,Q3,7,F,20190824.0,20200707.0,20191227,20200715,EXP,,NL-MYLANLABS-2019M1128221,MYLAN,,54.0,YR,,F,Y,84.5,KG,20200715.0,,HP,NL,NL,2020,Q3,Adult
172090597,17209059,8,SS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",7220.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q3,Ketoacidosis,,2020,Q3,7,F,20190824.0,20200707.0,20191227,20200715,EXP,,NL-MYLANLABS-2019M1128221,MYLAN,,54.0,YR,,F,Y,84.5,KG,20200715.0,,HP,NL,NL,2020,Q3,Adult
172090597,17209059,9,SS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",7220.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q3,Diabetic ketoacidosis,,2020,Q3,7,F,20190824.0,20200707.0,20191227,20200715,EXP,,NL-MYLANLABS-2019M1128221,MYLAN,,54.0,YR,,F,Y,84.5,KG,20200715.0,,HP,NL,NL,2020,Q3,Adult
172090597,17209059,9,SS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",7220.0,MG,D,,,,,10.0,MG,TABLET,QD,2020,Q3,Ketoacidosis,,2020,Q3,7,F,20190824.0,20200707.0,20191227,20200715,EXP,,NL-MYLANLABS-2019M1128221,MYLAN,,54.0,YR,,F,Y,84.5,KG,20200715.0,,HP,NL,NL,2020,Q3,Adult
172453849,17245384,14,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,2.5 MILLIGRAM,,,U,,,,,2.5,MG,,,2020,Q3,Myocarditis,,2020,Q3,9,F,20191225.0,20200720.0,20200108,20200721,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-124057,BRISTOL MYERS SQUIBB,,58.0,YR,,M,Y,79.0,KG,20200721.0,,HP,JP,JP,2020,Q3,Adult
174006424,17400642,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2020,Q3,Febrile neutropenia,,2020,Q3,4,F,,20200626.0,20200211,20200704,EXP,PT-EMA-20200204-AUTODUP-30640000,PT-ACCORD-172137,ACCORD,,58.0,YR,A,F,Y,,,20200704.0,,HP,PT,PT,2020,Q3,Adult
174006424,17400642,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2020,Q3,Flushing,,2020,Q3,4,F,,20200626.0,20200211,20200704,EXP,PT-EMA-20200204-AUTODUP-30640000,PT-ACCORD-172137,ACCORD,,58.0,YR,A,F,Y,,,20200704.0,,HP,PT,PT,2020,Q3,Adult
174006424,17400642,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2020,Q3,Gingival oedema,,2020,Q3,4,F,,20200626.0,20200211,20200704,EXP,PT-EMA-20200204-AUTODUP-30640000,PT-ACCORD-172137,ACCORD,,58.0,YR,A,F,Y,,,20200704.0,,HP,PT,PT,2020,Q3,Adult
174006424,17400642,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2020,Q3,Gingival swelling,,2020,Q3,4,F,,20200626.0,20200211,20200704,EXP,PT-EMA-20200204-AUTODUP-30640000,PT-ACCORD-172137,ACCORD,,58.0,YR,A,F,Y,,,20200704.0,,HP,PT,PT,2020,Q3,Adult
174006424,17400642,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2020,Q3,Headache,,2020,Q3,4,F,,20200626.0,20200211,20200704,EXP,PT-EMA-20200204-AUTODUP-30640000,PT-ACCORD-172137,ACCORD,,58.0,YR,A,F,Y,,,20200704.0,,HP,PT,PT,2020,Q3,Adult
174006424,17400642,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2020,Q3,Iatrogenic injury,,2020,Q3,4,F,,20200626.0,20200211,20200704,EXP,PT-EMA-20200204-AUTODUP-30640000,PT-ACCORD-172137,ACCORD,,58.0,YR,A,F,Y,,,20200704.0,,HP,PT,PT,2020,Q3,Adult
174006424,17400642,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2020,Q3,Leukopenia,,2020,Q3,4,F,,20200626.0,20200211,20200704,EXP,PT-EMA-20200204-AUTODUP-30640000,PT-ACCORD-172137,ACCORD,,58.0,YR,A,F,Y,,,20200704.0,,HP,PT,PT,2020,Q3,Adult
174006424,17400642,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2020,Q3,Lymphocyte morphology abnormal,,2020,Q3,4,F,,20200626.0,20200211,20200704,EXP,PT-EMA-20200204-AUTODUP-30640000,PT-ACCORD-172137,ACCORD,,58.0,YR,A,F,Y,,,20200704.0,,HP,PT,PT,2020,Q3,Adult
174006424,17400642,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2020,Q3,Mouth ulceration,,2020,Q3,4,F,,20200626.0,20200211,20200704,EXP,PT-EMA-20200204-AUTODUP-30640000,PT-ACCORD-172137,ACCORD,,58.0,YR,A,F,Y,,,20200704.0,,HP,PT,PT,2020,Q3,Adult
174006424,17400642,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2020,Q3,Myalgia,,2020,Q3,4,F,,20200626.0,20200211,20200704,EXP,PT-EMA-20200204-AUTODUP-30640000,PT-ACCORD-172137,ACCORD,,58.0,YR,A,F,Y,,,20200704.0,,HP,PT,PT,2020,Q3,Adult
174006424,17400642,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2020,Q3,Neutropenia,,2020,Q3,4,F,,20200626.0,20200211,20200704,EXP,PT-EMA-20200204-AUTODUP-30640000,PT-ACCORD-172137,ACCORD,,58.0,YR,A,F,Y,,,20200704.0,,HP,PT,PT,2020,Q3,Adult
174006424,17400642,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2020,Q3,Pyrexia,,2020,Q3,4,F,,20200626.0,20200211,20200704,EXP,PT-EMA-20200204-AUTODUP-30640000,PT-ACCORD-172137,ACCORD,,58.0,YR,A,F,Y,,,20200704.0,,HP,PT,PT,2020,Q3,Adult
174789132,17478913,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Abscess,,2020,Q3,2,F,20180824.0,20200626.0,20200228,20200707,EXP,,GB-JNJFOC-20191114475,JOHNSON AND JOHNSON,,67.0,YR,,M,Y,127.5,KG,20200707.0,,HP,GB,GB,2020,Q3,Elderly
174789132,17478913,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Ascites,,2020,Q3,2,F,20180824.0,20200626.0,20200228,20200707,EXP,,GB-JNJFOC-20191114475,JOHNSON AND JOHNSON,,67.0,YR,,M,Y,127.5,KG,20200707.0,,HP,GB,GB,2020,Q3,Elderly
174789132,17478913,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Diabetic ketoacidosis,,2020,Q3,2,F,20180824.0,20200626.0,20200228,20200707,EXP,,GB-JNJFOC-20191114475,JOHNSON AND JOHNSON,,67.0,YR,,M,Y,127.5,KG,20200707.0,,HP,GB,GB,2020,Q3,Elderly
174789132,17478913,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Sepsis,,2020,Q3,2,F,20180824.0,20200626.0,20200228,20200707,EXP,,GB-JNJFOC-20191114475,JOHNSON AND JOHNSON,,67.0,YR,,M,Y,127.5,KG,20200707.0,,HP,GB,GB,2020,Q3,Elderly
178855832,17885583,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"1 DOSAGE FORM, QD",,,,, UNK,,,1.0,DF,,QD,2020,Q3,Visual acuity reduced,,2020,Q3,2,F,,20200806.0,20200611,20200812,EXP,,GB-SYNTHON BV-IN51PV20_53761,SYNTHON,,84.0,YR,,M,Y,85.0,KG,20200812.0,,MD,NL,GB,2020,Q3,Elderly
179167292,17916729,2,SS,METFORMIN;DAPAGLIFLOZIN,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,,,,,,,,,2020,Q3,Diabetic ketoacidosis,,2020,Q3,2,F,20200506.0,20200705.0,20200619,20200714,EXP,PT-INFARMED-T202006-63,PT-BAUSCH-BL-2020-017243,BAUSCH AND LOMB,,79.0,YR,,F,Y,45.0,KG,20200714.0,,PH,PT,PT,2020,Q3,Elderly
179180932,17918093,2,SS,DAPAGLIFLOZIN W/METFORMIN,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,UNK,,,U,U,,,,,,,,2020,Q3,Diabetic ketoacidosis,,2020,Q3,2,F,20200506.0,20200707.0,20200619,20200716,EXP,PT-INFARMED-T202006-63,PT-MYLANLABS-2020M1057925,MYLAN,,79.0,YR,,F,Y,45.0,KG,20200716.0,,PH,PT,PT,2020,Q3,Elderly
179279703,17927970,2,SS,DAPAGLIFLOZIN W/METFORMIN,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,"METFORMIN + DAPAGLIFOZIN 1000 MG + 5 MG, WITH A DOSE OF 1000 MG + 5 MG ONCE A DAY PER ORAL",,,U,,,,,,,FILM-COATED TABLET,QD,2020,Q3,Diabetic ketoacidosis,,2020,Q3,3,F,20200506.0,20200714.0,20200623,20200715,EXP,PT-INFARMED-T202006-63,PT-EMD SERONO-E2B_90078272,EMD SERONO INC,,79.0,YR,,F,Y,45.0,KG,20200715.0,,PH,PT,PT,2020,Q3,Elderly
179318333,17931833,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,"10 OT, QD",,,Y,,,,,,,TABLET,QD,2020,Q3,Acute kidney injury,,2020,Q3,3,F,20191025.0,20200630.0,20200623,20200706,EXP,,NL-GLAXOSMITHKLINE-NL2019240132,GLAXOSMITHKLINE,,63.0,YR,,M,Y,,,20200706.0,,HP,NL,NL,2020,Q3,Adult
179318333,17931833,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,"10 OT, QD",,,Y,,,,,,,TABLET,QD,2020,Q3,Dehydration,,2020,Q3,3,F,20191025.0,20200630.0,20200623,20200706,EXP,,NL-GLAXOSMITHKLINE-NL2019240132,GLAXOSMITHKLINE,,63.0,YR,,M,Y,,,20200706.0,,HP,NL,NL,2020,Q3,Adult
179318333,17931833,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,"10 OT, QD",,,Y,,,,,,,TABLET,QD,2020,Q3,Intestinal ischaemia,,2020,Q3,3,F,20191025.0,20200630.0,20200623,20200706,EXP,,NL-GLAXOSMITHKLINE-NL2019240132,GLAXOSMITHKLINE,,63.0,YR,,M,Y,,,20200706.0,,HP,NL,NL,2020,Q3,Adult
179318333,17931833,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,"10 OT, QD",,,Y,,,,,,,TABLET,QD,2020,Q3,Metabolic acidosis,,2020,Q3,3,F,20191025.0,20200630.0,20200623,20200706,EXP,,NL-GLAXOSMITHKLINE-NL2019240132,GLAXOSMITHKLINE,,63.0,YR,,M,Y,,,20200706.0,,HP,NL,NL,2020,Q3,Adult
179318333,17931833,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,"10 OT, QD",,,Y,,,,,,,TABLET,QD,2020,Q3,Myocardial ischaemia,,2020,Q3,3,F,20191025.0,20200630.0,20200623,20200706,EXP,,NL-GLAXOSMITHKLINE-NL2019240132,GLAXOSMITHKLINE,,63.0,YR,,M,Y,,,20200706.0,,HP,NL,NL,2020,Q3,Adult
179318333,17931833,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,"10 OT, QD",,,Y,,,,,,,TABLET,QD,2020,Q3,Nausea,,2020,Q3,3,F,20191025.0,20200630.0,20200623,20200706,EXP,,NL-GLAXOSMITHKLINE-NL2019240132,GLAXOSMITHKLINE,,63.0,YR,,M,Y,,,20200706.0,,HP,NL,NL,2020,Q3,Adult
179318333,17931833,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,"10 OT, QD",,,Y,,,,,,,TABLET,QD,2020,Q3,Pneumonia klebsiella,,2020,Q3,3,F,20191025.0,20200630.0,20200623,20200706,EXP,,NL-GLAXOSMITHKLINE-NL2019240132,GLAXOSMITHKLINE,,63.0,YR,,M,Y,,,20200706.0,,HP,NL,NL,2020,Q3,Adult
179318333,17931833,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,"10 OT, QD",,,Y,,,,,,,TABLET,QD,2020,Q3,Renal failure,,2020,Q3,3,F,20191025.0,20200630.0,20200623,20200706,EXP,,NL-GLAXOSMITHKLINE-NL2019240132,GLAXOSMITHKLINE,,63.0,YR,,M,Y,,,20200706.0,,HP,NL,NL,2020,Q3,Adult
179318333,17931833,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,"10 OT, QD",,,Y,,,,,,,TABLET,QD,2020,Q3,Septic shock,,2020,Q3,3,F,20191025.0,20200630.0,20200623,20200706,EXP,,NL-GLAXOSMITHKLINE-NL2019240132,GLAXOSMITHKLINE,,63.0,YR,,M,Y,,,20200706.0,,HP,NL,NL,2020,Q3,Adult
179318333,17931833,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,"10 OT, QD",,,Y,,,,,,,TABLET,QD,2020,Q3,Vascular injury,,2020,Q3,3,F,20191025.0,20200630.0,20200623,20200706,EXP,,NL-GLAXOSMITHKLINE-NL2019240132,GLAXOSMITHKLINE,,63.0,YR,,M,Y,,,20200706.0,,HP,NL,NL,2020,Q3,Adult
179318333,17931833,8,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,"10 OT, QD",,,Y,,,,,,,TABLET,QD,2020,Q3,Vomiting,,2020,Q3,3,F,20191025.0,20200630.0,20200623,20200706,EXP,,NL-GLAXOSMITHKLINE-NL2019240132,GLAXOSMITHKLINE,,63.0,YR,,M,Y,,,20200706.0,,HP,NL,NL,2020,Q3,Adult
179413612,17941361,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Arthralgia,,2020,Q3,2,F,20200608.0,20200617.0,20200624,20200701,EXP,,US-ACTELION-A-NJ2018-168120,ACTELION,,46.0,YR,,M,Y,87.98,KG,20200701.0,,HP,US,US,2020,Q3,Adult
179413612,17941361,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Disease progression,,2020,Q3,2,F,20200608.0,20200617.0,20200624,20200701,EXP,,US-ACTELION-A-NJ2018-168120,ACTELION,,46.0,YR,,M,Y,87.98,KG,20200701.0,,HP,US,US,2020,Q3,Adult
179413612,17941361,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Dizziness,,2020,Q3,2,F,20200608.0,20200617.0,20200624,20200701,EXP,,US-ACTELION-A-NJ2018-168120,ACTELION,,46.0,YR,,M,Y,87.98,KG,20200701.0,,HP,US,US,2020,Q3,Adult
179413612,17941361,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Drug ineffective,,2020,Q3,2,F,20200608.0,20200617.0,20200624,20200701,EXP,,US-ACTELION-A-NJ2018-168120,ACTELION,,46.0,YR,,M,Y,87.98,KG,20200701.0,,HP,US,US,2020,Q3,Adult
179413612,17941361,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Dysgeusia,,2020,Q3,2,F,20200608.0,20200617.0,20200624,20200701,EXP,,US-ACTELION-A-NJ2018-168120,ACTELION,,46.0,YR,,M,Y,87.98,KG,20200701.0,,HP,US,US,2020,Q3,Adult
179413612,17941361,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Dyspnoea,,2020,Q3,2,F,20200608.0,20200617.0,20200624,20200701,EXP,,US-ACTELION-A-NJ2018-168120,ACTELION,,46.0,YR,,M,Y,87.98,KG,20200701.0,,HP,US,US,2020,Q3,Adult
179413612,17941361,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Headache,,2020,Q3,2,F,20200608.0,20200617.0,20200624,20200701,EXP,,US-ACTELION-A-NJ2018-168120,ACTELION,,46.0,YR,,M,Y,87.98,KG,20200701.0,,HP,US,US,2020,Q3,Adult
179413612,17941361,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Inappropriate schedule of product administration,,2020,Q3,2,F,20200608.0,20200617.0,20200624,20200701,EXP,,US-ACTELION-A-NJ2018-168120,ACTELION,,46.0,YR,,M,Y,87.98,KG,20200701.0,,HP,US,US,2020,Q3,Adult
179413612,17941361,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Malaise,,2020,Q3,2,F,20200608.0,20200617.0,20200624,20200701,EXP,,US-ACTELION-A-NJ2018-168120,ACTELION,,46.0,YR,,M,Y,87.98,KG,20200701.0,,HP,US,US,2020,Q3,Adult
179413612,17941361,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Pain in jaw,,2020,Q3,2,F,20200608.0,20200617.0,20200624,20200701,EXP,,US-ACTELION-A-NJ2018-168120,ACTELION,,46.0,YR,,M,Y,87.98,KG,20200701.0,,HP,US,US,2020,Q3,Adult
179413612,17941361,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Pulmonary arterial hypertension,,2020,Q3,2,F,20200608.0,20200617.0,20200624,20200701,EXP,,US-ACTELION-A-NJ2018-168120,ACTELION,,46.0,YR,,M,Y,87.98,KG,20200701.0,,HP,US,US,2020,Q3,Adult
179413612,17941361,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Syncope,,2020,Q3,2,F,20200608.0,20200617.0,20200624,20200701,EXP,,US-ACTELION-A-NJ2018-168120,ACTELION,,46.0,YR,,M,Y,87.98,KG,20200701.0,,HP,US,US,2020,Q3,Adult
179413612,17941361,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Therapy change,,2020,Q3,2,F,20200608.0,20200617.0,20200624,20200701,EXP,,US-ACTELION-A-NJ2018-168120,ACTELION,,46.0,YR,,M,Y,87.98,KG,20200701.0,,HP,US,US,2020,Q3,Adult
179413612,17941361,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Tooth infection,,2020,Q3,2,F,20200608.0,20200617.0,20200624,20200701,EXP,,US-ACTELION-A-NJ2018-168120,ACTELION,,46.0,YR,,M,Y,87.98,KG,20200701.0,,HP,US,US,2020,Q3,Adult
179413612,17941361,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Toothache,,2020,Q3,2,F,20200608.0,20200617.0,20200624,20200701,EXP,,US-ACTELION-A-NJ2018-168120,ACTELION,,46.0,YR,,M,Y,87.98,KG,20200701.0,,HP,US,US,2020,Q3,Adult
179413612,17941361,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Unevaluable event,,2020,Q3,2,F,20200608.0,20200617.0,20200624,20200701,EXP,,US-ACTELION-A-NJ2018-168120,ACTELION,,46.0,YR,,M,Y,87.98,KG,20200701.0,,HP,US,US,2020,Q3,Adult
179510352,17951035,2,SS,Metformina + Dapagliflozina,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,, UNKNOWN,,,,,,,2020,Q3,Diabetic ketoacidosis,,2020,Q3,2,F,20200506.0,20200708.0,20200626,20200720,EXP,PT-INFARMED-T202006-63,PT-TEVA-2020-PT-1791343,TEVA,,79.0,YR,,F,Y,45.0,KG,20200718.0,,PH,PT,PT,2020,Q3,Elderly
179671431,17967143,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0 ()",,,U,,,,,,,,,2020,Q3,Anaemia,,2020,Q3,1,I,,20200617.0,20200701,20200701,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-252048,RANBAXY,,66.0,YR,,F,Y,80.0,KG,20200701.0,,HP,NL,DE,2020,Q3,Elderly
179671431,17967143,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0 ()",,,U,,,,,,,,,2020,Q3,Dyspnoea,,2020,Q3,1,I,,20200617.0,20200701,20200701,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-252048,RANBAXY,,66.0,YR,,F,Y,80.0,KG,20200701.0,,HP,NL,DE,2020,Q3,Elderly
179671431,17967143,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0 ()",,,U,,,,,,,,,2020,Q3,Dyspnoea exertional,,2020,Q3,1,I,,20200617.0,20200701,20200701,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-252048,RANBAXY,,66.0,YR,,F,Y,80.0,KG,20200701.0,,HP,NL,DE,2020,Q3,Elderly
179671431,17967143,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0 ()",,,U,,,,,,,,,2020,Q3,General physical health deterioration,,2020,Q3,1,I,,20200617.0,20200701,20200701,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-252048,RANBAXY,,66.0,YR,,F,Y,80.0,KG,20200701.0,,HP,NL,DE,2020,Q3,Elderly
179671431,17967143,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0 ()",,,U,,,,,,,,,2020,Q3,Oedema peripheral,,2020,Q3,1,I,,20200617.0,20200701,20200701,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-252048,RANBAXY,,66.0,YR,,F,Y,80.0,KG,20200701.0,,HP,NL,DE,2020,Q3,Elderly
179671431,17967143,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0 ()",,,U,,,,,,,,,2020,Q3,Pallor,,2020,Q3,1,I,,20200617.0,20200701,20200701,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-252048,RANBAXY,,66.0,YR,,F,Y,80.0,KG,20200701.0,,HP,NL,DE,2020,Q3,Elderly
179671431,17967143,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0 ()",,,U,,,,,,,,,2020,Q3,Weight increased,,2020,Q3,1,I,,20200617.0,20200701,20200701,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-252048,RANBAXY,,66.0,YR,,F,Y,80.0,KG,20200701.0,,HP,NL,DE,2020,Q3,Elderly
179747691,17974769,18,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2020,Q3,Asthenia,,2020,Q3,1,I,20170308.0,20170630.0,20200702,20200702,EXP,,PHHY2017CA100820,NOVARTIS,,41.0,YR,,M,Y,130.3,KG,20200702.0,,MD,CA,CA,2020,Q3,Adult
179747691,17974769,18,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2020,Q3,Blood creatinine increased,,2020,Q3,1,I,20170308.0,20170630.0,20200702,20200702,EXP,,PHHY2017CA100820,NOVARTIS,,41.0,YR,,M,Y,130.3,KG,20200702.0,,MD,CA,CA,2020,Q3,Adult
179747691,17974769,18,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2020,Q3,Blood urea increased,,2020,Q3,1,I,20170308.0,20170630.0,20200702,20200702,EXP,,PHHY2017CA100820,NOVARTIS,,41.0,YR,,M,Y,130.3,KG,20200702.0,,MD,CA,CA,2020,Q3,Adult
179747691,17974769,18,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2020,Q3,Body mass index increased,,2020,Q3,1,I,20170308.0,20170630.0,20200702,20200702,EXP,,PHHY2017CA100820,NOVARTIS,,41.0,YR,,M,Y,130.3,KG,20200702.0,,MD,CA,CA,2020,Q3,Adult
179747691,17974769,18,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2020,Q3,Cardiac failure congestive,,2020,Q3,1,I,20170308.0,20170630.0,20200702,20200702,EXP,,PHHY2017CA100820,NOVARTIS,,41.0,YR,,M,Y,130.3,KG,20200702.0,,MD,CA,CA,2020,Q3,Adult
179747691,17974769,18,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2020,Q3,Decreased appetite,,2020,Q3,1,I,20170308.0,20170630.0,20200702,20200702,EXP,,PHHY2017CA100820,NOVARTIS,,41.0,YR,,M,Y,130.3,KG,20200702.0,,MD,CA,CA,2020,Q3,Adult
179747691,17974769,18,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2020,Q3,Dizziness exertional,,2020,Q3,1,I,20170308.0,20170630.0,20200702,20200702,EXP,,PHHY2017CA100820,NOVARTIS,,41.0,YR,,M,Y,130.3,KG,20200702.0,,MD,CA,CA,2020,Q3,Adult
179747691,17974769,18,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2020,Q3,Dyspnoea,,2020,Q3,1,I,20170308.0,20170630.0,20200702,20200702,EXP,,PHHY2017CA100820,NOVARTIS,,41.0,YR,,M,Y,130.3,KG,20200702.0,,MD,CA,CA,2020,Q3,Adult
179747691,17974769,18,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2020,Q3,Dyspnoea paroxysmal nocturnal,,2020,Q3,1,I,20170308.0,20170630.0,20200702,20200702,EXP,,PHHY2017CA100820,NOVARTIS,,41.0,YR,,M,Y,130.3,KG,20200702.0,,MD,CA,CA,2020,Q3,Adult
179747691,17974769,18,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2020,Q3,Fatigue,,2020,Q3,1,I,20170308.0,20170630.0,20200702,20200702,EXP,,PHHY2017CA100820,NOVARTIS,,41.0,YR,,M,Y,130.3,KG,20200702.0,,MD,CA,CA,2020,Q3,Adult
179747691,17974769,18,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2020,Q3,Hypervolaemia,,2020,Q3,1,I,20170308.0,20170630.0,20200702,20200702,EXP,,PHHY2017CA100820,NOVARTIS,,41.0,YR,,M,Y,130.3,KG,20200702.0,,MD,CA,CA,2020,Q3,Adult
179747691,17974769,18,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2020,Q3,Low cardiac output syndrome,,2020,Q3,1,I,20170308.0,20170630.0,20200702,20200702,EXP,,PHHY2017CA100820,NOVARTIS,,41.0,YR,,M,Y,130.3,KG,20200702.0,,MD,CA,CA,2020,Q3,Adult
179747691,17974769,18,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2020,Q3,Malaise,,2020,Q3,1,I,20170308.0,20170630.0,20200702,20200702,EXP,,PHHY2017CA100820,NOVARTIS,,41.0,YR,,M,Y,130.3,KG,20200702.0,,MD,CA,CA,2020,Q3,Adult
179747691,17974769,18,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2020,Q3,Nausea,,2020,Q3,1,I,20170308.0,20170630.0,20200702,20200702,EXP,,PHHY2017CA100820,NOVARTIS,,41.0,YR,,M,Y,130.3,KG,20200702.0,,MD,CA,CA,2020,Q3,Adult
179747691,17974769,18,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2020,Q3,Orthopnoea,,2020,Q3,1,I,20170308.0,20170630.0,20200702,20200702,EXP,,PHHY2017CA100820,NOVARTIS,,41.0,YR,,M,Y,130.3,KG,20200702.0,,MD,CA,CA,2020,Q3,Adult
179839061,17983906,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,TABLET,,2020,Q3,Diabetic ketoacidosis,,2020,Q3,1,I,,20200701.0,20200706,20200706,EXP,,GB-ASTRAZENECA-2020SE83415,ASTRAZENECA,,86.0,YR,,F,Y,,,20200706.0,,HP,GB,GB,2020,Q3,Elderly
179848212,17984821,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,,,2020,Q3,Diabetic ketoacidosis,,2020,Q3,2,F,20200506.0,20200715.0,20200706,20200717,EXP,PT-INFARMED-T202006-63,NVSC2020PT189137,NOVARTIS,,79.0,YR,,F,Y,45.0,KG,20200717.0,,HP,COUNTRY NOT SPECIFIED,PT,2020,Q3,Elderly
180052022,18005202,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2020,Q3,Autoimmune disorder,,2020,Q3,2,F,2017.0,20200708.0,20200710,20200718,EXP,,DE-LUPIN PHARMACEUTICALS INC.-2020-03131,LUPIN,,65.0,YR,,M,Y,,,20200718.0,,MD,GB,DE,2020,Q3,Elderly
180071221,18007122,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,5.0MG UNKNOWN,,,Y,,,,,5.0,MG,TABLET,,2020,Q3,Euglycaemic diabetic ketoacidosis,,2020,Q3,1,I,20200618.0,20200701.0,20200710,20200710,EXP,,GB-ASTRAZENECA-2020SE83423,ASTRAZENECA,,54.0,YR,,M,Y,80.2,KG,20200710.0,,,GB,GB,2020,Q3,Adult
180106861,18010686,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG,(1?0?0?0)",,,U,,,,,10.0,MG,,,2020,Q3,Anaemia,,2020,Q3,1,I,,20200702.0,20200710,20200710,EXP,,NVSC2020DE188556,NOVARTIS,,66.0,YR,,F,Y,80.0,KG,20200710.0,,HP,DE,DE,2020,Q3,Elderly
180106861,18010686,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG,(1?0?0?0)",,,U,,,,,10.0,MG,,,2020,Q3,Dyspnoea,,2020,Q3,1,I,,20200702.0,20200710,20200710,EXP,,NVSC2020DE188556,NOVARTIS,,66.0,YR,,F,Y,80.0,KG,20200710.0,,HP,DE,DE,2020,Q3,Elderly
180106861,18010686,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG,(1?0?0?0)",,,U,,,,,10.0,MG,,,2020,Q3,Dyspnoea exertional,,2020,Q3,1,I,,20200702.0,20200710,20200710,EXP,,NVSC2020DE188556,NOVARTIS,,66.0,YR,,F,Y,80.0,KG,20200710.0,,HP,DE,DE,2020,Q3,Elderly
180106861,18010686,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG,(1?0?0?0)",,,U,,,,,10.0,MG,,,2020,Q3,General physical health deterioration,,2020,Q3,1,I,,20200702.0,20200710,20200710,EXP,,NVSC2020DE188556,NOVARTIS,,66.0,YR,,F,Y,80.0,KG,20200710.0,,HP,DE,DE,2020,Q3,Elderly
180106861,18010686,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG,(1?0?0?0)",,,U,,,,,10.0,MG,,,2020,Q3,Oedema peripheral,,2020,Q3,1,I,,20200702.0,20200710,20200710,EXP,,NVSC2020DE188556,NOVARTIS,,66.0,YR,,F,Y,80.0,KG,20200710.0,,HP,DE,DE,2020,Q3,Elderly
180106861,18010686,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG,(1?0?0?0)",,,U,,,,,10.0,MG,,,2020,Q3,Pallor,,2020,Q3,1,I,,20200702.0,20200710,20200710,EXP,,NVSC2020DE188556,NOVARTIS,,66.0,YR,,F,Y,80.0,KG,20200710.0,,HP,DE,DE,2020,Q3,Elderly
180106861,18010686,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG,(1?0?0?0)",,,U,,,,,10.0,MG,,,2020,Q3,Weight increased,,2020,Q3,1,I,,20200702.0,20200710,20200710,EXP,,NVSC2020DE188556,NOVARTIS,,66.0,YR,,F,Y,80.0,KG,20200710.0,,HP,DE,DE,2020,Q3,Elderly
180156971,18015697,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,,,TABLET,,2020,Q3,Diabetic ketoacidosis,,2020,Q3,1,I,20200627.0,20200708.0,20200713,20200713,EXP,,GB-ASTRAZENECA-2020SE86335,ASTRAZENECA,,67.0,YR,,F,Y,70.0,KG,20200713.0,,,GB,GB,2020,Q3,Elderly
180157941,18015794,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,,10.0,MG,TABLET,,2020,Q3,Euglycaemic diabetic ketoacidosis,,2020,Q3,1,I,20200627.0,20200708.0,20200713,20200713,EXP,,GB-ASTRAZENECA-2020SE86342,ASTRAZENECA,,65.0,YR,,M,Y,88.0,KG,20200713.0,,MD,GB,GB,2020,Q3,Elderly
180331941,18033194,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,10.0,MG,Y,, LL2651/2002128,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Dizziness,,2020,Q3,1,I,20200508.0,20200708.0,20200716,20200716,EXP,,CN-ASTRAZENECA-2020SE88723,ASTRAZENECA,,17677.0,DY,,F,Y,,,20200716.0,,HP,CN,CN,2020,Q3,Elderly
180331941,18033194,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,10.0,MG,Y,, LL2651/2002128,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Seizure,,2020,Q3,1,I,20200508.0,20200708.0,20200716,20200716,EXP,,CN-ASTRAZENECA-2020SE88723,ASTRAZENECA,,17677.0,DY,,F,Y,,,20200716.0,,HP,CN,CN,2020,Q3,Elderly
180331941,18033194,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,10.0,MG,Y,, LL2651/2002128,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Dizziness,,2020,Q3,1,I,20200508.0,20200708.0,20200716,20200716,EXP,,CN-ASTRAZENECA-2020SE88723,ASTRAZENECA,,17677.0,DY,,F,Y,,,20200716.0,,HP,CN,CN,2020,Q3,Elderly
180331941,18033194,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,10.0,MG,Y,, LL2651/2002128,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Seizure,,2020,Q3,1,I,20200508.0,20200708.0,20200716,20200716,EXP,,CN-ASTRAZENECA-2020SE88723,ASTRAZENECA,,17677.0,DY,,F,Y,,,20200716.0,,HP,CN,CN,2020,Q3,Elderly
180437831,18043783,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,70.0,MG,Y,, 2003136,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Decreased appetite,,2020,Q3,1,I,20200701.0,20200711.0,20200720,20200720,EXP,,CN-ASTRAZENECA-2020SE89616,ASTRAZENECA,,51.0,YR,,F,Y,57.0,KG,20200720.0,,HP,CN,CN,2020,Q3,Adult
180437831,18043783,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,70.0,MG,Y,, 2003136,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Diabetic ketoacidosis,,2020,Q3,1,I,20200701.0,20200711.0,20200720,20200720,EXP,,CN-ASTRAZENECA-2020SE89616,ASTRAZENECA,,51.0,YR,,F,Y,57.0,KG,20200720.0,,HP,CN,CN,2020,Q3,Adult
180616261,18061626,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,,,,,10.0,MG,UNKNOWN,QD,2020,Q3,Anaemia,,2020,Q3,1,I,20180719.0,20180828.0,20200723,20200723,EXP,,DE-CELGENEUS-DEU-20180808778,CELGENE,,56.0,YR,,M,Y,152.0,KG,20200723.0,,MD,DE,DE,2020,Q3,Adult
180616261,18061626,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,,,,,10.0,MG,UNKNOWN,QD,2020,Q3,General physical health deterioration,,2020,Q3,1,I,20180719.0,20180828.0,20200723,20200723,EXP,,DE-CELGENEUS-DEU-20180808778,CELGENE,,56.0,YR,,M,Y,152.0,KG,20200723.0,,MD,DE,DE,2020,Q3,Adult
180641601,18064160,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,,,,202293.0,10.0,MG,TABLET,,2020,Q3,Skin necrosis,,2020,Q3,1,I,,20200716.0,20200724,20200724,EXP,,GB-ASTRAZENECA-2020SE89937,ASTRAZENECA,,78.0,YR,,M,Y,,,20200724.0,,HP,GB,GB,2020,Q3,Elderly
180726121,18072612,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,,10.0,MG,TABLET,,2020,Q3,Diabetic ketoacidosis,,2020,Q3,1,I,20200701.0,20200721.0,20200727,20200727,EXP,,GB-ASTRAZENECA-2020SE91332,ASTRAZENECA,,62.0,YR,,M,Y,,,20200727.0,,,GB,GB,2020,Q3,Adult
181037201,18103720,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,, UNK,,,,,,,2020,Q3,Heparin-induced thrombocytopenia,,2020,Q3,1,I,,20200729.0,20200803,20200803,EXP,,CZ-FRESENIUS KABI-FK202007837,FRESENIUS KABI,POLAK P. HEPARIN?INDUCED THROMBOCYTOPENIA: A CASE REPORT AND LITERATURE REVIEW.,62.0,YR,,F,Y,,,20200803.0,,,COUNTRY NOT SPECIFIED,CZ,2020,Q3,Adult
181037201,18103720,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,, UNK,,,,,,,2020,Q3,Incision site impaired healing,,2020,Q3,1,I,,20200729.0,20200803,20200803,EXP,,CZ-FRESENIUS KABI-FK202007837,FRESENIUS KABI,POLAK P. HEPARIN?INDUCED THROMBOCYTOPENIA: A CASE REPORT AND LITERATURE REVIEW.,62.0,YR,,F,Y,,,20200803.0,,,COUNTRY NOT SPECIFIED,CZ,2020,Q3,Adult
181037201,18103720,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,, UNK,,,,,,,2020,Q3,Off label use,,2020,Q3,1,I,,20200729.0,20200803,20200803,EXP,,CZ-FRESENIUS KABI-FK202007837,FRESENIUS KABI,POLAK P. HEPARIN?INDUCED THROMBOCYTOPENIA: A CASE REPORT AND LITERATURE REVIEW.,62.0,YR,,F,Y,,,20200803.0,,,COUNTRY NOT SPECIFIED,CZ,2020,Q3,Adult
181090951,18109095,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,50.0,MG,Y,, LC3182,,,10.0,MG,TABLET,QD,2020,Q3,Ketosis,,2020,Q3,1,I,20200623.0,20200719.0,20200804,20200804,EXP,,CN-ASTRAZENECA-2020SE93401,ASTRAZENECA,,70.0,YR,,M,Y,70.0,KG,20200804.0,,HP,CN,CN,2020,Q3,Elderly
181090961,18109096,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,, UNKNOWN,,,10.0,MG,TABLET,,2020,Q3,Diabetic ketoacidosis,,2020,Q3,1,I,20200709.0,20200727.0,20200804,20200804,EXP,,GB-ASTRAZENECA-2020SE94568,ASTRAZENECA,,66.0,YR,,F,Y,85.0,KG,20200804.0,,MD,GB,GB,2020,Q3,Elderly
181144001,18114400,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,,,,,,,,,,2020,Q3,Blood glucose increased,,2020,Q3,1,I,2018.0,20200724.0,20200805,20200805,EXP,,US-JNJFOC-20200741747,JOHNSON AND JOHNSON,,22.0,YR,A,M,Y,147.55,KG,20200805.0,,CN,US,US,2020,Q3,Youth
181144001,18114400,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,,,,,,,,,,2020,Q3,Cardiac arrest,,2020,Q3,1,I,2018.0,20200724.0,20200805,20200805,EXP,,US-JNJFOC-20200741747,JOHNSON AND JOHNSON,,22.0,YR,A,M,Y,147.55,KG,20200805.0,,CN,US,US,2020,Q3,Youth
181144001,18114400,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,,,,,,,,,,2020,Q3,Gout,,2020,Q3,1,I,2018.0,20200724.0,20200805,20200805,EXP,,US-JNJFOC-20200741747,JOHNSON AND JOHNSON,,22.0,YR,A,M,Y,147.55,KG,20200805.0,,CN,US,US,2020,Q3,Youth
181144001,18114400,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,,,,,,,,,,2020,Q3,Hypersensitivity,,2020,Q3,1,I,2018.0,20200724.0,20200805,20200805,EXP,,US-JNJFOC-20200741747,JOHNSON AND JOHNSON,,22.0,YR,A,M,Y,147.55,KG,20200805.0,,CN,US,US,2020,Q3,Youth
181144001,18114400,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,,,,,,,,,,2020,Q3,Psoriasis,,2020,Q3,1,I,2018.0,20200724.0,20200805,20200805,EXP,,US-JNJFOC-20200741747,JOHNSON AND JOHNSON,,22.0,YR,A,M,Y,147.55,KG,20200805.0,,CN,US,US,2020,Q3,Youth
181144001,18114400,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,,,,,,,,,,2020,Q3,Psoriatic arthropathy,,2020,Q3,1,I,2018.0,20200724.0,20200805,20200805,EXP,,US-JNJFOC-20200741747,JOHNSON AND JOHNSON,,22.0,YR,A,M,Y,147.55,KG,20200805.0,,CN,US,US,2020,Q3,Youth
181144001,18114400,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,,,,,,,,,,2020,Q3,Therapeutic product effect decreased,,2020,Q3,1,I,2018.0,20200724.0,20200805,20200805,EXP,,US-JNJFOC-20200741747,JOHNSON AND JOHNSON,,22.0,YR,A,M,Y,147.55,KG,20200805.0,,CN,US,US,2020,Q3,Youth
181156621,18115662,25,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Fournier's gangrene,,2020,Q3,1,I,20151210.0,20200728.0,20200805,20200805,EXP,,US-ASTRAZENECA-2020SE95731,ASTRAZENECA,,20254.0,DY,,M,Y,153.3,KG,20200805.0,,,US,US,2020,Q3,Elderly
181156621,18115662,25,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q3,Necrotising soft tissue infection,,2020,Q3,1,I,20151210.0,20200728.0,20200805,20200805,EXP,,US-ASTRAZENECA-2020SE95731,ASTRAZENECA,,20254.0,DY,,M,Y,153.3,KG,20200805.0,,,US,US,2020,Q3,Elderly
181160131,18116013,3,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2020,Q3,Diabetic ketoacidosis,,2020,Q3,1,I,,20200730.0,20200806,20200806,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-039258",BOEHRINGER INGELHEIM,,64.0,YR,,M,Y,,,20200806.0,,HP,CA,CA,2020,Q3,Adult
181160131,18116013,3,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2020,Q3,Ear infection,,2020,Q3,1,I,,20200730.0,20200806,20200806,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-039258",BOEHRINGER INGELHEIM,,64.0,YR,,M,Y,,,20200806.0,,HP,CA,CA,2020,Q3,Adult
181196781,18119678,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Acute kidney injury,,2020,Q3,1,I,,20200728.0,20200806,20200806,EXP,,JP-EMD SERONO-9177982,EMD SERONO INC,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT.. MEDICINE. 2020?99 (29):(E21202). DOI:HTTP://DX.DOI.ORG/10.1097/MD.0000000000021202",18.0,YR,A,F,Y,,,20200806.0,,MD,JP,JP,2020,Q3,Youth
181196781,18119678,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Capillary leak syndrome,,2020,Q3,1,I,,20200728.0,20200806,20200806,EXP,,JP-EMD SERONO-9177982,EMD SERONO INC,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT.. MEDICINE. 2020?99 (29):(E21202). DOI:HTTP://DX.DOI.ORG/10.1097/MD.0000000000021202",18.0,YR,A,F,Y,,,20200806.0,,MD,JP,JP,2020,Q3,Youth
181196781,18119678,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Compartment syndrome,,2020,Q3,1,I,,20200728.0,20200806,20200806,EXP,,JP-EMD SERONO-9177982,EMD SERONO INC,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT.. MEDICINE. 2020?99 (29):(E21202). DOI:HTTP://DX.DOI.ORG/10.1097/MD.0000000000021202",18.0,YR,A,F,Y,,,20200806.0,,MD,JP,JP,2020,Q3,Youth
181196781,18119678,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Disseminated intravascular coagulation,,2020,Q3,1,I,,20200728.0,20200806,20200806,EXP,,JP-EMD SERONO-9177982,EMD SERONO INC,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT.. MEDICINE. 2020?99 (29):(E21202). DOI:HTTP://DX.DOI.ORG/10.1097/MD.0000000000021202",18.0,YR,A,F,Y,,,20200806.0,,MD,JP,JP,2020,Q3,Youth
181196781,18119678,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Hypoglycaemia,,2020,Q3,1,I,,20200728.0,20200806,20200806,EXP,,JP-EMD SERONO-9177982,EMD SERONO INC,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT.. MEDICINE. 2020?99 (29):(E21202). DOI:HTTP://DX.DOI.ORG/10.1097/MD.0000000000021202",18.0,YR,A,F,Y,,,20200806.0,,MD,JP,JP,2020,Q3,Youth
181196781,18119678,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Hypovolaemia,,2020,Q3,1,I,,20200728.0,20200806,20200806,EXP,,JP-EMD SERONO-9177982,EMD SERONO INC,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT.. MEDICINE. 2020?99 (29):(E21202). DOI:HTTP://DX.DOI.ORG/10.1097/MD.0000000000021202",18.0,YR,A,F,Y,,,20200806.0,,MD,JP,JP,2020,Q3,Youth
181196781,18119678,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Intentional overdose,,2020,Q3,1,I,,20200728.0,20200806,20200806,EXP,,JP-EMD SERONO-9177982,EMD SERONO INC,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT.. MEDICINE. 2020?99 (29):(E21202). DOI:HTTP://DX.DOI.ORG/10.1097/MD.0000000000021202",18.0,YR,A,F,Y,,,20200806.0,,MD,JP,JP,2020,Q3,Youth
181196781,18119678,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Lactic acidosis,,2020,Q3,1,I,,20200728.0,20200806,20200806,EXP,,JP-EMD SERONO-9177982,EMD SERONO INC,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT.. MEDICINE. 2020?99 (29):(E21202). DOI:HTTP://DX.DOI.ORG/10.1097/MD.0000000000021202",18.0,YR,A,F,Y,,,20200806.0,,MD,JP,JP,2020,Q3,Youth
181196781,18119678,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Loss of consciousness,,2020,Q3,1,I,,20200728.0,20200806,20200806,EXP,,JP-EMD SERONO-9177982,EMD SERONO INC,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT.. MEDICINE. 2020?99 (29):(E21202). DOI:HTTP://DX.DOI.ORG/10.1097/MD.0000000000021202",18.0,YR,A,F,Y,,,20200806.0,,MD,JP,JP,2020,Q3,Youth
181196781,18119678,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Pneumonia aspiration,,2020,Q3,1,I,,20200728.0,20200806,20200806,EXP,,JP-EMD SERONO-9177982,EMD SERONO INC,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT.. MEDICINE. 2020?99 (29):(E21202). DOI:HTTP://DX.DOI.ORG/10.1097/MD.0000000000021202",18.0,YR,A,F,Y,,,20200806.0,,MD,JP,JP,2020,Q3,Youth
181196781,18119678,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Rhabdomyolysis,,2020,Q3,1,I,,20200728.0,20200806,20200806,EXP,,JP-EMD SERONO-9177982,EMD SERONO INC,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT.. MEDICINE. 2020?99 (29):(E21202). DOI:HTTP://DX.DOI.ORG/10.1097/MD.0000000000021202",18.0,YR,A,F,Y,,,20200806.0,,MD,JP,JP,2020,Q3,Youth
181196781,18119678,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Shock,,2020,Q3,1,I,,20200728.0,20200806,20200806,EXP,,JP-EMD SERONO-9177982,EMD SERONO INC,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT.. MEDICINE. 2020?99 (29):(E21202). DOI:HTTP://DX.DOI.ORG/10.1097/MD.0000000000021202",18.0,YR,A,F,Y,,,20200806.0,,MD,JP,JP,2020,Q3,Youth
181271801,18127180,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,TABLET,,2020,Q3,Acute kidney injury,,2020,Q3,1,I,,20200803.0,20200810,20200810,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-257011,RANBAXY,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE. 2020?99(29):E21202",18.0,YR,,F,Y,,,20200810.0,,MD,JP,JP,2020,Q3,Youth
181271801,18127180,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,TABLET,,2020,Q3,Compartment syndrome,,2020,Q3,1,I,,20200803.0,20200810,20200810,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-257011,RANBAXY,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE. 2020?99(29):E21202",18.0,YR,,F,Y,,,20200810.0,,MD,JP,JP,2020,Q3,Youth
181271801,18127180,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,TABLET,,2020,Q3,Overdose,,2020,Q3,1,I,,20200803.0,20200810,20200810,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-257011,RANBAXY,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE. 2020?99(29):E21202",18.0,YR,,F,Y,,,20200810.0,,MD,JP,JP,2020,Q3,Youth
181271801,18127180,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,TABLET,,2020,Q3,Suicide attempt,,2020,Q3,1,I,,20200803.0,20200810,20200810,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-257011,RANBAXY,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE. 2020?99(29):E21202",18.0,YR,,F,Y,,,20200810.0,,MD,JP,JP,2020,Q3,Youth
181292841,18129284,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,,10.0,MG,TABLET,,2020,Q3,Diabetic ketoacidosis,,2020,Q3,1,I,20200714.0,20200804.0,20200810,20200810,EXP,,GB-ASTRAZENECA-2020SE97694,ASTRAZENECA,,52.0,YR,,M,Y,82.0,KG,20200810.0,,,GB,GB,2020,Q3,Adult
181338191,18133819,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"10 MG, 0?1?0?0",,,,,,,,,,,,2020,Q3,Abdominal distension,,2020,Q3,1,I,,20200804.0,20200811,20200811,EXP,DE-BFARM-20008408,DE-ACCORD-194985,ACCORD,,62.0,YR,A,F,Y,74.0,KG,20200811.0,,PH,DE,DE,2020,Q3,Adult
181338191,18133819,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"10 MG, 0?1?0?0",,,,,,,,,,,,2020,Q3,Flatulence,,2020,Q3,1,I,,20200804.0,20200811,20200811,EXP,DE-BFARM-20008408,DE-ACCORD-194985,ACCORD,,62.0,YR,A,F,Y,74.0,KG,20200811.0,,PH,DE,DE,2020,Q3,Adult
181338191,18133819,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"10 MG, 0?1?0?0",,,,,,,,,,,,2020,Q3,General physical health deterioration,,2020,Q3,1,I,,20200804.0,20200811,20200811,EXP,DE-BFARM-20008408,DE-ACCORD-194985,ACCORD,,62.0,YR,A,F,Y,74.0,KG,20200811.0,,PH,DE,DE,2020,Q3,Adult
181338191,18133819,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"10 MG, 0?1?0?0",,,,,,,,,,,,2020,Q3,Nausea,,2020,Q3,1,I,,20200804.0,20200811,20200811,EXP,DE-BFARM-20008408,DE-ACCORD-194985,ACCORD,,62.0,YR,A,F,Y,74.0,KG,20200811.0,,PH,DE,DE,2020,Q3,Adult
181338191,18133819,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"10 MG, 0?1?0?0",,,,,,,,,,,,2020,Q3,Vomiting,,2020,Q3,1,I,,20200804.0,20200811,20200811,EXP,DE-BFARM-20008408,DE-ACCORD-194985,ACCORD,,62.0,YR,A,F,Y,74.0,KG,20200811.0,,PH,DE,DE,2020,Q3,Adult
181359181,18135918,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,,,,202293.0,10.0,MG,TABLET,,2020,Q3,Pemphigoid,,2020,Q3,1,I,20200701.0,20200803.0,20200811,20200811,EXP,,LB-ASTRAZENECA-2020SE98243,ASTRAZENECA,,77.0,YR,,M,Y,,,20200811.0,,MD,LB,LB,2020,Q3,Elderly
181359181,18135918,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,,,,202293.0,10.0,MG,TABLET,,2020,Q3,Pemphigoid,,2020,Q3,1,I,20200701.0,20200803.0,20200811,20200811,EXP,,LB-ASTRAZENECA-2020SE98243,ASTRAZENECA,,77.0,YR,,M,Y,,,20200811.0,,MD,LB,LB,2020,Q3,Elderly
181360701,18136070,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 TABLETS, 5MG",,,D,,,,,5.0,DF,TABLET,,2020,Q3,Acute kidney injury,,2020,Q3,1,I,,20200731.0,20200811,20200811,EXP,,JP-AMNEAL PHARMACEUTICALS-2020-AMRX-02397,AMNEAL,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE. 2020?99 (29):E21202",18.0,YR,,F,Y,,,20200811.0,,MD,JP,JP,2020,Q3,Youth
181360701,18136070,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 TABLETS, 5MG",,,D,,,,,5.0,DF,TABLET,,2020,Q3,Capillary leak syndrome,,2020,Q3,1,I,,20200731.0,20200811,20200811,EXP,,JP-AMNEAL PHARMACEUTICALS-2020-AMRX-02397,AMNEAL,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE. 2020?99 (29):E21202",18.0,YR,,F,Y,,,20200811.0,,MD,JP,JP,2020,Q3,Youth
181360701,18136070,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 TABLETS, 5MG",,,D,,,,,5.0,DF,TABLET,,2020,Q3,Compartment syndrome,,2020,Q3,1,I,,20200731.0,20200811,20200811,EXP,,JP-AMNEAL PHARMACEUTICALS-2020-AMRX-02397,AMNEAL,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE. 2020?99 (29):E21202",18.0,YR,,F,Y,,,20200811.0,,MD,JP,JP,2020,Q3,Youth
181360701,18136070,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 TABLETS, 5MG",,,D,,,,,5.0,DF,TABLET,,2020,Q3,Hypoglycaemia,,2020,Q3,1,I,,20200731.0,20200811,20200811,EXP,,JP-AMNEAL PHARMACEUTICALS-2020-AMRX-02397,AMNEAL,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE. 2020?99 (29):E21202",18.0,YR,,F,Y,,,20200811.0,,MD,JP,JP,2020,Q3,Youth
181360701,18136070,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 TABLETS, 5MG",,,D,,,,,5.0,DF,TABLET,,2020,Q3,Intentional overdose,,2020,Q3,1,I,,20200731.0,20200811,20200811,EXP,,JP-AMNEAL PHARMACEUTICALS-2020-AMRX-02397,AMNEAL,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE. 2020?99 (29):E21202",18.0,YR,,F,Y,,,20200811.0,,MD,JP,JP,2020,Q3,Youth
181360701,18136070,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 TABLETS, 5MG",,,D,,,,,5.0,DF,TABLET,,2020,Q3,Lactic acidosis,,2020,Q3,1,I,,20200731.0,20200811,20200811,EXP,,JP-AMNEAL PHARMACEUTICALS-2020-AMRX-02397,AMNEAL,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE. 2020?99 (29):E21202",18.0,YR,,F,Y,,,20200811.0,,MD,JP,JP,2020,Q3,Youth
181360701,18136070,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 TABLETS, 5MG",,,D,,,,,5.0,DF,TABLET,,2020,Q3,Rhabdomyolysis,,2020,Q3,1,I,,20200731.0,20200811,20200811,EXP,,JP-AMNEAL PHARMACEUTICALS-2020-AMRX-02397,AMNEAL,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE. 2020?99 (29):E21202",18.0,YR,,F,Y,,,20200811.0,,MD,JP,JP,2020,Q3,Youth
181360701,18136070,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 TABLETS, 5MG",,,D,,,,,5.0,DF,TABLET,,2020,Q3,Shock,,2020,Q3,1,I,,20200731.0,20200811,20200811,EXP,,JP-AMNEAL PHARMACEUTICALS-2020-AMRX-02397,AMNEAL,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE. 2020?99 (29):E21202",18.0,YR,,F,Y,,,20200811.0,,MD,JP,JP,2020,Q3,Youth
181375801,18137580,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"10 MG, 0?1?0?0",,,,,,,,,,,,2020,Q3,Abdominal distension,,2020,Q3,1,I,,20200807.0,20200812,20200812,EXP,,DE-ROCHE-2656120,ROCHE,,62.0,YR,,F,Y,74.0,KG,20200812.0,,PH,DE,DE,2020,Q3,Adult
181375801,18137580,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"10 MG, 0?1?0?0",,,,,,,,,,,,2020,Q3,Flatulence,,2020,Q3,1,I,,20200807.0,20200812,20200812,EXP,,DE-ROCHE-2656120,ROCHE,,62.0,YR,,F,Y,74.0,KG,20200812.0,,PH,DE,DE,2020,Q3,Adult
181375801,18137580,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"10 MG, 0?1?0?0",,,,,,,,,,,,2020,Q3,General physical health deterioration,,2020,Q3,1,I,,20200807.0,20200812,20200812,EXP,,DE-ROCHE-2656120,ROCHE,,62.0,YR,,F,Y,74.0,KG,20200812.0,,PH,DE,DE,2020,Q3,Adult
181375801,18137580,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"10 MG, 0?1?0?0",,,,,,,,,,,,2020,Q3,Nausea,,2020,Q3,1,I,,20200807.0,20200812,20200812,EXP,,DE-ROCHE-2656120,ROCHE,,62.0,YR,,F,Y,74.0,KG,20200812.0,,PH,DE,DE,2020,Q3,Adult
181375801,18137580,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"10 MG, 0?1?0?0",,,,,,,,,,,,2020,Q3,Vomiting,,2020,Q3,1,I,,20200807.0,20200812,20200812,EXP,,DE-ROCHE-2656120,ROCHE,,62.0,YR,,F,Y,74.0,KG,20200812.0,,PH,DE,DE,2020,Q3,Adult
181377141,18137714,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS,,,,,,,,5.0,DF,TABLET,,2020,Q3,Acute kidney injury,,2020,Q3,1,I,,20200803.0,20200811,20200811,EXP,,JP-PRINSTON PHARMACEUTICAL INC.-2020PRN00269,PRINSTON PHARMACEUTICAL,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE (BALTIMORE). 2020?99(29):E21202",18.0,YR,,F,Y,,,20200811.0,,MD,JP,JP,2020,Q3,Youth
181377141,18137714,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS,,,,,,,,5.0,DF,TABLET,,2020,Q3,Capillary leak syndrome,,2020,Q3,1,I,,20200803.0,20200811,20200811,EXP,,JP-PRINSTON PHARMACEUTICAL INC.-2020PRN00269,PRINSTON PHARMACEUTICAL,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE (BALTIMORE). 2020?99(29):E21202",18.0,YR,,F,Y,,,20200811.0,,MD,JP,JP,2020,Q3,Youth
181377141,18137714,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS,,,,,,,,5.0,DF,TABLET,,2020,Q3,Compartment syndrome,,2020,Q3,1,I,,20200803.0,20200811,20200811,EXP,,JP-PRINSTON PHARMACEUTICAL INC.-2020PRN00269,PRINSTON PHARMACEUTICAL,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE (BALTIMORE). 2020?99(29):E21202",18.0,YR,,F,Y,,,20200811.0,,MD,JP,JP,2020,Q3,Youth
181377141,18137714,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS,,,,,,,,5.0,DF,TABLET,,2020,Q3,Disseminated intravascular coagulation,,2020,Q3,1,I,,20200803.0,20200811,20200811,EXP,,JP-PRINSTON PHARMACEUTICAL INC.-2020PRN00269,PRINSTON PHARMACEUTICAL,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE (BALTIMORE). 2020?99(29):E21202",18.0,YR,,F,Y,,,20200811.0,,MD,JP,JP,2020,Q3,Youth
181377141,18137714,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS,,,,,,,,5.0,DF,TABLET,,2020,Q3,Lactic acidosis,,2020,Q3,1,I,,20200803.0,20200811,20200811,EXP,,JP-PRINSTON PHARMACEUTICAL INC.-2020PRN00269,PRINSTON PHARMACEUTICAL,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE (BALTIMORE). 2020?99(29):E21202",18.0,YR,,F,Y,,,20200811.0,,MD,JP,JP,2020,Q3,Youth
181377141,18137714,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS,,,,,,,,5.0,DF,TABLET,,2020,Q3,Loss of consciousness,,2020,Q3,1,I,,20200803.0,20200811,20200811,EXP,,JP-PRINSTON PHARMACEUTICAL INC.-2020PRN00269,PRINSTON PHARMACEUTICAL,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE (BALTIMORE). 2020?99(29):E21202",18.0,YR,,F,Y,,,20200811.0,,MD,JP,JP,2020,Q3,Youth
181377141,18137714,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS,,,,,,,,5.0,DF,TABLET,,2020,Q3,Overdose,,2020,Q3,1,I,,20200803.0,20200811,20200811,EXP,,JP-PRINSTON PHARMACEUTICAL INC.-2020PRN00269,PRINSTON PHARMACEUTICAL,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE (BALTIMORE). 2020?99(29):E21202",18.0,YR,,F,Y,,,20200811.0,,MD,JP,JP,2020,Q3,Youth
181377141,18137714,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS,,,,,,,,5.0,DF,TABLET,,2020,Q3,Pneumonia aspiration,,2020,Q3,1,I,,20200803.0,20200811,20200811,EXP,,JP-PRINSTON PHARMACEUTICAL INC.-2020PRN00269,PRINSTON PHARMACEUTICAL,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE (BALTIMORE). 2020?99(29):E21202",18.0,YR,,F,Y,,,20200811.0,,MD,JP,JP,2020,Q3,Youth
181377141,18137714,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS,,,,,,,,5.0,DF,TABLET,,2020,Q3,Shock,,2020,Q3,1,I,,20200803.0,20200811,20200811,EXP,,JP-PRINSTON PHARMACEUTICAL INC.-2020PRN00269,PRINSTON PHARMACEUTICAL,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE (BALTIMORE). 2020?99(29):E21202",18.0,YR,,F,Y,,,20200811.0,,MD,JP,JP,2020,Q3,Youth
181436571,18143657,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, TOTAL",,,D,, UNKNOWN,,,25.0,MG,TABLET,,2020,Q3,Blood creatinine increased,,2020,Q3,1,I,,20200731.0,20200813,20200813,EXP,,JP-LUPIN PHARMACEUTICALS INC.-2020-04346,LUPIN,,18.0,YR,,F,Y,,,20200813.0,,MD,JP,JP,2020,Q3,Youth
181436571,18143657,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, TOTAL",,,D,, UNKNOWN,,,25.0,MG,TABLET,,2020,Q3,Blood pressure abnormal,,2020,Q3,1,I,,20200731.0,20200813,20200813,EXP,,JP-LUPIN PHARMACEUTICALS INC.-2020-04346,LUPIN,,18.0,YR,,F,Y,,,20200813.0,,MD,JP,JP,2020,Q3,Youth
181436571,18143657,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, TOTAL",,,D,, UNKNOWN,,,25.0,MG,TABLET,,2020,Q3,Bradypnoea,,2020,Q3,1,I,,20200731.0,20200813,20200813,EXP,,JP-LUPIN PHARMACEUTICALS INC.-2020-04346,LUPIN,,18.0,YR,,F,Y,,,20200813.0,,MD,JP,JP,2020,Q3,Youth
181436571,18143657,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, TOTAL",,,D,, UNKNOWN,,,25.0,MG,TABLET,,2020,Q3,Capillary leak syndrome,,2020,Q3,1,I,,20200731.0,20200813,20200813,EXP,,JP-LUPIN PHARMACEUTICALS INC.-2020-04346,LUPIN,,18.0,YR,,F,Y,,,20200813.0,,MD,JP,JP,2020,Q3,Youth
181436571,18143657,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, TOTAL",,,D,, UNKNOWN,,,25.0,MG,TABLET,,2020,Q3,Compartment syndrome,,2020,Q3,1,I,,20200731.0,20200813,20200813,EXP,,JP-LUPIN PHARMACEUTICALS INC.-2020-04346,LUPIN,,18.0,YR,,F,Y,,,20200813.0,,MD,JP,JP,2020,Q3,Youth
181436571,18143657,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, TOTAL",,,D,, UNKNOWN,,,25.0,MG,TABLET,,2020,Q3,Hypoglycaemia,,2020,Q3,1,I,,20200731.0,20200813,20200813,EXP,,JP-LUPIN PHARMACEUTICALS INC.-2020-04346,LUPIN,,18.0,YR,,F,Y,,,20200813.0,,MD,JP,JP,2020,Q3,Youth
181436571,18143657,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, TOTAL",,,D,, UNKNOWN,,,25.0,MG,TABLET,,2020,Q3,Intentional overdose,,2020,Q3,1,I,,20200731.0,20200813,20200813,EXP,,JP-LUPIN PHARMACEUTICALS INC.-2020-04346,LUPIN,,18.0,YR,,F,Y,,,20200813.0,,MD,JP,JP,2020,Q3,Youth
181436571,18143657,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, TOTAL",,,D,, UNKNOWN,,,25.0,MG,TABLET,,2020,Q3,Lactic acidosis,,2020,Q3,1,I,,20200731.0,20200813,20200813,EXP,,JP-LUPIN PHARMACEUTICALS INC.-2020-04346,LUPIN,,18.0,YR,,F,Y,,,20200813.0,,MD,JP,JP,2020,Q3,Youth
181436571,18143657,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, TOTAL",,,D,, UNKNOWN,,,25.0,MG,TABLET,,2020,Q3,Suicide attempt,,2020,Q3,1,I,,20200731.0,20200813,20200813,EXP,,JP-LUPIN PHARMACEUTICALS INC.-2020-04346,LUPIN,,18.0,YR,,F,Y,,,20200813.0,,MD,JP,JP,2020,Q3,Youth
181470861,18147086,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF 5 MG,,,D,, UNK,,,,,TABLET,,2020,Q3,Capillary leak syndrome,,2020,Q3,1,I,,20200731.0,20200814,20200814,EXP,,JP-NOVAST LABORATORIES LTD.-2020NOV000289,NOVAST,,18.0,YR,,F,Y,,,20200813.0,,MD,JP,JP,2020,Q3,Youth
181470861,18147086,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF 5 MG,,,D,, UNK,,,,,TABLET,,2020,Q3,Compartment syndrome,,2020,Q3,1,I,,20200731.0,20200814,20200814,EXP,,JP-NOVAST LABORATORIES LTD.-2020NOV000289,NOVAST,,18.0,YR,,F,Y,,,20200813.0,,MD,JP,JP,2020,Q3,Youth
181470861,18147086,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF 5 MG,,,D,, UNK,,,,,TABLET,,2020,Q3,Intentional overdose,,2020,Q3,1,I,,20200731.0,20200814,20200814,EXP,,JP-NOVAST LABORATORIES LTD.-2020NOV000289,NOVAST,,18.0,YR,,F,Y,,,20200813.0,,MD,JP,JP,2020,Q3,Youth
181526121,18152612,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,TABLET,QD,2020,Q3,Diabetic ketoacidosis,,2020,Q3,1,I,20191216.0,20200806.0,20200814,20200814,EXP,,GB-ASTRAZENECA-2020SE98997,ASTRAZENECA,,63.0,YR,,F,Y,,,20200814.0,,,GB,GB,2020,Q3,Adult
181577631,18157763,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,,,2020,Q3,Acute kidney injury,,2020,Q3,1,I,,20200803.0,20200817,20200817,EXP,,JP-AJANTA PHARMA USA INC.-2088687,AJANTA PHARMA,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE (BALTIMORE). 2020?99(29):E21202.",18.0,YR,,F,Y,,,20200817.0,,HP,JP,JP,2020,Q3,Youth
181577631,18157763,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,,,2020,Q3,Capillary leak syndrome,,2020,Q3,1,I,,20200803.0,20200817,20200817,EXP,,JP-AJANTA PHARMA USA INC.-2088687,AJANTA PHARMA,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE (BALTIMORE). 2020?99(29):E21202.",18.0,YR,,F,Y,,,20200817.0,,HP,JP,JP,2020,Q3,Youth
181577631,18157763,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,,,2020,Q3,Compartment syndrome,,2020,Q3,1,I,,20200803.0,20200817,20200817,EXP,,JP-AJANTA PHARMA USA INC.-2088687,AJANTA PHARMA,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE (BALTIMORE). 2020?99(29):E21202.",18.0,YR,,F,Y,,,20200817.0,,HP,JP,JP,2020,Q3,Youth
181577631,18157763,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,,,2020,Q3,Disseminated intravascular coagulation,,2020,Q3,1,I,,20200803.0,20200817,20200817,EXP,,JP-AJANTA PHARMA USA INC.-2088687,AJANTA PHARMA,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE (BALTIMORE). 2020?99(29):E21202.",18.0,YR,,F,Y,,,20200817.0,,HP,JP,JP,2020,Q3,Youth
181577631,18157763,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,,,2020,Q3,Lactic acidosis,,2020,Q3,1,I,,20200803.0,20200817,20200817,EXP,,JP-AJANTA PHARMA USA INC.-2088687,AJANTA PHARMA,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE (BALTIMORE). 2020?99(29):E21202.",18.0,YR,,F,Y,,,20200817.0,,HP,JP,JP,2020,Q3,Youth
181577631,18157763,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,,,2020,Q3,Loss of consciousness,,2020,Q3,1,I,,20200803.0,20200817,20200817,EXP,,JP-AJANTA PHARMA USA INC.-2088687,AJANTA PHARMA,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE (BALTIMORE). 2020?99(29):E21202.",18.0,YR,,F,Y,,,20200817.0,,HP,JP,JP,2020,Q3,Youth
181577631,18157763,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,,,2020,Q3,Overdose,,2020,Q3,1,I,,20200803.0,20200817,20200817,EXP,,JP-AJANTA PHARMA USA INC.-2088687,AJANTA PHARMA,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE (BALTIMORE). 2020?99(29):E21202.",18.0,YR,,F,Y,,,20200817.0,,HP,JP,JP,2020,Q3,Youth
181577631,18157763,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,,,2020,Q3,Pneumonia aspiration,,2020,Q3,1,I,,20200803.0,20200817,20200817,EXP,,JP-AJANTA PHARMA USA INC.-2088687,AJANTA PHARMA,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE (BALTIMORE). 2020?99(29):E21202.",18.0,YR,,F,Y,,,20200817.0,,HP,JP,JP,2020,Q3,Youth
181577631,18157763,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,,,2020,Q3,Shock,,2020,Q3,1,I,,20200803.0,20200817,20200817,EXP,,JP-AJANTA PHARMA USA INC.-2088687,AJANTA PHARMA,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE (BALTIMORE). 2020?99(29):E21202.",18.0,YR,,F,Y,,,20200817.0,,HP,JP,JP,2020,Q3,Youth
181577631,18157763,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,,,2020,Q3,Suicide attempt,,2020,Q3,1,I,,20200803.0,20200817,20200817,EXP,,JP-AJANTA PHARMA USA INC.-2088687,AJANTA PHARMA,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE (BALTIMORE). 2020?99(29):E21202.",18.0,YR,,F,Y,,,20200817.0,,HP,JP,JP,2020,Q3,Youth
181580921,18158092,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS,,,,,,,,5.0,DF,TABLET,,2020,Q3,Acute kidney injury,,2020,Q3,1,I,,20200803.0,20200817,20200817,EXP,,JP-BEXIMCO-2020BEX00037,BEXIMCO PHARMACEUTICALS,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE (BALTIMORE). 2020?99:E21202",18.0,YR,,F,Y,,,20200811.0,,HP,JP,JP,2020,Q3,Youth
181580921,18158092,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS,,,,,,,,5.0,DF,TABLET,,2020,Q3,Capillary leak syndrome,,2020,Q3,1,I,,20200803.0,20200817,20200817,EXP,,JP-BEXIMCO-2020BEX00037,BEXIMCO PHARMACEUTICALS,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE (BALTIMORE). 2020?99:E21202",18.0,YR,,F,Y,,,20200811.0,,HP,JP,JP,2020,Q3,Youth
181580921,18158092,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS,,,,,,,,5.0,DF,TABLET,,2020,Q3,Compartment syndrome,,2020,Q3,1,I,,20200803.0,20200817,20200817,EXP,,JP-BEXIMCO-2020BEX00037,BEXIMCO PHARMACEUTICALS,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE (BALTIMORE). 2020?99:E21202",18.0,YR,,F,Y,,,20200811.0,,HP,JP,JP,2020,Q3,Youth
181580921,18158092,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS,,,,,,,,5.0,DF,TABLET,,2020,Q3,Disseminated intravascular coagulation,,2020,Q3,1,I,,20200803.0,20200817,20200817,EXP,,JP-BEXIMCO-2020BEX00037,BEXIMCO PHARMACEUTICALS,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE (BALTIMORE). 2020?99:E21202",18.0,YR,,F,Y,,,20200811.0,,HP,JP,JP,2020,Q3,Youth
181580921,18158092,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS,,,,,,,,5.0,DF,TABLET,,2020,Q3,Lactic acidosis,,2020,Q3,1,I,,20200803.0,20200817,20200817,EXP,,JP-BEXIMCO-2020BEX00037,BEXIMCO PHARMACEUTICALS,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE (BALTIMORE). 2020?99:E21202",18.0,YR,,F,Y,,,20200811.0,,HP,JP,JP,2020,Q3,Youth
181580921,18158092,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS,,,,,,,,5.0,DF,TABLET,,2020,Q3,Loss of consciousness,,2020,Q3,1,I,,20200803.0,20200817,20200817,EXP,,JP-BEXIMCO-2020BEX00037,BEXIMCO PHARMACEUTICALS,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE (BALTIMORE). 2020?99:E21202",18.0,YR,,F,Y,,,20200811.0,,HP,JP,JP,2020,Q3,Youth
181580921,18158092,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS,,,,,,,,5.0,DF,TABLET,,2020,Q3,Overdose,,2020,Q3,1,I,,20200803.0,20200817,20200817,EXP,,JP-BEXIMCO-2020BEX00037,BEXIMCO PHARMACEUTICALS,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE (BALTIMORE). 2020?99:E21202",18.0,YR,,F,Y,,,20200811.0,,HP,JP,JP,2020,Q3,Youth
181580921,18158092,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS,,,,,,,,5.0,DF,TABLET,,2020,Q3,Pneumonia aspiration,,2020,Q3,1,I,,20200803.0,20200817,20200817,EXP,,JP-BEXIMCO-2020BEX00037,BEXIMCO PHARMACEUTICALS,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE (BALTIMORE). 2020?99:E21202",18.0,YR,,F,Y,,,20200811.0,,HP,JP,JP,2020,Q3,Youth
181580921,18158092,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS,,,,,,,,5.0,DF,TABLET,,2020,Q3,Shock,,2020,Q3,1,I,,20200803.0,20200817,20200817,EXP,,JP-BEXIMCO-2020BEX00037,BEXIMCO PHARMACEUTICALS,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE (BALTIMORE). 2020?99:E21202",18.0,YR,,F,Y,,,20200811.0,,HP,JP,JP,2020,Q3,Youth
181687151,18168715,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10 MILLIGRAM DAILY; 0?1?0?0,,,,,,,,10.0,MG,,QD,2020,Q3,Abdominal distension,,2020,Q3,1,I,,20200811.0,20200819,20200819,EXP,,DE-TEVA-2020-DE-1815361,TEVA,,62.0,YR,A,F,Y,74.0,KG,20200819.0,,PH,DE,DE,2020,Q3,Adult
181687151,18168715,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10 MILLIGRAM DAILY; 0?1?0?0,,,,,,,,10.0,MG,,QD,2020,Q3,Flatulence,,2020,Q3,1,I,,20200811.0,20200819,20200819,EXP,,DE-TEVA-2020-DE-1815361,TEVA,,62.0,YR,A,F,Y,74.0,KG,20200819.0,,PH,DE,DE,2020,Q3,Adult
181687151,18168715,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10 MILLIGRAM DAILY; 0?1?0?0,,,,,,,,10.0,MG,,QD,2020,Q3,General physical health deterioration,,2020,Q3,1,I,,20200811.0,20200819,20200819,EXP,,DE-TEVA-2020-DE-1815361,TEVA,,62.0,YR,A,F,Y,74.0,KG,20200819.0,,PH,DE,DE,2020,Q3,Adult
181687151,18168715,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10 MILLIGRAM DAILY; 0?1?0?0,,,,,,,,10.0,MG,,QD,2020,Q3,Nausea,,2020,Q3,1,I,,20200811.0,20200819,20200819,EXP,,DE-TEVA-2020-DE-1815361,TEVA,,62.0,YR,A,F,Y,74.0,KG,20200819.0,,PH,DE,DE,2020,Q3,Adult
181687151,18168715,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10 MILLIGRAM DAILY; 0?1?0?0,,,,,,,,10.0,MG,,QD,2020,Q3,Vomiting,,2020,Q3,1,I,,20200811.0,20200819,20200819,EXP,,DE-TEVA-2020-DE-1815361,TEVA,,62.0,YR,A,F,Y,74.0,KG,20200819.0,,PH,DE,DE,2020,Q3,Adult
181708661,18170866,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, 0?1?0?0",,,,, UNKNOWN,,,,,UNKNOWN,,2020,Q3,Abdominal distension,,2020,Q3,1,I,,20200813.0,20200819,20200819,EXP,,DE-FRESENIUS KABI-FK202008400,FRESENIUS KABI,,62.0,YR,,F,Y,74.0,KG,20200819.0,,HP,NL,DE,2020,Q3,Adult
181708661,18170866,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, 0?1?0?0",,,,, UNKNOWN,,,,,UNKNOWN,,2020,Q3,Flatulence,,2020,Q3,1,I,,20200813.0,20200819,20200819,EXP,,DE-FRESENIUS KABI-FK202008400,FRESENIUS KABI,,62.0,YR,,F,Y,74.0,KG,20200819.0,,HP,NL,DE,2020,Q3,Adult
181708661,18170866,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, 0?1?0?0",,,,, UNKNOWN,,,,,UNKNOWN,,2020,Q3,General physical health deterioration,,2020,Q3,1,I,,20200813.0,20200819,20200819,EXP,,DE-FRESENIUS KABI-FK202008400,FRESENIUS KABI,,62.0,YR,,F,Y,74.0,KG,20200819.0,,HP,NL,DE,2020,Q3,Adult
181708661,18170866,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, 0?1?0?0",,,,, UNKNOWN,,,,,UNKNOWN,,2020,Q3,Nausea,,2020,Q3,1,I,,20200813.0,20200819,20200819,EXP,,DE-FRESENIUS KABI-FK202008400,FRESENIUS KABI,,62.0,YR,,F,Y,74.0,KG,20200819.0,,HP,NL,DE,2020,Q3,Adult
181708661,18170866,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, 0?1?0?0",,,,, UNKNOWN,,,,,UNKNOWN,,2020,Q3,Vomiting,,2020,Q3,1,I,,20200813.0,20200819,20200819,EXP,,DE-FRESENIUS KABI-FK202008400,FRESENIUS KABI,,62.0,YR,,F,Y,74.0,KG,20200819.0,,HP,NL,DE,2020,Q3,Adult
181708931,18170893,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,10430.0,MG,Y,, UNKNOWN,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Confusional state,,2020,Q3,1,I,20200428.0,20200814.0,20200819,20200819,EXP,,GB-ASTRAZENECA-2020SF03730,ASTRAZENECA,,60.0,YR,,F,Y,82.3,KG,20200819.0,,,GB,GB,2020,Q3,Adult
181708931,18170893,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,10430.0,MG,Y,, UNKNOWN,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Crepitations,,2020,Q3,1,I,20200428.0,20200814.0,20200819,20200819,EXP,,GB-ASTRAZENECA-2020SF03730,ASTRAZENECA,,60.0,YR,,F,Y,82.3,KG,20200819.0,,,GB,GB,2020,Q3,Adult
181708931,18170893,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,10430.0,MG,Y,, UNKNOWN,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Fournier's gangrene,,2020,Q3,1,I,20200428.0,20200814.0,20200819,20200819,EXP,,GB-ASTRAZENECA-2020SF03730,ASTRAZENECA,,60.0,YR,,F,Y,82.3,KG,20200819.0,,,GB,GB,2020,Q3,Adult
181708931,18170893,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,10430.0,MG,Y,, UNKNOWN,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Osteomyelitis,,2020,Q3,1,I,20200428.0,20200814.0,20200819,20200819,EXP,,GB-ASTRAZENECA-2020SF03730,ASTRAZENECA,,60.0,YR,,F,Y,82.3,KG,20200819.0,,,GB,GB,2020,Q3,Adult
181708931,18170893,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,10430.0,MG,Y,, UNKNOWN,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Septic shock,,2020,Q3,1,I,20200428.0,20200814.0,20200819,20200819,EXP,,GB-ASTRAZENECA-2020SF03730,ASTRAZENECA,,60.0,YR,,F,Y,82.3,KG,20200819.0,,,GB,GB,2020,Q3,Adult
181708931,18170893,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,10430.0,MG,Y,, UNKNOWN,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Vulvovaginal swelling,,2020,Q3,1,I,20200428.0,20200814.0,20200819,20200819,EXP,,GB-ASTRAZENECA-2020SF03730,ASTRAZENECA,,60.0,YR,,F,Y,82.3,KG,20200819.0,,,GB,GB,2020,Q3,Adult
181708931,18170893,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,10430.0,MG,Y,, UNKNOWN,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Wound infection,,2020,Q3,1,I,20200428.0,20200814.0,20200819,20200819,EXP,,GB-ASTRAZENECA-2020SF03730,ASTRAZENECA,,60.0,YR,,F,Y,82.3,KG,20200819.0,,,GB,GB,2020,Q3,Adult
181756581,18175658,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Acute kidney injury,,2020,Q3,1,I,,20200810.0,20200820,20200820,EXP,,JP-TEVA-2020-JP-1814994,TEVA,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE 2020?99:NO. 29.",18.0,YR,A,F,Y,,,20200820.0,,MD,JP,JP,2020,Q3,Youth
181756581,18175658,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Adrenal insufficiency,,2020,Q3,1,I,,20200810.0,20200820,20200820,EXP,,JP-TEVA-2020-JP-1814994,TEVA,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE 2020?99:NO. 29.",18.0,YR,A,F,Y,,,20200820.0,,MD,JP,JP,2020,Q3,Youth
181756581,18175658,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Bradypnoea,,2020,Q3,1,I,,20200810.0,20200820,20200820,EXP,,JP-TEVA-2020-JP-1814994,TEVA,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE 2020?99:NO. 29.",18.0,YR,A,F,Y,,,20200820.0,,MD,JP,JP,2020,Q3,Youth
181756581,18175658,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Capillary leak syndrome,,2020,Q3,1,I,,20200810.0,20200820,20200820,EXP,,JP-TEVA-2020-JP-1814994,TEVA,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE 2020?99:NO. 29.",18.0,YR,A,F,Y,,,20200820.0,,MD,JP,JP,2020,Q3,Youth
181756581,18175658,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Compartment syndrome,,2020,Q3,1,I,,20200810.0,20200820,20200820,EXP,,JP-TEVA-2020-JP-1814994,TEVA,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE 2020?99:NO. 29.",18.0,YR,A,F,Y,,,20200820.0,,MD,JP,JP,2020,Q3,Youth
181756581,18175658,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Disseminated intravascular coagulation,,2020,Q3,1,I,,20200810.0,20200820,20200820,EXP,,JP-TEVA-2020-JP-1814994,TEVA,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE 2020?99:NO. 29.",18.0,YR,A,F,Y,,,20200820.0,,MD,JP,JP,2020,Q3,Youth
181756581,18175658,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Drug abuse,,2020,Q3,1,I,,20200810.0,20200820,20200820,EXP,,JP-TEVA-2020-JP-1814994,TEVA,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE 2020?99:NO. 29.",18.0,YR,A,F,Y,,,20200820.0,,MD,JP,JP,2020,Q3,Youth
181756581,18175658,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Drug ineffective,,2020,Q3,1,I,,20200810.0,20200820,20200820,EXP,,JP-TEVA-2020-JP-1814994,TEVA,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE 2020?99:NO. 29.",18.0,YR,A,F,Y,,,20200820.0,,MD,JP,JP,2020,Q3,Youth
181756581,18175658,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Fluid overload,,2020,Q3,1,I,,20200810.0,20200820,20200820,EXP,,JP-TEVA-2020-JP-1814994,TEVA,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE 2020?99:NO. 29.",18.0,YR,A,F,Y,,,20200820.0,,MD,JP,JP,2020,Q3,Youth
181756581,18175658,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Hypoglycaemia,,2020,Q3,1,I,,20200810.0,20200820,20200820,EXP,,JP-TEVA-2020-JP-1814994,TEVA,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE 2020?99:NO. 29.",18.0,YR,A,F,Y,,,20200820.0,,MD,JP,JP,2020,Q3,Youth
181756581,18175658,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Hypotension,,2020,Q3,1,I,,20200810.0,20200820,20200820,EXP,,JP-TEVA-2020-JP-1814994,TEVA,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE 2020?99:NO. 29.",18.0,YR,A,F,Y,,,20200820.0,,MD,JP,JP,2020,Q3,Youth
181756581,18175658,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Intentional overdose,,2020,Q3,1,I,,20200810.0,20200820,20200820,EXP,,JP-TEVA-2020-JP-1814994,TEVA,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE 2020?99:NO. 29.",18.0,YR,A,F,Y,,,20200820.0,,MD,JP,JP,2020,Q3,Youth
181756581,18175658,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Lactic acidosis,,2020,Q3,1,I,,20200810.0,20200820,20200820,EXP,,JP-TEVA-2020-JP-1814994,TEVA,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE 2020?99:NO. 29.",18.0,YR,A,F,Y,,,20200820.0,,MD,JP,JP,2020,Q3,Youth
181756581,18175658,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Loss of consciousness,,2020,Q3,1,I,,20200810.0,20200820,20200820,EXP,,JP-TEVA-2020-JP-1814994,TEVA,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE 2020?99:NO. 29.",18.0,YR,A,F,Y,,,20200820.0,,MD,JP,JP,2020,Q3,Youth
181756581,18175658,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Muscle contracture,,2020,Q3,1,I,,20200810.0,20200820,20200820,EXP,,JP-TEVA-2020-JP-1814994,TEVA,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE 2020?99:NO. 29.",18.0,YR,A,F,Y,,,20200820.0,,MD,JP,JP,2020,Q3,Youth
181756581,18175658,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Paralysis,,2020,Q3,1,I,,20200810.0,20200820,20200820,EXP,,JP-TEVA-2020-JP-1814994,TEVA,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE 2020?99:NO. 29.",18.0,YR,A,F,Y,,,20200820.0,,MD,JP,JP,2020,Q3,Youth
181756581,18175658,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Pneumonia aspiration,,2020,Q3,1,I,,20200810.0,20200820,20200820,EXP,,JP-TEVA-2020-JP-1814994,TEVA,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE 2020?99:NO. 29.",18.0,YR,A,F,Y,,,20200820.0,,MD,JP,JP,2020,Q3,Youth
181756581,18175658,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Prescription drug used without a prescription,,2020,Q3,1,I,,20200810.0,20200820,20200820,EXP,,JP-TEVA-2020-JP-1814994,TEVA,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE 2020?99:NO. 29.",18.0,YR,A,F,Y,,,20200820.0,,MD,JP,JP,2020,Q3,Youth
181756581,18175658,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Rhabdomyolysis,,2020,Q3,1,I,,20200810.0,20200820,20200820,EXP,,JP-TEVA-2020-JP-1814994,TEVA,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE 2020?99:NO. 29.",18.0,YR,A,F,Y,,,20200820.0,,MD,JP,JP,2020,Q3,Youth
181756581,18175658,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Septic shock,,2020,Q3,1,I,,20200810.0,20200820,20200820,EXP,,JP-TEVA-2020-JP-1814994,TEVA,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE 2020?99:NO. 29.",18.0,YR,A,F,Y,,,20200820.0,,MD,JP,JP,2020,Q3,Youth
181756581,18175658,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN,,,D,,,,,5.0,DF,TABLET,,2020,Q3,Suicide attempt,,2020,Q3,1,I,,20200810.0,20200820,20200820,EXP,,JP-TEVA-2020-JP-1814994,TEVA,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT. MEDICINE 2020?99:NO. 29.",18.0,YR,A,F,Y,,,20200820.0,,MD,JP,JP,2020,Q3,Youth
181768661,18176866,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,,,TABLET,,2020,Q3,Accidental overdose,,2020,Q3,1,I,,20200812.0,20200820,20200820,EXP,,US-ASTRAZENECA-2020SF02460,ASTRAZENECA,"MCGEE C, LESSING H. SPEED UP A SLOW DOWN: RECOGNIZING GLP?1 GASTROPARESIS AND SGLT?2 EUGLYCEMIC DKA. 43RD ANNUAL NATIONAL MEETING OF THE SOCIETY OF GENERAL INTERNAL MEDICINE (SGIM) 2020?",62.0,YR,,M,Y,,,20200820.0,,HP,US,US,2020,Q3,Adult
181768661,18176866,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,,,TABLET,,2020,Q3,Euglycaemic diabetic ketoacidosis,,2020,Q3,1,I,,20200812.0,20200820,20200820,EXP,,US-ASTRAZENECA-2020SF02460,ASTRAZENECA,"MCGEE C, LESSING H. SPEED UP A SLOW DOWN: RECOGNIZING GLP?1 GASTROPARESIS AND SGLT?2 EUGLYCEMIC DKA. 43RD ANNUAL NATIONAL MEETING OF THE SOCIETY OF GENERAL INTERNAL MEDICINE (SGIM) 2020?",62.0,YR,,M,Y,,,20200820.0,,HP,US,US,2020,Q3,Adult
181768661,18176866,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,,,TABLET,,2020,Q3,Impaired gastric emptying,,2020,Q3,1,I,,20200812.0,20200820,20200820,EXP,,US-ASTRAZENECA-2020SF02460,ASTRAZENECA,"MCGEE C, LESSING H. SPEED UP A SLOW DOWN: RECOGNIZING GLP?1 GASTROPARESIS AND SGLT?2 EUGLYCEMIC DKA. 43RD ANNUAL NATIONAL MEETING OF THE SOCIETY OF GENERAL INTERNAL MEDICINE (SGIM) 2020?",62.0,YR,,M,Y,,,20200820.0,,HP,US,US,2020,Q3,Adult
181780791,18178079,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,5 TABLETS OF DAPAGLIFLOZIN?5MG,,,D,, UNKNOWN,,,,,TABLET,,2020,Q3,Drug abuse,,2020,Q3,1,I,,20200811.0,20200821,20200821,EXP,,JP-MICRO LABS LIMITED-ML2020-02433,MICRO LABS,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT.. MEDICINE. 2020?99:29.",18.0,YR,,F,Y,,,20200821.0,,MD,JP,JP,2020,Q3,Youth
181780791,18178079,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,5 TABLETS OF DAPAGLIFLOZIN?5MG,,,D,, UNKNOWN,,,,,TABLET,,2020,Q3,Intentional overdose,,2020,Q3,1,I,,20200811.0,20200821,20200821,EXP,,JP-MICRO LABS LIMITED-ML2020-02433,MICRO LABS,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT.. MEDICINE. 2020?99:29.",18.0,YR,,F,Y,,,20200821.0,,MD,JP,JP,2020,Q3,Youth
181780791,18178079,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,5 TABLETS OF DAPAGLIFLOZIN?5MG,,,D,, UNKNOWN,,,,,TABLET,,2020,Q3,Loss of consciousness,,2020,Q3,1,I,,20200811.0,20200821,20200821,EXP,,JP-MICRO LABS LIMITED-ML2020-02433,MICRO LABS,"KASUGAI D, TAJIMA K, JINGUSHI N, UENISHI N, HIRAKAWA A. MULTIPLE LIMB COMPARTMENT SYNDROME AS A MANIFESTATION OF CAPILLARY LEAK SYNDROME SECONDARY TO METFORMIN AND DIPEPTIDYL PEPTIDASE IV INHIBITOR OVERDOSE: A CASE REPORT.. MEDICINE. 2020?99:29.",18.0,YR,,F,Y,,,20200821.0,,MD,JP,JP,2020,Q3,Youth
181815141,18181514,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN?5MG,25.0,MG,U,,,,,5.0,MG,TABLET,,2020,Q3,Acute kidney injury,Acute kidney injury,2020,Q3,1,I,,20200810.0,20200821,20200821,EXP,,JP-ALS-000085,ALIGNSCIENCE PHARMA,,18.0,YR,A,F,Y,,,20200821.0,,MD,JP,JP,2020,Q3,Youth
181815141,18181514,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN?5MG,25.0,MG,U,,,,,5.0,MG,TABLET,,2020,Q3,Bradypnoea,Bradypnoea,2020,Q3,1,I,,20200810.0,20200821,20200821,EXP,,JP-ALS-000085,ALIGNSCIENCE PHARMA,,18.0,YR,A,F,Y,,,20200821.0,,MD,JP,JP,2020,Q3,Youth
181815141,18181514,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN?5MG,25.0,MG,U,,,,,5.0,MG,TABLET,,2020,Q3,Capillary leak syndrome,Capillary leak syndrome,2020,Q3,1,I,,20200810.0,20200821,20200821,EXP,,JP-ALS-000085,ALIGNSCIENCE PHARMA,,18.0,YR,A,F,Y,,,20200821.0,,MD,JP,JP,2020,Q3,Youth
181815141,18181514,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN?5MG,25.0,MG,U,,,,,5.0,MG,TABLET,,2020,Q3,Compartment syndrome,Compartment syndrome,2020,Q3,1,I,,20200810.0,20200821,20200821,EXP,,JP-ALS-000085,ALIGNSCIENCE PHARMA,,18.0,YR,A,F,Y,,,20200821.0,,MD,JP,JP,2020,Q3,Youth
181815141,18181514,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN?5MG,25.0,MG,U,,,,,5.0,MG,TABLET,,2020,Q3,Hypoglycaemia,Hypoglycaemia,2020,Q3,1,I,,20200810.0,20200821,20200821,EXP,,JP-ALS-000085,ALIGNSCIENCE PHARMA,,18.0,YR,A,F,Y,,,20200821.0,,MD,JP,JP,2020,Q3,Youth
181815141,18181514,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN?5MG,25.0,MG,U,,,,,5.0,MG,TABLET,,2020,Q3,Hypotension,Hypotension,2020,Q3,1,I,,20200810.0,20200821,20200821,EXP,,JP-ALS-000085,ALIGNSCIENCE PHARMA,,18.0,YR,A,F,Y,,,20200821.0,,MD,JP,JP,2020,Q3,Youth
181815141,18181514,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN?5MG,25.0,MG,U,,,,,5.0,MG,TABLET,,2020,Q3,Intentional overdose,Intentional overdose,2020,Q3,1,I,,20200810.0,20200821,20200821,EXP,,JP-ALS-000085,ALIGNSCIENCE PHARMA,,18.0,YR,A,F,Y,,,20200821.0,,MD,JP,JP,2020,Q3,Youth
181815141,18181514,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN?5MG,25.0,MG,U,,,,,5.0,MG,TABLET,,2020,Q3,Lactic acidosis,Lactic acidosis,2020,Q3,1,I,,20200810.0,20200821,20200821,EXP,,JP-ALS-000085,ALIGNSCIENCE PHARMA,,18.0,YR,A,F,Y,,,20200821.0,,MD,JP,JP,2020,Q3,Youth
181815141,18181514,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN?5MG,25.0,MG,U,,,,,5.0,MG,TABLET,,2020,Q3,Loss of consciousness,Loss of consciousness,2020,Q3,1,I,,20200810.0,20200821,20200821,EXP,,JP-ALS-000085,ALIGNSCIENCE PHARMA,,18.0,YR,A,F,Y,,,20200821.0,,MD,JP,JP,2020,Q3,Youth
181815141,18181514,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN?5MG,25.0,MG,U,,,,,5.0,MG,TABLET,,2020,Q3,Muscle contracture,Muscle contracture,2020,Q3,1,I,,20200810.0,20200821,20200821,EXP,,JP-ALS-000085,ALIGNSCIENCE PHARMA,,18.0,YR,A,F,Y,,,20200821.0,,MD,JP,JP,2020,Q3,Youth
181815141,18181514,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN?5MG,25.0,MG,U,,,,,5.0,MG,TABLET,,2020,Q3,Paralysis,Paralysis,2020,Q3,1,I,,20200810.0,20200821,20200821,EXP,,JP-ALS-000085,ALIGNSCIENCE PHARMA,,18.0,YR,A,F,Y,,,20200821.0,,MD,JP,JP,2020,Q3,Youth
181815141,18181514,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN?5MG,25.0,MG,U,,,,,5.0,MG,TABLET,,2020,Q3,Pneumonia aspiration,Pneumonia aspiration,2020,Q3,1,I,,20200810.0,20200821,20200821,EXP,,JP-ALS-000085,ALIGNSCIENCE PHARMA,,18.0,YR,A,F,Y,,,20200821.0,,MD,JP,JP,2020,Q3,Youth
181815141,18181514,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN?5MG,25.0,MG,U,,,,,5.0,MG,TABLET,,2020,Q3,Suicide attempt,Suicide attempt,2020,Q3,1,I,,20200810.0,20200821,20200821,EXP,,JP-ALS-000085,ALIGNSCIENCE PHARMA,,18.0,YR,A,F,Y,,,20200821.0,,MD,JP,JP,2020,Q3,Youth
181815141,18181514,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF DAPAGLIFLOZIN?5MG,25.0,MG,U,,,,,5.0,MG,TABLET,,2020,Q3,Unresponsive to stimuli,Unresponsive to stimuli,2020,Q3,1,I,,20200810.0,20200821,20200821,EXP,,JP-ALS-000085,ALIGNSCIENCE PHARMA,,18.0,YR,A,F,Y,,,20200821.0,,MD,JP,JP,2020,Q3,Youth
181872281,18187228,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF 5 MG,,,,,,,,,,,,2020,Q3,Capillary leak syndrome,,2020,Q3,1,I,,20200820.0,20200824,20200824,EXP,,JP-SCIEGEN-2020SCILIT00247,SCIEGEN,,18.0,YR,T,F,Y,,,20200824.0,,MD,JP,JP,2020,Q3,Youth
181872281,18187228,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF 5 MG,,,,,,,,,,,,2020,Q3,Compartment syndrome,,2020,Q3,1,I,,20200820.0,20200824,20200824,EXP,,JP-SCIEGEN-2020SCILIT00247,SCIEGEN,,18.0,YR,T,F,Y,,,20200824.0,,MD,JP,JP,2020,Q3,Youth
181872281,18187228,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF 5 MG,,,,,,,,,,,,2020,Q3,Drug abuse,,2020,Q3,1,I,,20200820.0,20200824,20200824,EXP,,JP-SCIEGEN-2020SCILIT00247,SCIEGEN,,18.0,YR,T,F,Y,,,20200824.0,,MD,JP,JP,2020,Q3,Youth
181872281,18187228,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF 5 MG,,,,,,,,,,,,2020,Q3,Lactic acidosis,,2020,Q3,1,I,,20200820.0,20200824,20200824,EXP,,JP-SCIEGEN-2020SCILIT00247,SCIEGEN,,18.0,YR,T,F,Y,,,20200824.0,,MD,JP,JP,2020,Q3,Youth
181872281,18187228,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF 5 MG,,,,,,,,,,,,2020,Q3,Overdose,,2020,Q3,1,I,,20200820.0,20200824,20200824,EXP,,JP-SCIEGEN-2020SCILIT00247,SCIEGEN,,18.0,YR,T,F,Y,,,20200824.0,,MD,JP,JP,2020,Q3,Youth
181872281,18187228,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,5 TABLETS OF 5 MG,,,,,,,,,,,,2020,Q3,Suicide attempt,,2020,Q3,1,I,,20200820.0,20200824,20200824,EXP,,JP-SCIEGEN-2020SCILIT00247,SCIEGEN,,18.0,YR,T,F,Y,,,20200824.0,,MD,JP,JP,2020,Q3,Youth
181971651,18197165,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MILLIGRAM DAILY;,,,Y,,,,,10.0,MG,TABLET,,2020,Q3,Acute kidney injury,,2020,Q3,1,I,20171011.0,20180531.0,20200826,20200826,EXP,GB-MHRA-ADR 24290440,GB-EMCURE PHARMACEUTICALS LTD-2018-EPL-002026,EMCURE,,72.0,YR,,,Y,,,20200826.0,,PH,GB,GB,2020,Q3,Elderly
181971651,18197165,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MILLIGRAM DAILY;,,,Y,,,,,10.0,MG,TABLET,,2020,Q3,Arrhythmia,,2020,Q3,1,I,20171011.0,20180531.0,20200826,20200826,EXP,GB-MHRA-ADR 24290440,GB-EMCURE PHARMACEUTICALS LTD-2018-EPL-002026,EMCURE,,72.0,YR,,,Y,,,20200826.0,,PH,GB,GB,2020,Q3,Elderly
181971651,18197165,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MILLIGRAM DAILY;,,,Y,,,,,10.0,MG,TABLET,,2020,Q3,Dehydration,,2020,Q3,1,I,20171011.0,20180531.0,20200826,20200826,EXP,GB-MHRA-ADR 24290440,GB-EMCURE PHARMACEUTICALS LTD-2018-EPL-002026,EMCURE,,72.0,YR,,,Y,,,20200826.0,,PH,GB,GB,2020,Q3,Elderly
181971651,18197165,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MILLIGRAM DAILY;,,,Y,,,,,10.0,MG,TABLET,,2020,Q3,Metabolic acidosis,,2020,Q3,1,I,20171011.0,20180531.0,20200826,20200826,EXP,GB-MHRA-ADR 24290440,GB-EMCURE PHARMACEUTICALS LTD-2018-EPL-002026,EMCURE,,72.0,YR,,,Y,,,20200826.0,,PH,GB,GB,2020,Q3,Elderly
182017631,18201763,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,1 DOSAGE FORM DAILY,1.0,DF,,,,,,1.0,DF,,,2020,Q3,Abdominal discomfort,,2020,Q3,1,I,20180712.0,20200814.0,20200827,20200827,EXP,GB-MHRA-ADR 24329045,GB-EMCURE PHARMACEUTICALS LTD-2020-EPL-001198,EMCURE,,52.0,YR,,F,Y,82.0,KG,20200827.0,,MD,GB,GB,2020,Q3,Adult
182017631,18201763,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,1 DOSAGE FORM DAILY,1.0,DF,,,,,,1.0,DF,,,2020,Q3,Abdominal pain,,2020,Q3,1,I,20180712.0,20200814.0,20200827,20200827,EXP,GB-MHRA-ADR 24329045,GB-EMCURE PHARMACEUTICALS LTD-2020-EPL-001198,EMCURE,,52.0,YR,,F,Y,82.0,KG,20200827.0,,MD,GB,GB,2020,Q3,Adult
182017631,18201763,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,1 DOSAGE FORM DAILY,1.0,DF,,,,,,1.0,DF,,,2020,Q3,Diarrhoea,,2020,Q3,1,I,20180712.0,20200814.0,20200827,20200827,EXP,GB-MHRA-ADR 24329045,GB-EMCURE PHARMACEUTICALS LTD-2020-EPL-001198,EMCURE,,52.0,YR,,F,Y,82.0,KG,20200827.0,,MD,GB,GB,2020,Q3,Adult
182017631,18201763,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,1 DOSAGE FORM DAILY,1.0,DF,,,,,,1.0,DF,,,2020,Q3,Drug intolerance,,2020,Q3,1,I,20180712.0,20200814.0,20200827,20200827,EXP,GB-MHRA-ADR 24329045,GB-EMCURE PHARMACEUTICALS LTD-2020-EPL-001198,EMCURE,,52.0,YR,,F,Y,82.0,KG,20200827.0,,MD,GB,GB,2020,Q3,Adult
182144411,18214441,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1250.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Aortic valve incompetence,,2020,Q3,1,I,20200801.0,20200820.0,20200831,20200831,EXP,,CN-ASTRAZENECA-2020SF07113,ASTRAZENECA,,32085.0,DY,,F,Y,49.0,KG,20200831.0,,HP,CN,CN,2020,Q3,Elderly
182144411,18214441,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1250.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Carotid arteriosclerosis,,2020,Q3,1,I,20200801.0,20200820.0,20200831,20200831,EXP,,CN-ASTRAZENECA-2020SF07113,ASTRAZENECA,,32085.0,DY,,F,Y,49.0,KG,20200831.0,,HP,CN,CN,2020,Q3,Elderly
182144411,18214441,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1250.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Carotid intima-media thickness increased,,2020,Q3,1,I,20200801.0,20200820.0,20200831,20200831,EXP,,CN-ASTRAZENECA-2020SF07113,ASTRAZENECA,,32085.0,DY,,F,Y,49.0,KG,20200831.0,,HP,CN,CN,2020,Q3,Elderly
182144411,18214441,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1250.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Cerebral arteriosclerosis,,2020,Q3,1,I,20200801.0,20200820.0,20200831,20200831,EXP,,CN-ASTRAZENECA-2020SF07113,ASTRAZENECA,,32085.0,DY,,F,Y,49.0,KG,20200831.0,,HP,CN,CN,2020,Q3,Elderly
182144411,18214441,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1250.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Cerebral atrophy,,2020,Q3,1,I,20200801.0,20200820.0,20200831,20200831,EXP,,CN-ASTRAZENECA-2020SF07113,ASTRAZENECA,,32085.0,DY,,F,Y,49.0,KG,20200831.0,,HP,CN,CN,2020,Q3,Elderly
182144411,18214441,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1250.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Cerebral infarction,,2020,Q3,1,I,20200801.0,20200820.0,20200831,20200831,EXP,,CN-ASTRAZENECA-2020SF07113,ASTRAZENECA,,32085.0,DY,,F,Y,49.0,KG,20200831.0,,HP,CN,CN,2020,Q3,Elderly
182144411,18214441,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1250.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Cerebral thrombosis,,2020,Q3,1,I,20200801.0,20200820.0,20200831,20200831,EXP,,CN-ASTRAZENECA-2020SF07113,ASTRAZENECA,,32085.0,DY,,F,Y,49.0,KG,20200831.0,,HP,CN,CN,2020,Q3,Elderly
182144411,18214441,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1250.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Chest discomfort,,2020,Q3,1,I,20200801.0,20200820.0,20200831,20200831,EXP,,CN-ASTRAZENECA-2020SF07113,ASTRAZENECA,,32085.0,DY,,F,Y,49.0,KG,20200831.0,,HP,CN,CN,2020,Q3,Elderly
182144411,18214441,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1250.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Coronary artery disease,,2020,Q3,1,I,20200801.0,20200820.0,20200831,20200831,EXP,,CN-ASTRAZENECA-2020SF07113,ASTRAZENECA,,32085.0,DY,,F,Y,49.0,KG,20200831.0,,HP,CN,CN,2020,Q3,Elderly
182144411,18214441,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1250.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Hyperuricaemia,,2020,Q3,1,I,20200801.0,20200820.0,20200831,20200831,EXP,,CN-ASTRAZENECA-2020SF07113,ASTRAZENECA,,32085.0,DY,,F,Y,49.0,KG,20200831.0,,HP,CN,CN,2020,Q3,Elderly
182144411,18214441,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1250.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Hypomagnesaemia,,2020,Q3,1,I,20200801.0,20200820.0,20200831,20200831,EXP,,CN-ASTRAZENECA-2020SF07113,ASTRAZENECA,,32085.0,DY,,F,Y,49.0,KG,20200831.0,,HP,CN,CN,2020,Q3,Elderly
182144411,18214441,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1250.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Hypoproteinaemia,,2020,Q3,1,I,20200801.0,20200820.0,20200831,20200831,EXP,,CN-ASTRAZENECA-2020SF07113,ASTRAZENECA,,32085.0,DY,,F,Y,49.0,KG,20200831.0,,HP,CN,CN,2020,Q3,Elderly
182144411,18214441,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1250.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Left ventricular dysfunction,,2020,Q3,1,I,20200801.0,20200820.0,20200831,20200831,EXP,,CN-ASTRAZENECA-2020SF07113,ASTRAZENECA,,32085.0,DY,,F,Y,49.0,KG,20200831.0,,HP,CN,CN,2020,Q3,Elderly
182144411,18214441,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1250.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Renal failure,,2020,Q3,1,I,20200801.0,20200820.0,20200831,20200831,EXP,,CN-ASTRAZENECA-2020SF07113,ASTRAZENECA,,32085.0,DY,,F,Y,49.0,KG,20200831.0,,HP,CN,CN,2020,Q3,Elderly
182144411,18214441,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1250.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Ventricular hypertrophy,,2020,Q3,1,I,20200801.0,20200820.0,20200831,20200831,EXP,,CN-ASTRAZENECA-2020SF07113,ASTRAZENECA,,32085.0,DY,,F,Y,49.0,KG,20200831.0,,HP,CN,CN,2020,Q3,Elderly
182144411,18214441,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1250.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Aortic valve incompetence,,2020,Q3,1,I,20200801.0,20200820.0,20200831,20200831,EXP,,CN-ASTRAZENECA-2020SF07113,ASTRAZENECA,,32085.0,DY,,F,Y,49.0,KG,20200831.0,,HP,CN,CN,2020,Q3,Elderly
182144411,18214441,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1250.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Carotid arteriosclerosis,,2020,Q3,1,I,20200801.0,20200820.0,20200831,20200831,EXP,,CN-ASTRAZENECA-2020SF07113,ASTRAZENECA,,32085.0,DY,,F,Y,49.0,KG,20200831.0,,HP,CN,CN,2020,Q3,Elderly
182144411,18214441,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1250.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Carotid intima-media thickness increased,,2020,Q3,1,I,20200801.0,20200820.0,20200831,20200831,EXP,,CN-ASTRAZENECA-2020SF07113,ASTRAZENECA,,32085.0,DY,,F,Y,49.0,KG,20200831.0,,HP,CN,CN,2020,Q3,Elderly
182144411,18214441,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1250.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Cerebral arteriosclerosis,,2020,Q3,1,I,20200801.0,20200820.0,20200831,20200831,EXP,,CN-ASTRAZENECA-2020SF07113,ASTRAZENECA,,32085.0,DY,,F,Y,49.0,KG,20200831.0,,HP,CN,CN,2020,Q3,Elderly
182144411,18214441,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1250.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Cerebral atrophy,,2020,Q3,1,I,20200801.0,20200820.0,20200831,20200831,EXP,,CN-ASTRAZENECA-2020SF07113,ASTRAZENECA,,32085.0,DY,,F,Y,49.0,KG,20200831.0,,HP,CN,CN,2020,Q3,Elderly
182144411,18214441,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1250.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Cerebral infarction,,2020,Q3,1,I,20200801.0,20200820.0,20200831,20200831,EXP,,CN-ASTRAZENECA-2020SF07113,ASTRAZENECA,,32085.0,DY,,F,Y,49.0,KG,20200831.0,,HP,CN,CN,2020,Q3,Elderly
182144411,18214441,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1250.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Cerebral thrombosis,,2020,Q3,1,I,20200801.0,20200820.0,20200831,20200831,EXP,,CN-ASTRAZENECA-2020SF07113,ASTRAZENECA,,32085.0,DY,,F,Y,49.0,KG,20200831.0,,HP,CN,CN,2020,Q3,Elderly
182144411,18214441,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1250.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Chest discomfort,,2020,Q3,1,I,20200801.0,20200820.0,20200831,20200831,EXP,,CN-ASTRAZENECA-2020SF07113,ASTRAZENECA,,32085.0,DY,,F,Y,49.0,KG,20200831.0,,HP,CN,CN,2020,Q3,Elderly
182144411,18214441,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1250.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Coronary artery disease,,2020,Q3,1,I,20200801.0,20200820.0,20200831,20200831,EXP,,CN-ASTRAZENECA-2020SF07113,ASTRAZENECA,,32085.0,DY,,F,Y,49.0,KG,20200831.0,,HP,CN,CN,2020,Q3,Elderly
182144411,18214441,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1250.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Hyperuricaemia,,2020,Q3,1,I,20200801.0,20200820.0,20200831,20200831,EXP,,CN-ASTRAZENECA-2020SF07113,ASTRAZENECA,,32085.0,DY,,F,Y,49.0,KG,20200831.0,,HP,CN,CN,2020,Q3,Elderly
182144411,18214441,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1250.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Hypomagnesaemia,,2020,Q3,1,I,20200801.0,20200820.0,20200831,20200831,EXP,,CN-ASTRAZENECA-2020SF07113,ASTRAZENECA,,32085.0,DY,,F,Y,49.0,KG,20200831.0,,HP,CN,CN,2020,Q3,Elderly
182144411,18214441,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1250.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Hypoproteinaemia,,2020,Q3,1,I,20200801.0,20200820.0,20200831,20200831,EXP,,CN-ASTRAZENECA-2020SF07113,ASTRAZENECA,,32085.0,DY,,F,Y,49.0,KG,20200831.0,,HP,CN,CN,2020,Q3,Elderly
182144411,18214441,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1250.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Left ventricular dysfunction,,2020,Q3,1,I,20200801.0,20200820.0,20200831,20200831,EXP,,CN-ASTRAZENECA-2020SF07113,ASTRAZENECA,,32085.0,DY,,F,Y,49.0,KG,20200831.0,,HP,CN,CN,2020,Q3,Elderly
182144411,18214441,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1250.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Renal failure,,2020,Q3,1,I,20200801.0,20200820.0,20200831,20200831,EXP,,CN-ASTRAZENECA-2020SF07113,ASTRAZENECA,,32085.0,DY,,F,Y,49.0,KG,20200831.0,,HP,CN,CN,2020,Q3,Elderly
182144411,18214441,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1250.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Ventricular hypertrophy,,2020,Q3,1,I,20200801.0,20200820.0,20200831,20200831,EXP,,CN-ASTRAZENECA-2020SF07113,ASTRAZENECA,,32085.0,DY,,F,Y,49.0,KG,20200831.0,,HP,CN,CN,2020,Q3,Elderly
182208741,18220874,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2020,Q3,Chest pain,Chest pain,2020,Q3,1,I,,20190827.0,20200902,20200902,EXP,,SG-SUN PHARMACEUTICAL INDUSTRIES LTD-2019R1-219915,RANBAXY,"PANG T, GUDI A. CHEST PAIN FOLLOWING THE USE OF FLUVOXAMINE IN DEPRESSION. PROCEED SINGAPORE HEALTHC. 2019?28(2):138?140",66.0,YR,,F,Y,,,20200902.0,,HP,SG,SG,2020,Q3,Elderly
182208741,18220874,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2020,Q3,Drug interaction,,2020,Q3,1,I,,20190827.0,20200902,20200902,EXP,,SG-SUN PHARMACEUTICAL INDUSTRIES LTD-2019R1-219915,RANBAXY,"PANG T, GUDI A. CHEST PAIN FOLLOWING THE USE OF FLUVOXAMINE IN DEPRESSION. PROCEED SINGAPORE HEALTHC. 2019?28(2):138?140",66.0,YR,,F,Y,,,20200902.0,,HP,SG,SG,2020,Q3,Elderly
182275131,18227513,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,,10.0,MG,TABLET,,2020,Q3,Euglycaemic diabetic ketoacidosis,,2020,Q3,1,I,20200630.0,20200826.0,20200903,20200903,EXP,,GB-ASTRAZENECA-2020SF08737,ASTRAZENECA,,31.0,YR,,F,Y,85.0,KG,20200903.0,,,GB,GB,2020,Q3,Young Adult
182294301,18229430,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,50.0,MG,U,, 2004067,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Blood glucose increased,,2020,Q3,1,I,20200730.0,20200829.0,20200903,20200903,EXP,,CN-ASTRAZENECA-2020SF12381,ASTRAZENECA,,25568.0,DY,,M,Y,52.8,KG,20200903.0,,HP,CN,CN,2020,Q3,Elderly
182294301,18229430,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,50.0,MG,U,, 2004067,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Dizziness,,2020,Q3,1,I,20200730.0,20200829.0,20200903,20200903,EXP,,CN-ASTRAZENECA-2020SF12381,ASTRAZENECA,,25568.0,DY,,M,Y,52.8,KG,20200903.0,,HP,CN,CN,2020,Q3,Elderly
182294301,18229430,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,50.0,MG,U,, 2004067,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Faeces discoloured,,2020,Q3,1,I,20200730.0,20200829.0,20200903,20200903,EXP,,CN-ASTRAZENECA-2020SF12381,ASTRAZENECA,,25568.0,DY,,M,Y,52.8,KG,20200903.0,,HP,CN,CN,2020,Q3,Elderly
182294301,18229430,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,50.0,MG,U,, 2004067,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Hypovolaemic shock,,2020,Q3,1,I,20200730.0,20200829.0,20200903,20200903,EXP,,CN-ASTRAZENECA-2020SF12381,ASTRAZENECA,,25568.0,DY,,M,Y,52.8,KG,20200903.0,,HP,CN,CN,2020,Q3,Elderly
182339401,18233940,1,PS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,2440.0,MG,Y,,,,,10.0,MG,TABLET,QD,2020,Q3,Diabetic ketoacidosis,,2020,Q3,1,I,20200813.0,20200831.0,20200904,20200904,EXP,,NL-ASTRAZENECA-2020SF10446,ASTRAZENECA,,83.0,YR,,M,Y,61.0,KG,20200904.0,,MD,NL,NL,2020,Q3,Elderly
182362401,18236240,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Diabetic ketoacidosis,,2020,Q3,1,I,20200815.0,20200902.0,20200906,20200906,EXP,,GB-ASTRAZENECA-2020SF11763,ASTRAZENECA,,57.0,YR,,F,Y,,,20200907.0,,PH,GB,GB,2020,Q3,Adult
182362401,18236240,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Flank pain,,2020,Q3,1,I,20200815.0,20200902.0,20200906,20200906,EXP,,GB-ASTRAZENECA-2020SF11763,ASTRAZENECA,,57.0,YR,,F,Y,,,20200907.0,,PH,GB,GB,2020,Q3,Adult
182362401,18236240,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Vomiting,,2020,Q3,1,I,20200815.0,20200902.0,20200906,20200906,EXP,,GB-ASTRAZENECA-2020SF11763,ASTRAZENECA,,57.0,YR,,F,Y,,,20200907.0,,PH,GB,GB,2020,Q3,Adult
182379271,18237927,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,, 1904105,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Chills,,2020,Q3,1,I,,20200901.0,20200907,20200907,EXP,,CN-ASTRAZENECA-2020SF12756,ASTRAZENECA,,31.0,YR,,F,Y,,,20200907.0,,MD,CN,CN,2020,Q3,Young Adult
182379271,18237927,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,, 1904105,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Decreased appetite,,2020,Q3,1,I,,20200901.0,20200907,20200907,EXP,,CN-ASTRAZENECA-2020SF12756,ASTRAZENECA,,31.0,YR,,F,Y,,,20200907.0,,MD,CN,CN,2020,Q3,Young Adult
182379271,18237927,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,, 1904105,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Ketoacidosis,,2020,Q3,1,I,,20200901.0,20200907,20200907,EXP,,CN-ASTRAZENECA-2020SF12756,ASTRAZENECA,,31.0,YR,,F,Y,,,20200907.0,,MD,CN,CN,2020,Q3,Young Adult
182415751,18241575,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2020,Q3,Acute coronary syndrome,,2020,Q3,1,I,,20200831.0,20200908,20200908,EXP,,CA-ASTRAZENECA-2020SF10755,ASTRAZENECA,,56.0,YR,,M,Y,82.0,KG,20200908.0,,MD,CA,CA,2020,Q3,Adult
182415751,18241575,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2020,Q3,Angina unstable,,2020,Q3,1,I,,20200831.0,20200908,20200908,EXP,,CA-ASTRAZENECA-2020SF10755,ASTRAZENECA,,56.0,YR,,M,Y,82.0,KG,20200908.0,,MD,CA,CA,2020,Q3,Adult
182415751,18241575,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2020,Q3,Blood cholesterol increased,,2020,Q3,1,I,,20200831.0,20200908,20200908,EXP,,CA-ASTRAZENECA-2020SF10755,ASTRAZENECA,,56.0,YR,,M,Y,82.0,KG,20200908.0,,MD,CA,CA,2020,Q3,Adult
182415751,18241575,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2020,Q3,Blood creatine phosphokinase increased,,2020,Q3,1,I,,20200831.0,20200908,20200908,EXP,,CA-ASTRAZENECA-2020SF10755,ASTRAZENECA,,56.0,YR,,M,Y,82.0,KG,20200908.0,,MD,CA,CA,2020,Q3,Adult
182415751,18241575,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2020,Q3,Blood parathyroid hormone increased,,2020,Q3,1,I,,20200831.0,20200908,20200908,EXP,,CA-ASTRAZENECA-2020SF10755,ASTRAZENECA,,56.0,YR,,M,Y,82.0,KG,20200908.0,,MD,CA,CA,2020,Q3,Adult
182415751,18241575,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2020,Q3,Blood triglycerides increased,,2020,Q3,1,I,,20200831.0,20200908,20200908,EXP,,CA-ASTRAZENECA-2020SF10755,ASTRAZENECA,,56.0,YR,,M,Y,82.0,KG,20200908.0,,MD,CA,CA,2020,Q3,Adult
182415751,18241575,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2020,Q3,Coronary artery stenosis,,2020,Q3,1,I,,20200831.0,20200908,20200908,EXP,,CA-ASTRAZENECA-2020SF10755,ASTRAZENECA,,56.0,YR,,M,Y,82.0,KG,20200908.0,,MD,CA,CA,2020,Q3,Adult
182415751,18241575,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2020,Q3,High density lipoprotein decreased,,2020,Q3,1,I,,20200831.0,20200908,20200908,EXP,,CA-ASTRAZENECA-2020SF10755,ASTRAZENECA,,56.0,YR,,M,Y,82.0,KG,20200908.0,,MD,CA,CA,2020,Q3,Adult
182415751,18241575,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2020,Q3,Low density lipoprotein increased,,2020,Q3,1,I,,20200831.0,20200908,20200908,EXP,,CA-ASTRAZENECA-2020SF10755,ASTRAZENECA,,56.0,YR,,M,Y,82.0,KG,20200908.0,,MD,CA,CA,2020,Q3,Adult
182415751,18241575,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2020,Q3,Muscular weakness,,2020,Q3,1,I,,20200831.0,20200908,20200908,EXP,,CA-ASTRAZENECA-2020SF10755,ASTRAZENECA,,56.0,YR,,M,Y,82.0,KG,20200908.0,,MD,CA,CA,2020,Q3,Adult
182415751,18241575,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2020,Q3,Myalgia,,2020,Q3,1,I,,20200831.0,20200908,20200908,EXP,,CA-ASTRAZENECA-2020SF10755,ASTRAZENECA,,56.0,YR,,M,Y,82.0,KG,20200908.0,,MD,CA,CA,2020,Q3,Adult
182415751,18241575,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2020,Q3,Myopathy,,2020,Q3,1,I,,20200831.0,20200908,20200908,EXP,,CA-ASTRAZENECA-2020SF10755,ASTRAZENECA,,56.0,YR,,M,Y,82.0,KG,20200908.0,,MD,CA,CA,2020,Q3,Adult
182415751,18241575,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2020,Q3,Total cholesterol/HDL ratio increased,,2020,Q3,1,I,,20200831.0,20200908,20200908,EXP,,CA-ASTRAZENECA-2020SF10755,ASTRAZENECA,,56.0,YR,,M,Y,82.0,KG,20200908.0,,MD,CA,CA,2020,Q3,Adult
182567341,18256734,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Diabetic ketoacidosis,,2020,Q3,1,I,,20200909.0,20200911,20200911,EXP,,AU-ASTRAZENECA-2020SF15582,ASTRAZENECA,,60.0,YR,,M,Y,,,20200911.0,,MD,AU,AU,2020,Q3,Adult
182567341,18256734,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Gastrointestinal disorder,,2020,Q3,1,I,,20200909.0,20200911,20200911,EXP,,AU-ASTRAZENECA-2020SF15582,ASTRAZENECA,,60.0,YR,,M,Y,,,20200911.0,,MD,AU,AU,2020,Q3,Adult
182668451,18266845,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Abdominal discomfort,,2020,Q3,1,I,,20200908.0,20200915,20200915,EXP,,NVSC2020CA247552,NOVARTIS,,55.0,YR,,M,Y,,,20200915.0,,HP,CA,CA,2020,Q3,Adult
182668451,18266845,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Arthralgia,,2020,Q3,1,I,,20200908.0,20200915,20200915,EXP,,NVSC2020CA247552,NOVARTIS,,55.0,YR,,M,Y,,,20200915.0,,HP,CA,CA,2020,Q3,Adult
182668451,18266845,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Arthritis,,2020,Q3,1,I,,20200908.0,20200915,20200915,EXP,,NVSC2020CA247552,NOVARTIS,,55.0,YR,,M,Y,,,20200915.0,,HP,CA,CA,2020,Q3,Adult
182668451,18266845,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Blood glucose abnormal,,2020,Q3,1,I,,20200908.0,20200915,20200915,EXP,,NVSC2020CA247552,NOVARTIS,,55.0,YR,,M,Y,,,20200915.0,,HP,CA,CA,2020,Q3,Adult
182668451,18266845,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Cataract,,2020,Q3,1,I,,20200908.0,20200915,20200915,EXP,,NVSC2020CA247552,NOVARTIS,,55.0,YR,,M,Y,,,20200915.0,,HP,CA,CA,2020,Q3,Adult
182668451,18266845,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Dizziness,,2020,Q3,1,I,,20200908.0,20200915,20200915,EXP,,NVSC2020CA247552,NOVARTIS,,55.0,YR,,M,Y,,,20200915.0,,HP,CA,CA,2020,Q3,Adult
182668451,18266845,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Ear discomfort,,2020,Q3,1,I,,20200908.0,20200915,20200915,EXP,,NVSC2020CA247552,NOVARTIS,,55.0,YR,,M,Y,,,20200915.0,,HP,CA,CA,2020,Q3,Adult
182668451,18266845,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Erythema,,2020,Q3,1,I,,20200908.0,20200915,20200915,EXP,,NVSC2020CA247552,NOVARTIS,,55.0,YR,,M,Y,,,20200915.0,,HP,CA,CA,2020,Q3,Adult
182668451,18266845,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Fatigue,,2020,Q3,1,I,,20200908.0,20200915,20200915,EXP,,NVSC2020CA247552,NOVARTIS,,55.0,YR,,M,Y,,,20200915.0,,HP,CA,CA,2020,Q3,Adult
182668451,18266845,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Headache,,2020,Q3,1,I,,20200908.0,20200915,20200915,EXP,,NVSC2020CA247552,NOVARTIS,,55.0,YR,,M,Y,,,20200915.0,,HP,CA,CA,2020,Q3,Adult
182668451,18266845,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Hypotension,,2020,Q3,1,I,,20200908.0,20200915,20200915,EXP,,NVSC2020CA247552,NOVARTIS,,55.0,YR,,M,Y,,,20200915.0,,HP,CA,CA,2020,Q3,Adult
182668451,18266845,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Inappropriate schedule of product administration,,2020,Q3,1,I,,20200908.0,20200915,20200915,EXP,,NVSC2020CA247552,NOVARTIS,,55.0,YR,,M,Y,,,20200915.0,,HP,CA,CA,2020,Q3,Adult
182668451,18266845,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Joint stiffness,,2020,Q3,1,I,,20200908.0,20200915,20200915,EXP,,NVSC2020CA247552,NOVARTIS,,55.0,YR,,M,Y,,,20200915.0,,HP,CA,CA,2020,Q3,Adult
182668451,18266845,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Muscle spasms,,2020,Q3,1,I,,20200908.0,20200915,20200915,EXP,,NVSC2020CA247552,NOVARTIS,,55.0,YR,,M,Y,,,20200915.0,,HP,CA,CA,2020,Q3,Adult
182668451,18266845,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Nausea,,2020,Q3,1,I,,20200908.0,20200915,20200915,EXP,,NVSC2020CA247552,NOVARTIS,,55.0,YR,,M,Y,,,20200915.0,,HP,CA,CA,2020,Q3,Adult
182668451,18266845,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Rheumatoid arthritis,,2020,Q3,1,I,,20200908.0,20200915,20200915,EXP,,NVSC2020CA247552,NOVARTIS,,55.0,YR,,M,Y,,,20200915.0,,HP,CA,CA,2020,Q3,Adult
182668451,18266845,7,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Vomiting,,2020,Q3,1,I,,20200908.0,20200915,20200915,EXP,,NVSC2020CA247552,NOVARTIS,,55.0,YR,,M,Y,,,20200915.0,,HP,CA,CA,2020,Q3,Adult
182702231,18270223,1,PS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,1D1,8830.0,MG,Y,,,,,10.0,MG,TABLET,QD,2020,Q3,Ketoacidosis,,2020,Q3,1,I,20200823.0,20200909.0,20200915,20200915,EXP,,NL-ASTRAZENECA-2020SF16017,ASTRAZENECA,,55.0,YR,,F,Y,79.0,KG,20200915.0,,CN,NL,NL,2020,Q3,Adult
182702231,18270223,1,PS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,1D1,8830.0,MG,Y,,,,,10.0,MG,TABLET,QD,2020,Q3,Ketonuria,,2020,Q3,1,I,20200823.0,20200909.0,20200915,20200915,EXP,,NL-ASTRAZENECA-2020SF16017,ASTRAZENECA,,55.0,YR,,F,Y,79.0,KG,20200915.0,,CN,NL,NL,2020,Q3,Adult
182725981,18272598,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Abdominal discomfort,,2020,Q3,1,I,,20200908.0,20200916,20200916,EXP,,NVSC2020CA247449,NOVARTIS,,55.0,YR,,M,Y,,,20200916.0,,HP,CA,CA,2020,Q3,Adult
182725981,18272598,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Arthralgia,,2020,Q3,1,I,,20200908.0,20200916,20200916,EXP,,NVSC2020CA247449,NOVARTIS,,55.0,YR,,M,Y,,,20200916.0,,HP,CA,CA,2020,Q3,Adult
182725981,18272598,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Arthritis,,2020,Q3,1,I,,20200908.0,20200916,20200916,EXP,,NVSC2020CA247449,NOVARTIS,,55.0,YR,,M,Y,,,20200916.0,,HP,CA,CA,2020,Q3,Adult
182725981,18272598,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Blood glucose abnormal,,2020,Q3,1,I,,20200908.0,20200916,20200916,EXP,,NVSC2020CA247449,NOVARTIS,,55.0,YR,,M,Y,,,20200916.0,,HP,CA,CA,2020,Q3,Adult
182725981,18272598,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Cataract,,2020,Q3,1,I,,20200908.0,20200916,20200916,EXP,,NVSC2020CA247449,NOVARTIS,,55.0,YR,,M,Y,,,20200916.0,,HP,CA,CA,2020,Q3,Adult
182725981,18272598,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Cholelithiasis,,2020,Q3,1,I,,20200908.0,20200916,20200916,EXP,,NVSC2020CA247449,NOVARTIS,,55.0,YR,,M,Y,,,20200916.0,,HP,CA,CA,2020,Q3,Adult
182725981,18272598,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Dizziness,,2020,Q3,1,I,,20200908.0,20200916,20200916,EXP,,NVSC2020CA247449,NOVARTIS,,55.0,YR,,M,Y,,,20200916.0,,HP,CA,CA,2020,Q3,Adult
182725981,18272598,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Ear discomfort,,2020,Q3,1,I,,20200908.0,20200916,20200916,EXP,,NVSC2020CA247449,NOVARTIS,,55.0,YR,,M,Y,,,20200916.0,,HP,CA,CA,2020,Q3,Adult
182725981,18272598,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Erythema,,2020,Q3,1,I,,20200908.0,20200916,20200916,EXP,,NVSC2020CA247449,NOVARTIS,,55.0,YR,,M,Y,,,20200916.0,,HP,CA,CA,2020,Q3,Adult
182725981,18272598,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Facial neuralgia,,2020,Q3,1,I,,20200908.0,20200916,20200916,EXP,,NVSC2020CA247449,NOVARTIS,,55.0,YR,,M,Y,,,20200916.0,,HP,CA,CA,2020,Q3,Adult
182725981,18272598,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Fatigue,,2020,Q3,1,I,,20200908.0,20200916,20200916,EXP,,NVSC2020CA247449,NOVARTIS,,55.0,YR,,M,Y,,,20200916.0,,HP,CA,CA,2020,Q3,Adult
182725981,18272598,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Groin pain,,2020,Q3,1,I,,20200908.0,20200916,20200916,EXP,,NVSC2020CA247449,NOVARTIS,,55.0,YR,,M,Y,,,20200916.0,,HP,CA,CA,2020,Q3,Adult
182725981,18272598,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Headache,,2020,Q3,1,I,,20200908.0,20200916,20200916,EXP,,NVSC2020CA247449,NOVARTIS,,55.0,YR,,M,Y,,,20200916.0,,HP,CA,CA,2020,Q3,Adult
182725981,18272598,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Hypotension,,2020,Q3,1,I,,20200908.0,20200916,20200916,EXP,,NVSC2020CA247449,NOVARTIS,,55.0,YR,,M,Y,,,20200916.0,,HP,CA,CA,2020,Q3,Adult
182725981,18272598,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Inappropriate schedule of product administration,,2020,Q3,1,I,,20200908.0,20200916,20200916,EXP,,NVSC2020CA247449,NOVARTIS,,55.0,YR,,M,Y,,,20200916.0,,HP,CA,CA,2020,Q3,Adult
182725981,18272598,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Joint stiffness,,2020,Q3,1,I,,20200908.0,20200916,20200916,EXP,,NVSC2020CA247449,NOVARTIS,,55.0,YR,,M,Y,,,20200916.0,,HP,CA,CA,2020,Q3,Adult
182725981,18272598,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Labyrinthitis,,2020,Q3,1,I,,20200908.0,20200916,20200916,EXP,,NVSC2020CA247449,NOVARTIS,,55.0,YR,,M,Y,,,20200916.0,,HP,CA,CA,2020,Q3,Adult
182725981,18272598,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Muscle spasms,,2020,Q3,1,I,,20200908.0,20200916,20200916,EXP,,NVSC2020CA247449,NOVARTIS,,55.0,YR,,M,Y,,,20200916.0,,HP,CA,CA,2020,Q3,Adult
182725981,18272598,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Nausea,,2020,Q3,1,I,,20200908.0,20200916,20200916,EXP,,NVSC2020CA247449,NOVARTIS,,55.0,YR,,M,Y,,,20200916.0,,HP,CA,CA,2020,Q3,Adult
182725981,18272598,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Rheumatoid arthritis,,2020,Q3,1,I,,20200908.0,20200916,20200916,EXP,,NVSC2020CA247449,NOVARTIS,,55.0,YR,,M,Y,,,20200916.0,,HP,CA,CA,2020,Q3,Adult
182725981,18272598,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Visual impairment,,2020,Q3,1,I,,20200908.0,20200916,20200916,EXP,,NVSC2020CA247449,NOVARTIS,,55.0,YR,,M,Y,,,20200916.0,,HP,CA,CA,2020,Q3,Adult
182725981,18272598,8,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,"5.0 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q3,Vomiting,,2020,Q3,1,I,,20200908.0,20200916,20200916,EXP,,NVSC2020CA247449,NOVARTIS,,55.0,YR,,M,Y,,,20200916.0,,HP,CA,CA,2020,Q3,Adult
182788141,18278814,1,PS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,,,,U,,,,202293.0,1.0,DF,TABLET,QD,2020,Q3,Diverticulum intestinal,,2020,Q3,1,I,,20200914.0,20200917,20200917,EXP,,CA-ASTRAZENECA-2020SF18122,ASTRAZENECA,,58.0,YR,,F,Y,,,20200917.0,,CN,CA,CA,2020,Q3,Adult
182788141,18278814,1,PS,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,,,,U,,,,202293.0,1.0,DF,TABLET,QD,2020,Q3,Nephrolithiasis,,2020,Q3,1,I,,20200914.0,20200917,20200917,EXP,,CA-ASTRAZENECA-2020SF18122,ASTRAZENECA,,58.0,YR,,F,Y,,,20200917.0,,CN,CA,CA,2020,Q3,Adult
182790211,18279021,6,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q3,Cardiac failure congestive,,2020,Q3,1,I,20200601.0,20200910.0,20200917,20200917,EXP,,NVSC2020US249066,NOVARTIS,,58.0,YR,,M,Y,142.86,KG,20200917.0,,HP,CH,US,2020,Q3,Adult
182790211,18279021,6,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q3,Cough,,2020,Q3,1,I,20200601.0,20200910.0,20200917,20200917,EXP,,NVSC2020US249066,NOVARTIS,,58.0,YR,,M,Y,142.86,KG,20200917.0,,HP,CH,US,2020,Q3,Adult
182790211,18279021,6,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q3,Dyspnoea,,2020,Q3,1,I,20200601.0,20200910.0,20200917,20200917,EXP,,NVSC2020US249066,NOVARTIS,,58.0,YR,,M,Y,142.86,KG,20200917.0,,HP,CH,US,2020,Q3,Adult
182790211,18279021,6,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q3,Pneumonia,,2020,Q3,1,I,20200601.0,20200910.0,20200917,20200917,EXP,,NVSC2020US249066,NOVARTIS,,58.0,YR,,M,Y,142.86,KG,20200917.0,,HP,CH,US,2020,Q3,Adult
182790211,18279021,6,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q3,Weight increased,,2020,Q3,1,I,20200601.0,20200910.0,20200917,20200917,EXP,,NVSC2020US249066,NOVARTIS,,58.0,YR,,M,Y,142.86,KG,20200917.0,,HP,CH,US,2020,Q3,Adult
183001961,18300196,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2020,Q3,Abdominal pain,,2020,Q3,1,I,,20200911.0,20200923,20200923,EXP,,CA-APOTEX-2020AP018168,APOTEX,,69.0,YR,,F,Y,,,20200923.0,,CN,CA,CA,2020,Q3,Elderly
183001961,18300196,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2020,Q3,Anaemia,,2020,Q3,1,I,,20200911.0,20200923,20200923,EXP,,CA-APOTEX-2020AP018168,APOTEX,,69.0,YR,,F,Y,,,20200923.0,,CN,CA,CA,2020,Q3,Elderly
183001961,18300196,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2020,Q3,Blood pressure diastolic abnormal,,2020,Q3,1,I,,20200911.0,20200923,20200923,EXP,,CA-APOTEX-2020AP018168,APOTEX,,69.0,YR,,F,Y,,,20200923.0,,CN,CA,CA,2020,Q3,Elderly
183001961,18300196,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2020,Q3,Blood pressure diastolic decreased,,2020,Q3,1,I,,20200911.0,20200923,20200923,EXP,,CA-APOTEX-2020AP018168,APOTEX,,69.0,YR,,F,Y,,,20200923.0,,CN,CA,CA,2020,Q3,Elderly
183001961,18300196,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2020,Q3,Blood pressure systolic abnormal,,2020,Q3,1,I,,20200911.0,20200923,20200923,EXP,,CA-APOTEX-2020AP018168,APOTEX,,69.0,YR,,F,Y,,,20200923.0,,CN,CA,CA,2020,Q3,Elderly
183001961,18300196,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2020,Q3,Blood pressure systolic increased,,2020,Q3,1,I,,20200911.0,20200923,20200923,EXP,,CA-APOTEX-2020AP018168,APOTEX,,69.0,YR,,F,Y,,,20200923.0,,CN,CA,CA,2020,Q3,Elderly
183001961,18300196,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2020,Q3,Chronic obstructive pulmonary disease,,2020,Q3,1,I,,20200911.0,20200923,20200923,EXP,,CA-APOTEX-2020AP018168,APOTEX,,69.0,YR,,F,Y,,,20200923.0,,CN,CA,CA,2020,Q3,Elderly
183001961,18300196,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2020,Q3,Cough,,2020,Q3,1,I,,20200911.0,20200923,20200923,EXP,,CA-APOTEX-2020AP018168,APOTEX,,69.0,YR,,F,Y,,,20200923.0,,CN,CA,CA,2020,Q3,Elderly
183001961,18300196,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2020,Q3,Eczema,,2020,Q3,1,I,,20200911.0,20200923,20200923,EXP,,CA-APOTEX-2020AP018168,APOTEX,,69.0,YR,,F,Y,,,20200923.0,,CN,CA,CA,2020,Q3,Elderly
183001961,18300196,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2020,Q3,Gastritis,,2020,Q3,1,I,,20200911.0,20200923,20200923,EXP,,CA-APOTEX-2020AP018168,APOTEX,,69.0,YR,,F,Y,,,20200923.0,,CN,CA,CA,2020,Q3,Elderly
183001961,18300196,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2020,Q3,Gastrointestinal disorder,,2020,Q3,1,I,,20200911.0,20200923,20200923,EXP,,CA-APOTEX-2020AP018168,APOTEX,,69.0,YR,,F,Y,,,20200923.0,,CN,CA,CA,2020,Q3,Elderly
183001961,18300196,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2020,Q3,Gout,,2020,Q3,1,I,,20200911.0,20200923,20200923,EXP,,CA-APOTEX-2020AP018168,APOTEX,,69.0,YR,,F,Y,,,20200923.0,,CN,CA,CA,2020,Q3,Elderly
183001961,18300196,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2020,Q3,Heart rate increased,,2020,Q3,1,I,,20200911.0,20200923,20200923,EXP,,CA-APOTEX-2020AP018168,APOTEX,,69.0,YR,,F,Y,,,20200923.0,,CN,CA,CA,2020,Q3,Elderly
183001961,18300196,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2020,Q3,Oropharyngeal pain,,2020,Q3,1,I,,20200911.0,20200923,20200923,EXP,,CA-APOTEX-2020AP018168,APOTEX,,69.0,YR,,F,Y,,,20200923.0,,CN,CA,CA,2020,Q3,Elderly
183001961,18300196,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2020,Q3,Oxygen saturation decreased,,2020,Q3,1,I,,20200911.0,20200923,20200923,EXP,,CA-APOTEX-2020AP018168,APOTEX,,69.0,YR,,F,Y,,,20200923.0,,CN,CA,CA,2020,Q3,Elderly
183001961,18300196,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2020,Q3,Sleep disorder,,2020,Q3,1,I,,20200911.0,20200923,20200923,EXP,,CA-APOTEX-2020AP018168,APOTEX,,69.0,YR,,F,Y,,,20200923.0,,CN,CA,CA,2020,Q3,Elderly
183024541,18302454,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,360.0,MG,N,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Fournier's gangrene,,2020,Q3,1,I,20200806.0,20200918.0,20200923,20200923,EXP,,GB-ASTRAZENECA-2020SF21607,ASTRAZENECA,,63.0,YR,,M,Y,118.0,KG,20200923.0,,HP,GB,GB,2020,Q3,Adult
183024541,18302454,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,360.0,MG,N,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Hypovolaemic shock,,2020,Q3,1,I,20200806.0,20200918.0,20200923,20200923,EXP,,GB-ASTRAZENECA-2020SF21607,ASTRAZENECA,,63.0,YR,,M,Y,118.0,KG,20200923.0,,HP,GB,GB,2020,Q3,Adult
183024541,18302454,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,360.0,MG,N,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Metabolic acidosis,,2020,Q3,1,I,20200806.0,20200918.0,20200923,20200923,EXP,,GB-ASTRAZENECA-2020SF21607,ASTRAZENECA,,63.0,YR,,M,Y,118.0,KG,20200923.0,,HP,GB,GB,2020,Q3,Adult
183024541,18302454,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,360.0,MG,N,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Pilonidal cyst,,2020,Q3,1,I,20200806.0,20200918.0,20200923,20200923,EXP,,GB-ASTRAZENECA-2020SF21607,ASTRAZENECA,,63.0,YR,,M,Y,118.0,KG,20200923.0,,HP,GB,GB,2020,Q3,Adult
183024541,18302454,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,360.0,MG,N,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Respiratory acidosis,,2020,Q3,1,I,20200806.0,20200918.0,20200923,20200923,EXP,,GB-ASTRAZENECA-2020SF21607,ASTRAZENECA,,63.0,YR,,M,Y,118.0,KG,20200923.0,,HP,GB,GB,2020,Q3,Adult
183024541,18302454,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,360.0,MG,N,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Septic shock,,2020,Q3,1,I,20200806.0,20200918.0,20200923,20200923,EXP,,GB-ASTRAZENECA-2020SF21607,ASTRAZENECA,,63.0,YR,,M,Y,118.0,KG,20200923.0,,HP,GB,GB,2020,Q3,Adult
183071611,18307161,3,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,,, UNKNOWN,,,,,,,2020,Q3,Hepatitis acute,,2020,Q3,1,I,20200812.0,20200915.0,20200924,20200924,EXP,GB-MHRA-EYC 00228118,GB-TEVA-2020-GB-1830142,TEVA,,52.0,YR,A,F,Y,70.0,KG,20200924.0,,PH,GB,GB,2020,Q3,Adult
183071611,18307161,3,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,,, UNKNOWN,,,,,,,2020,Q3,Jaundice,,2020,Q3,1,I,20200812.0,20200915.0,20200924,20200924,EXP,GB-MHRA-EYC 00228118,GB-TEVA-2020-GB-1830142,TEVA,,52.0,YR,A,F,Y,70.0,KG,20200924.0,,PH,GB,GB,2020,Q3,Adult
183071611,18307161,3,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,,, UNKNOWN,,,,,,,2020,Q3,Lethargy,,2020,Q3,1,I,20200812.0,20200915.0,20200924,20200924,EXP,GB-MHRA-EYC 00228118,GB-TEVA-2020-GB-1830142,TEVA,,52.0,YR,A,F,Y,70.0,KG,20200924.0,,PH,GB,GB,2020,Q3,Adult
183071611,18307161,3,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,,, UNKNOWN,,,,,,,2020,Q3,Pain,,2020,Q3,1,I,20200812.0,20200915.0,20200924,20200924,EXP,GB-MHRA-EYC 00228118,GB-TEVA-2020-GB-1830142,TEVA,,52.0,YR,A,F,Y,70.0,KG,20200924.0,,PH,GB,GB,2020,Q3,Adult
183071611,18307161,3,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,,, UNKNOWN,,,,,,,2020,Q3,Periportal oedema,,2020,Q3,1,I,20200812.0,20200915.0,20200924,20200924,EXP,GB-MHRA-EYC 00228118,GB-TEVA-2020-GB-1830142,TEVA,,52.0,YR,A,F,Y,70.0,KG,20200924.0,,PH,GB,GB,2020,Q3,Adult
183071611,18307161,3,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,,,,,,, UNKNOWN,,,,,,,2020,Q3,Pruritus,,2020,Q3,1,I,20200812.0,20200915.0,20200924,20200924,EXP,GB-MHRA-EYC 00228118,GB-TEVA-2020-GB-1830142,TEVA,,52.0,YR,A,F,Y,70.0,KG,20200924.0,,PH,GB,GB,2020,Q3,Adult
183078681,18307868,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNKNOWN,,,U,,,,202293.0,,,TABLET,,2020,Q3,Fournier's gangrene,,2020,Q3,1,I,202007.0,20200914.0,20200924,20200924,EXP,,ES-ASTRAZENECA-2020SF19403,ASTRAZENECA,,82.0,YR,,M,Y,,,20200924.0,,,ES,ES,2020,Q3,Elderly
183078681,18307868,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNKNOWN,,,U,,,,202293.0,,,TABLET,,2020,Q3,Septic shock,,2020,Q3,1,I,202007.0,20200914.0,20200924,20200924,EXP,,ES-ASTRAZENECA-2020SF19403,ASTRAZENECA,,82.0,YR,,M,Y,,,20200924.0,,,ES,ES,2020,Q3,Elderly
183121181,18312118,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,N,, UNKNOWN,,202293.0,10.0,MG,TABLET,,2020,Q3,Cutaneous vasculitis,,2020,Q3,1,I,20200901.0,20200918.0,20200925,20200925,EXP,,BR-ASTRAZENECA-2020SF21853,ASTRAZENECA,,55.0,YR,,F,Y,,,20200925.0,,,BR,BR,2020,Q3,Adult
183175801,18317580,5,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2020,Q3,Abdominal pain lower,,2020,Q3,1,I,20200903.0,20200921.0,20200928,20200928,EXP,GB-MHRA-EYC 00228816,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-049714",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,97.0,KG,20200928.0,,CN,GB,GB,2020,Q3,Elderly
183175801,18317580,5,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2020,Q3,Back pain,,2020,Q3,1,I,20200903.0,20200921.0,20200928,20200928,EXP,GB-MHRA-EYC 00228816,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-049714",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,97.0,KG,20200928.0,,CN,GB,GB,2020,Q3,Elderly
183175801,18317580,5,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,,,,,,,,,,,,,2020,Q3,Flank pain,,2020,Q3,1,I,20200903.0,20200921.0,20200928,20200928,EXP,GB-MHRA-EYC 00228816,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-049714",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,97.0,KG,20200928.0,,CN,GB,GB,2020,Q3,Elderly
183234791,18323479,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Abdominal discomfort,,2020,Q3,1,I,,20200924.0,20200929,20200929,EXP,E2B_03268369,CA-ACCORD-203096,ACCORD,,55.0,YR,,M,Y,,,20200929.0,,HP,CA,CA,2020,Q3,Adult
183234791,18323479,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Arthralgia,,2020,Q3,1,I,,20200924.0,20200929,20200929,EXP,E2B_03268369,CA-ACCORD-203096,ACCORD,,55.0,YR,,M,Y,,,20200929.0,,HP,CA,CA,2020,Q3,Adult
183234791,18323479,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Arthritis,,2020,Q3,1,I,,20200924.0,20200929,20200929,EXP,E2B_03268369,CA-ACCORD-203096,ACCORD,,55.0,YR,,M,Y,,,20200929.0,,HP,CA,CA,2020,Q3,Adult
183234791,18323479,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Blood glucose abnormal,,2020,Q3,1,I,,20200924.0,20200929,20200929,EXP,E2B_03268369,CA-ACCORD-203096,ACCORD,,55.0,YR,,M,Y,,,20200929.0,,HP,CA,CA,2020,Q3,Adult
183234791,18323479,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Cataract,,2020,Q3,1,I,,20200924.0,20200929,20200929,EXP,E2B_03268369,CA-ACCORD-203096,ACCORD,,55.0,YR,,M,Y,,,20200929.0,,HP,CA,CA,2020,Q3,Adult
183234791,18323479,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Cholelithiasis,,2020,Q3,1,I,,20200924.0,20200929,20200929,EXP,E2B_03268369,CA-ACCORD-203096,ACCORD,,55.0,YR,,M,Y,,,20200929.0,,HP,CA,CA,2020,Q3,Adult
183234791,18323479,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Dizziness,,2020,Q3,1,I,,20200924.0,20200929,20200929,EXP,E2B_03268369,CA-ACCORD-203096,ACCORD,,55.0,YR,,M,Y,,,20200929.0,,HP,CA,CA,2020,Q3,Adult
183234791,18323479,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Ear discomfort,,2020,Q3,1,I,,20200924.0,20200929,20200929,EXP,E2B_03268369,CA-ACCORD-203096,ACCORD,,55.0,YR,,M,Y,,,20200929.0,,HP,CA,CA,2020,Q3,Adult
183234791,18323479,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Erythema,,2020,Q3,1,I,,20200924.0,20200929,20200929,EXP,E2B_03268369,CA-ACCORD-203096,ACCORD,,55.0,YR,,M,Y,,,20200929.0,,HP,CA,CA,2020,Q3,Adult
183234791,18323479,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Facial neuralgia,,2020,Q3,1,I,,20200924.0,20200929,20200929,EXP,E2B_03268369,CA-ACCORD-203096,ACCORD,,55.0,YR,,M,Y,,,20200929.0,,HP,CA,CA,2020,Q3,Adult
183234791,18323479,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Fatigue,,2020,Q3,1,I,,20200924.0,20200929,20200929,EXP,E2B_03268369,CA-ACCORD-203096,ACCORD,,55.0,YR,,M,Y,,,20200929.0,,HP,CA,CA,2020,Q3,Adult
183234791,18323479,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Groin pain,,2020,Q3,1,I,,20200924.0,20200929,20200929,EXP,E2B_03268369,CA-ACCORD-203096,ACCORD,,55.0,YR,,M,Y,,,20200929.0,,HP,CA,CA,2020,Q3,Adult
183234791,18323479,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Headache,,2020,Q3,1,I,,20200924.0,20200929,20200929,EXP,E2B_03268369,CA-ACCORD-203096,ACCORD,,55.0,YR,,M,Y,,,20200929.0,,HP,CA,CA,2020,Q3,Adult
183234791,18323479,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Hypotension,,2020,Q3,1,I,,20200924.0,20200929,20200929,EXP,E2B_03268369,CA-ACCORD-203096,ACCORD,,55.0,YR,,M,Y,,,20200929.0,,HP,CA,CA,2020,Q3,Adult
183234791,18323479,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Inappropriate schedule of product administration,,2020,Q3,1,I,,20200924.0,20200929,20200929,EXP,E2B_03268369,CA-ACCORD-203096,ACCORD,,55.0,YR,,M,Y,,,20200929.0,,HP,CA,CA,2020,Q3,Adult
183234791,18323479,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Joint stiffness,,2020,Q3,1,I,,20200924.0,20200929,20200929,EXP,E2B_03268369,CA-ACCORD-203096,ACCORD,,55.0,YR,,M,Y,,,20200929.0,,HP,CA,CA,2020,Q3,Adult
183234791,18323479,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Labyrinthitis,,2020,Q3,1,I,,20200924.0,20200929,20200929,EXP,E2B_03268369,CA-ACCORD-203096,ACCORD,,55.0,YR,,M,Y,,,20200929.0,,HP,CA,CA,2020,Q3,Adult
183234791,18323479,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Muscle spasms,,2020,Q3,1,I,,20200924.0,20200929,20200929,EXP,E2B_03268369,CA-ACCORD-203096,ACCORD,,55.0,YR,,M,Y,,,20200929.0,,HP,CA,CA,2020,Q3,Adult
183234791,18323479,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Nausea,,2020,Q3,1,I,,20200924.0,20200929,20200929,EXP,E2B_03268369,CA-ACCORD-203096,ACCORD,,55.0,YR,,M,Y,,,20200929.0,,HP,CA,CA,2020,Q3,Adult
183234791,18323479,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Rheumatoid arthritis,,2020,Q3,1,I,,20200924.0,20200929,20200929,EXP,E2B_03268369,CA-ACCORD-203096,ACCORD,,55.0,YR,,M,Y,,,20200929.0,,HP,CA,CA,2020,Q3,Adult
183234791,18323479,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Visual impairment,,2020,Q3,1,I,,20200924.0,20200929,20200929,EXP,E2B_03268369,CA-ACCORD-203096,ACCORD,,55.0,YR,,M,Y,,,20200929.0,,HP,CA,CA,2020,Q3,Adult
183234791,18323479,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Vomiting,,2020,Q3,1,I,,20200924.0,20200929,20200929,EXP,E2B_03268369,CA-ACCORD-203096,ACCORD,,55.0,YR,,M,Y,,,20200929.0,,HP,CA,CA,2020,Q3,Adult
183250611,18325061,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Confusional state,,2020,Q3,1,I,,20200921.0,20200929,20200929,EXP,,GB-ASTRAZENECA-2020SF21398,ASTRAZENECA,,59.0,YR,,F,Y,,,20200929.0,,,GB,GB,2020,Q3,Adult
183250611,18325061,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Suprapubic pain,,2020,Q3,1,I,,20200921.0,20200929,20200929,EXP,,GB-ASTRAZENECA-2020SF21398,ASTRAZENECA,,59.0,YR,,F,Y,,,20200929.0,,,GB,GB,2020,Q3,Adult
183250611,18325061,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Urinary tract infection,,2020,Q3,1,I,,20200921.0,20200929,20200929,EXP,,GB-ASTRAZENECA-2020SF21398,ASTRAZENECA,,59.0,YR,,F,Y,,,20200929.0,,,GB,GB,2020,Q3,Adult
183287001,18328700,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Abdominal discomfort,,2020,Q3,1,I,,20200924.0,20200930,20200930,EXP,E2B_03266535,CA-ACCORD-203020,ACCORD,,55.0,YR,,M,Y,,,20200930.0,,HP,CA,CA,2020,Q3,Adult
183287001,18328700,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Arthralgia,,2020,Q3,1,I,,20200924.0,20200930,20200930,EXP,E2B_03266535,CA-ACCORD-203020,ACCORD,,55.0,YR,,M,Y,,,20200930.0,,HP,CA,CA,2020,Q3,Adult
183287001,18328700,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Arthritis,,2020,Q3,1,I,,20200924.0,20200930,20200930,EXP,E2B_03266535,CA-ACCORD-203020,ACCORD,,55.0,YR,,M,Y,,,20200930.0,,HP,CA,CA,2020,Q3,Adult
183287001,18328700,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Blood glucose abnormal,,2020,Q3,1,I,,20200924.0,20200930,20200930,EXP,E2B_03266535,CA-ACCORD-203020,ACCORD,,55.0,YR,,M,Y,,,20200930.0,,HP,CA,CA,2020,Q3,Adult
183287001,18328700,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Cataract,,2020,Q3,1,I,,20200924.0,20200930,20200930,EXP,E2B_03266535,CA-ACCORD-203020,ACCORD,,55.0,YR,,M,Y,,,20200930.0,,HP,CA,CA,2020,Q3,Adult
183287001,18328700,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Dizziness,,2020,Q3,1,I,,20200924.0,20200930,20200930,EXP,E2B_03266535,CA-ACCORD-203020,ACCORD,,55.0,YR,,M,Y,,,20200930.0,,HP,CA,CA,2020,Q3,Adult
183287001,18328700,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Ear discomfort,,2020,Q3,1,I,,20200924.0,20200930,20200930,EXP,E2B_03266535,CA-ACCORD-203020,ACCORD,,55.0,YR,,M,Y,,,20200930.0,,HP,CA,CA,2020,Q3,Adult
183287001,18328700,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Erythema,,2020,Q3,1,I,,20200924.0,20200930,20200930,EXP,E2B_03266535,CA-ACCORD-203020,ACCORD,,55.0,YR,,M,Y,,,20200930.0,,HP,CA,CA,2020,Q3,Adult
183287001,18328700,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Fatigue,,2020,Q3,1,I,,20200924.0,20200930,20200930,EXP,E2B_03266535,CA-ACCORD-203020,ACCORD,,55.0,YR,,M,Y,,,20200930.0,,HP,CA,CA,2020,Q3,Adult
183287001,18328700,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Headache,,2020,Q3,1,I,,20200924.0,20200930,20200930,EXP,E2B_03266535,CA-ACCORD-203020,ACCORD,,55.0,YR,,M,Y,,,20200930.0,,HP,CA,CA,2020,Q3,Adult
183287001,18328700,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Hypotension,,2020,Q3,1,I,,20200924.0,20200930,20200930,EXP,E2B_03266535,CA-ACCORD-203020,ACCORD,,55.0,YR,,M,Y,,,20200930.0,,HP,CA,CA,2020,Q3,Adult
183287001,18328700,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Inappropriate schedule of product administration,,2020,Q3,1,I,,20200924.0,20200930,20200930,EXP,E2B_03266535,CA-ACCORD-203020,ACCORD,,55.0,YR,,M,Y,,,20200930.0,,HP,CA,CA,2020,Q3,Adult
183287001,18328700,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Joint stiffness,,2020,Q3,1,I,,20200924.0,20200930,20200930,EXP,E2B_03266535,CA-ACCORD-203020,ACCORD,,55.0,YR,,M,Y,,,20200930.0,,HP,CA,CA,2020,Q3,Adult
183287001,18328700,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Muscle spasms,,2020,Q3,1,I,,20200924.0,20200930,20200930,EXP,E2B_03266535,CA-ACCORD-203020,ACCORD,,55.0,YR,,M,Y,,,20200930.0,,HP,CA,CA,2020,Q3,Adult
183287001,18328700,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Nausea,,2020,Q3,1,I,,20200924.0,20200930,20200930,EXP,E2B_03266535,CA-ACCORD-203020,ACCORD,,55.0,YR,,M,Y,,,20200930.0,,HP,CA,CA,2020,Q3,Adult
183287001,18328700,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Rheumatoid arthritis,,2020,Q3,1,I,,20200924.0,20200930,20200930,EXP,E2B_03266535,CA-ACCORD-203020,ACCORD,,55.0,YR,,M,Y,,,20200930.0,,HP,CA,CA,2020,Q3,Adult
183287001,18328700,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,5.0,MG,,,2020,Q3,Vomiting,,2020,Q3,1,I,,20200924.0,20200930,20200930,EXP,E2B_03266535,CA-ACCORD-203020,ACCORD,,55.0,YR,,M,Y,,,20200930.0,,HP,CA,CA,2020,Q3,Adult
183301081,18330108,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,7380.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,COVID-19,,2020,Q3,1,I,20200908.0,20200925.0,20200930,20200930,EXP,,GB-ASTRAZENECA-2020SF24334,ASTRAZENECA,,43.0,YR,,M,Y,96.0,KG,20200930.0,,PH,GB,GB,2020,Q3,Adult
183301081,18330108,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,7380.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q3,Euglycaemic diabetic ketoacidosis,,2020,Q3,1,I,20200908.0,20200925.0,20200930,20200930,EXP,,GB-ASTRAZENECA-2020SF24334,ASTRAZENECA,,43.0,YR,,M,Y,96.0,KG,20200930.0,,PH,GB,GB,2020,Q3,Adult
140681634,14068163,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Hyponatraemia,,2020,Q4,4,F,20170926.0,20201001.0,20171010,20201007,EXP,,HU-ROCHE-2004266,ROCHE,,66.0,YR,,M,Y,95.0,KG,20201008.0,,MD,HU,HU,2020,Q4,Elderly
140681634,14068163,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Hypotension,,2020,Q4,4,F,20170926.0,20201001.0,20171010,20201007,EXP,,HU-ROCHE-2004266,ROCHE,,66.0,YR,,M,Y,95.0,KG,20201008.0,,MD,HU,HU,2020,Q4,Elderly
140681634,14068163,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Lethargy,,2020,Q4,4,F,20170926.0,20201001.0,20171010,20201007,EXP,,HU-ROCHE-2004266,ROCHE,,66.0,YR,,M,Y,95.0,KG,20201008.0,,MD,HU,HU,2020,Q4,Elderly
140681634,14068163,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Muscular weakness,,2020,Q4,4,F,20170926.0,20201001.0,20171010,20201007,EXP,,HU-ROCHE-2004266,ROCHE,,66.0,YR,,M,Y,95.0,KG,20201008.0,,MD,HU,HU,2020,Q4,Elderly
140681634,14068163,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Hyponatraemia,,2020,Q4,4,F,20170926.0,20201001.0,20171010,20201007,EXP,,HU-ROCHE-2004266,ROCHE,,66.0,YR,,M,Y,95.0,KG,20201008.0,,MD,HU,HU,2020,Q4,Elderly
140681634,14068163,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Hypotension,,2020,Q4,4,F,20170926.0,20201001.0,20171010,20201007,EXP,,HU-ROCHE-2004266,ROCHE,,66.0,YR,,M,Y,95.0,KG,20201008.0,,MD,HU,HU,2020,Q4,Elderly
140681634,14068163,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Lethargy,,2020,Q4,4,F,20170926.0,20201001.0,20171010,20201007,EXP,,HU-ROCHE-2004266,ROCHE,,66.0,YR,,M,Y,95.0,KG,20201008.0,,MD,HU,HU,2020,Q4,Elderly
140681634,14068163,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Muscular weakness,,2020,Q4,4,F,20170926.0,20201001.0,20171010,20201007,EXP,,HU-ROCHE-2004266,ROCHE,,66.0,YR,,M,Y,95.0,KG,20201008.0,,MD,HU,HU,2020,Q4,Elderly
1483540311,14835403,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q4,Decreased vibratory sense,,2020,Q4,11,F,2016.0,20201111.0,20180502,20201123,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017;7:22,61.0,YR,,F,Y,97.0,KG,20201123.0,,MD,DE,DE,2020,Q4,Adult
1483540311,14835403,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q4,Diabetes mellitus inadequate control,,2020,Q4,11,F,2016.0,20201111.0,20180502,20201123,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017;7:22,61.0,YR,,F,Y,97.0,KG,20201123.0,,MD,DE,DE,2020,Q4,Adult
1483540311,14835403,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q4,Gastrointestinal disorder,,2020,Q4,11,F,2016.0,20201111.0,20180502,20201123,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017;7:22,61.0,YR,,F,Y,97.0,KG,20201123.0,,MD,DE,DE,2020,Q4,Adult
1483540311,14835403,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q4,Limb discomfort,,2020,Q4,11,F,2016.0,20201111.0,20180502,20201123,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017;7:22,61.0,YR,,F,Y,97.0,KG,20201123.0,,MD,DE,DE,2020,Q4,Adult
1483540311,14835403,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q4,Neuropathy peripheral,,2020,Q4,11,F,2016.0,20201111.0,20180502,20201123,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017;7:22,61.0,YR,,F,Y,97.0,KG,20201123.0,,MD,DE,DE,2020,Q4,Adult
1483540311,14835403,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q4,Pain in extremity,,2020,Q4,11,F,2016.0,20201111.0,20180502,20201123,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017;7:22,61.0,YR,,F,Y,97.0,KG,20201123.0,,MD,DE,DE,2020,Q4,Adult
1483540311,14835403,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q4,Sensory disturbance,,2020,Q4,11,F,2016.0,20201111.0,20180502,20201123,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017;7:22,61.0,YR,,F,Y,97.0,KG,20201123.0,,MD,DE,DE,2020,Q4,Adult
1483540311,14835403,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q4,Sleep disorder,,2020,Q4,11,F,2016.0,20201111.0,20180502,20201123,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017;7:22,61.0,YR,,F,Y,97.0,KG,20201123.0,,MD,DE,DE,2020,Q4,Adult
1483540311,14835403,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q4,Temperature perception test abnormal,,2020,Q4,11,F,2016.0,20201111.0,20180502,20201123,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017;7:22,61.0,YR,,F,Y,97.0,KG,20201123.0,,MD,DE,DE,2020,Q4,Adult
1483540311,14835403,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q4,Visual impairment,,2020,Q4,11,F,2016.0,20201111.0,20180502,20201123,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017;7:22,61.0,YR,,F,Y,97.0,KG,20201123.0,,MD,DE,DE,2020,Q4,Adult
1483540311,14835403,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q4,Decreased vibratory sense,,2020,Q4,11,F,2016.0,20201111.0,20180502,20201123,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017;7:22,61.0,YR,,F,Y,97.0,KG,20201123.0,,MD,DE,DE,2020,Q4,Adult
1483540311,14835403,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q4,Diabetes mellitus inadequate control,,2020,Q4,11,F,2016.0,20201111.0,20180502,20201123,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017;7:22,61.0,YR,,F,Y,97.0,KG,20201123.0,,MD,DE,DE,2020,Q4,Adult
1483540311,14835403,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q4,Gastrointestinal disorder,,2020,Q4,11,F,2016.0,20201111.0,20180502,20201123,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017;7:22,61.0,YR,,F,Y,97.0,KG,20201123.0,,MD,DE,DE,2020,Q4,Adult
1483540311,14835403,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q4,Limb discomfort,,2020,Q4,11,F,2016.0,20201111.0,20180502,20201123,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017;7:22,61.0,YR,,F,Y,97.0,KG,20201123.0,,MD,DE,DE,2020,Q4,Adult
1483540311,14835403,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q4,Neuropathy peripheral,,2020,Q4,11,F,2016.0,20201111.0,20180502,20201123,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017;7:22,61.0,YR,,F,Y,97.0,KG,20201123.0,,MD,DE,DE,2020,Q4,Adult
1483540311,14835403,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q4,Pain in extremity,,2020,Q4,11,F,2016.0,20201111.0,20180502,20201123,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017;7:22,61.0,YR,,F,Y,97.0,KG,20201123.0,,MD,DE,DE,2020,Q4,Adult
1483540311,14835403,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q4,Sensory disturbance,,2020,Q4,11,F,2016.0,20201111.0,20180502,20201123,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017;7:22,61.0,YR,,F,Y,97.0,KG,20201123.0,,MD,DE,DE,2020,Q4,Adult
1483540311,14835403,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q4,Sleep disorder,,2020,Q4,11,F,2016.0,20201111.0,20180502,20201123,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017;7:22,61.0,YR,,F,Y,97.0,KG,20201123.0,,MD,DE,DE,2020,Q4,Adult
1483540311,14835403,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q4,Temperature perception test abnormal,,2020,Q4,11,F,2016.0,20201111.0,20180502,20201123,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017;7:22,61.0,YR,,F,Y,97.0,KG,20201123.0,,MD,DE,DE,2020,Q4,Adult
1483540311,14835403,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,U,,,,,,TABLET,,2020,Q4,Visual impairment,,2020,Q4,11,F,2016.0,20201111.0,20180502,20201123,EXP,,DE-AUROBINDO-AUR-APL-2018-014909,AUROBINDO,HOLLENRIEDER V.. SPECIAL DIABETES MELLITUS. LEG PAIN BECAUSE OF GOOD COMPLIANCE.. ARZTE WOCHE .. 2017;7:22,61.0,YR,,F,Y,97.0,KG,20201123.0,,MD,DE,DE,2020,Q4,Adult
149375994,14937599,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,,,,,,,TABLET,,2020,Q4,Decreased vibratory sense,,2020,Q4,4,F,2016.0,20201005.0,20180525,20201006,EXP,,PHHY2018DE003343,NOVARTIS,HOLLENRIEDER V. BEINSCHMERZEN WEGER GUTTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11(3):6-7,61.0,YR,,F,Y,97.0,KG,20201006.0,,HP,DE,DE,2020,Q4,Adult
149375994,14937599,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,,,,,,,TABLET,,2020,Q4,Diabetes mellitus inadequate control,,2020,Q4,4,F,2016.0,20201005.0,20180525,20201006,EXP,,PHHY2018DE003343,NOVARTIS,HOLLENRIEDER V. BEINSCHMERZEN WEGER GUTTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11(3):6-7,61.0,YR,,F,Y,97.0,KG,20201006.0,,HP,DE,DE,2020,Q4,Adult
149375994,14937599,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,,,,,,,TABLET,,2020,Q4,Gastrointestinal disorder,,2020,Q4,4,F,2016.0,20201005.0,20180525,20201006,EXP,,PHHY2018DE003343,NOVARTIS,HOLLENRIEDER V. BEINSCHMERZEN WEGER GUTTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11(3):6-7,61.0,YR,,F,Y,97.0,KG,20201006.0,,HP,DE,DE,2020,Q4,Adult
149375994,14937599,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,,,,,,,TABLET,,2020,Q4,Limb discomfort,,2020,Q4,4,F,2016.0,20201005.0,20180525,20201006,EXP,,PHHY2018DE003343,NOVARTIS,HOLLENRIEDER V. BEINSCHMERZEN WEGER GUTTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11(3):6-7,61.0,YR,,F,Y,97.0,KG,20201006.0,,HP,DE,DE,2020,Q4,Adult
149375994,14937599,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,,,,,,,TABLET,,2020,Q4,Neuropathy peripheral,,2020,Q4,4,F,2016.0,20201005.0,20180525,20201006,EXP,,PHHY2018DE003343,NOVARTIS,HOLLENRIEDER V. BEINSCHMERZEN WEGER GUTTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11(3):6-7,61.0,YR,,F,Y,97.0,KG,20201006.0,,HP,DE,DE,2020,Q4,Adult
149375994,14937599,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,,,,,,,TABLET,,2020,Q4,Pain in extremity,,2020,Q4,4,F,2016.0,20201005.0,20180525,20201006,EXP,,PHHY2018DE003343,NOVARTIS,HOLLENRIEDER V. BEINSCHMERZEN WEGER GUTTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11(3):6-7,61.0,YR,,F,Y,97.0,KG,20201006.0,,HP,DE,DE,2020,Q4,Adult
149375994,14937599,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,,,,,,,TABLET,,2020,Q4,Sensory disturbance,,2020,Q4,4,F,2016.0,20201005.0,20180525,20201006,EXP,,PHHY2018DE003343,NOVARTIS,HOLLENRIEDER V. BEINSCHMERZEN WEGER GUTTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11(3):6-7,61.0,YR,,F,Y,97.0,KG,20201006.0,,HP,DE,DE,2020,Q4,Adult
149375994,14937599,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,,,,,,,TABLET,,2020,Q4,Sleep disorder,,2020,Q4,4,F,2016.0,20201005.0,20180525,20201006,EXP,,PHHY2018DE003343,NOVARTIS,HOLLENRIEDER V. BEINSCHMERZEN WEGER GUTTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11(3):6-7,61.0,YR,,F,Y,97.0,KG,20201006.0,,HP,DE,DE,2020,Q4,Adult
149375994,14937599,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,,,,,,,TABLET,,2020,Q4,Temperature perception test abnormal,,2020,Q4,4,F,2016.0,20201005.0,20180525,20201006,EXP,,PHHY2018DE003343,NOVARTIS,HOLLENRIEDER V. BEINSCHMERZEN WEGER GUTTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11(3):6-7,61.0,YR,,F,Y,97.0,KG,20201006.0,,HP,DE,DE,2020,Q4,Adult
149375994,14937599,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,Y,,,,,,,TABLET,,2020,Q4,Visual impairment,,2020,Q4,4,F,2016.0,20201005.0,20180525,20201006,EXP,,PHHY2018DE003343,NOVARTIS,HOLLENRIEDER V. BEINSCHMERZEN WEGER GUTTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11(3):6-7,61.0,YR,,F,Y,97.0,KG,20201006.0,,HP,DE,DE,2020,Q4,Adult
149375994,14937599,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,,2020,Q4,Decreased vibratory sense,,2020,Q4,4,F,2016.0,20201005.0,20180525,20201006,EXP,,PHHY2018DE003343,NOVARTIS,HOLLENRIEDER V. BEINSCHMERZEN WEGER GUTTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11(3):6-7,61.0,YR,,F,Y,97.0,KG,20201006.0,,HP,DE,DE,2020,Q4,Adult
149375994,14937599,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,,2020,Q4,Diabetes mellitus inadequate control,,2020,Q4,4,F,2016.0,20201005.0,20180525,20201006,EXP,,PHHY2018DE003343,NOVARTIS,HOLLENRIEDER V. BEINSCHMERZEN WEGER GUTTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11(3):6-7,61.0,YR,,F,Y,97.0,KG,20201006.0,,HP,DE,DE,2020,Q4,Adult
149375994,14937599,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,,2020,Q4,Gastrointestinal disorder,,2020,Q4,4,F,2016.0,20201005.0,20180525,20201006,EXP,,PHHY2018DE003343,NOVARTIS,HOLLENRIEDER V. BEINSCHMERZEN WEGER GUTTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11(3):6-7,61.0,YR,,F,Y,97.0,KG,20201006.0,,HP,DE,DE,2020,Q4,Adult
149375994,14937599,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,,2020,Q4,Limb discomfort,,2020,Q4,4,F,2016.0,20201005.0,20180525,20201006,EXP,,PHHY2018DE003343,NOVARTIS,HOLLENRIEDER V. BEINSCHMERZEN WEGER GUTTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11(3):6-7,61.0,YR,,F,Y,97.0,KG,20201006.0,,HP,DE,DE,2020,Q4,Adult
149375994,14937599,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,,2020,Q4,Neuropathy peripheral,,2020,Q4,4,F,2016.0,20201005.0,20180525,20201006,EXP,,PHHY2018DE003343,NOVARTIS,HOLLENRIEDER V. BEINSCHMERZEN WEGER GUTTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11(3):6-7,61.0,YR,,F,Y,97.0,KG,20201006.0,,HP,DE,DE,2020,Q4,Adult
149375994,14937599,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,,2020,Q4,Pain in extremity,,2020,Q4,4,F,2016.0,20201005.0,20180525,20201006,EXP,,PHHY2018DE003343,NOVARTIS,HOLLENRIEDER V. BEINSCHMERZEN WEGER GUTTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11(3):6-7,61.0,YR,,F,Y,97.0,KG,20201006.0,,HP,DE,DE,2020,Q4,Adult
149375994,14937599,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,,2020,Q4,Sensory disturbance,,2020,Q4,4,F,2016.0,20201005.0,20180525,20201006,EXP,,PHHY2018DE003343,NOVARTIS,HOLLENRIEDER V. BEINSCHMERZEN WEGER GUTTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11(3):6-7,61.0,YR,,F,Y,97.0,KG,20201006.0,,HP,DE,DE,2020,Q4,Adult
149375994,14937599,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,,2020,Q4,Sleep disorder,,2020,Q4,4,F,2016.0,20201005.0,20180525,20201006,EXP,,PHHY2018DE003343,NOVARTIS,HOLLENRIEDER V. BEINSCHMERZEN WEGER GUTTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11(3):6-7,61.0,YR,,F,Y,97.0,KG,20201006.0,,HP,DE,DE,2020,Q4,Adult
149375994,14937599,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,,2020,Q4,Temperature perception test abnormal,,2020,Q4,4,F,2016.0,20201005.0,20180525,20201006,EXP,,PHHY2018DE003343,NOVARTIS,HOLLENRIEDER V. BEINSCHMERZEN WEGER GUTTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11(3):6-7,61.0,YR,,F,Y,97.0,KG,20201006.0,,HP,DE,DE,2020,Q4,Adult
149375994,14937599,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,TABLET,,2020,Q4,Visual impairment,,2020,Q4,4,F,2016.0,20201005.0,20180525,20201006,EXP,,PHHY2018DE003343,NOVARTIS,HOLLENRIEDER V. BEINSCHMERZEN WEGER GUTTER COMPLIANCE. INFO DIABETOLOGIE. 2017;11(3):6-7,61.0,YR,,F,Y,97.0,KG,20201006.0,,HP,DE,DE,2020,Q4,Adult
149845123,14984512,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN FREQ.",,,,,,,,,,FORMULATION UNKNOWN,,2020,Q4,Adverse drug reaction,,2020,Q4,3,F,2018.0,20201028.0,20180607,20201106,EXP,,AU-ASTELLAS-2018US026058,ASTELLAS,,42.0,YR,,M,Y,,,20201106.0,,CN,GB,AU,2020,Q4,Adult
149845123,14984512,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN FREQ.",,,,,,,,,,FORMULATION UNKNOWN,,2020,Q4,Immune reconstitution inflammatory syndrome,,2020,Q4,3,F,2018.0,20201028.0,20180607,20201106,EXP,,AU-ASTELLAS-2018US026058,ASTELLAS,,42.0,YR,,M,Y,,,20201106.0,,CN,GB,AU,2020,Q4,Adult
149845123,14984512,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN FREQ.",,,,,,,,,,FORMULATION UNKNOWN,,2020,Q4,Pyrexia,,2020,Q4,3,F,2018.0,20201028.0,20180607,20201106,EXP,,AU-ASTELLAS-2018US026058,ASTELLAS,,42.0,YR,,M,Y,,,20201106.0,,CN,GB,AU,2020,Q4,Adult
149845123,14984512,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN FREQ.",,,,,,,,,,FORMULATION UNKNOWN,,2020,Q4,Renal failure,,2020,Q4,3,F,2018.0,20201028.0,20180607,20201106,EXP,,AU-ASTELLAS-2018US026058,ASTELLAS,,42.0,YR,,M,Y,,,20201106.0,,CN,GB,AU,2020,Q4,Adult
149845123,14984512,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN FREQ.",,,,,,,,,,FORMULATION UNKNOWN,,2020,Q4,Respiratory failure,,2020,Q4,3,F,2018.0,20201028.0,20180607,20201106,EXP,,AU-ASTELLAS-2018US026058,ASTELLAS,,42.0,YR,,M,Y,,,20201106.0,,CN,GB,AU,2020,Q4,Adult
158452125,15845212,10,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,FORMULATION UNKNOWN,QD,2020,Q4,COVID-19 pneumonia,,2020,Q4,5,F,201811.0,20201112.0,20190119,20201118,EXP,,CO-ASTELLAS-2019US002216,ASTELLAS,,32.0,YR,,F,Y,59.0,KG,20201118.0,,CN,CO,CO,2020,Q4,Young Adult
158452125,15845212,10,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,FORMULATION UNKNOWN,QD,2020,Q4,Influenza,,2020,Q4,5,F,201811.0,20201112.0,20190119,20201118,EXP,,CO-ASTELLAS-2019US002216,ASTELLAS,,32.0,YR,,F,Y,59.0,KG,20201118.0,,CN,CO,CO,2020,Q4,Young Adult
158452125,15845212,10,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,FORMULATION UNKNOWN,QD,2020,Q4,Respiratory alkalosis,,2020,Q4,5,F,201811.0,20201112.0,20190119,20201118,EXP,,CO-ASTELLAS-2019US002216,ASTELLAS,,32.0,YR,,F,Y,59.0,KG,20201118.0,,CN,CO,CO,2020,Q4,Young Adult
158452125,15845212,10,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,FORMULATION UNKNOWN,QD,2020,Q4,Tachycardia,,2020,Q4,5,F,201811.0,20201112.0,20190119,20201118,EXP,,CO-ASTELLAS-2019US002216,ASTELLAS,,32.0,YR,,F,Y,59.0,KG,20201118.0,,CN,CO,CO,2020,Q4,Young Adult
158452125,15845212,10,I,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,FORMULATION UNKNOWN,QD,2020,Q4,Tremor,,2020,Q4,5,F,201811.0,20201112.0,20190119,20201118,EXP,,CO-ASTELLAS-2019US002216,ASTELLAS,,32.0,YR,,F,Y,59.0,KG,20201118.0,,CN,CO,CO,2020,Q4,Young Adult
160271417,16027141,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q4,Cellulitis,,2020,Q4,7,F,20181225.0,20201104.0,20190303,20201110,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-019559,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,130.0,KG,20201110.0,,HP,DE,DE,2020,Q4,Adult
160271417,16027141,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q4,Lymphangitis,,2020,Q4,7,F,20181225.0,20201104.0,20190303,20201110,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-019559,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,130.0,KG,20201110.0,,HP,DE,DE,2020,Q4,Adult
160271417,16027141,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q4,Necrosis,,2020,Q4,7,F,20181225.0,20201104.0,20190303,20201110,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-019559,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,130.0,KG,20201110.0,,HP,DE,DE,2020,Q4,Adult
160271417,16027141,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"5 MG, QD",,,U,,,,,5.0,MG,,QD,2020,Q4,Soft tissue infection,,2020,Q4,7,F,20181225.0,20201104.0,20190303,20201110,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-019559,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,130.0,KG,20201110.0,,HP,DE,DE,2020,Q4,Adult
162060753,16206075,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2020,Q4,Cerebrovascular accident,,2020,Q4,3,F,,20201006.0,20190417,20201009,EXP,,"HR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-017403",BOEHRINGER INGELHEIM,,65.0,YR,A,F,Y,,,20201009.0,,PH,HR,HR,2020,Q4,Elderly
162060753,16206075,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2020,Q4,Drug interaction,,2020,Q4,3,F,,20201006.0,20190417,20201009,EXP,,"HR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-017403",BOEHRINGER INGELHEIM,,65.0,YR,A,F,Y,,,20201009.0,,PH,HR,HR,2020,Q4,Elderly
162060753,16206075,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2020,Q4,Off label use,,2020,Q4,3,F,,20201006.0,20190417,20201009,EXP,,"HR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-017403",BOEHRINGER INGELHEIM,,65.0,YR,A,F,Y,,,20201009.0,,PH,HR,HR,2020,Q4,Elderly
163712952,16371295,21,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Anaphylactic shock,,2020,Q4,2,F,,20200929.0,20190530,20201008,EXP,,CA-APOTEX-2019AP015110,APOTEX,,57.0,YR,,F,Y,,,20201008.0,,CN,CA,CA,2020,Q4,Adult
163712952,16371295,21,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Asthma,,2020,Q4,2,F,,20200929.0,20190530,20201008,EXP,,CA-APOTEX-2019AP015110,APOTEX,,57.0,YR,,F,Y,,,20201008.0,,CN,CA,CA,2020,Q4,Adult
163712952,16371295,21,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Back pain,,2020,Q4,2,F,,20200929.0,20190530,20201008,EXP,,CA-APOTEX-2019AP015110,APOTEX,,57.0,YR,,F,Y,,,20201008.0,,CN,CA,CA,2020,Q4,Adult
163712952,16371295,21,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Blood count abnormal,,2020,Q4,2,F,,20200929.0,20190530,20201008,EXP,,CA-APOTEX-2019AP015110,APOTEX,,57.0,YR,,F,Y,,,20201008.0,,CN,CA,CA,2020,Q4,Adult
163712952,16371295,21,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Body mass index increased,,2020,Q4,2,F,,20200929.0,20190530,20201008,EXP,,CA-APOTEX-2019AP015110,APOTEX,,57.0,YR,,F,Y,,,20201008.0,,CN,CA,CA,2020,Q4,Adult
163712952,16371295,21,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Cough,,2020,Q4,2,F,,20200929.0,20190530,20201008,EXP,,CA-APOTEX-2019AP015110,APOTEX,,57.0,YR,,F,Y,,,20201008.0,,CN,CA,CA,2020,Q4,Adult
163712952,16371295,21,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Crepitations,,2020,Q4,2,F,,20200929.0,20190530,20201008,EXP,,CA-APOTEX-2019AP015110,APOTEX,,57.0,YR,,F,Y,,,20201008.0,,CN,CA,CA,2020,Q4,Adult
163712952,16371295,21,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Diverticulum,,2020,Q4,2,F,,20200929.0,20190530,20201008,EXP,,CA-APOTEX-2019AP015110,APOTEX,,57.0,YR,,F,Y,,,20201008.0,,CN,CA,CA,2020,Q4,Adult
163712952,16371295,21,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Dysphonia,,2020,Q4,2,F,,20200929.0,20190530,20201008,EXP,,CA-APOTEX-2019AP015110,APOTEX,,57.0,YR,,F,Y,,,20201008.0,,CN,CA,CA,2020,Q4,Adult
163712952,16371295,21,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Dyspnoea,,2020,Q4,2,F,,20200929.0,20190530,20201008,EXP,,CA-APOTEX-2019AP015110,APOTEX,,57.0,YR,,F,Y,,,20201008.0,,CN,CA,CA,2020,Q4,Adult
163712952,16371295,21,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Dyspnoea exertional,,2020,Q4,2,F,,20200929.0,20190530,20201008,EXP,,CA-APOTEX-2019AP015110,APOTEX,,57.0,YR,,F,Y,,,20201008.0,,CN,CA,CA,2020,Q4,Adult
163712952,16371295,21,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Feeling hot,,2020,Q4,2,F,,20200929.0,20190530,20201008,EXP,,CA-APOTEX-2019AP015110,APOTEX,,57.0,YR,,F,Y,,,20201008.0,,CN,CA,CA,2020,Q4,Adult
163712952,16371295,21,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Haemoptysis,,2020,Q4,2,F,,20200929.0,20190530,20201008,EXP,,CA-APOTEX-2019AP015110,APOTEX,,57.0,YR,,F,Y,,,20201008.0,,CN,CA,CA,2020,Q4,Adult
163712952,16371295,21,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Headache,,2020,Q4,2,F,,20200929.0,20190530,20201008,EXP,,CA-APOTEX-2019AP015110,APOTEX,,57.0,YR,,F,Y,,,20201008.0,,CN,CA,CA,2020,Q4,Adult
163712952,16371295,21,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Heart sounds,,2020,Q4,2,F,,20200929.0,20190530,20201008,EXP,,CA-APOTEX-2019AP015110,APOTEX,,57.0,YR,,F,Y,,,20201008.0,,CN,CA,CA,2020,Q4,Adult
163712952,16371295,21,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Hyperglycaemia,,2020,Q4,2,F,,20200929.0,20190530,20201008,EXP,,CA-APOTEX-2019AP015110,APOTEX,,57.0,YR,,F,Y,,,20201008.0,,CN,CA,CA,2020,Q4,Adult
163712952,16371295,21,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Hypersensitivity,,2020,Q4,2,F,,20200929.0,20190530,20201008,EXP,,CA-APOTEX-2019AP015110,APOTEX,,57.0,YR,,F,Y,,,20201008.0,,CN,CA,CA,2020,Q4,Adult
163712952,16371295,21,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Iron deficiency,,2020,Q4,2,F,,20200929.0,20190530,20201008,EXP,,CA-APOTEX-2019AP015110,APOTEX,,57.0,YR,,F,Y,,,20201008.0,,CN,CA,CA,2020,Q4,Adult
163712952,16371295,21,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Obstructive airways disorder,,2020,Q4,2,F,,20200929.0,20190530,20201008,EXP,,CA-APOTEX-2019AP015110,APOTEX,,57.0,YR,,F,Y,,,20201008.0,,CN,CA,CA,2020,Q4,Adult
163712952,16371295,21,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Productive cough,,2020,Q4,2,F,,20200929.0,20190530,20201008,EXP,,CA-APOTEX-2019AP015110,APOTEX,,57.0,YR,,F,Y,,,20201008.0,,CN,CA,CA,2020,Q4,Adult
163712952,16371295,21,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Rash,,2020,Q4,2,F,,20200929.0,20190530,20201008,EXP,,CA-APOTEX-2019AP015110,APOTEX,,57.0,YR,,F,Y,,,20201008.0,,CN,CA,CA,2020,Q4,Adult
163712952,16371295,21,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Sinus congestion,,2020,Q4,2,F,,20200929.0,20190530,20201008,EXP,,CA-APOTEX-2019AP015110,APOTEX,,57.0,YR,,F,Y,,,20201008.0,,CN,CA,CA,2020,Q4,Adult
163712952,16371295,21,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Skin ulcer,,2020,Q4,2,F,,20200929.0,20190530,20201008,EXP,,CA-APOTEX-2019AP015110,APOTEX,,57.0,YR,,F,Y,,,20201008.0,,CN,CA,CA,2020,Q4,Adult
163712952,16371295,21,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Sputum discoloured,,2020,Q4,2,F,,20200929.0,20190530,20201008,EXP,,CA-APOTEX-2019AP015110,APOTEX,,57.0,YR,,F,Y,,,20201008.0,,CN,CA,CA,2020,Q4,Adult
163712952,16371295,21,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Swelling face,,2020,Q4,2,F,,20200929.0,20190530,20201008,EXP,,CA-APOTEX-2019AP015110,APOTEX,,57.0,YR,,F,Y,,,20201008.0,,CN,CA,CA,2020,Q4,Adult
163712952,16371295,21,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Symptom recurrence,,2020,Q4,2,F,,20200929.0,20190530,20201008,EXP,,CA-APOTEX-2019AP015110,APOTEX,,57.0,YR,,F,Y,,,20201008.0,,CN,CA,CA,2020,Q4,Adult
163712952,16371295,21,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Throat clearing,,2020,Q4,2,F,,20200929.0,20190530,20201008,EXP,,CA-APOTEX-2019AP015110,APOTEX,,57.0,YR,,F,Y,,,20201008.0,,CN,CA,CA,2020,Q4,Adult
163712952,16371295,21,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Upper respiratory tract inflammation,,2020,Q4,2,F,,20200929.0,20190530,20201008,EXP,,CA-APOTEX-2019AP015110,APOTEX,,57.0,YR,,F,Y,,,20201008.0,,CN,CA,CA,2020,Q4,Adult
163712952,16371295,21,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Urinary incontinence,,2020,Q4,2,F,,20200929.0,20190530,20201008,EXP,,CA-APOTEX-2019AP015110,APOTEX,,57.0,YR,,F,Y,,,20201008.0,,CN,CA,CA,2020,Q4,Adult
163712952,16371295,21,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Urticaria,,2020,Q4,2,F,,20200929.0,20190530,20201008,EXP,,CA-APOTEX-2019AP015110,APOTEX,,57.0,YR,,F,Y,,,20201008.0,,CN,CA,CA,2020,Q4,Adult
163712952,16371295,21,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Weight increased,,2020,Q4,2,F,,20200929.0,20190530,20201008,EXP,,CA-APOTEX-2019AP015110,APOTEX,,57.0,YR,,F,Y,,,20201008.0,,CN,CA,CA,2020,Q4,Adult
163712952,16371295,21,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Wheezing,,2020,Q4,2,F,,20200929.0,20190530,20201008,EXP,,CA-APOTEX-2019AP015110,APOTEX,,57.0,YR,,F,Y,,,20201008.0,,CN,CA,CA,2020,Q4,Adult
164073542,16407354,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2020,Q4,Drug interaction,,2020,Q4,2,F,,20201006.0,20190608,20201009,EXP,,"HR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-017405",BOEHRINGER INGELHEIM,,65.0,YR,A,F,Y,,,20201009.0,,PH,HR,HR,2020,Q4,Elderly
164073542,16407354,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2020,Q4,Ischaemic stroke,,2020,Q4,2,F,,20201006.0,20190608,20201009,EXP,,"HR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-017405",BOEHRINGER INGELHEIM,,65.0,YR,A,F,Y,,,20201009.0,,PH,HR,HR,2020,Q4,Elderly
164073542,16407354,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2020,Q4,Off label use,,2020,Q4,2,F,,20201006.0,20190608,20201009,EXP,,"HR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-017405",BOEHRINGER INGELHEIM,,65.0,YR,A,F,Y,,,20201009.0,,PH,HR,HR,2020,Q4,Elderly
164073542,16407354,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2020,Q4,Sinus rhythm,,2020,Q4,2,F,,20201006.0,20190608,20201009,EXP,,"HR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-017405",BOEHRINGER INGELHEIM,,65.0,YR,A,F,Y,,,20201009.0,,PH,HR,HR,2020,Q4,Elderly
164260902,16426090,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG,QD",,,U,,,,,10.0,MG,,QD,2020,Q4,Cerebrovascular accident,,2020,Q4,2,F,,20201127.0,20190613,20201130,EXP,,PHHY2019HR135750,NOVARTIS,,65.0,YR,,F,Y,,,20201130.0,,HP,HR,HR,2020,Q4,Elderly
164260902,16426090,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG,QD",,,U,,,,,10.0,MG,,QD,2020,Q4,Drug interaction,,2020,Q4,2,F,,20201127.0,20190613,20201130,EXP,,PHHY2019HR135750,NOVARTIS,,65.0,YR,,F,Y,,,20201130.0,,HP,HR,HR,2020,Q4,Elderly
164260902,16426090,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG,QD",,,U,,,,,10.0,MG,,QD,2020,Q4,Off label use,,2020,Q4,2,F,,20201127.0,20190613,20201130,EXP,,PHHY2019HR135750,NOVARTIS,,65.0,YR,,F,Y,,,20201130.0,,HP,HR,HR,2020,Q4,Elderly
164288792,16428879,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2020,Q4,Drug interaction,,2020,Q4,2,F,,20201127.0,20190613,20201201,EXP,,PHHY2019HR135740,NOVARTIS,,65.0,YR,,F,Y,,,20201201.0,,HP,HR,HR,2020,Q4,Elderly
164288792,16428879,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2020,Q4,Ischaemic stroke,,2020,Q4,2,F,,20201127.0,20190613,20201201,EXP,,PHHY2019HR135740,NOVARTIS,,65.0,YR,,F,Y,,,20201201.0,,HP,HR,HR,2020,Q4,Elderly
164288792,16428879,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2020,Q4,Off label use,,2020,Q4,2,F,,20201127.0,20190613,20201201,EXP,,PHHY2019HR135740,NOVARTIS,,65.0,YR,,F,Y,,,20201201.0,,HP,HR,HR,2020,Q4,Elderly
164288792,16428879,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2020,Q4,Sinus rhythm,,2020,Q4,2,F,,20201127.0,20190613,20201201,EXP,,PHHY2019HR135740,NOVARTIS,,65.0,YR,,F,Y,,,20201201.0,,HP,HR,HR,2020,Q4,Elderly
168249326,16824932,7,SS,Dapagliflozine,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",7880.0,MG,Y,U,,,,10.0,MG,TABLET,QD,2020,Q4,Diabetic ketoacidosis,,2020,Q4,6,F,20190824.0,20201029.0,20190918,20201109,EXP,,NL-AUROBINDO-AUR-APL-2019-061211,AUROBINDO,,54.0,YR,,F,Y,84.5,KG,20201110.0,,HP,NL,NL,2020,Q4,Adult
168249326,16824932,7,SS,Dapagliflozine,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",7880.0,MG,Y,U,,,,10.0,MG,TABLET,QD,2020,Q4,Ketoacidosis,,2020,Q4,6,F,20190824.0,20201029.0,20190918,20201109,EXP,,NL-AUROBINDO-AUR-APL-2019-061211,AUROBINDO,,54.0,YR,,F,Y,84.5,KG,20201110.0,,HP,NL,NL,2020,Q4,Adult
168249326,16824932,8,SS,Dapagliflozine,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",7880.0,MG,Y,U,,,,10.0,MG,TABLET,QD,2020,Q4,Diabetic ketoacidosis,,2020,Q4,6,F,20190824.0,20201029.0,20190918,20201109,EXP,,NL-AUROBINDO-AUR-APL-2019-061211,AUROBINDO,,54.0,YR,,F,Y,84.5,KG,20201110.0,,HP,NL,NL,2020,Q4,Adult
168249326,16824932,8,SS,Dapagliflozine,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",7880.0,MG,Y,U,,,,10.0,MG,TABLET,QD,2020,Q4,Ketoacidosis,,2020,Q4,6,F,20190824.0,20201029.0,20190918,20201109,EXP,,NL-AUROBINDO-AUR-APL-2019-061211,AUROBINDO,,54.0,YR,,F,Y,84.5,KG,20201110.0,,HP,NL,NL,2020,Q4,Adult
169431194,16943119,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2020,Q4,Abdominal discomfort,,2020,Q4,4,F,20190902.0,20200611.0,20191021,20201020,EXP,,GB-NOVOPROD-684930,NOVO NORDISK,,60.0,YR,,M,Y,115.8,KG,20201020.0,,MD,GB,GB,2020,Q4,Adult
169431194,16943119,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2020,Q4,Abdominal distension,,2020,Q4,4,F,20190902.0,20200611.0,20191021,20201020,EXP,,GB-NOVOPROD-684930,NOVO NORDISK,,60.0,YR,,M,Y,115.8,KG,20201020.0,,MD,GB,GB,2020,Q4,Adult
169431194,16943119,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2020,Q4,Constipation,,2020,Q4,4,F,20190902.0,20200611.0,20191021,20201020,EXP,,GB-NOVOPROD-684930,NOVO NORDISK,,60.0,YR,,M,Y,115.8,KG,20201020.0,,MD,GB,GB,2020,Q4,Adult
169431194,16943119,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2020,Q4,Diarrhoea,,2020,Q4,4,F,20190902.0,20200611.0,20191021,20201020,EXP,,GB-NOVOPROD-684930,NOVO NORDISK,,60.0,YR,,M,Y,115.8,KG,20201020.0,,MD,GB,GB,2020,Q4,Adult
169431194,16943119,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2020,Q4,Illness,,2020,Q4,4,F,20190902.0,20200611.0,20191021,20201020,EXP,,GB-NOVOPROD-684930,NOVO NORDISK,,60.0,YR,,M,Y,115.8,KG,20201020.0,,MD,GB,GB,2020,Q4,Adult
170095092,17009509,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,ONCE/SINGLE ADMINISTRATION,,,U,," UNKNOWN,UNKNOWN",,202293.0,,,TABLET,,2020,Q4,Intentional overdose,,2020,Q4,2,F,20191019.0,20191031.0,20191108,20201222,EXP,,DE-ASTRAZENECA-2019SF55161,ASTRAZENECA,,78.0,YR,,F,Y,,,20201222.0,,,DE,DE,2020,Q4,Elderly
170095092,17009509,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,ONCE/SINGLE ADMINISTRATION,,,U,," UNKNOWN,UNKNOWN",,202293.0,,,TABLET,,2020,Q4,Suicide attempt,,2020,Q4,2,F,20191019.0,20191031.0,20191108,20201222,EXP,,DE-ASTRAZENECA-2019SF55161,ASTRAZENECA,,78.0,YR,,F,Y,,,20201222.0,,,DE,DE,2020,Q4,Elderly
170095092,17009509,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,," UNKNOWN,UNKNOWN",,202293.0,,,TABLET,,2020,Q4,Intentional overdose,,2020,Q4,2,F,20191019.0,20191031.0,20191108,20201222,EXP,,DE-ASTRAZENECA-2019SF55161,ASTRAZENECA,,78.0,YR,,F,Y,,,20201222.0,,,DE,DE,2020,Q4,Elderly
170095092,17009509,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,," UNKNOWN,UNKNOWN",,202293.0,,,TABLET,,2020,Q4,Suicide attempt,,2020,Q4,2,F,20191019.0,20191031.0,20191108,20201222,EXP,,DE-ASTRAZENECA-2019SF55161,ASTRAZENECA,,78.0,YR,,F,Y,,,20201222.0,,,DE,DE,2020,Q4,Elderly
1712797117,17127971,7,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,5.0,MG,TABLETS,,2020,Q4,Hypoglycaemia,,2020,Q4,17,F,20191201.0,20201104.0,20191209,20201110,PER,,BR-EISAI MEDICAL RESEARCH-EC-2019-066649,EISAI,,63.0,YR,A,F,Y,56.8,KG,20201110.0,,MD,BR,BR,2020,Q4,Adult
171657643,17165764,13,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE W/METFO,,2,,1700/ 10MG QD,,,,,,,,,,,QD,2020,Q4,Bladder tamponade,,2020,Q4,3,F,20191006.0,20200120.0,20191217,20201020,EXP,,DE-JNJFOC-20191209452,JOHNSON AND JOHNSON,,71.0,YR,E,M,Y,93.0,KG,20201020.0,,MD,DE,DE,2020,Q4,Elderly
171657643,17165764,13,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE W/METFO,,2,,1700/ 10MG QD,,,,,,,,,,,QD,2020,Q4,Haematuria,,2020,Q4,3,F,20191006.0,20200120.0,20191217,20201020,EXP,,DE-JNJFOC-20191209452,JOHNSON AND JOHNSON,,71.0,YR,E,M,Y,93.0,KG,20201020.0,,MD,DE,DE,2020,Q4,Elderly
1724538410,17245384,14,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,2.5 MILLIGRAM,,,U,,,,,2.5,MG,,,2020,Q4,Myocarditis,,2020,Q4,10,F,20191225.0,20201203.0,20200108,20201204,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-124057,BRISTOL MYERS SQUIBB,,58.0,YR,,M,Y,79.0,KG,20201204.0,,HP,JP,JP,2020,Q4,Adult
173081702,17308170,16,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"UNK, QD",,,U,U," UNKNOWN,UNKNOWN",,,,,TABLET,QD,2020,Q4,Intentional overdose,,2020,Q4,2,F,20191019.0,20201218.0,20200123,20201225,EXP,,NVSC2020DE010898,NOVARTIS,,78.0,YR,,F,Y,,,20201225.0,,HP,DE,DE,2020,Q4,Elderly
173081702,17308170,16,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"UNK, QD",,,U,U," UNKNOWN,UNKNOWN",,,,,TABLET,QD,2020,Q4,Suicide attempt,,2020,Q4,2,F,20191019.0,20201218.0,20200123,20201225,EXP,,NVSC2020DE010898,NOVARTIS,,78.0,YR,,F,Y,,,20201225.0,,HP,DE,DE,2020,Q4,Elderly
173081702,17308170,17,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U," UNKNOWN,UNKNOWN",,,,,TABLET,,2020,Q4,Intentional overdose,,2020,Q4,2,F,20191019.0,20201218.0,20200123,20201225,EXP,,NVSC2020DE010898,NOVARTIS,,78.0,YR,,F,Y,,,20201225.0,,HP,DE,DE,2020,Q4,Elderly
173081702,17308170,17,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U," UNKNOWN,UNKNOWN",,,,,TABLET,,2020,Q4,Suicide attempt,,2020,Q4,2,F,20191019.0,20201218.0,20200123,20201225,EXP,,NVSC2020DE010898,NOVARTIS,,78.0,YR,,F,Y,,,20201225.0,,HP,DE,DE,2020,Q4,Elderly
174131493,17413149,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,,,TABLET,,2020,Q4,Ketoacidosis,,2020,Q4,3,F,20200121.0,20200305.0,20200213,20201029,EXP,,DE-ASTRAZENECA-2020SE18646,ASTRAZENECA,,6417.0,DY,,M,Y,78.0,KG,20201029.0,,MD,DE,DE,2020,Q4,Elderly
174131493,17413149,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,,,TABLET,,2020,Q4,Off label use,,2020,Q4,3,F,20200121.0,20200305.0,20200213,20201029,EXP,,DE-ASTRAZENECA-2020SE18646,ASTRAZENECA,,6417.0,DY,,M,Y,78.0,KG,20201029.0,,MD,DE,DE,2020,Q4,Elderly
174131493,17413149,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,,,TABLET,,2020,Q4,Product use in unapproved indication,,2020,Q4,3,F,20200121.0,20200305.0,20200213,20201029,EXP,,DE-ASTRAZENECA-2020SE18646,ASTRAZENECA,,6417.0,DY,,M,Y,78.0,KG,20201029.0,,MD,DE,DE,2020,Q4,Elderly
175467545,17546754,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2020,Q4,Lethargy,,2020,Q4,5,F,20190624.0,20200728.0,20200316,20201020,EXP,,GB-NOVOPROD-710766,NOVO NORDISK,,61.0,YR,,M,Y,99.0,KG,20201020.0,,MD,GB,GB,2020,Q4,Adult
175467545,17546754,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2020,Q4,Nausea,,2020,Q4,5,F,20190624.0,20200728.0,20200316,20201020,EXP,,GB-NOVOPROD-710766,NOVO NORDISK,,61.0,YR,,M,Y,99.0,KG,20201020.0,,MD,GB,GB,2020,Q4,Adult
175467545,17546754,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2020,Q4,Pancreatic cyst,,2020,Q4,5,F,20190624.0,20200728.0,20200316,20201020,EXP,,GB-NOVOPROD-710766,NOVO NORDISK,,61.0,YR,,M,Y,99.0,KG,20201020.0,,MD,GB,GB,2020,Q4,Adult
175467545,17546754,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,,QD,2020,Q4,Vomiting,,2020,Q4,5,F,20190624.0,20200728.0,20200316,20201020,EXP,,GB-NOVOPROD-710766,NOVO NORDISK,,61.0,YR,,M,Y,99.0,KG,20201020.0,,MD,GB,GB,2020,Q4,Adult
177176882,17717688,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,, JJ2181,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Diabetic ketoacidosis,,2020,Q4,2,F,20181124.0,20200929.0,20200428,20201007,EXP,,CN-ASTRAZENECA-2020SE56123,ASTRAZENECA,,48.0,YR,,F,Y,,,20201007.0,,MD,CN,CN,2020,Q4,Adult
180221738,18022173,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q4,Heparin-induced thrombocytopenia,,2020,Q4,8,F,,20201209.0,20200714,20201221,EXP,,CZ-MYLANLABS-2020M1063775,MYLAN,"POLAK P ET AL. HEPARIN-INDUCED THROMBOCYTOPENIA: A CASE REPORT AND LITERATURE REVIEW. VNITRNI LEARSTVI. 2020;66(4):242-244,246-248",62.0,YR,,F,Y,,,20201221.0,,MD,CZ,CZ,2020,Q4,Adult
180221738,18022173,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q4,Incision site impaired healing,,2020,Q4,8,F,,20201209.0,20200714,20201221,EXP,,CZ-MYLANLABS-2020M1063775,MYLAN,"POLAK P ET AL. HEPARIN-INDUCED THROMBOCYTOPENIA: A CASE REPORT AND LITERATURE REVIEW. VNITRNI LEARSTVI. 2020;66(4):242-244,246-248",62.0,YR,,F,Y,,,20201221.0,,MD,CZ,CZ,2020,Q4,Adult
180221738,18022173,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2020,Q4,Off label use,,2020,Q4,8,F,,20201209.0,20200714,20201221,EXP,,CZ-MYLANLABS-2020M1063775,MYLAN,"POLAK P ET AL. HEPARIN-INDUCED THROMBOCYTOPENIA: A CASE REPORT AND LITERATURE REVIEW. VNITRNI LEARSTVI. 2020;66(4):242-244,246-248",62.0,YR,,F,Y,,,20201221.0,,MD,CZ,CZ,2020,Q4,Adult
181141333,18114133,13,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2020,Q4,Heparin-induced thrombocytopenia,,2020,Q4,3,F,,20201006.0,20200805,20201014,EXP,CZ-EMA-DD-20200724-SAHARAN_H-115818,CZ-AXELLIA-003295,XELLIA PHARMACEUTICALS,,62.0,YR,A,F,Y,,,20201014.0,,HP,CZ,CZ,2020,Q4,Adult
181141333,18114133,13,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2020,Q4,Incision site impaired healing,,2020,Q4,3,F,,20201006.0,20200805,20201014,EXP,CZ-EMA-DD-20200724-SAHARAN_H-115818,CZ-AXELLIA-003295,XELLIA PHARMACEUTICALS,,62.0,YR,A,F,Y,,,20201014.0,,HP,CZ,CZ,2020,Q4,Adult
181256343,18125634,24,C,DAPAGLIFLOZIN PROPYLENE GLYCOLATE HYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,5 MILLIGRAM DAILY;,,,,,,,,5.0,MG,TABLET,QD,2020,Q4,Condition aggravated,,2020,Q4,3,F,20200414.0,20201027.0,20200807,20201104,EXP,,JP-TEVA-2020-JP-1790469,TEVA,,72.0,YR,E,M,Y,,,20201104.0,,CN,JP,JP,2020,Q4,Elderly
181256343,18125634,24,C,DAPAGLIFLOZIN PROPYLENE GLYCOLATE HYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,5 MILLIGRAM DAILY;,,,,,,,,5.0,MG,TABLET,QD,2020,Q4,Cytomegalovirus infection,,2020,Q4,3,F,20200414.0,20201027.0,20200807,20201104,EXP,,JP-TEVA-2020-JP-1790469,TEVA,,72.0,YR,E,M,Y,,,20201104.0,,CN,JP,JP,2020,Q4,Elderly
181256343,18125634,24,C,DAPAGLIFLOZIN PROPYLENE GLYCOLATE HYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,5 MILLIGRAM DAILY;,,,,,,,,5.0,MG,TABLET,QD,2020,Q4,Decreased appetite,,2020,Q4,3,F,20200414.0,20201027.0,20200807,20201104,EXP,,JP-TEVA-2020-JP-1790469,TEVA,,72.0,YR,E,M,Y,,,20201104.0,,CN,JP,JP,2020,Q4,Elderly
181256343,18125634,24,C,DAPAGLIFLOZIN PROPYLENE GLYCOLATE HYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,5 MILLIGRAM DAILY;,,,,,,,,5.0,MG,TABLET,QD,2020,Q4,Liver disorder,,2020,Q4,3,F,20200414.0,20201027.0,20200807,20201104,EXP,,JP-TEVA-2020-JP-1790469,TEVA,,72.0,YR,E,M,Y,,,20201104.0,,CN,JP,JP,2020,Q4,Elderly
181256343,18125634,24,C,DAPAGLIFLOZIN PROPYLENE GLYCOLATE HYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,5 MILLIGRAM DAILY;,,,,,,,,5.0,MG,TABLET,QD,2020,Q4,Malaise,,2020,Q4,3,F,20200414.0,20201027.0,20200807,20201104,EXP,,JP-TEVA-2020-JP-1790469,TEVA,,72.0,YR,E,M,Y,,,20201104.0,,CN,JP,JP,2020,Q4,Elderly
181256343,18125634,24,C,DAPAGLIFLOZIN PROPYLENE GLYCOLATE HYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,5 MILLIGRAM DAILY;,,,,,,,,5.0,MG,TABLET,QD,2020,Q4,Oesophageal candidiasis,,2020,Q4,3,F,20200414.0,20201027.0,20200807,20201104,EXP,,JP-TEVA-2020-JP-1790469,TEVA,,72.0,YR,E,M,Y,,,20201104.0,,CN,JP,JP,2020,Q4,Elderly
181256343,18125634,24,C,DAPAGLIFLOZIN PROPYLENE GLYCOLATE HYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,5 MILLIGRAM DAILY;,,,,,,,,5.0,MG,TABLET,QD,2020,Q4,Platelet count decreased,,2020,Q4,3,F,20200414.0,20201027.0,20200807,20201104,EXP,,JP-TEVA-2020-JP-1790469,TEVA,,72.0,YR,E,M,Y,,,20201104.0,,CN,JP,JP,2020,Q4,Elderly
182509275,18250927,16,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Adiposis dolorosa,,2020,Q4,5,F,202002.0,20201125.0,20200910,20201201,EXP,,US-ABBVIE-20K-163-3554299-00,ABBVIE,,65.0,YR,,M,Y,145.28,KG,20201201.0,,CN,US,US,2020,Q4,Elderly
182509275,18250927,16,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Cyst,,2020,Q4,5,F,202002.0,20201125.0,20200910,20201201,EXP,,US-ABBVIE-20K-163-3554299-00,ABBVIE,,65.0,YR,,M,Y,145.28,KG,20201201.0,,CN,US,US,2020,Q4,Elderly
182509275,18250927,16,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Fall,,2020,Q4,5,F,202002.0,20201125.0,20200910,20201201,EXP,,US-ABBVIE-20K-163-3554299-00,ABBVIE,,65.0,YR,,M,Y,145.28,KG,20201201.0,,CN,US,US,2020,Q4,Elderly
182509275,18250927,16,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Muscle rupture,,2020,Q4,5,F,202002.0,20201125.0,20200910,20201201,EXP,,US-ABBVIE-20K-163-3554299-00,ABBVIE,,65.0,YR,,M,Y,145.28,KG,20201201.0,,CN,US,US,2020,Q4,Elderly
182509275,18250927,16,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Rotator cuff syndrome,,2020,Q4,5,F,202002.0,20201125.0,20200910,20201201,EXP,,US-ABBVIE-20K-163-3554299-00,ABBVIE,,65.0,YR,,M,Y,145.28,KG,20201201.0,,CN,US,US,2020,Q4,Elderly
183212562,18321256,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,3660.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Acute kidney injury,,2020,Q4,2,F,20200112.0,20201016.0,20200928,20201021,EXP,,PT-ASTRAZENECA-2020SF21993,ASTRAZENECA,,75.0,YR,,F,Y,,,20201021.0,,HP,PT,PT,2020,Q4,Elderly
183212562,18321256,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,3660.0,MG,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Diabetic ketoacidosis,,2020,Q4,2,F,20200112.0,20201016.0,20200928,20201021,EXP,,PT-ASTRAZENECA-2020SF21993,ASTRAZENECA,,75.0,YR,,F,Y,,,20201021.0,,HP,PT,PT,2020,Q4,Elderly
183367601,18336760,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,10.0,MG,Y,, 1912168,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Altered state of consciousness,,2020,Q4,1,I,20200714.0,20200924.0,20201001,20201001,EXP,,CN-ASTRAZENECA-2020SF25475,ASTRAZENECA,,22676.0,DY,,F,Y,62.0,KG,20201001.0,,HP,CN,CN,2020,Q4,Elderly
183367601,18336760,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,10.0,MG,Y,, 1912168,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Vertigo,,2020,Q4,1,I,20200714.0,20200924.0,20201001,20201001,EXP,,CN-ASTRAZENECA-2020SF25475,ASTRAZENECA,,22676.0,DY,,F,Y,62.0,KG,20201001.0,,HP,CN,CN,2020,Q4,Elderly
183367601,18336760,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,10.0,MG,Y,, 1912168,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Vomiting,,2020,Q4,1,I,20200714.0,20200924.0,20201001,20201001,EXP,,CN-ASTRAZENECA-2020SF25475,ASTRAZENECA,,22676.0,DY,,F,Y,62.0,KG,20201001.0,,HP,CN,CN,2020,Q4,Elderly
183383471,18338347,4,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Acetonaemia,,2020,Q4,1,I,,20200923.0,20201002,20201002,EXP,,PT-BAYER-2020-207601,BAYER,"LOURENCO CRUZ, ANA RAQUEL SOARES, TORCATO MOREIRA MARQUES, VALENTINA TOSATTO, CRISTIANO SILVA CRUZ, PAULA NASCIMENTO, ANDRE ALMEIDA, RITA BARATA MOURA, ANTONIA SOUSA GUERREIRO. ENDOCRINE, METABOLIC  AND NUTRITIONAL DISEASES - PE318 PARADOXALLY EUGLICEMIC DIABETIC KETOACIDOSIS ASSOCIATED WITH SGLT2 INHIBITOR. CONGRESSO NACIONAL DE MEDICINA INTERNA",75.0,YR,E,F,Y,,,20201002.0,,HP,PT,PT,2020,Q4,Elderly
183383471,18338347,4,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Acute kidney injury,,2020,Q4,1,I,,20200923.0,20201002,20201002,EXP,,PT-BAYER-2020-207601,BAYER,"LOURENCO CRUZ, ANA RAQUEL SOARES, TORCATO MOREIRA MARQUES, VALENTINA TOSATTO, CRISTIANO SILVA CRUZ, PAULA NASCIMENTO, ANDRE ALMEIDA, RITA BARATA MOURA, ANTONIA SOUSA GUERREIRO. ENDOCRINE, METABOLIC  AND NUTRITIONAL DISEASES - PE318 PARADOXALLY EUGLICEMIC DIABETIC KETOACIDOSIS ASSOCIATED WITH SGLT2 INHIBITOR. CONGRESSO NACIONAL DE MEDICINA INTERNA",75.0,YR,E,F,Y,,,20201002.0,,HP,PT,PT,2020,Q4,Elderly
183383471,18338347,4,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Dehydration,,2020,Q4,1,I,,20200923.0,20201002,20201002,EXP,,PT-BAYER-2020-207601,BAYER,"LOURENCO CRUZ, ANA RAQUEL SOARES, TORCATO MOREIRA MARQUES, VALENTINA TOSATTO, CRISTIANO SILVA CRUZ, PAULA NASCIMENTO, ANDRE ALMEIDA, RITA BARATA MOURA, ANTONIA SOUSA GUERREIRO. ENDOCRINE, METABOLIC  AND NUTRITIONAL DISEASES - PE318 PARADOXALLY EUGLICEMIC DIABETIC KETOACIDOSIS ASSOCIATED WITH SGLT2 INHIBITOR. CONGRESSO NACIONAL DE MEDICINA INTERNA",75.0,YR,E,F,Y,,,20201002.0,,HP,PT,PT,2020,Q4,Elderly
183383471,18338347,4,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Diabetic ketoacidosis,,2020,Q4,1,I,,20200923.0,20201002,20201002,EXP,,PT-BAYER-2020-207601,BAYER,"LOURENCO CRUZ, ANA RAQUEL SOARES, TORCATO MOREIRA MARQUES, VALENTINA TOSATTO, CRISTIANO SILVA CRUZ, PAULA NASCIMENTO, ANDRE ALMEIDA, RITA BARATA MOURA, ANTONIA SOUSA GUERREIRO. ENDOCRINE, METABOLIC  AND NUTRITIONAL DISEASES - PE318 PARADOXALLY EUGLICEMIC DIABETIC KETOACIDOSIS ASSOCIATED WITH SGLT2 INHIBITOR. CONGRESSO NACIONAL DE MEDICINA INTERNA",75.0,YR,E,F,Y,,,20201002.0,,HP,PT,PT,2020,Q4,Elderly
183383471,18338347,4,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Fatigue,,2020,Q4,1,I,,20200923.0,20201002,20201002,EXP,,PT-BAYER-2020-207601,BAYER,"LOURENCO CRUZ, ANA RAQUEL SOARES, TORCATO MOREIRA MARQUES, VALENTINA TOSATTO, CRISTIANO SILVA CRUZ, PAULA NASCIMENTO, ANDRE ALMEIDA, RITA BARATA MOURA, ANTONIA SOUSA GUERREIRO. ENDOCRINE, METABOLIC  AND NUTRITIONAL DISEASES - PE318 PARADOXALLY EUGLICEMIC DIABETIC KETOACIDOSIS ASSOCIATED WITH SGLT2 INHIBITOR. CONGRESSO NACIONAL DE MEDICINA INTERNA",75.0,YR,E,F,Y,,,20201002.0,,HP,PT,PT,2020,Q4,Elderly
183383471,18338347,4,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Ketoacidosis,,2020,Q4,1,I,,20200923.0,20201002,20201002,EXP,,PT-BAYER-2020-207601,BAYER,"LOURENCO CRUZ, ANA RAQUEL SOARES, TORCATO MOREIRA MARQUES, VALENTINA TOSATTO, CRISTIANO SILVA CRUZ, PAULA NASCIMENTO, ANDRE ALMEIDA, RITA BARATA MOURA, ANTONIA SOUSA GUERREIRO. ENDOCRINE, METABOLIC  AND NUTRITIONAL DISEASES - PE318 PARADOXALLY EUGLICEMIC DIABETIC KETOACIDOSIS ASSOCIATED WITH SGLT2 INHIBITOR. CONGRESSO NACIONAL DE MEDICINA INTERNA",75.0,YR,E,F,Y,,,20201002.0,,HP,PT,PT,2020,Q4,Elderly
183383471,18338347,4,C,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Weight decreased,,2020,Q4,1,I,,20200923.0,20201002,20201002,EXP,,PT-BAYER-2020-207601,BAYER,"LOURENCO CRUZ, ANA RAQUEL SOARES, TORCATO MOREIRA MARQUES, VALENTINA TOSATTO, CRISTIANO SILVA CRUZ, PAULA NASCIMENTO, ANDRE ALMEIDA, RITA BARATA MOURA, ANTONIA SOUSA GUERREIRO. ENDOCRINE, METABOLIC  AND NUTRITIONAL DISEASES - PE318 PARADOXALLY EUGLICEMIC DIABETIC KETOACIDOSIS ASSOCIATED WITH SGLT2 INHIBITOR. CONGRESSO NACIONAL DE MEDICINA INTERNA",75.0,YR,E,F,Y,,,20201002.0,,HP,PT,PT,2020,Q4,Elderly
183383891,18338389,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,85.0,MG,N,, 2006165,,,5.0,MG,TABLET,QD,2020,Q4,Ketoacidosis,,2020,Q4,1,I,20200913.0,20200923.0,20201002,20201002,EXP,,CN-ASTRAZENECA-2020SF24607,ASTRAZENECA,,23011.0,DY,,M,Y,,,20201002.0,,HP,CN,CN,2020,Q4,Elderly
183383891,18338389,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,85.0,MG,N,, 2006165,,,10.0,MG,TABLET,QD,2020,Q4,Ketoacidosis,,2020,Q4,1,I,20200913.0,20200923.0,20201002,20201002,EXP,,CN-ASTRAZENECA-2020SF24607,ASTRAZENECA,,23011.0,DY,,M,Y,,,20201002.0,,HP,CN,CN,2020,Q4,Elderly
183496661,18349666,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2020,Q4,Diabetic ketoacidosis,,2020,Q4,1,I,,20200928.0,20201006,20201006,EXP,,GB-ASTRAZENECA-2020SF24304,ASTRAZENECA,,53.0,YR,,M,Y,70.0,KG,20201006.0,,HP,GB,GB,2020,Q4,Adult
183603781,18360378,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U,,,,,,TABLET,,2020,Q4,Diabetic ketoacidosis,,2020,Q4,1,I,,20200929.0,20201008,20201008,EXP,,GB-ASTRAZENECA-2020SF25303,ASTRAZENECA,,64.0,YR,,M,Y,,,20201008.0,,PH,GB,GB,2020,Q4,Adult
183637151,18363715,3,SS,DAPAGLIFLOZIN PROPYLENE GLYCOLATE HYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,,,,,,,,,5.0,MG,TABLET,QD,2020,Q4,Hypoglycaemic coma,,2020,Q4,1,I,,20200928.0,20201009,20201009,EXP,,JP-JNJFOC-20201003540,JOHNSON AND JOHNSON,KANEZAKI Y. A CASE OF TYPE 2 DIABETES MELLITUS IN AN ELDERLY PATIENT WHO DEVELOPED SEVERE HYPOGLYCEMIA WHILETAKING REPAGLINIDE AND DAPAGLIFLOZIN AND SUFFERED A PROGRESSION FROM TWO BUNDLE-BRANCH BLOCK TO COMPLETE ATRIOVENTRICULAR BLOCK ONEMONTH LATER. JOURNAL OF NEW REMEDIES AND CLINICS. 2020;69(9):1099-1107.,9.0,DEC,E,M,Y,65.0,KG,20201008.0,,MD,JP,JP,2020,Q4,Child
183637151,18363715,3,SS,DAPAGLIFLOZIN PROPYLENE GLYCOLATE HYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,,,,,,,,,5.0,MG,TABLET,QD,2020,Q4,Potentiating drug interaction,,2020,Q4,1,I,,20200928.0,20201009,20201009,EXP,,JP-JNJFOC-20201003540,JOHNSON AND JOHNSON,KANEZAKI Y. A CASE OF TYPE 2 DIABETES MELLITUS IN AN ELDERLY PATIENT WHO DEVELOPED SEVERE HYPOGLYCEMIA WHILETAKING REPAGLINIDE AND DAPAGLIFLOZIN AND SUFFERED A PROGRESSION FROM TWO BUNDLE-BRANCH BLOCK TO COMPLETE ATRIOVENTRICULAR BLOCK ONEMONTH LATER. JOURNAL OF NEW REMEDIES AND CLINICS. 2020;69(9):1099-1107.,9.0,DEC,E,M,Y,65.0,KG,20201008.0,,MD,JP,JP,2020,Q4,Child
183757331,18375733,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2020,Q4,Euglycaemic diabetic ketoacidosis,,2020,Q4,1,I,20201009.0,,20201009,20201009,DIR,,,FDA-CTU,,46.0,YR,,M,N,80.0,KG,20201009.0,N,PH,US,US,2020,Q4,Adult
183757331,18375733,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2020,Q4,Urinary tract infection,,2020,Q4,1,I,20201009.0,,20201009,20201009,DIR,,,FDA-CTU,,46.0,YR,,M,N,80.0,KG,20201009.0,N,PH,US,US,2020,Q4,Adult
183879882,18387988,1,PS,DAPAGLIFLOZIN PROPYLENE GLYCOLATE HYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,DOSE UNKNOWN,,,U,,,,,,,TABLET,,2020,Q4,Ketoacidosis,,2020,Q4,2,F,2020.0,20201012.0,20201015,20201021,EXP,,JP-ASTRAZENECA-2020SF31243,ASTRAZENECA,,70.0,YR,,M,Y,,,20201021.0,,,JP,JP,2020,Q4,Elderly
183988151,18398815,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,120.0,MG,Y,,,,,10.0,MG,,QD,2020,Q4,Diabetic ketoacidosis,,2020,Q4,1,I,20200923.0,20201014.0,20201019,20201019,EXP,,GB-ASTRAZENECA-2020SF33055,ASTRAZENECA,,60.0,YR,,M,Y,105.0,KG,20201019.0,,PH,GB,GB,2020,Q4,Adult
184008361,18400836,19,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,U,,,,,10.0,MG,,QD,2020,Q4,Diarrhoea,,2020,Q4,1,I,20200511.0,20200622.0,20201019,20201019,EXP,,NVSC2020DE178412,NOVARTIS,,74.0,YR,,M,Y,91.0,KG,20201019.0,,HP,DE,DE,2020,Q4,Elderly
184008361,18400836,19,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,U,,,,,10.0,MG,,QD,2020,Q4,Peripheral arterial occlusive disease,,2020,Q4,1,I,20200511.0,20200622.0,20201019,20201019,EXP,,NVSC2020DE178412,NOVARTIS,,74.0,YR,,M,Y,91.0,KG,20201019.0,,HP,DE,DE,2020,Q4,Elderly
184008361,18400836,19,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,U,,,,,10.0,MG,,QD,2020,Q4,Peripheral ischaemia,,2020,Q4,1,I,20200511.0,20200622.0,20201019,20201019,EXP,,NVSC2020DE178412,NOVARTIS,,74.0,YR,,M,Y,91.0,KG,20201019.0,,HP,DE,DE,2020,Q4,Elderly
184008361,18400836,20,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,U,,,,,10.0,MG,,QD,2020,Q4,Diarrhoea,,2020,Q4,1,I,20200511.0,20200622.0,20201019,20201019,EXP,,NVSC2020DE178412,NOVARTIS,,74.0,YR,,M,Y,91.0,KG,20201019.0,,HP,DE,DE,2020,Q4,Elderly
184008361,18400836,20,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,U,,,,,10.0,MG,,QD,2020,Q4,Peripheral arterial occlusive disease,,2020,Q4,1,I,20200511.0,20200622.0,20201019,20201019,EXP,,NVSC2020DE178412,NOVARTIS,,74.0,YR,,M,Y,91.0,KG,20201019.0,,HP,DE,DE,2020,Q4,Elderly
184008361,18400836,20,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,U,,,,,10.0,MG,,QD,2020,Q4,Peripheral ischaemia,,2020,Q4,1,I,20200511.0,20200622.0,20201019,20201019,EXP,,NVSC2020DE178412,NOVARTIS,,74.0,YR,,M,Y,91.0,KG,20201019.0,,HP,DE,DE,2020,Q4,Elderly
184116031,18411603,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2020,Q4,Drug intolerance,,2020,Q4,1,I,,20200731.0,20201021,20201021,PER,,ES-LUPIN PHARMACEUTICALS INC.-2020-04452,LUPIN,,45.0,YR,,F,Y,,,20201021.0,,HP,ES,ES,2020,Q4,Adult
184116031,18411603,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2020,Q4,Gastrointestinal disorder,,2020,Q4,1,I,,20200731.0,20201021,20201021,PER,,ES-LUPIN PHARMACEUTICALS INC.-2020-04452,LUPIN,,45.0,YR,,F,Y,,,20201021.0,,HP,ES,ES,2020,Q4,Adult
184145931,18414593,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,100.0,MG,Y,,,,202293.0,10.0,MG,,QD,2020,Q4,Abnormal loss of weight,,2020,Q4,1,I,20200918.0,20201014.0,20201022,20201022,EXP,,GB-ASTRAZENECA-2020SF33226,ASTRAZENECA,,71.0,YR,,F,Y,63.0,KG,20201022.0,,,GB,GB,2020,Q4,Elderly
184145931,18414593,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,100.0,MG,Y,,,,202293.0,10.0,MG,,QD,2020,Q4,Euglycaemic diabetic ketoacidosis,,2020,Q4,1,I,20200918.0,20201014.0,20201022,20201022,EXP,,GB-ASTRAZENECA-2020SF33226,ASTRAZENECA,,71.0,YR,,F,Y,63.0,KG,20201022.0,,,GB,GB,2020,Q4,Elderly
184145931,18414593,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,100.0,MG,Y,,,,202293.0,10.0,MG,,QD,2020,Q4,Fatigue,,2020,Q4,1,I,20200918.0,20201014.0,20201022,20201022,EXP,,GB-ASTRAZENECA-2020SF33226,ASTRAZENECA,,71.0,YR,,F,Y,63.0,KG,20201022.0,,,GB,GB,2020,Q4,Elderly
184145931,18414593,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,100.0,MG,Y,,,,202293.0,10.0,MG,,QD,2020,Q4,Nausea,,2020,Q4,1,I,20200918.0,20201014.0,20201022,20201022,EXP,,GB-ASTRAZENECA-2020SF33226,ASTRAZENECA,,71.0,YR,,F,Y,63.0,KG,20201022.0,,,GB,GB,2020,Q4,Elderly
184204451,18420445,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2020,Q4,Throat irritation,,2020,Q4,1,I,20200928.0,20201016.0,20201023,20201023,EXP,,GB-AUROBINDO-AUR-APL-2020-053189,AUROBINDO,,60.0,YR,,F,Y,81.7,KG,20201023.0,,CN,GB,GB,2020,Q4,Adult
184204451,18420445,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2020,Q4,Tongue coated,,2020,Q4,1,I,20200928.0,20201016.0,20201023,20201023,EXP,,GB-AUROBINDO-AUR-APL-2020-053189,AUROBINDO,,60.0,YR,,F,Y,81.7,KG,20201023.0,,CN,GB,GB,2020,Q4,Adult
184238211,18423821,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,,2020,Q4,Glycosylated haemoglobin increased,,2020,Q4,1,I,,20201013.0,20201024,20201024,EXP,,US-GLENMARK PHARMACEUTICALS-2020GMK050086,GLENMARK,"SUJANANI SM, ELFISHAWI MM, ZARGHAMRAVANBAKSH P, CUEVAS CASTILLO FJ, REICH DM.. DAPAGLIFLOZIN-INDUCED ACUTE PANCREATITIS: A CASE REPORT AND REVIEW OF LITERATURE.. CASE REPORTS IN ENDOCRINOLOGY.. 2020;2020:1-4",51.0,YR,,M,Y,,,20201024.0,,HP,US,US,2020,Q4,Adult
184238211,18423821,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, UNK",,,,,,,,10.0,MG,,,2020,Q4,Glycosylated haemoglobin increased,,2020,Q4,1,I,,20201013.0,20201024,20201024,EXP,,US-GLENMARK PHARMACEUTICALS-2020GMK050086,GLENMARK,"SUJANANI SM, ELFISHAWI MM, ZARGHAMRAVANBAKSH P, CUEVAS CASTILLO FJ, REICH DM.. DAPAGLIFLOZIN-INDUCED ACUTE PANCREATITIS: A CASE REPORT AND REVIEW OF LITERATURE.. CASE REPORTS IN ENDOCRINOLOGY.. 2020;2020:1-4",51.0,YR,,M,Y,,,20201024.0,,HP,US,US,2020,Q4,Adult
184270901,18427090,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,,QD,2020,Q4,Euglycaemic diabetic ketoacidosis,,2020,Q4,1,I,20201010.0,,20201026,20201026,DIR,,,FDA-CTU,,71.0,YR,,M,N,69.6,KG,20201026.0,N,,US,US,2020,Q4,Elderly
184278681,18427868,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,5MG/10MG,,,Y,,,,202293.0,,,TABLET,,2020,Q4,Coronavirus infection,,2020,Q4,1,I,20200929.0,20201021.0,20201026,20201026,EXP,,GB-ASTRAZENECA-2020SF37882,ASTRAZENECA,,62.0,YR,,M,Y,76.0,KG,20201026.0,,,GB,GB,2020,Q4,Adult
184278681,18427868,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,5MG/10MG,,,Y,,,,202293.0,,,TABLET,,2020,Q4,Diabetic ketoacidosis,,2020,Q4,1,I,20200929.0,20201021.0,20201026,20201026,EXP,,GB-ASTRAZENECA-2020SF37882,ASTRAZENECA,,62.0,YR,,M,Y,76.0,KG,20201026.0,,,GB,GB,2020,Q4,Adult
184278681,18427868,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,5MG/10MG,,,Y,,,,202293.0,,,TABLET,,2020,Q4,Metabolic acidosis,,2020,Q4,1,I,20200929.0,20201021.0,20201026,20201026,EXP,,GB-ASTRAZENECA-2020SF37882,ASTRAZENECA,,62.0,YR,,M,Y,76.0,KG,20201026.0,,,GB,GB,2020,Q4,Adult
184278681,18427868,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,5MG/10MG,,,Y,,,,202293.0,,,TABLET,,2020,Q4,Sepsis,,2020,Q4,1,I,20200929.0,20201021.0,20201026,20201026,EXP,,GB-ASTRAZENECA-2020SF37882,ASTRAZENECA,,62.0,YR,,M,Y,76.0,KG,20201026.0,,,GB,GB,2020,Q4,Adult
184280121,18428012,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,,,TABLET,,2020,Q4,Diabetic ketoacidosis,,2020,Q4,1,I,,20201019.0,20201026,20201026,EXP,,ES-ASTRAZENECA-2020SF38451,ASTRAZENECA,,88.0,YR,,M,Y,,,20201026.0,,HP,ES,ES,2020,Q4,Elderly
184280131,18428013,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,10.0,MG,TABLET,,2020,Q4,Diabetic ketoacidosis,,2020,Q4,1,I,,20201019.0,20201026,20201026,EXP,,ES-ASTRAZENECA-2020SF38473,ASTRAZENECA,,67.0,YR,,F,Y,,,20201026.0,,HP,ES,ES,2020,Q4,Elderly
184280131,18428013,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,10.0,MG,TABLET,,2020,Q4,Off label use,,2020,Q4,1,I,,20201019.0,20201026,20201026,EXP,,ES-ASTRAZENECA-2020SF38473,ASTRAZENECA,,67.0,YR,,F,Y,,,20201026.0,,HP,ES,ES,2020,Q4,Elderly
184287181,18428718,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,202293.0,,,TABLET,,2020,Q4,Ketosis,,2020,Q4,1,I,,20201019.0,20201026,20201026,EXP,,ES-ASTRAZENECA-2020SF38623,ASTRAZENECA,,64.0,YR,,M,Y,,,20201026.0,,HP,ES,ES,2020,Q4,Adult
184292521,18429252,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, UNKNOWN",,,U,,,,,10.0,MG,TABLET,,2020,Q4,Cardiac ventricular thrombosis,,2020,Q4,1,I,20200828.0,20201019.0,20201026,20201026,EXP,,NVSC2020CN285955,NOVARTIS,,57.0,YR,,M,Y,,,20201026.0,,MD,CN,CN,2020,Q4,Adult
184292521,18429252,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, UNKNOWN",,,U,,,,,10.0,MG,TABLET,,2020,Q4,Ventricular arrhythmia,,2020,Q4,1,I,20200828.0,20201019.0,20201026,20201026,EXP,,NVSC2020CN285955,NOVARTIS,,57.0,YR,,M,Y,,,20201026.0,,MD,CN,CN,2020,Q4,Adult
184329941,18432994,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,,QD,2020,Q4,Euglycaemic diabetic ketoacidosis,,2020,Q4,1,I,20200915.0,20201021.0,20201027,20201027,EXP,,GB-ASTRAZENECA-2020SF38156,ASTRAZENECA,,64.0,YR,,M,Y,,,20201027.0,,,GB,GB,2020,Q4,Adult
184339631,18433963,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,2 DOSAGE FORMS,220.0,DF,,, UNKNOWN,,,2.0,DF,,,2020,Q4,Drug intolerance,,2020,Q4,1,I,20200920.0,20201018.0,20201028,20201028,EXP,GB-MHRA-TPP49348130C2438106YC1600626320589,GB-TEVA-2020-GB-1840980,TEVA,,52.0,YR,A,F,Y,64.0,KG,20201028.0,,MD,GB,GB,2020,Q4,Adult
184339631,18433963,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,2 DOSAGE FORMS,220.0,DF,,, UNKNOWN,,,2.0,DF,,,2020,Q4,Liver function test abnormal,,2020,Q4,1,I,20200920.0,20201018.0,20201028,20201028,EXP,GB-MHRA-TPP49348130C2438106YC1600626320589,GB-TEVA-2020-GB-1840980,TEVA,,52.0,YR,A,F,Y,64.0,KG,20201028.0,,MD,GB,GB,2020,Q4,Adult
184344103,18434410,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q4,Diarrhoea,,2020,Q4,3,F,20201022.0,20201113.0,20201027,20201124,EXP,,NVSC2020NG286316,NOVARTIS,,67.0,YR,,M,Y,,,20201124.0,,HP,NG,NG,2020,Q4,Elderly
184344103,18434410,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q4,Pyrexia,,2020,Q4,3,F,20201022.0,20201113.0,20201027,20201124,EXP,,NVSC2020NG286316,NOVARTIS,,67.0,YR,,M,Y,,,20201124.0,,HP,NG,NG,2020,Q4,Elderly
184344103,18434410,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q4,Vomiting,,2020,Q4,3,F,20201022.0,20201113.0,20201027,20201124,EXP,,NVSC2020NG286316,NOVARTIS,,67.0,YR,,M,Y,,,20201124.0,,HP,NG,NG,2020,Q4,Elderly
184406051,18440605,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q4,Abdominal pain,,2020,Q4,1,I,,20201027.0,20201029,20201029,EXP,,CA-PFIZER INC-2020416981,PFIZER,,69.0,YR,,F,Y,,,20201029.0,,HP,CA,CA,2020,Q4,Elderly
184406051,18440605,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q4,Anaemia,,2020,Q4,1,I,,20201027.0,20201029,20201029,EXP,,CA-PFIZER INC-2020416981,PFIZER,,69.0,YR,,F,Y,,,20201029.0,,HP,CA,CA,2020,Q4,Elderly
184406051,18440605,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q4,Blood pressure diastolic abnormal,,2020,Q4,1,I,,20201027.0,20201029,20201029,EXP,,CA-PFIZER INC-2020416981,PFIZER,,69.0,YR,,F,Y,,,20201029.0,,HP,CA,CA,2020,Q4,Elderly
184406051,18440605,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q4,Blood pressure diastolic decreased,,2020,Q4,1,I,,20201027.0,20201029,20201029,EXP,,CA-PFIZER INC-2020416981,PFIZER,,69.0,YR,,F,Y,,,20201029.0,,HP,CA,CA,2020,Q4,Elderly
184406051,18440605,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q4,Blood pressure systolic abnormal,,2020,Q4,1,I,,20201027.0,20201029,20201029,EXP,,CA-PFIZER INC-2020416981,PFIZER,,69.0,YR,,F,Y,,,20201029.0,,HP,CA,CA,2020,Q4,Elderly
184406051,18440605,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q4,Blood pressure systolic increased,,2020,Q4,1,I,,20201027.0,20201029,20201029,EXP,,CA-PFIZER INC-2020416981,PFIZER,,69.0,YR,,F,Y,,,20201029.0,,HP,CA,CA,2020,Q4,Elderly
184406051,18440605,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q4,Chronic obstructive pulmonary disease,,2020,Q4,1,I,,20201027.0,20201029,20201029,EXP,,CA-PFIZER INC-2020416981,PFIZER,,69.0,YR,,F,Y,,,20201029.0,,HP,CA,CA,2020,Q4,Elderly
184406051,18440605,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q4,Cough,,2020,Q4,1,I,,20201027.0,20201029,20201029,EXP,,CA-PFIZER INC-2020416981,PFIZER,,69.0,YR,,F,Y,,,20201029.0,,HP,CA,CA,2020,Q4,Elderly
184406051,18440605,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q4,Eczema,,2020,Q4,1,I,,20201027.0,20201029,20201029,EXP,,CA-PFIZER INC-2020416981,PFIZER,,69.0,YR,,F,Y,,,20201029.0,,HP,CA,CA,2020,Q4,Elderly
184406051,18440605,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q4,Gastritis,,2020,Q4,1,I,,20201027.0,20201029,20201029,EXP,,CA-PFIZER INC-2020416981,PFIZER,,69.0,YR,,F,Y,,,20201029.0,,HP,CA,CA,2020,Q4,Elderly
184406051,18440605,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q4,Gastrointestinal disorder,,2020,Q4,1,I,,20201027.0,20201029,20201029,EXP,,CA-PFIZER INC-2020416981,PFIZER,,69.0,YR,,F,Y,,,20201029.0,,HP,CA,CA,2020,Q4,Elderly
184406051,18440605,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q4,Gout,,2020,Q4,1,I,,20201027.0,20201029,20201029,EXP,,CA-PFIZER INC-2020416981,PFIZER,,69.0,YR,,F,Y,,,20201029.0,,HP,CA,CA,2020,Q4,Elderly
184406051,18440605,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q4,Heart rate increased,,2020,Q4,1,I,,20201027.0,20201029,20201029,EXP,,CA-PFIZER INC-2020416981,PFIZER,,69.0,YR,,F,Y,,,20201029.0,,HP,CA,CA,2020,Q4,Elderly
184406051,18440605,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q4,Oropharyngeal pain,,2020,Q4,1,I,,20201027.0,20201029,20201029,EXP,,CA-PFIZER INC-2020416981,PFIZER,,69.0,YR,,F,Y,,,20201029.0,,HP,CA,CA,2020,Q4,Elderly
184406051,18440605,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q4,Oxygen saturation decreased,,2020,Q4,1,I,,20201027.0,20201029,20201029,EXP,,CA-PFIZER INC-2020416981,PFIZER,,69.0,YR,,F,Y,,,20201029.0,,HP,CA,CA,2020,Q4,Elderly
184406051,18440605,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2020,Q4,Sleep disorder,,2020,Q4,1,I,,20201027.0,20201029,20201029,EXP,,CA-PFIZER INC-2020416981,PFIZER,,69.0,YR,,F,Y,,,20201029.0,,HP,CA,CA,2020,Q4,Elderly
184460281,18446028,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,N,,,,202293.0,10.0,MG,TABLET,,2020,Q4,Diabetic foot,,2020,Q4,1,I,20201004.0,20201023.0,20201030,20201030,EXP,,GB-ASTRAZENECA-2020SF39296,ASTRAZENECA,,74.0,YR,,M,Y,105.7,KG,20201030.0,,,GB,GB,2020,Q4,Elderly
184460281,18446028,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,N,,,,202293.0,10.0,MG,TABLET,,2020,Q4,Skin necrosis,,2020,Q4,1,I,20201004.0,20201023.0,20201030,20201030,EXP,,GB-ASTRAZENECA-2020SF39296,ASTRAZENECA,,74.0,YR,,M,Y,105.7,KG,20201030.0,,,GB,GB,2020,Q4,Elderly
184555771,18455577,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q4,Chromaturia,,2020,Q4,1,I,20201006.0,20201026.0,20201102,20201102,EXP,,GB-ASTRAZENECA-2020SF39693,ASTRAZENECA,,52.0,YR,,M,Y,99.5,KG,20201103.0,,PH,GB,GB,2020,Q4,Adult
184555771,18455577,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q4,Dizziness,,2020,Q4,1,I,20201006.0,20201026.0,20201102,20201102,EXP,,GB-ASTRAZENECA-2020SF39693,ASTRAZENECA,,52.0,YR,,M,Y,99.5,KG,20201103.0,,PH,GB,GB,2020,Q4,Adult
184555771,18455577,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q4,Euglycaemic diabetic ketoacidosis,,2020,Q4,1,I,20201006.0,20201026.0,20201102,20201102,EXP,,GB-ASTRAZENECA-2020SF39693,ASTRAZENECA,,52.0,YR,,M,Y,99.5,KG,20201103.0,,PH,GB,GB,2020,Q4,Adult
184555771,18455577,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q4,Malaise,,2020,Q4,1,I,20201006.0,20201026.0,20201102,20201102,EXP,,GB-ASTRAZENECA-2020SF39693,ASTRAZENECA,,52.0,YR,,M,Y,99.5,KG,20201103.0,,PH,GB,GB,2020,Q4,Adult
184555771,18455577,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q4,Urine output decreased,,2020,Q4,1,I,20201006.0,20201026.0,20201102,20201102,EXP,,GB-ASTRAZENECA-2020SF39693,ASTRAZENECA,,52.0,YR,,M,Y,99.5,KG,20201103.0,,PH,GB,GB,2020,Q4,Adult
184555771,18455577,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q4,Vomiting,,2020,Q4,1,I,20201006.0,20201026.0,20201102,20201102,EXP,,GB-ASTRAZENECA-2020SF39693,ASTRAZENECA,,52.0,YR,,M,Y,99.5,KG,20201103.0,,PH,GB,GB,2020,Q4,Adult
184567751,18456775,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Anal abscess,,2020,Q4,1,I,20200920.0,20201103.0,20201103,20201103,EXP,GB-MHRA-EYC 00231804,GB-ABBVIE-20K-167-3635657-00,ABBVIE,,44.0,YR,,F,Y,107.0,KG,20201103.0,,MD,GB,GB,2020,Q4,Adult
184584501,18458450,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,,,,202293.0,10.0,MG,TABLET,,2020,Q4,Iliac artery stenosis,,2020,Q4,1,I,202002.0,20201026.0,20201103,20201103,EXP,,PL-ASTRAZENECA-2020SF43015,ASTRAZENECA,,60.0,YR,,M,Y,72.0,KG,20201103.0,,MD,PL,PL,2020,Q4,Adult
184584501,18458450,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,,,,202293.0,10.0,MG,TABLET,,2020,Q4,Necrosis,,2020,Q4,1,I,202002.0,20201026.0,20201103,20201103,EXP,,PL-ASTRAZENECA-2020SF43015,ASTRAZENECA,,60.0,YR,,M,Y,72.0,KG,20201103.0,,MD,PL,PL,2020,Q4,Adult
184588691,18458869,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAMS, 24 - EVERY HOUR",,,Y,,,,202293.0,,,TABLET,,2020,Q4,Abdominal pain,,2020,Q4,1,I,20201012.0,20201027.0,20201103,20201103,EXP,,ES-ASTRAZENECA-2020SF40267,ASTRAZENECA,,46.0,YR,,M,Y,,,20201103.0,,MD,ES,ES,2020,Q4,Adult
184588691,18458869,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAMS, 24 - EVERY HOUR",,,Y,,,,202293.0,,,TABLET,,2020,Q4,Penile discomfort,,2020,Q4,1,I,20201012.0,20201027.0,20201103,20201103,EXP,,ES-ASTRAZENECA-2020SF40267,ASTRAZENECA,,46.0,YR,,M,Y,,,20201103.0,,MD,ES,ES,2020,Q4,Adult
184588691,18458869,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAMS, 24 - EVERY HOUR",,,Y,,,,202293.0,,,TABLET,,2020,Q4,Spinal pain,,2020,Q4,1,I,20201012.0,20201027.0,20201103,20201103,EXP,,ES-ASTRAZENECA-2020SF40267,ASTRAZENECA,,46.0,YR,,M,Y,,,20201103.0,,MD,ES,ES,2020,Q4,Adult
184588691,18458869,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAMS, 24 - EVERY HOUR",,,Y,,,,202293.0,,,TABLET,,2020,Q4,Weight decreased,,2020,Q4,1,I,20201012.0,20201027.0,20201103,20201103,EXP,,ES-ASTRAZENECA-2020SF40267,ASTRAZENECA,,46.0,YR,,M,Y,,,20201103.0,,MD,ES,ES,2020,Q4,Adult
184620281,18462028,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10 MG,,,,,,,,,,,,2020,Q4,Injection site erythema,,2020,Q4,1,I,20200918.0,20201024.0,20201104,20201104,EXP,GB-MHRA-EYC 00230559,GB-NOVOPROD-762666,NOVO NORDISK,,63.0,YR,,M,Y,103.0,KG,20201104.0,,CN,GB,GB,2020,Q4,Adult
184620281,18462028,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10 MG,,,,,,,,,,,,2020,Q4,Injection site mass,,2020,Q4,1,I,20200918.0,20201024.0,20201104,20201104,EXP,GB-MHRA-EYC 00230559,GB-NOVOPROD-762666,NOVO NORDISK,,63.0,YR,,M,Y,103.0,KG,20201104.0,,CN,GB,GB,2020,Q4,Adult
184620281,18462028,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,10 MG,,,,,,,,,,,,2020,Q4,Pruritus,,2020,Q4,1,I,20200918.0,20201024.0,20201104,20201104,EXP,GB-MHRA-EYC 00230559,GB-NOVOPROD-762666,NOVO NORDISK,,63.0,YR,,M,Y,103.0,KG,20201104.0,,CN,GB,GB,2020,Q4,Adult
184628611,18462861,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,,10.0,MG,,,2020,Q4,Diabetic ketoacidosis,,2020,Q4,1,I,20200930.0,20201026.0,20201104,20201104,EXP,,GB-ASTRAZENECA-2020SF39425,ASTRAZENECA,,32.0,YR,,F,Y,74.0,KG,20201104.0,,MD,GB,GB,2020,Q4,Young Adult
184679501,18467950,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,,10.0,MG,,,2020,Q4,Euglycaemic diabetic ketoacidosis,,2020,Q4,1,I,20201014.0,20201030.0,20201105,20201105,EXP,,GB-ASTRAZENECA-2020SF42338,ASTRAZENECA,,65.0,YR,,M,Y,,,20201105.0,,PH,GB,GB,2020,Q4,Elderly
184714981,18471498,15,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2020,Q4,Upper gastrointestinal haemorrhage,,2020,Q4,1,I,20201005.0,20201028.0,20201106,20201106,EXP,GB-MHRA-EYC 00231182,GB-APOTEX-2020AP021132,APOTEX,,73.0,YR,,M,Y,,,20201106.0,,CN,GB,GB,2020,Q4,Elderly
184722473,18472247,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,202293.0,,,TABLET,,2020,Q4,Anaphylactic shock,,2020,Q4,3,F,,20201126.0,20201106,20201207,EXP,,DE-ASTRAZENECA-2020SF43339,ASTRAZENECA,,76.0,YR,,M,Y,,,20201207.0,,MD,DE,DE,2020,Q4,Elderly
184722473,18472247,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,202293.0,,,TABLET,,2020,Q4,Euglycaemic diabetic ketoacidosis,,2020,Q4,3,F,,20201126.0,20201106,20201207,EXP,,DE-ASTRAZENECA-2020SF43339,ASTRAZENECA,,76.0,YR,,M,Y,,,20201207.0,,MD,DE,DE,2020,Q4,Elderly
184722473,18472247,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,202293.0,,,TABLET,,2020,Q4,Haemodynamic instability,,2020,Q4,3,F,,20201126.0,20201106,20201207,EXP,,DE-ASTRAZENECA-2020SF43339,ASTRAZENECA,,76.0,YR,,M,Y,,,20201207.0,,MD,DE,DE,2020,Q4,Elderly
184722473,18472247,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,202293.0,,,TABLET,,2020,Q4,Intentional product use issue,,2020,Q4,3,F,,20201126.0,20201106,20201207,EXP,,DE-ASTRAZENECA-2020SF43339,ASTRAZENECA,,76.0,YR,,M,Y,,,20201207.0,,MD,DE,DE,2020,Q4,Elderly
184722473,18472247,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,202293.0,,,TABLET,,2020,Q4,Lactic acidosis,,2020,Q4,3,F,,20201126.0,20201106,20201207,EXP,,DE-ASTRAZENECA-2020SF43339,ASTRAZENECA,,76.0,YR,,M,Y,,,20201207.0,,MD,DE,DE,2020,Q4,Elderly
184722473,18472247,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,202293.0,,,TABLET,,2020,Q4,Off label use,,2020,Q4,3,F,,20201126.0,20201106,20201207,EXP,,DE-ASTRAZENECA-2020SF43339,ASTRAZENECA,,76.0,YR,,M,Y,,,20201207.0,,MD,DE,DE,2020,Q4,Elderly
184722473,18472247,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,202293.0,,,TABLET,,2020,Q4,Shock,,2020,Q4,3,F,,20201126.0,20201106,20201207,EXP,,DE-ASTRAZENECA-2020SF43339,ASTRAZENECA,,76.0,YR,,M,Y,,,20201207.0,,MD,DE,DE,2020,Q4,Elderly
184722473,18472247,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,202293.0,,,TABLET,,2020,Q4,Toxicity to various agents,,2020,Q4,3,F,,20201126.0,20201106,20201207,EXP,,DE-ASTRAZENECA-2020SF43339,ASTRAZENECA,,76.0,YR,,M,Y,,,20201207.0,,MD,DE,DE,2020,Q4,Elderly
184722473,18472247,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,202293.0,,,TABLET,,2020,Q4,Ventricular tachycardia,,2020,Q4,3,F,,20201126.0,20201106,20201207,EXP,,DE-ASTRAZENECA-2020SF43339,ASTRAZENECA,,76.0,YR,,M,Y,,,20201207.0,,MD,DE,DE,2020,Q4,Elderly
184738363,18473836,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,D,,,,,,,,,2020,Q4,Distributive shock,,2020,Q4,3,F,,20201209.0,20201106,20201218,EXP,,DE-EMD SERONO-9196420,EMD SERONO INC,"MALICEK D, WAGNER S, KAISER S, MEININGER D, KHANDOGA A. SEVERE CONDITION OF SHOCK WITH COMBINED LACTIC AND KETOACIDOSIS IN A PATIENT AFTER LEFTSIDED PANCREAS RESECTION UNDER PERMANENT THERAPY WITH METFORMIN AND DAPAGLIFLOZIN. ANASTHESIOLOGIE UND INTENSIVMEDIZIN. 2020 OCT 01;61(10):472-478. DOI:10.19224/AI2020.472",76.0,YR,E,M,Y,,,20201218.0,,MD,DE,DE,2020,Q4,Elderly
184738363,18473836,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,D,,,,,,,,,2020,Q4,Lactic acidosis,,2020,Q4,3,F,,20201209.0,20201106,20201218,EXP,,DE-EMD SERONO-9196420,EMD SERONO INC,"MALICEK D, WAGNER S, KAISER S, MEININGER D, KHANDOGA A. SEVERE CONDITION OF SHOCK WITH COMBINED LACTIC AND KETOACIDOSIS IN A PATIENT AFTER LEFTSIDED PANCREAS RESECTION UNDER PERMANENT THERAPY WITH METFORMIN AND DAPAGLIFLOZIN. ANASTHESIOLOGIE UND INTENSIVMEDIZIN. 2020 OCT 01;61(10):472-478. DOI:10.19224/AI2020.472",76.0,YR,E,M,Y,,,20201218.0,,MD,DE,DE,2020,Q4,Elderly
184780851,18478085,15,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2020,Q4,Upper gastrointestinal haemorrhage,,2020,Q4,1,I,20201005.0,20201026.0,20201108,20201108,EXP,,GB-AUROBINDO-AUR-APL-2020-054653,AUROBINDO,,73.0,YR,,M,Y,,,20201109.0,,PH,GB,GB,2020,Q4,Elderly
184797903,18479790,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,"10.0,MG,",,,,,,,,,,,,2020,Q4,Hypoglycaemia,,2020,Q4,3,F,20201028.0,20201124.0,20201109,20201203,EXP,,BR-NOVOPROD-764252,NOVO NORDISK,,83.0,YR,,M,Y,96.0,KG,20201203.0,,MD,BR,BR,2020,Q4,Elderly
184804911,18480491,15,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,, UNKNOWN,,,,,,,2020,Q4,Upper gastrointestinal haemorrhage,,2020,Q4,1,I,20201005.0,20201030.0,20201109,20201109,EXP,GB-MHRA-EYC 00231182,GB-TEVA-2020-GB-1845317,TEVA,,73.0,YR,E,M,Y,,,20201109.0,,PH,GB,GB,2020,Q4,Elderly
184815661,18481566,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Diabetes insipidus,,2020,Q4,1,I,,20201102.0,20201109,20201109,EXP,,GB-ASTRAZENECA-2020SF43885,ASTRAZENECA,,35.0,YR,,F,Y,,,20201109.0,,PH,GB,GB,2020,Q4,Adult
184815661,18481566,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Euglycaemic diabetic ketoacidosis,,2020,Q4,1,I,,20201102.0,20201109,20201109,EXP,,GB-ASTRAZENECA-2020SF43885,ASTRAZENECA,,35.0,YR,,F,Y,,,20201109.0,,PH,GB,GB,2020,Q4,Adult
184815661,18481566,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Ketonuria,,2020,Q4,1,I,,20201102.0,20201109,20201109,EXP,,GB-ASTRAZENECA-2020SF43885,ASTRAZENECA,,35.0,YR,,F,Y,,,20201109.0,,PH,GB,GB,2020,Q4,Adult
184815661,18481566,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Metabolic acidosis,,2020,Q4,1,I,,20201102.0,20201109,20201109,EXP,,GB-ASTRAZENECA-2020SF43885,ASTRAZENECA,,35.0,YR,,F,Y,,,20201109.0,,PH,GB,GB,2020,Q4,Adult
184815661,18481566,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Polyuria,,2020,Q4,1,I,,20201102.0,20201109,20201109,EXP,,GB-ASTRAZENECA-2020SF43885,ASTRAZENECA,,35.0,YR,,F,Y,,,20201109.0,,PH,GB,GB,2020,Q4,Adult
184870253,18487025,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,WAS TAKEN UNTIL THE EVENING BEFORE SURGERY,,,Y,,,,,,,TABLET,,2020,Q4,Anaphylactic shock,,2020,Q4,3,F,,20201130.0,20201110,20201202,EXP,,NVSC2020DE300966,NOVARTIS,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEININGER D. SEVERE SHOCK CONDITION WITH COMBINED LACTATE AND KETOACIDOSIS IN A PATIENT FOLLOWING PANCREATIC LEFT RESECTION WITH METFORMIN AND DAPAGLIFLOZIN PERMANENT THERAPY. ANAESTHESIOLOGIE AND INTENSIVMEDIZIN. 2020;61(10):472-8",76.0,YR,,M,Y,,,20201202.0,,HP,DE,DE,2020,Q4,Elderly
184870253,18487025,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,WAS TAKEN UNTIL THE EVENING BEFORE SURGERY,,,Y,,,,,,,TABLET,,2020,Q4,Euglycaemic diabetic ketoacidosis,,2020,Q4,3,F,,20201130.0,20201110,20201202,EXP,,NVSC2020DE300966,NOVARTIS,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEININGER D. SEVERE SHOCK CONDITION WITH COMBINED LACTATE AND KETOACIDOSIS IN A PATIENT FOLLOWING PANCREATIC LEFT RESECTION WITH METFORMIN AND DAPAGLIFLOZIN PERMANENT THERAPY. ANAESTHESIOLOGIE AND INTENSIVMEDIZIN. 2020;61(10):472-8",76.0,YR,,M,Y,,,20201202.0,,HP,DE,DE,2020,Q4,Elderly
184870253,18487025,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,WAS TAKEN UNTIL THE EVENING BEFORE SURGERY,,,Y,,,,,,,TABLET,,2020,Q4,Haemodynamic instability,,2020,Q4,3,F,,20201130.0,20201110,20201202,EXP,,NVSC2020DE300966,NOVARTIS,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEININGER D. SEVERE SHOCK CONDITION WITH COMBINED LACTATE AND KETOACIDOSIS IN A PATIENT FOLLOWING PANCREATIC LEFT RESECTION WITH METFORMIN AND DAPAGLIFLOZIN PERMANENT THERAPY. ANAESTHESIOLOGIE AND INTENSIVMEDIZIN. 2020;61(10):472-8",76.0,YR,,M,Y,,,20201202.0,,HP,DE,DE,2020,Q4,Elderly
184870253,18487025,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,WAS TAKEN UNTIL THE EVENING BEFORE SURGERY,,,Y,,,,,,,TABLET,,2020,Q4,Intentional product use issue,,2020,Q4,3,F,,20201130.0,20201110,20201202,EXP,,NVSC2020DE300966,NOVARTIS,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEININGER D. SEVERE SHOCK CONDITION WITH COMBINED LACTATE AND KETOACIDOSIS IN A PATIENT FOLLOWING PANCREATIC LEFT RESECTION WITH METFORMIN AND DAPAGLIFLOZIN PERMANENT THERAPY. ANAESTHESIOLOGIE AND INTENSIVMEDIZIN. 2020;61(10):472-8",76.0,YR,,M,Y,,,20201202.0,,HP,DE,DE,2020,Q4,Elderly
184870253,18487025,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,WAS TAKEN UNTIL THE EVENING BEFORE SURGERY,,,Y,,,,,,,TABLET,,2020,Q4,Lactic acidosis,,2020,Q4,3,F,,20201130.0,20201110,20201202,EXP,,NVSC2020DE300966,NOVARTIS,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEININGER D. SEVERE SHOCK CONDITION WITH COMBINED LACTATE AND KETOACIDOSIS IN A PATIENT FOLLOWING PANCREATIC LEFT RESECTION WITH METFORMIN AND DAPAGLIFLOZIN PERMANENT THERAPY. ANAESTHESIOLOGIE AND INTENSIVMEDIZIN. 2020;61(10):472-8",76.0,YR,,M,Y,,,20201202.0,,HP,DE,DE,2020,Q4,Elderly
184870253,18487025,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,WAS TAKEN UNTIL THE EVENING BEFORE SURGERY,,,Y,,,,,,,TABLET,,2020,Q4,Off label use,,2020,Q4,3,F,,20201130.0,20201110,20201202,EXP,,NVSC2020DE300966,NOVARTIS,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEININGER D. SEVERE SHOCK CONDITION WITH COMBINED LACTATE AND KETOACIDOSIS IN A PATIENT FOLLOWING PANCREATIC LEFT RESECTION WITH METFORMIN AND DAPAGLIFLOZIN PERMANENT THERAPY. ANAESTHESIOLOGIE AND INTENSIVMEDIZIN. 2020;61(10):472-8",76.0,YR,,M,Y,,,20201202.0,,HP,DE,DE,2020,Q4,Elderly
184870253,18487025,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,WAS TAKEN UNTIL THE EVENING BEFORE SURGERY,,,Y,,,,,,,TABLET,,2020,Q4,Shock,,2020,Q4,3,F,,20201130.0,20201110,20201202,EXP,,NVSC2020DE300966,NOVARTIS,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEININGER D. SEVERE SHOCK CONDITION WITH COMBINED LACTATE AND KETOACIDOSIS IN A PATIENT FOLLOWING PANCREATIC LEFT RESECTION WITH METFORMIN AND DAPAGLIFLOZIN PERMANENT THERAPY. ANAESTHESIOLOGIE AND INTENSIVMEDIZIN. 2020;61(10):472-8",76.0,YR,,M,Y,,,20201202.0,,HP,DE,DE,2020,Q4,Elderly
184870253,18487025,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,WAS TAKEN UNTIL THE EVENING BEFORE SURGERY,,,Y,,,,,,,TABLET,,2020,Q4,Toxicity to various agents,,2020,Q4,3,F,,20201130.0,20201110,20201202,EXP,,NVSC2020DE300966,NOVARTIS,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEININGER D. SEVERE SHOCK CONDITION WITH COMBINED LACTATE AND KETOACIDOSIS IN A PATIENT FOLLOWING PANCREATIC LEFT RESECTION WITH METFORMIN AND DAPAGLIFLOZIN PERMANENT THERAPY. ANAESTHESIOLOGIE AND INTENSIVMEDIZIN. 2020;61(10):472-8",76.0,YR,,M,Y,,,20201202.0,,HP,DE,DE,2020,Q4,Elderly
184870253,18487025,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,WAS TAKEN UNTIL THE EVENING BEFORE SURGERY,,,Y,,,,,,,TABLET,,2020,Q4,Ventricular tachycardia,,2020,Q4,3,F,,20201130.0,20201110,20201202,EXP,,NVSC2020DE300966,NOVARTIS,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEININGER D. SEVERE SHOCK CONDITION WITH COMBINED LACTATE AND KETOACIDOSIS IN A PATIENT FOLLOWING PANCREATIC LEFT RESECTION WITH METFORMIN AND DAPAGLIFLOZIN PERMANENT THERAPY. ANAESTHESIOLOGIE AND INTENSIVMEDIZIN. 2020;61(10):472-8",76.0,YR,,M,Y,,,20201202.0,,HP,DE,DE,2020,Q4,Elderly
184875792,18487579,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2020,Q4,Ischaemic stroke,,2020,Q4,2,F,20201025.0,20201123.0,20201110,20201128,EXP,,NVSC2020GB298622,NOVARTIS,,54.0,YR,,M,Y,79.1,KG,20201128.0,,HP,GB,GB,2020,Q4,Adult
184883722,18488372,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Ketoacidosis,,2020,Q4,2,F,,20201124.0,20201111,20201202,EXP,,DE-AJANTA PHARMA USA INC.-2095786,AJANTA PHARMA,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEININGER D. SEVERE CONDITION OF SHOCK WITH COMBINED LACTIC AND KETOACIDOSIS IN A PATIENT AFTER LEFT-SIDED PANCREAS RESECTION UNDER PERMANENT THERAPY WITH METFORMIN AND DAPAGLIFLOZIN. ANASTEHSIOL INTENSIVMED. 2020; 61(10): 472-478.",76.0,YR,,M,Y,,,20201202.0,,HP,DE,DE,2020,Q4,Elderly
184883722,18488372,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Lactic acidosis,,2020,Q4,2,F,,20201124.0,20201111,20201202,EXP,,DE-AJANTA PHARMA USA INC.-2095786,AJANTA PHARMA,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEININGER D. SEVERE CONDITION OF SHOCK WITH COMBINED LACTIC AND KETOACIDOSIS IN A PATIENT AFTER LEFT-SIDED PANCREAS RESECTION UNDER PERMANENT THERAPY WITH METFORMIN AND DAPAGLIFLOZIN. ANASTEHSIOL INTENSIVMED. 2020; 61(10): 472-478.",76.0,YR,,M,Y,,,20201202.0,,HP,DE,DE,2020,Q4,Elderly
184903201,18490320,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Diabetic nephropathy,,2020,Q4,1,I,,20201101.0,20201111,20201111,EXP,,BG-ASTRAZENECA-2020SF45649,ASTRAZENECA,,53.0,YR,,M,Y,,,20201111.0,,MD,BG,BG,2020,Q4,Adult
184903201,18490320,6,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Hypertensive nephropathy,,2020,Q4,1,I,,20201101.0,20201111,20201111,EXP,,BG-ASTRAZENECA-2020SF45649,ASTRAZENECA,,53.0,YR,,M,Y,,,20201111.0,,MD,BG,BG,2020,Q4,Adult
184905841,18490584,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2020,Q4,Carcinoid crisis,,2020,Q4,1,I,,20201105.0,20201111,20201111,EXP,,DE-FRESENIUS KABI-FK202011946,FRESENIUS KABI,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEINENGER D. SEVERE CONDITION OF SHOCK WITH COMBINED LACTIC AND KETOACIDOSIS IN A PATIENT AFTER LEFT-SIDED PANCREAS RESECTION UNDER PERMANENT THERAPY WITH METFORMIN AND DAPAGLIFLOZIN. ANASTHESIOLOGIE AND INTENSIVMEDIZIN. 2020 OCT;61 (10):472-478.",76.0,YR,,M,Y,,,20201111.0,,HP,DE,DE,2020,Q4,Elderly
184905841,18490584,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2020,Q4,Off label use,,2020,Q4,1,I,,20201105.0,20201111,20201111,EXP,,DE-FRESENIUS KABI-FK202011946,FRESENIUS KABI,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEINENGER D. SEVERE CONDITION OF SHOCK WITH COMBINED LACTIC AND KETOACIDOSIS IN A PATIENT AFTER LEFT-SIDED PANCREAS RESECTION UNDER PERMANENT THERAPY WITH METFORMIN AND DAPAGLIFLOZIN. ANASTHESIOLOGIE AND INTENSIVMEDIZIN. 2020 OCT;61 (10):472-478.",76.0,YR,,M,Y,,,20201111.0,,HP,DE,DE,2020,Q4,Elderly
184905841,18490584,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2020,Q4,Poisoning,,2020,Q4,1,I,,20201105.0,20201111,20201111,EXP,,DE-FRESENIUS KABI-FK202011946,FRESENIUS KABI,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEINENGER D. SEVERE CONDITION OF SHOCK WITH COMBINED LACTIC AND KETOACIDOSIS IN A PATIENT AFTER LEFT-SIDED PANCREAS RESECTION UNDER PERMANENT THERAPY WITH METFORMIN AND DAPAGLIFLOZIN. ANASTHESIOLOGIE AND INTENSIVMEDIZIN. 2020 OCT;61 (10):472-478.",76.0,YR,,M,Y,,,20201111.0,,HP,DE,DE,2020,Q4,Elderly
184923613,18492361,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,,QD,2020,Q4,Euglycaemic diabetic ketoacidosis,,2020,Q4,3,F,,20201209.0,20201111,20201223,EXP,,DE-BAUSCH-BL-2020-032614,BAUSCH AND LOMB,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEININGER D. SCHWERER SCHOCKZUSTAND MIT KOMBINIERTER LAKTAT- UND KETOAZIDOSE BEI EINEM PATIENTEN NACH PANKREAS-LINKSRESEKTION UNTER METFORMIN- UND DAPAGLIFLOZIN-DAUERTHERAPIE. ANASTH INTENSIVMED. 2020;61(10):472-478. DOI:10.19224/AI2020.472",76.0,YR,,M,Y,100.0,KG,20201223.0,,MD,DE,DE,2020,Q4,Elderly
184923613,18492361,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,,QD,2020,Q4,Haemodynamic instability,,2020,Q4,3,F,,20201209.0,20201111,20201223,EXP,,DE-BAUSCH-BL-2020-032614,BAUSCH AND LOMB,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEININGER D. SCHWERER SCHOCKZUSTAND MIT KOMBINIERTER LAKTAT- UND KETOAZIDOSE BEI EINEM PATIENTEN NACH PANKREAS-LINKSRESEKTION UNTER METFORMIN- UND DAPAGLIFLOZIN-DAUERTHERAPIE. ANASTH INTENSIVMED. 2020;61(10):472-478. DOI:10.19224/AI2020.472",76.0,YR,,M,Y,100.0,KG,20201223.0,,MD,DE,DE,2020,Q4,Elderly
184923613,18492361,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,,QD,2020,Q4,Lactic acidosis,,2020,Q4,3,F,,20201209.0,20201111,20201223,EXP,,DE-BAUSCH-BL-2020-032614,BAUSCH AND LOMB,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEININGER D. SCHWERER SCHOCKZUSTAND MIT KOMBINIERTER LAKTAT- UND KETOAZIDOSE BEI EINEM PATIENTEN NACH PANKREAS-LINKSRESEKTION UNTER METFORMIN- UND DAPAGLIFLOZIN-DAUERTHERAPIE. ANASTH INTENSIVMED. 2020;61(10):472-478. DOI:10.19224/AI2020.472",76.0,YR,,M,Y,100.0,KG,20201223.0,,MD,DE,DE,2020,Q4,Elderly
184970022,18497002,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2020,Q4,Diabetic ketoacidosis,,2020,Q4,2,F,,20201123.0,20201112,20201201,EXP,,DE-PRINSTON PHARMACEUTICAL INC.-2020PRN00379,PRINSTON PHARMACEUTICAL,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEININGER D.. SEVERE CONDITION OF SHOCK WITH COMBINED LACTIC AND KETOACIDOSIS IN A PATIENT AFTER LEFT-SIDED PANCREAS RESECTION UNDER PERMANENT THERAPY WITH METFORMIN AND DAPAGLIFLOZIN.. ANASTEHSIOL INTENSIVMED.. 2020;61(10):472-478",76.0,YR,,M,Y,,,20201201.0,,MD,DE,DE,2020,Q4,Elderly
184970022,18497002,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2020,Q4,Lactic acidosis,,2020,Q4,2,F,,20201123.0,20201112,20201201,EXP,,DE-PRINSTON PHARMACEUTICAL INC.-2020PRN00379,PRINSTON PHARMACEUTICAL,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEININGER D.. SEVERE CONDITION OF SHOCK WITH COMBINED LACTIC AND KETOACIDOSIS IN A PATIENT AFTER LEFT-SIDED PANCREAS RESECTION UNDER PERMANENT THERAPY WITH METFORMIN AND DAPAGLIFLOZIN.. ANASTEHSIOL INTENSIVMED.. 2020;61(10):472-478",76.0,YR,,M,Y,,,20201201.0,,MD,DE,DE,2020,Q4,Elderly
184970731,18497073,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,, NOT KNOWN,,202293.0,10.0,MG,TABLET,,2020,Q4,Abdominal pain,,2020,Q4,1,I,20201015.0,20201104.0,20201112,20201112,EXP,,GB-ASTRAZENECA-2020SF45052,ASTRAZENECA,,32.0,YR,,M,Y,131.6,KG,20201112.0,,,GB,GB,2020,Q4,Young Adult
184970731,18497073,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,, NOT KNOWN,,202293.0,10.0,MG,TABLET,,2020,Q4,Euglycaemic diabetic ketoacidosis,,2020,Q4,1,I,20201015.0,20201104.0,20201112,20201112,EXP,,GB-ASTRAZENECA-2020SF45052,ASTRAZENECA,,32.0,YR,,M,Y,131.6,KG,20201112.0,,,GB,GB,2020,Q4,Young Adult
184978021,18497802,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,540.0,MG,Y,,,,202293.0,10.0,MG,,QD,2020,Q4,Genital swelling,,2020,Q4,1,I,20200810.0,20201106.0,20201112,20201112,EXP,,GB-ASTRAZENECA-2020SF46157,ASTRAZENECA,,55.0,YR,,F,Y,68.0,KG,20201112.0,,HP,GB,GB,2020,Q4,Adult
184978021,18497802,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,540.0,MG,Y,,,,202293.0,10.0,MG,,QD,2020,Q4,Pruritus genital,,2020,Q4,1,I,20200810.0,20201106.0,20201112,20201112,EXP,,GB-ASTRAZENECA-2020SF46157,ASTRAZENECA,,55.0,YR,,F,Y,68.0,KG,20201112.0,,HP,GB,GB,2020,Q4,Adult
184978391,18497839,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2020,Q4,Euglycaemic diabetic ketoacidosis,,2020,Q4,1,I,,20201112.0,20201112,20201112,EXP,,NVSC2020DE303627,NOVARTIS,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEININGER D. SEVERE CONDITION OF SHOCK WITH COMBINED LACTIC AND KETOACIDOSIS IN A PATIENT AFTER LEFT-SIDED PANCREAS RESECTION UNDER PERMANENT THERAPY WITH METFORMIN AND DAPAGLIFLOZIN. ANASTHESIOLOGIE AND INTENSIVMEDIZIN. 2020;61(10):472-8",76.0,YR,,M,Y,,,20201112.0,,HP,DE,DE,2020,Q4,Elderly
184978391,18497839,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2020,Q4,Lactic acidosis,,2020,Q4,1,I,,20201112.0,20201112,20201112,EXP,,NVSC2020DE303627,NOVARTIS,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEININGER D. SEVERE CONDITION OF SHOCK WITH COMBINED LACTIC AND KETOACIDOSIS IN A PATIENT AFTER LEFT-SIDED PANCREAS RESECTION UNDER PERMANENT THERAPY WITH METFORMIN AND DAPAGLIFLOZIN. ANASTHESIOLOGIE AND INTENSIVMEDIZIN. 2020;61(10):472-8",76.0,YR,,M,Y,,,20201112.0,,HP,DE,DE,2020,Q4,Elderly
184990181,18499018,12,SS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,"10 MG, QD",7880.0,MG,Y,, UNKNOWN,,,10.0,MG,TABLET,,2020,Q4,Diabetic ketoacidosis,,2020,Q4,1,I,20190824.0,20200108.0,20201113,20201113,EXP,,NL-TEVA-2020-NL-1168014,TEVA,,54.0,YR,A,F,Y,84.5,KG,20201113.0,,HP,NL,NL,2020,Q4,Adult
184990181,18499018,13,SS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,7880.0,MG,Y,, UNKNOWN,,,10.0,MG,,,2020,Q4,Diabetic ketoacidosis,,2020,Q4,1,I,20190824.0,20200108.0,20201113,20201113,EXP,,NL-TEVA-2020-NL-1168014,TEVA,,54.0,YR,A,F,Y,84.5,KG,20201113.0,,HP,NL,NL,2020,Q4,Adult
184990492,18499049,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, UNKNOWN",,,U,,,,,10.0,MG,,,2020,Q4,Adverse drug reaction,,2020,Q4,2,F,,20201116.0,20201112,20201123,EXP,,NVSC2020SG299075,NOVARTIS,,55.0,YR,,F,Y,,,20201123.0,,MD,SG,SG,2020,Q4,Adult
184990492,18499049,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, UNKNOWN",,,U,,,,,10.0,MG,,,2020,Q4,Hepatic cirrhosis,,2020,Q4,2,F,,20201116.0,20201112,20201123,EXP,,NVSC2020SG299075,NOVARTIS,,55.0,YR,,F,Y,,,20201123.0,,MD,SG,SG,2020,Q4,Adult
184990492,18499049,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, UNKNOWN",,,U,,,,,10.0,MG,,,2020,Q4,Hepatic steatosis,,2020,Q4,2,F,,20201116.0,20201112,20201123,EXP,,NVSC2020SG299075,NOVARTIS,,55.0,YR,,F,Y,,,20201123.0,,MD,SG,SG,2020,Q4,Adult
184990492,18499049,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, UNKNOWN",,,U,,,,,10.0,MG,,,2020,Q4,Hypothyroidism,,2020,Q4,2,F,,20201116.0,20201112,20201123,EXP,,NVSC2020SG299075,NOVARTIS,,55.0,YR,,F,Y,,,20201123.0,,MD,SG,SG,2020,Q4,Adult
184990492,18499049,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, UNKNOWN",,,U,,,,,10.0,MG,,,2020,Q4,Immunosuppression,,2020,Q4,2,F,,20201116.0,20201112,20201123,EXP,,NVSC2020SG299075,NOVARTIS,,55.0,YR,,F,Y,,,20201123.0,,MD,SG,SG,2020,Q4,Adult
184990492,18499049,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, UNKNOWN",,,U,,,,,10.0,MG,,,2020,Q4,Mass,,2020,Q4,2,F,,20201116.0,20201112,20201123,EXP,,NVSC2020SG299075,NOVARTIS,,55.0,YR,,F,Y,,,20201123.0,,MD,SG,SG,2020,Q4,Adult
184990492,18499049,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, UNKNOWN",,,U,,,,,10.0,MG,,,2020,Q4,Neoplasm malignant,,2020,Q4,2,F,,20201116.0,20201112,20201123,EXP,,NVSC2020SG299075,NOVARTIS,,55.0,YR,,F,Y,,,20201123.0,,MD,SG,SG,2020,Q4,Adult
184990492,18499049,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MG, UNKNOWN",,,U,,,,,10.0,MG,,,2020,Q4,Thyroid mass,,2020,Q4,2,F,,20201116.0,20201112,20201123,EXP,,NVSC2020SG299075,NOVARTIS,,55.0,YR,,F,Y,,,20201123.0,,MD,SG,SG,2020,Q4,Adult
185009272,18500927,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,,,2020,Q4,Euglycaemic diabetic ketoacidosis,,2020,Q4,2,F,,20201202.0,20201113,20201210,EXP,,DE-MYLANLABS-2020M1094518,MYLAN,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEININGER D. SEVERE CONDITION OF SHOCK WITH COMBINED LACTIC AND KETOACIDOSIS IN A PATIENT AFTER LEFT-SIDED PANCREAS RESECTION UNDER PERMANENT THERAPY WITH METFORMIN AND DAPAGLIFLOZIN. [GERMAN]. ANASTHESIOL-INTENSIVMED 2020;61(10):472-478.",76.0,YR,,M,Y,100.0,KG,20201210.0,,MD,DE,DE,2020,Q4,Elderly
185009272,18500927,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,,,2020,Q4,Haemodynamic instability,,2020,Q4,2,F,,20201202.0,20201113,20201210,EXP,,DE-MYLANLABS-2020M1094518,MYLAN,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEININGER D. SEVERE CONDITION OF SHOCK WITH COMBINED LACTIC AND KETOACIDOSIS IN A PATIENT AFTER LEFT-SIDED PANCREAS RESECTION UNDER PERMANENT THERAPY WITH METFORMIN AND DAPAGLIFLOZIN. [GERMAN]. ANASTHESIOL-INTENSIVMED 2020;61(10):472-478.",76.0,YR,,M,Y,100.0,KG,20201210.0,,MD,DE,DE,2020,Q4,Elderly
185009272,18500927,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,,,2020,Q4,Lactic acidosis,,2020,Q4,2,F,,20201202.0,20201113,20201210,EXP,,DE-MYLANLABS-2020M1094518,MYLAN,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEININGER D. SEVERE CONDITION OF SHOCK WITH COMBINED LACTIC AND KETOACIDOSIS IN A PATIENT AFTER LEFT-SIDED PANCREAS RESECTION UNDER PERMANENT THERAPY WITH METFORMIN AND DAPAGLIFLOZIN. [GERMAN]. ANASTHESIOL-INTENSIVMED 2020;61(10):472-478.",76.0,YR,,M,Y,100.0,KG,20201210.0,,MD,DE,DE,2020,Q4,Elderly
185009272,18500927,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,,,2020,Q4,Shock,,2020,Q4,2,F,,20201202.0,20201113,20201210,EXP,,DE-MYLANLABS-2020M1094518,MYLAN,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEININGER D. SEVERE CONDITION OF SHOCK WITH COMBINED LACTIC AND KETOACIDOSIS IN A PATIENT AFTER LEFT-SIDED PANCREAS RESECTION UNDER PERMANENT THERAPY WITH METFORMIN AND DAPAGLIFLOZIN. [GERMAN]. ANASTHESIOL-INTENSIVMED 2020;61(10):472-478.",76.0,YR,,M,Y,100.0,KG,20201210.0,,MD,DE,DE,2020,Q4,Elderly
185049126,18504912,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q4,Anaphylactic shock,,2020,Q4,6,F,,20201209.0,20201115,20201218,EXP,,DE-AUROBINDO-AUR-APL-2020-055698,AUROBINDO,,76.0,YR,,M,Y,100.0,KG,20201218.0,,HP,DE,DE,2020,Q4,Elderly
185049126,18504912,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q4,Atrial flutter,,2020,Q4,6,F,,20201209.0,20201115,20201218,EXP,,DE-AUROBINDO-AUR-APL-2020-055698,AUROBINDO,,76.0,YR,,M,Y,100.0,KG,20201218.0,,HP,DE,DE,2020,Q4,Elderly
185049126,18504912,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q4,Euglycaemic diabetic ketoacidosis,,2020,Q4,6,F,,20201209.0,20201115,20201218,EXP,,DE-AUROBINDO-AUR-APL-2020-055698,AUROBINDO,,76.0,YR,,M,Y,100.0,KG,20201218.0,,HP,DE,DE,2020,Q4,Elderly
185049126,18504912,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q4,Haemodynamic instability,,2020,Q4,6,F,,20201209.0,20201115,20201218,EXP,,DE-AUROBINDO-AUR-APL-2020-055698,AUROBINDO,,76.0,YR,,M,Y,100.0,KG,20201218.0,,HP,DE,DE,2020,Q4,Elderly
185049126,18504912,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q4,Intentional product use issue,,2020,Q4,6,F,,20201209.0,20201115,20201218,EXP,,DE-AUROBINDO-AUR-APL-2020-055698,AUROBINDO,,76.0,YR,,M,Y,100.0,KG,20201218.0,,HP,DE,DE,2020,Q4,Elderly
185049126,18504912,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q4,Lactic acidosis,,2020,Q4,6,F,,20201209.0,20201115,20201218,EXP,,DE-AUROBINDO-AUR-APL-2020-055698,AUROBINDO,,76.0,YR,,M,Y,100.0,KG,20201218.0,,HP,DE,DE,2020,Q4,Elderly
185049126,18504912,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q4,Metabolic acidosis,,2020,Q4,6,F,,20201209.0,20201115,20201218,EXP,,DE-AUROBINDO-AUR-APL-2020-055698,AUROBINDO,,76.0,YR,,M,Y,100.0,KG,20201218.0,,HP,DE,DE,2020,Q4,Elderly
185049126,18504912,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q4,Off label use,,2020,Q4,6,F,,20201209.0,20201115,20201218,EXP,,DE-AUROBINDO-AUR-APL-2020-055698,AUROBINDO,,76.0,YR,,M,Y,100.0,KG,20201218.0,,HP,DE,DE,2020,Q4,Elderly
185049126,18504912,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q4,Shock,,2020,Q4,6,F,,20201209.0,20201115,20201218,EXP,,DE-AUROBINDO-AUR-APL-2020-055698,AUROBINDO,,76.0,YR,,M,Y,100.0,KG,20201218.0,,HP,DE,DE,2020,Q4,Elderly
185049126,18504912,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q4,Supraventricular tachycardia,,2020,Q4,6,F,,20201209.0,20201115,20201218,EXP,,DE-AUROBINDO-AUR-APL-2020-055698,AUROBINDO,,76.0,YR,,M,Y,100.0,KG,20201218.0,,HP,DE,DE,2020,Q4,Elderly
185049126,18504912,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q4,Toxicity to various agents,,2020,Q4,6,F,,20201209.0,20201115,20201218,EXP,,DE-AUROBINDO-AUR-APL-2020-055698,AUROBINDO,,76.0,YR,,M,Y,100.0,KG,20201218.0,,HP,DE,DE,2020,Q4,Elderly
185049126,18504912,5,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, ONCE A DAY",,,Y,U,,,,10.0,MG,TABLET,QD,2020,Q4,Ventricular tachycardia,,2020,Q4,6,F,,20201209.0,20201115,20201218,EXP,,DE-AUROBINDO-AUR-APL-2020-055698,AUROBINDO,,76.0,YR,,M,Y,100.0,KG,20201218.0,,HP,DE,DE,2020,Q4,Elderly
185049126,18504912,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,Y,U,,,,,,TABLET,,2020,Q4,Anaphylactic shock,,2020,Q4,6,F,,20201209.0,20201115,20201218,EXP,,DE-AUROBINDO-AUR-APL-2020-055698,AUROBINDO,,76.0,YR,,M,Y,100.0,KG,20201218.0,,HP,DE,DE,2020,Q4,Elderly
185049126,18504912,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,Y,U,,,,,,TABLET,,2020,Q4,Atrial flutter,,2020,Q4,6,F,,20201209.0,20201115,20201218,EXP,,DE-AUROBINDO-AUR-APL-2020-055698,AUROBINDO,,76.0,YR,,M,Y,100.0,KG,20201218.0,,HP,DE,DE,2020,Q4,Elderly
185049126,18504912,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,Y,U,,,,,,TABLET,,2020,Q4,Euglycaemic diabetic ketoacidosis,,2020,Q4,6,F,,20201209.0,20201115,20201218,EXP,,DE-AUROBINDO-AUR-APL-2020-055698,AUROBINDO,,76.0,YR,,M,Y,100.0,KG,20201218.0,,HP,DE,DE,2020,Q4,Elderly
185049126,18504912,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,Y,U,,,,,,TABLET,,2020,Q4,Haemodynamic instability,,2020,Q4,6,F,,20201209.0,20201115,20201218,EXP,,DE-AUROBINDO-AUR-APL-2020-055698,AUROBINDO,,76.0,YR,,M,Y,100.0,KG,20201218.0,,HP,DE,DE,2020,Q4,Elderly
185049126,18504912,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,Y,U,,,,,,TABLET,,2020,Q4,Intentional product use issue,,2020,Q4,6,F,,20201209.0,20201115,20201218,EXP,,DE-AUROBINDO-AUR-APL-2020-055698,AUROBINDO,,76.0,YR,,M,Y,100.0,KG,20201218.0,,HP,DE,DE,2020,Q4,Elderly
185049126,18504912,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,Y,U,,,,,,TABLET,,2020,Q4,Lactic acidosis,,2020,Q4,6,F,,20201209.0,20201115,20201218,EXP,,DE-AUROBINDO-AUR-APL-2020-055698,AUROBINDO,,76.0,YR,,M,Y,100.0,KG,20201218.0,,HP,DE,DE,2020,Q4,Elderly
185049126,18504912,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,Y,U,,,,,,TABLET,,2020,Q4,Metabolic acidosis,,2020,Q4,6,F,,20201209.0,20201115,20201218,EXP,,DE-AUROBINDO-AUR-APL-2020-055698,AUROBINDO,,76.0,YR,,M,Y,100.0,KG,20201218.0,,HP,DE,DE,2020,Q4,Elderly
185049126,18504912,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,Y,U,,,,,,TABLET,,2020,Q4,Off label use,,2020,Q4,6,F,,20201209.0,20201115,20201218,EXP,,DE-AUROBINDO-AUR-APL-2020-055698,AUROBINDO,,76.0,YR,,M,Y,100.0,KG,20201218.0,,HP,DE,DE,2020,Q4,Elderly
185049126,18504912,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,Y,U,,,,,,TABLET,,2020,Q4,Shock,,2020,Q4,6,F,,20201209.0,20201115,20201218,EXP,,DE-AUROBINDO-AUR-APL-2020-055698,AUROBINDO,,76.0,YR,,M,Y,100.0,KG,20201218.0,,HP,DE,DE,2020,Q4,Elderly
185049126,18504912,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,Y,U,,,,,,TABLET,,2020,Q4,Supraventricular tachycardia,,2020,Q4,6,F,,20201209.0,20201115,20201218,EXP,,DE-AUROBINDO-AUR-APL-2020-055698,AUROBINDO,,76.0,YR,,M,Y,100.0,KG,20201218.0,,HP,DE,DE,2020,Q4,Elderly
185049126,18504912,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,Y,U,,,,,,TABLET,,2020,Q4,Toxicity to various agents,,2020,Q4,6,F,,20201209.0,20201115,20201218,EXP,,DE-AUROBINDO-AUR-APL-2020-055698,AUROBINDO,,76.0,YR,,M,Y,100.0,KG,20201218.0,,HP,DE,DE,2020,Q4,Elderly
185049126,18504912,6,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,Y,U,,,,,,TABLET,,2020,Q4,Ventricular tachycardia,,2020,Q4,6,F,,20201209.0,20201115,20201218,EXP,,DE-AUROBINDO-AUR-APL-2020-055698,AUROBINDO,,76.0,YR,,M,Y,100.0,KG,20201218.0,,HP,DE,DE,2020,Q4,Elderly
185071471,18507147,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2020,Q4,Ketoacidosis,,2020,Q4,1,I,,20201102.0,20201116,20201116,EXP,,DE-BEXIMCO-2020BEX00162,BEXIMCO PHARMACEUTICALS,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEININGER D.. SEVERE CONDITION OF SHOCK WITH COMBINED LACTIC AND KETOACIDOSIS IN A PATIENT AFTER LEFT-SIDED PANCREAS RESECTION UNDER PERMANENT THERAPY WITH METFORMIN AND DAPAGLIFLOZIN.. ANASTEHSIOL INTENSIVMED.. 2020;61(10):472-748",76.0,YR,,M,Y,,,20201112.0,,HP,DE,DE,2020,Q4,Elderly
185071471,18507147,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2020,Q4,Lactic acidosis,,2020,Q4,1,I,,20201102.0,20201116,20201116,EXP,,DE-BEXIMCO-2020BEX00162,BEXIMCO PHARMACEUTICALS,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEININGER D.. SEVERE CONDITION OF SHOCK WITH COMBINED LACTIC AND KETOACIDOSIS IN A PATIENT AFTER LEFT-SIDED PANCREAS RESECTION UNDER PERMANENT THERAPY WITH METFORMIN AND DAPAGLIFLOZIN.. ANASTEHSIOL INTENSIVMED.. 2020;61(10):472-748",76.0,YR,,M,Y,,,20201112.0,,HP,DE,DE,2020,Q4,Elderly
185117401,18511740,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q4,Glycosylated haemoglobin increased,,2020,Q4,1,I,20200917.0,20201111.0,20201117,20201117,EXP,,DE-ASTRAZENECA-2020SF48505,ASTRAZENECA,,69.0,YR,,F,Y,,,20201117.0,,,DE,DE,2020,Q4,Elderly
185117401,18511740,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q4,Hyperglycaemia,,2020,Q4,1,I,20200917.0,20201111.0,20201117,20201117,EXP,,DE-ASTRAZENECA-2020SF48505,ASTRAZENECA,,69.0,YR,,F,Y,,,20201117.0,,,DE,DE,2020,Q4,Elderly
185117401,18511740,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q4,Ketoacidosis,,2020,Q4,1,I,20200917.0,20201111.0,20201117,20201117,EXP,,DE-ASTRAZENECA-2020SF48505,ASTRAZENECA,,69.0,YR,,F,Y,,,20201117.0,,,DE,DE,2020,Q4,Elderly
185139211,18513921,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2020,Q4,Infusion site joint swelling,,2020,Q4,1,I,20201019.0,20201020.0,20201118,20201118,EXP,,DE-OCTA-GAM22020DE,OCTAPHARMA,,31.0,YR,A,M,Y,102.0,KG,20201117.0,,CN,DE,DE,2020,Q4,Young Adult
185139211,18513921,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2020,Q4,Infusion site pain,,2020,Q4,1,I,20201019.0,20201020.0,20201118,20201118,EXP,,DE-OCTA-GAM22020DE,OCTAPHARMA,,31.0,YR,A,M,Y,102.0,KG,20201117.0,,CN,DE,DE,2020,Q4,Young Adult
185139211,18513921,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2020,Q4,Infusion site warmth,,2020,Q4,1,I,20201019.0,20201020.0,20201118,20201118,EXP,,DE-OCTA-GAM22020DE,OCTAPHARMA,,31.0,YR,A,M,Y,102.0,KG,20201117.0,,CN,DE,DE,2020,Q4,Young Adult
185139211,18513921,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2020,Q4,Leukopenia,,2020,Q4,1,I,20201019.0,20201020.0,20201118,20201118,EXP,,DE-OCTA-GAM22020DE,OCTAPHARMA,,31.0,YR,A,M,Y,102.0,KG,20201117.0,,CN,DE,DE,2020,Q4,Young Adult
185139211,18513921,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2020,Q4,Pyrexia,,2020,Q4,1,I,20201019.0,20201020.0,20201118,20201118,EXP,,DE-OCTA-GAM22020DE,OCTAPHARMA,,31.0,YR,A,M,Y,102.0,KG,20201117.0,,CN,DE,DE,2020,Q4,Young Adult
185166622,18516662,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, PER DAY",,,,,,,,10.0,MG,,,2020,Q4,Carcinoid crisis,,2020,Q4,2,F,,20201217.0,20201118,20201228,EXP,DE-MLMSERVICE-20201028-2553710-1,DE-STRIDES ARCOLAB LIMITED-2020SP014037,STRIDES,,76.0,YR,,M,Y,100.0,KG,20201228.0,,,NL,DE,2020,Q4,Elderly
185166622,18516662,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, PER DAY",,,,,,,,10.0,MG,,,2020,Q4,Haemodynamic instability,,2020,Q4,2,F,,20201217.0,20201118,20201228,EXP,DE-MLMSERVICE-20201028-2553710-1,DE-STRIDES ARCOLAB LIMITED-2020SP014037,STRIDES,,76.0,YR,,M,Y,100.0,KG,20201228.0,,,NL,DE,2020,Q4,Elderly
185166622,18516662,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, PER DAY",,,,,,,,10.0,MG,,,2020,Q4,Toxicity to various agents,,2020,Q4,2,F,,20201217.0,20201118,20201228,EXP,DE-MLMSERVICE-20201028-2553710-1,DE-STRIDES ARCOLAB LIMITED-2020SP014037,STRIDES,,76.0,YR,,M,Y,100.0,KG,20201228.0,,,NL,DE,2020,Q4,Elderly
185173601,18517360,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2020,Q4,Diabetic ketoacidosis,,2020,Q4,1,I,20200408.0,,20201118,20201118,DIR,,,FDA-CTU,,52.0,YR,,M,N,74.1,KG,20201118.0,N,PH,US,US,2020,Q4,Adult
185173601,18517360,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2020,Q4,Therapy cessation,,2020,Q4,1,I,20200408.0,,20201118,20201118,DIR,,,FDA-CTU,,52.0,YR,,M,N,74.1,KG,20201118.0,N,PH,US,US,2020,Q4,Adult
185196152,18519615,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,, UNKNOWN,,,,,,,2020,Q4,Carcinoid crisis,,2020,Q4,2,F,,20201123.0,20201119,20201128,EXP,,DE-LUPIN PHARMACEUTICALS INC.-2020-08977,LUPIN,,76.0,YR,,M,Y,,,20201128.0,,MD,DE,DE,2020,Q4,Elderly
185196152,18519615,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,, UNKNOWN,,,,,,,2020,Q4,Euglycaemic diabetic ketoacidosis,,2020,Q4,2,F,,20201123.0,20201119,20201128,EXP,,DE-LUPIN PHARMACEUTICALS INC.-2020-08977,LUPIN,,76.0,YR,,M,Y,,,20201128.0,,MD,DE,DE,2020,Q4,Elderly
185196152,18519615,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,, UNKNOWN,,,,,,,2020,Q4,Lactic acidosis,,2020,Q4,2,F,,20201123.0,20201119,20201128,EXP,,DE-LUPIN PHARMACEUTICALS INC.-2020-08977,LUPIN,,76.0,YR,,M,Y,,,20201128.0,,MD,DE,DE,2020,Q4,Elderly
185196152,18519615,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,, UNKNOWN,,,,,,,2020,Q4,Shock,,2020,Q4,2,F,,20201123.0,20201119,20201128,EXP,,DE-LUPIN PHARMACEUTICALS INC.-2020-08977,LUPIN,,76.0,YR,,M,Y,,,20201128.0,,MD,DE,DE,2020,Q4,Elderly
185220701,18522070,5,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2020,Q4,Taste disorder,,2020,Q4,1,I,,20201109.0,20201119,20201119,EXP,GB-MHRA-EYC 00232196,GB-NOVOPROD-766270,NOVO NORDISK,,59.0,YR,,M,Y,78.7,KG,20201119.0,,CN,GB,GB,2020,Q4,Adult
185274561,18527456,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,N,,,,202293.0,10.0,MG,,QD,2020,Q4,Diabetic ketoacidosis,,2020,Q4,1,I,20201028.0,20201116.0,20201120,20201120,EXP,,GB-ASTRAZENECA-2020SF51665,ASTRAZENECA,,65.0,YR,,M,Y,55.3,KG,20201120.0,,HP,GB,GB,2020,Q4,Elderly
185341821,18534182,1,PS,DAPAGLIFLOZINE,DAPAGLIFLOZIN,1,Oral,,3910.0,MG,Y,,,,,10.0,MG,TABLET,QD,2020,Q4,Diabetic ketoacidosis,,2020,Q4,1,I,20201103.0,20201113.0,20201123,20201123,EXP,,NL-ASTRAZENECA-2020SF50135,ASTRAZENECA,,54.0,YR,,M,Y,72.0,KG,20201123.0,,MD,NL,NL,2020,Q4,Adult
185481691,18548169,2,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE;METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2020,Q4,Anaemia,,2020,Q4,1,I,2020.0,20201119.0,20201126,20201126,EXP,,BR-JNJFOC-20201137833,JOHNSON AND JOHNSON,,60.0,YR,A,F,Y,,,20201126.0,,CN,BR,BR,2020,Q4,Adult
185481691,18548169,2,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE;METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2020,Q4,COVID-19,,2020,Q4,1,I,2020.0,20201119.0,20201126,20201126,EXP,,BR-JNJFOC-20201137833,JOHNSON AND JOHNSON,,60.0,YR,A,F,Y,,,20201126.0,,CN,BR,BR,2020,Q4,Adult
185492163,18549216,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2020,Q4,Carcinoid crisis,,2020,Q4,3,F,,20201215.0,20201126,20201223,EXP,,DE-TEVA-2020-DE-1851274,TEVA,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEININGER D. SEVERE CONDITION OF SHOCK WITH COMBINED LACTIC AND KETOACIDOSIS IN A PATIENT AFTER LEFT-SIDED PANCREAS RESECTION UNDER PERMANENT THERAPY WITH METFORMIN AND DAPAGLIFLOZIN. [GERMAN]. ANASTHESIOL-INTENSIVMED 2020;61(10):472-478.",76.0,YR,E,M,Y,,,20201223.0,,MD,DE,DE,2020,Q4,Elderly
185492163,18549216,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2020,Q4,Euglycaemic diabetic ketoacidosis,,2020,Q4,3,F,,20201215.0,20201126,20201223,EXP,,DE-TEVA-2020-DE-1851274,TEVA,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEININGER D. SEVERE CONDITION OF SHOCK WITH COMBINED LACTIC AND KETOACIDOSIS IN A PATIENT AFTER LEFT-SIDED PANCREAS RESECTION UNDER PERMANENT THERAPY WITH METFORMIN AND DAPAGLIFLOZIN. [GERMAN]. ANASTHESIOL-INTENSIVMED 2020;61(10):472-478.",76.0,YR,E,M,Y,,,20201223.0,,MD,DE,DE,2020,Q4,Elderly
185492163,18549216,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2020,Q4,Lactic acidosis,,2020,Q4,3,F,,20201215.0,20201126,20201223,EXP,,DE-TEVA-2020-DE-1851274,TEVA,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEININGER D. SEVERE CONDITION OF SHOCK WITH COMBINED LACTIC AND KETOACIDOSIS IN A PATIENT AFTER LEFT-SIDED PANCREAS RESECTION UNDER PERMANENT THERAPY WITH METFORMIN AND DAPAGLIFLOZIN. [GERMAN]. ANASTHESIOL-INTENSIVMED 2020;61(10):472-478.",76.0,YR,E,M,Y,,,20201223.0,,MD,DE,DE,2020,Q4,Elderly
185492163,18549216,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2020,Q4,Off label use,,2020,Q4,3,F,,20201215.0,20201126,20201223,EXP,,DE-TEVA-2020-DE-1851274,TEVA,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEININGER D. SEVERE CONDITION OF SHOCK WITH COMBINED LACTIC AND KETOACIDOSIS IN A PATIENT AFTER LEFT-SIDED PANCREAS RESECTION UNDER PERMANENT THERAPY WITH METFORMIN AND DAPAGLIFLOZIN. [GERMAN]. ANASTHESIOL-INTENSIVMED 2020;61(10):472-478.",76.0,YR,E,M,Y,,,20201223.0,,MD,DE,DE,2020,Q4,Elderly
185492163,18549216,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2020,Q4,Shock,,2020,Q4,3,F,,20201215.0,20201126,20201223,EXP,,DE-TEVA-2020-DE-1851274,TEVA,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEININGER D. SEVERE CONDITION OF SHOCK WITH COMBINED LACTIC AND KETOACIDOSIS IN A PATIENT AFTER LEFT-SIDED PANCREAS RESECTION UNDER PERMANENT THERAPY WITH METFORMIN AND DAPAGLIFLOZIN. [GERMAN]. ANASTHESIOL-INTENSIVMED 2020;61(10):472-478.",76.0,YR,E,M,Y,,,20201223.0,,MD,DE,DE,2020,Q4,Elderly
185492163,18549216,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2020,Q4,Toxicity to various agents,,2020,Q4,3,F,,20201215.0,20201126,20201223,EXP,,DE-TEVA-2020-DE-1851274,TEVA,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEININGER D. SEVERE CONDITION OF SHOCK WITH COMBINED LACTIC AND KETOACIDOSIS IN A PATIENT AFTER LEFT-SIDED PANCREAS RESECTION UNDER PERMANENT THERAPY WITH METFORMIN AND DAPAGLIFLOZIN. [GERMAN]. ANASTHESIOL-INTENSIVMED 2020;61(10):472-478.",76.0,YR,E,M,Y,,,20201223.0,,MD,DE,DE,2020,Q4,Elderly
185494942,18549494,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,3930.417,MG,N,,,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Diabetic ketoacidosis,,2020,Q4,2,F,20201103.0,20201120.0,20201126,20201211,EXP,,GB-ASTRAZENECA-2020SF54879,ASTRAZENECA,,49.0,YR,,M,Y,,,20201211.0,,PH,GB,GB,2020,Q4,Adult
185505303,18550530,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,WAS TAKEN UNTIL THE EVENING BEFORE SURGERY,,,,,,,,,,,,2020,Q4,Haemodynamic instability,,2020,Q4,3,F,,20201204.0,20201126,20201208,EXP,,DE-ABBVIE-20K-062-3666852-00,ABBVIE,"MALICEK D, WAGNER S, KAISER S, ET AL.. SEVERE CONDITION OF SHOCK WITH COMBINED LACTIC AND KETOACIDOSIS IN A PATIENT AFTER LEFT-SIDED PANCREAS RESECTION UNDER PERMANENT THERAPY WITH METFORMIN AND DAPAGLIFLOZIN. ANASTHESIOL-INTENSIVMED.. 2020;61(10):472-478.",76.0,YR,,M,Y,,,20201208.0,,HP,COUNTRY NOT SPECIFIED,DE,2020,Q4,Elderly
185505303,18550530,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,WAS TAKEN UNTIL THE EVENING BEFORE SURGERY,,,,,,,,,,,,2020,Q4,Ventricular tachycardia,,2020,Q4,3,F,,20201204.0,20201126,20201208,EXP,,DE-ABBVIE-20K-062-3666852-00,ABBVIE,"MALICEK D, WAGNER S, KAISER S, ET AL.. SEVERE CONDITION OF SHOCK WITH COMBINED LACTIC AND KETOACIDOSIS IN A PATIENT AFTER LEFT-SIDED PANCREAS RESECTION UNDER PERMANENT THERAPY WITH METFORMIN AND DAPAGLIFLOZIN. ANASTHESIOL-INTENSIVMED.. 2020;61(10):472-478.",76.0,YR,,M,Y,,,20201208.0,,HP,COUNTRY NOT SPECIFIED,DE,2020,Q4,Elderly
185523551,18552355,3,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Off label use,,2020,Q4,1,I,,20200518.0,20201127,20201127,PER,,US-ALVOGEN-2020-ALVOGEN-108482,ALVOGEN,,44.0,YR,,M,Y,136.53,KG,20201127.0,,MD,US,US,2020,Q4,Adult
185552911,18555291,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,510.0,MG,Y,,,,202293.0,10.0,MG,,QD,2020,Q4,Necrosis,,2020,Q4,1,I,20201015.0,20201120.0,20201127,20201127,EXP,,GB-ASTRAZENECA-2020SF54572,ASTRAZENECA,,81.0,YR,,F,Y,,,20201127.0,,,GB,GB,2020,Q4,Elderly
185552911,18555291,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,510.0,MG,Y,,,,202293.0,10.0,MG,,QD,2020,Q4,Pain,,2020,Q4,1,I,20201015.0,20201120.0,20201127,20201127,EXP,,GB-ASTRAZENECA-2020SF54572,ASTRAZENECA,,81.0,YR,,F,Y,,,20201127.0,,,GB,GB,2020,Q4,Elderly
185552911,18555291,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,510.0,MG,Y,,,,202293.0,10.0,MG,,QD,2020,Q4,Skin discolouration,,2020,Q4,1,I,20201015.0,20201120.0,20201127,20201127,EXP,,GB-ASTRAZENECA-2020SF54572,ASTRAZENECA,,81.0,YR,,F,Y,,,20201127.0,,,GB,GB,2020,Q4,Elderly
185554881,18555488,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U, MA3239,,,10.0,MG,TABLET,QD,2020,Q4,Pyrexia,,2020,Q4,1,I,20200717.0,20201118.0,20201127,20201127,EXP,,"CN-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-063306",BOEHRINGER INGELHEIM,,78.0,YR,E,F,Y,51.0,KG,20201127.0,,CN,CN,CN,2020,Q4,Elderly
185554881,18555488,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,U, MA3239,,,10.0,MG,TABLET,QD,2020,Q4,Urinary tract infection,,2020,Q4,1,I,20200717.0,20201118.0,20201127,20201127,EXP,,"CN-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-063306",BOEHRINGER INGELHEIM,,78.0,YR,E,F,Y,51.0,KG,20201127.0,,CN,CN,CN,2020,Q4,Elderly
185556461,18555646,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,610.0,MG,Y,, MA2079,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Ketosis,,2020,Q4,1,I,20201111.0,20201120.0,20201127,20201127,EXP,,CN-ASTRAZENECA-2020SF56576,ASTRAZENECA,,24472.0,DY,,F,Y,48.0,KG,20201127.0,,HP,CN,CN,2020,Q4,Elderly
185556461,18555646,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,610.0,MG,Y,, MA2079,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Urinary tract infection,,2020,Q4,1,I,20201111.0,20201120.0,20201127,20201127,EXP,,CN-ASTRAZENECA-2020SF56576,ASTRAZENECA,,24472.0,DY,,F,Y,48.0,KG,20201127.0,,HP,CN,CN,2020,Q4,Elderly
185556461,18555646,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,610.0,MG,Y,, MA2079,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Ketosis,,2020,Q4,1,I,20201111.0,20201120.0,20201127,20201127,EXP,,CN-ASTRAZENECA-2020SF56576,ASTRAZENECA,,24472.0,DY,,F,Y,48.0,KG,20201127.0,,HP,CN,CN,2020,Q4,Elderly
185556461,18555646,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,610.0,MG,Y,, MA2079,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Urinary tract infection,,2020,Q4,1,I,20201111.0,20201120.0,20201127,20201127,EXP,,CN-ASTRAZENECA-2020SF56576,ASTRAZENECA,,24472.0,DY,,F,Y,48.0,KG,20201127.0,,HP,CN,CN,2020,Q4,Elderly
185564521,18556452,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2020,Q4,Left ventricular dysfunction,,2020,Q4,1,I,,20201120.0,20201128,20201128,EXP,,NVSC2020VN313937,NOVARTIS,,61.0,YR,,M,Y,,,20201128.0,,MD,VN,VN,2020,Q4,Adult
185564521,18556452,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2020,Q4,Mitral valve incompetence,,2020,Q4,1,I,,20201120.0,20201128,20201128,EXP,,NVSC2020VN313937,NOVARTIS,,61.0,YR,,M,Y,,,20201128.0,,MD,VN,VN,2020,Q4,Adult
185564521,18556452,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2020,Q4,Pulmonary arterial pressure increased,,2020,Q4,1,I,,20201120.0,20201128,20201128,EXP,,NVSC2020VN313937,NOVARTIS,,61.0,YR,,M,Y,,,20201128.0,,MD,VN,VN,2020,Q4,Adult
185564521,18556452,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2020,Q4,Tricuspid valve incompetence,,2020,Q4,1,I,,20201120.0,20201128,20201128,EXP,,NVSC2020VN313937,NOVARTIS,,61.0,YR,,M,Y,,,20201128.0,,MD,VN,VN,2020,Q4,Adult
185564521,18556452,11,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2020,Q4,Wall motion score index abnormal,,2020,Q4,1,I,,20201120.0,20201128,20201128,EXP,,NVSC2020VN313937,NOVARTIS,,61.0,YR,,M,Y,,,20201128.0,,MD,VN,VN,2020,Q4,Adult
185596611,18559661,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,,,2020,Q4,Euglycaemic diabetic ketoacidosis,,2020,Q4,1,I,20200630.0,20201124.0,20201130,20201130,EXP,,ES-ASTRAZENECA-2020SF55347,ASTRAZENECA,,60.0,YR,,M,Y,,,20201130.0,,PH,ES,ES,2020,Q4,Adult
185604171,18560417,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,, 2004145,,202293.0,1.0,DF,TABLET,QD,2020,Q4,Renal injury,,2020,Q4,1,I,20201027.0,20201122.0,20201130,20201130,EXP,,CN-ASTRAZENECA-2020SF58522,ASTRAZENECA,,20454.0,DY,,M,Y,74.0,KG,20201130.0,,HP,CN,CN,2020,Q4,Elderly
185604171,18560417,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,, 2004145,,202293.0,1.0,DF,TABLET,QD,2020,Q4,Urinary tract infection,,2020,Q4,1,I,20201027.0,20201122.0,20201130,20201130,EXP,,CN-ASTRAZENECA-2020SF58522,ASTRAZENECA,,20454.0,DY,,M,Y,74.0,KG,20201130.0,,HP,CN,CN,2020,Q4,Elderly
185629211,18562921,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,,, 2006157,,,10.0,MG,TABLET,QD,2020,Q4,Hepatic function abnormal,,2020,Q4,1,I,20201023.0,20201121.0,20201201,20201201,EXP,,CN-ABBVIE-20P-035-3670577-00,ABBVIE,,53.0,YR,,M,Y,97.0,KG,20201201.0,,HP,CN,CN,2020,Q4,Adult
185630491,18563049,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Chest pain,,2020,Q4,1,I,20201105.0,20201125.0,20201201,20201201,EXP,,GB-ASTRAZENECA-2020SF56516,ASTRAZENECA,,48.0,YR,,M,Y,,,20201201.0,,PH,GB,GB,2020,Q4,Adult
185630491,18563049,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Dizziness,,2020,Q4,1,I,20201105.0,20201125.0,20201201,20201201,EXP,,GB-ASTRAZENECA-2020SF56516,ASTRAZENECA,,48.0,YR,,M,Y,,,20201201.0,,PH,GB,GB,2020,Q4,Adult
185630491,18563049,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Duodenal ulcer haemorrhage,,2020,Q4,1,I,20201105.0,20201125.0,20201201,20201201,EXP,,GB-ASTRAZENECA-2020SF56516,ASTRAZENECA,,48.0,YR,,M,Y,,,20201201.0,,PH,GB,GB,2020,Q4,Adult
185630491,18563049,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Haematemesis,,2020,Q4,1,I,20201105.0,20201125.0,20201201,20201201,EXP,,GB-ASTRAZENECA-2020SF56516,ASTRAZENECA,,48.0,YR,,M,Y,,,20201201.0,,PH,GB,GB,2020,Q4,Adult
185630491,18563049,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Syncope,,2020,Q4,1,I,20201105.0,20201125.0,20201201,20201201,EXP,,GB-ASTRAZENECA-2020SF56516,ASTRAZENECA,,48.0,YR,,M,Y,,,20201201.0,,PH,GB,GB,2020,Q4,Adult
185630491,18563049,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Unresponsive to stimuli,,2020,Q4,1,I,20201105.0,20201125.0,20201201,20201201,EXP,,GB-ASTRAZENECA-2020SF56516,ASTRAZENECA,,48.0,YR,,M,Y,,,20201201.0,,PH,GB,GB,2020,Q4,Adult
185630491,18563049,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Upper gastrointestinal haemorrhage,,2020,Q4,1,I,20201105.0,20201125.0,20201201,20201201,EXP,,GB-ASTRAZENECA-2020SF56516,ASTRAZENECA,,48.0,YR,,M,Y,,,20201201.0,,PH,GB,GB,2020,Q4,Adult
185659351,18565935,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,, UNKNOWN,,202293.0,10.0,MG,TABLET,,2020,Q4,Cardiac failure chronic,,2020,Q4,1,I,,20201123.0,20201201,20201201,EXP,,DE-ASTRAZENECA-2020SF57342,ASTRAZENECA,,61.0,YR,,M,Y,,,20201201.0,,,DE,DE,2020,Q4,Adult
185659461,18565946,1,PS,METFORMIN/DAPAGLIFLOZIN,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,"850/5 MG,TWO TIMES A DAY",,,U,, UNKNOWN,,205649.0,,,TABLET,,2020,Q4,Atrial fibrillation,,2020,Q4,1,I,2017.0,20201123.0,20201201,20201201,EXP,,DE-ASTRAZENECA-2020SF57334,ASTRAZENECA,,54.0,YR,,F,Y,,,20201201.0,,,DE,DE,2020,Q4,Adult
185659461,18565946,1,PS,METFORMIN/DAPAGLIFLOZIN,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,"850/5 MG,TWO TIMES A DAY",,,U,, UNKNOWN,,205649.0,,,TABLET,,2020,Q4,Pulmonary arterial pressure increased,,2020,Q4,1,I,2017.0,20201123.0,20201201,20201201,EXP,,DE-ASTRAZENECA-2020SF57334,ASTRAZENECA,,54.0,YR,,F,Y,,,20201201.0,,,DE,DE,2020,Q4,Adult
185668771,18566877,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q4,Diabetic ketoacidosis,,2020,Q4,1,I,,20201124.0,20201201,20201201,EXP,,GR-ASTRAZENECA-2020SF55437,ASTRAZENECA,,52.0,YR,,F,Y,,,20201201.0,,MD,GR,GR,2020,Q4,Adult
185668771,18566877,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q4,Pyrexia,,2020,Q4,1,I,,20201124.0,20201201,20201201,EXP,,GR-ASTRAZENECA-2020SF55437,ASTRAZENECA,,52.0,YR,,F,Y,,,20201201.0,,MD,GR,GR,2020,Q4,Adult
185671281,18567128,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MG,,,Y,,,,202293.0,,,TABLET,,2020,Q4,Diabetic ketoacidosis,,2020,Q4,1,I,,20201124.0,20201201,20201201,EXP,,GR-ASTRAZENECA-2020SF55490,ASTRAZENECA,,37.0,YR,,M,Y,,,20201201.0,,HP,GR,GR,2020,Q4,Adult
185671301,18567130,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MG,,,Y,,,,202293.0,,,TABLET,,2020,Q4,Diabetic ketoacidosis,,2020,Q4,1,I,,20201125.0,20201201,20201201,EXP,,GR-ASTRAZENECA-2020SF56120,ASTRAZENECA,,39.0,YR,,F,Y,,,20201201.0,,HP,GR,GR,2020,Q4,Adult
185671461,18567146,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,, UNKNOWN,,202293.0,10.0,MG,TABLET,,2020,Q4,Acute myocardial infarction,,2020,Q4,1,I,2010.0,20201125.0,20201201,20201201,EXP,,DE-ASTRAZENECA-2020SF58403,ASTRAZENECA,,78.0,YR,,M,Y,,,20201201.0,,MD,DE,DE,2020,Q4,Elderly
185671461,18567146,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,, UNKNOWN,,202293.0,10.0,MG,TABLET,,2020,Q4,Aortic valve incompetence,,2020,Q4,1,I,2010.0,20201125.0,20201201,20201201,EXP,,DE-ASTRAZENECA-2020SF58403,ASTRAZENECA,,78.0,YR,,M,Y,,,20201201.0,,MD,DE,DE,2020,Q4,Elderly
185671461,18567146,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,, UNKNOWN,,202293.0,10.0,MG,TABLET,,2020,Q4,Chronic kidney disease,,2020,Q4,1,I,2010.0,20201125.0,20201201,20201201,EXP,,DE-ASTRAZENECA-2020SF58403,ASTRAZENECA,,78.0,YR,,M,Y,,,20201201.0,,MD,DE,DE,2020,Q4,Elderly
185671461,18567146,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,, UNKNOWN,,202293.0,10.0,MG,TABLET,,2020,Q4,Cough,,2020,Q4,1,I,2010.0,20201125.0,20201201,20201201,EXP,,DE-ASTRAZENECA-2020SF58403,ASTRAZENECA,,78.0,YR,,M,Y,,,20201201.0,,MD,DE,DE,2020,Q4,Elderly
185671461,18567146,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,, UNKNOWN,,202293.0,10.0,MG,TABLET,,2020,Q4,Diastolic dysfunction,,2020,Q4,1,I,2010.0,20201125.0,20201201,20201201,EXP,,DE-ASTRAZENECA-2020SF58403,ASTRAZENECA,,78.0,YR,,M,Y,,,20201201.0,,MD,DE,DE,2020,Q4,Elderly
185671461,18567146,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,, UNKNOWN,,202293.0,10.0,MG,TABLET,,2020,Q4,Dyslipidaemia,,2020,Q4,1,I,2010.0,20201125.0,20201201,20201201,EXP,,DE-ASTRAZENECA-2020SF58403,ASTRAZENECA,,78.0,YR,,M,Y,,,20201201.0,,MD,DE,DE,2020,Q4,Elderly
185671461,18567146,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,, UNKNOWN,,202293.0,10.0,MG,TABLET,,2020,Q4,Haematoma,,2020,Q4,1,I,2010.0,20201125.0,20201201,20201201,EXP,,DE-ASTRAZENECA-2020SF58403,ASTRAZENECA,,78.0,YR,,M,Y,,,20201201.0,,MD,DE,DE,2020,Q4,Elderly
185671461,18567146,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,, UNKNOWN,,202293.0,10.0,MG,TABLET,,2020,Q4,Hepatotoxicity,,2020,Q4,1,I,2010.0,20201125.0,20201201,20201201,EXP,,DE-ASTRAZENECA-2020SF58403,ASTRAZENECA,,78.0,YR,,M,Y,,,20201201.0,,MD,DE,DE,2020,Q4,Elderly
185671461,18567146,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,, UNKNOWN,,202293.0,10.0,MG,TABLET,,2020,Q4,Hypoglycaemia,,2020,Q4,1,I,2010.0,20201125.0,20201201,20201201,EXP,,DE-ASTRAZENECA-2020SF58403,ASTRAZENECA,,78.0,YR,,M,Y,,,20201201.0,,MD,DE,DE,2020,Q4,Elderly
185671461,18567146,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,, UNKNOWN,,202293.0,10.0,MG,TABLET,,2020,Q4,Neuropathy peripheral,,2020,Q4,1,I,2010.0,20201125.0,20201201,20201201,EXP,,DE-ASTRAZENECA-2020SF58403,ASTRAZENECA,,78.0,YR,,M,Y,,,20201201.0,,MD,DE,DE,2020,Q4,Elderly
185671461,18567146,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,, UNKNOWN,,202293.0,10.0,MG,TABLET,,2020,Q4,Off label use,,2020,Q4,1,I,2010.0,20201125.0,20201201,20201201,EXP,,DE-ASTRAZENECA-2020SF58403,ASTRAZENECA,,78.0,YR,,M,Y,,,20201201.0,,MD,DE,DE,2020,Q4,Elderly
185671461,18567146,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,, UNKNOWN,,202293.0,10.0,MG,TABLET,,2020,Q4,Polyneuropathy,,2020,Q4,1,I,2010.0,20201125.0,20201201,20201201,EXP,,DE-ASTRAZENECA-2020SF58403,ASTRAZENECA,,78.0,YR,,M,Y,,,20201201.0,,MD,DE,DE,2020,Q4,Elderly
185671461,18567146,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,, UNKNOWN,,202293.0,10.0,MG,TABLET,,2020,Q4,Pulmonary congestion,,2020,Q4,1,I,2010.0,20201125.0,20201201,20201201,EXP,,DE-ASTRAZENECA-2020SF58403,ASTRAZENECA,,78.0,YR,,M,Y,,,20201201.0,,MD,DE,DE,2020,Q4,Elderly
185671461,18567146,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,, UNKNOWN,,202293.0,10.0,MG,TABLET,,2020,Q4,Right ventricular failure,,2020,Q4,1,I,2010.0,20201125.0,20201201,20201201,EXP,,DE-ASTRAZENECA-2020SF58403,ASTRAZENECA,,78.0,YR,,M,Y,,,20201201.0,,MD,DE,DE,2020,Q4,Elderly
185671461,18567146,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,, UNKNOWN,,202293.0,10.0,MG,TABLET,,2020,Q4,Tricuspid valve incompetence,,2020,Q4,1,I,2010.0,20201125.0,20201201,20201201,EXP,,DE-ASTRAZENECA-2020SF58403,ASTRAZENECA,,78.0,YR,,M,Y,,,20201201.0,,MD,DE,DE,2020,Q4,Elderly
185671461,18567146,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,, UNKNOWN,,202293.0,10.0,MG,TABLET,,2020,Q4,Vascular stent thrombosis,,2020,Q4,1,I,2010.0,20201125.0,20201201,20201201,EXP,,DE-ASTRAZENECA-2020SF58403,ASTRAZENECA,,78.0,YR,,M,Y,,,20201201.0,,MD,DE,DE,2020,Q4,Elderly
185671461,18567146,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,, UNKNOWN,,202293.0,10.0,MG,TABLET,,2020,Q4,Weight decreased,,2020,Q4,1,I,2010.0,20201125.0,20201201,20201201,EXP,,DE-ASTRAZENECA-2020SF58403,ASTRAZENECA,,78.0,YR,,M,Y,,,20201201.0,,MD,DE,DE,2020,Q4,Elderly
185708581,18570858,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2020,Q4,Alopecia universalis,,2020,Q4,1,I,,20201123.0,20201202,20201202,EXP,,DE-ANIPHARMA-2020-DE-000303,ANI,,64.0,YR,,M,Y,,,20201202.0,,MD,DE,DE,2020,Q4,Adult
185708591,18570859,12,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MG UNK,,,U,,,,,,,TABLET,,2020,Q4,Acute myocardial infarction,,2020,Q4,1,I,2010.0,20201201.0,20201202,20201202,EXP,,DE-ANIPHARMA-2020-DE-000301,ANI,,78.0,YR,,M,Y,,,20201202.0,,MD,DE,DE,2020,Q4,Elderly
185708591,18570859,12,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MG UNK,,,U,,,,,,,TABLET,,2020,Q4,Aortic valve incompetence,,2020,Q4,1,I,2010.0,20201201.0,20201202,20201202,EXP,,DE-ANIPHARMA-2020-DE-000301,ANI,,78.0,YR,,M,Y,,,20201202.0,,MD,DE,DE,2020,Q4,Elderly
185708591,18570859,12,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MG UNK,,,U,,,,,,,TABLET,,2020,Q4,Chronic kidney disease,,2020,Q4,1,I,2010.0,20201201.0,20201202,20201202,EXP,,DE-ANIPHARMA-2020-DE-000301,ANI,,78.0,YR,,M,Y,,,20201202.0,,MD,DE,DE,2020,Q4,Elderly
185708591,18570859,12,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MG UNK,,,U,,,,,,,TABLET,,2020,Q4,Cough,,2020,Q4,1,I,2010.0,20201201.0,20201202,20201202,EXP,,DE-ANIPHARMA-2020-DE-000301,ANI,,78.0,YR,,M,Y,,,20201202.0,,MD,DE,DE,2020,Q4,Elderly
185708591,18570859,12,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MG UNK,,,U,,,,,,,TABLET,,2020,Q4,Diastolic dysfunction,,2020,Q4,1,I,2010.0,20201201.0,20201202,20201202,EXP,,DE-ANIPHARMA-2020-DE-000301,ANI,,78.0,YR,,M,Y,,,20201202.0,,MD,DE,DE,2020,Q4,Elderly
185708591,18570859,12,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MG UNK,,,U,,,,,,,TABLET,,2020,Q4,Dyslipidaemia,,2020,Q4,1,I,2010.0,20201201.0,20201202,20201202,EXP,,DE-ANIPHARMA-2020-DE-000301,ANI,,78.0,YR,,M,Y,,,20201202.0,,MD,DE,DE,2020,Q4,Elderly
185708591,18570859,12,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MG UNK,,,U,,,,,,,TABLET,,2020,Q4,Haematoma,,2020,Q4,1,I,2010.0,20201201.0,20201202,20201202,EXP,,DE-ANIPHARMA-2020-DE-000301,ANI,,78.0,YR,,M,Y,,,20201202.0,,MD,DE,DE,2020,Q4,Elderly
185708591,18570859,12,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MG UNK,,,U,,,,,,,TABLET,,2020,Q4,Hepatotoxicity,,2020,Q4,1,I,2010.0,20201201.0,20201202,20201202,EXP,,DE-ANIPHARMA-2020-DE-000301,ANI,,78.0,YR,,M,Y,,,20201202.0,,MD,DE,DE,2020,Q4,Elderly
185708591,18570859,12,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MG UNK,,,U,,,,,,,TABLET,,2020,Q4,Hypoglycaemia,,2020,Q4,1,I,2010.0,20201201.0,20201202,20201202,EXP,,DE-ANIPHARMA-2020-DE-000301,ANI,,78.0,YR,,M,Y,,,20201202.0,,MD,DE,DE,2020,Q4,Elderly
185708591,18570859,12,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MG UNK,,,U,,,,,,,TABLET,,2020,Q4,Neuropathy peripheral,,2020,Q4,1,I,2010.0,20201201.0,20201202,20201202,EXP,,DE-ANIPHARMA-2020-DE-000301,ANI,,78.0,YR,,M,Y,,,20201202.0,,MD,DE,DE,2020,Q4,Elderly
185708591,18570859,12,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MG UNK,,,U,,,,,,,TABLET,,2020,Q4,Polyneuropathy,,2020,Q4,1,I,2010.0,20201201.0,20201202,20201202,EXP,,DE-ANIPHARMA-2020-DE-000301,ANI,,78.0,YR,,M,Y,,,20201202.0,,MD,DE,DE,2020,Q4,Elderly
185708591,18570859,12,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MG UNK,,,U,,,,,,,TABLET,,2020,Q4,Pulmonary congestion,,2020,Q4,1,I,2010.0,20201201.0,20201202,20201202,EXP,,DE-ANIPHARMA-2020-DE-000301,ANI,,78.0,YR,,M,Y,,,20201202.0,,MD,DE,DE,2020,Q4,Elderly
185708591,18570859,12,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MG UNK,,,U,,,,,,,TABLET,,2020,Q4,Right ventricular failure,,2020,Q4,1,I,2010.0,20201201.0,20201202,20201202,EXP,,DE-ANIPHARMA-2020-DE-000301,ANI,,78.0,YR,,M,Y,,,20201202.0,,MD,DE,DE,2020,Q4,Elderly
185708591,18570859,12,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MG UNK,,,U,,,,,,,TABLET,,2020,Q4,Tricuspid valve incompetence,,2020,Q4,1,I,2010.0,20201201.0,20201202,20201202,EXP,,DE-ANIPHARMA-2020-DE-000301,ANI,,78.0,YR,,M,Y,,,20201202.0,,MD,DE,DE,2020,Q4,Elderly
185708591,18570859,12,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MG UNK,,,U,,,,,,,TABLET,,2020,Q4,Vascular stent thrombosis,,2020,Q4,1,I,2010.0,20201201.0,20201202,20201202,EXP,,DE-ANIPHARMA-2020-DE-000301,ANI,,78.0,YR,,M,Y,,,20201202.0,,MD,DE,DE,2020,Q4,Elderly
185708591,18570859,12,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MG UNK,,,U,,,,,,,TABLET,,2020,Q4,Weight decreased,,2020,Q4,1,I,2010.0,20201201.0,20201202,20201202,EXP,,DE-ANIPHARMA-2020-DE-000301,ANI,,78.0,YR,,M,Y,,,20201202.0,,MD,DE,DE,2020,Q4,Elderly
185725761,18572576,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,90.0,MG,Y,, 2005095,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Dysuria,,2020,Q4,1,I,20201021.0,20201125.0,20201202,20201202,EXP,,CN-ASTRAZENECA-2020SF59084,ASTRAZENECA,,20195.0,DY,,M,Y,92.0,KG,20201203.0,,HP,CN,CN,2020,Q4,Elderly
185725761,18572576,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,90.0,MG,Y,, 2005095,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Micturition urgency,,2020,Q4,1,I,20201021.0,20201125.0,20201202,20201202,EXP,,CN-ASTRAZENECA-2020SF59084,ASTRAZENECA,,20195.0,DY,,M,Y,92.0,KG,20201203.0,,HP,CN,CN,2020,Q4,Elderly
185725761,18572576,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,90.0,MG,Y,, 2005095,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Pollakiuria,,2020,Q4,1,I,20201021.0,20201125.0,20201202,20201202,EXP,,CN-ASTRAZENECA-2020SF59084,ASTRAZENECA,,20195.0,DY,,M,Y,92.0,KG,20201203.0,,HP,CN,CN,2020,Q4,Elderly
185750971,18575097,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,,,TABLET,,2020,Q4,Euglycaemic diabetic ketoacidosis,,2020,Q4,1,I,,20201124.0,20201203,20201203,EXP,,US-ASTRAZENECA-2020SF59103,ASTRAZENECA,,89.0,YR,,F,Y,,,20201203.0,,MD,US,US,2020,Q4,Elderly
185754461,18575446,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,,,,202293.0,10.0,MG,TABLET,,2020,Q4,Blood creatine increased,,2020,Q4,1,I,,20201125.0,20201203,20201203,EXP,,DE-ASTRAZENECA-2020SF58366,ASTRAZENECA,,75.0,YR,,M,Y,89.9,KG,20201203.0,,MD,DE,DE,2020,Q4,Elderly
185754461,18575446,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,,,,202293.0,10.0,MG,TABLET,,2020,Q4,Diabetic nephropathy,,2020,Q4,1,I,,20201125.0,20201203,20201203,EXP,,DE-ASTRAZENECA-2020SF58366,ASTRAZENECA,,75.0,YR,,M,Y,89.9,KG,20201203.0,,MD,DE,DE,2020,Q4,Elderly
185754461,18575446,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,,,,202293.0,10.0,MG,TABLET,,2020,Q4,Glomerular filtration rate decreased,,2020,Q4,1,I,,20201125.0,20201203,20201203,EXP,,DE-ASTRAZENECA-2020SF58366,ASTRAZENECA,,75.0,YR,,M,Y,89.9,KG,20201203.0,,MD,DE,DE,2020,Q4,Elderly
185754461,18575446,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,,,,202293.0,10.0,MG,TABLET,,2020,Q4,Glycosylated haemoglobin abnormal,,2020,Q4,1,I,,20201125.0,20201203,20201203,EXP,,DE-ASTRAZENECA-2020SF58366,ASTRAZENECA,,75.0,YR,,M,Y,89.9,KG,20201203.0,,MD,DE,DE,2020,Q4,Elderly
185754461,18575446,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,,,,202293.0,10.0,MG,TABLET,,2020,Q4,Hypertensive nephropathy,,2020,Q4,1,I,,20201125.0,20201203,20201203,EXP,,DE-ASTRAZENECA-2020SF58366,ASTRAZENECA,,75.0,YR,,M,Y,89.9,KG,20201203.0,,MD,DE,DE,2020,Q4,Elderly
185754461,18575446,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,U,,,,202293.0,10.0,MG,TABLET,,2020,Q4,Polyuria,,2020,Q4,1,I,,20201125.0,20201203,20201203,EXP,,DE-ASTRAZENECA-2020SF58366,ASTRAZENECA,,75.0,YR,,M,Y,89.9,KG,20201203.0,,MD,DE,DE,2020,Q4,Elderly
185763251,18576325,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,, UNKNOWN,,202293.0,10.0,MG,TABLET,,2020,Q4,Acute coronary syndrome,,2020,Q4,1,I,20201029.0,20201125.0,20201203,20201203,EXP,,DE-ASTRAZENECA-2020SF58365,ASTRAZENECA,,71.0,YR,,M,Y,70.7,KG,20201203.0,,MD,DE,DE,2020,Q4,Elderly
185763251,18576325,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,, UNKNOWN,,202293.0,10.0,MG,TABLET,,2020,Q4,Chest pain,,2020,Q4,1,I,20201029.0,20201125.0,20201203,20201203,EXP,,DE-ASTRAZENECA-2020SF58365,ASTRAZENECA,,71.0,YR,,M,Y,70.7,KG,20201203.0,,MD,DE,DE,2020,Q4,Elderly
185763251,18576325,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,, UNKNOWN,,202293.0,10.0,MG,TABLET,,2020,Q4,Coronary artery disease,,2020,Q4,1,I,20201029.0,20201125.0,20201203,20201203,EXP,,DE-ASTRAZENECA-2020SF58365,ASTRAZENECA,,71.0,YR,,M,Y,70.7,KG,20201203.0,,MD,DE,DE,2020,Q4,Elderly
185763251,18576325,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,, UNKNOWN,,202293.0,10.0,MG,TABLET,,2020,Q4,Left ventricular dysfunction,,2020,Q4,1,I,20201029.0,20201125.0,20201203,20201203,EXP,,DE-ASTRAZENECA-2020SF58365,ASTRAZENECA,,71.0,YR,,M,Y,70.7,KG,20201203.0,,MD,DE,DE,2020,Q4,Elderly
185763251,18576325,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,, UNKNOWN,,202293.0,10.0,MG,TABLET,,2020,Q4,Weight decreased,,2020,Q4,1,I,20201029.0,20201125.0,20201203,20201203,EXP,,DE-ASTRAZENECA-2020SF58365,ASTRAZENECA,,71.0,YR,,M,Y,70.7,KG,20201203.0,,MD,DE,DE,2020,Q4,Elderly
185763251,18576325,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,REDUCED UNKNOWN,,,Y,, UNKNOWN,,202293.0,,,TABLET,,2020,Q4,Acute coronary syndrome,,2020,Q4,1,I,20201029.0,20201125.0,20201203,20201203,EXP,,DE-ASTRAZENECA-2020SF58365,ASTRAZENECA,,71.0,YR,,M,Y,70.7,KG,20201203.0,,MD,DE,DE,2020,Q4,Elderly
185763251,18576325,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,REDUCED UNKNOWN,,,Y,, UNKNOWN,,202293.0,,,TABLET,,2020,Q4,Chest pain,,2020,Q4,1,I,20201029.0,20201125.0,20201203,20201203,EXP,,DE-ASTRAZENECA-2020SF58365,ASTRAZENECA,,71.0,YR,,M,Y,70.7,KG,20201203.0,,MD,DE,DE,2020,Q4,Elderly
185763251,18576325,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,REDUCED UNKNOWN,,,Y,, UNKNOWN,,202293.0,,,TABLET,,2020,Q4,Coronary artery disease,,2020,Q4,1,I,20201029.0,20201125.0,20201203,20201203,EXP,,DE-ASTRAZENECA-2020SF58365,ASTRAZENECA,,71.0,YR,,M,Y,70.7,KG,20201203.0,,MD,DE,DE,2020,Q4,Elderly
185763251,18576325,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,REDUCED UNKNOWN,,,Y,, UNKNOWN,,202293.0,,,TABLET,,2020,Q4,Left ventricular dysfunction,,2020,Q4,1,I,20201029.0,20201125.0,20201203,20201203,EXP,,DE-ASTRAZENECA-2020SF58365,ASTRAZENECA,,71.0,YR,,M,Y,70.7,KG,20201203.0,,MD,DE,DE,2020,Q4,Elderly
185763251,18576325,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,REDUCED UNKNOWN,,,Y,, UNKNOWN,,202293.0,,,TABLET,,2020,Q4,Weight decreased,,2020,Q4,1,I,20201029.0,20201125.0,20201203,20201203,EXP,,DE-ASTRAZENECA-2020SF58365,ASTRAZENECA,,71.0,YR,,M,Y,70.7,KG,20201203.0,,MD,DE,DE,2020,Q4,Elderly
185809901,18580990,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Haematuria,,2020,Q4,1,I,,20201127.0,20201204,20201204,EXP,,GB-ASTRAZENECA-2020SF58153,ASTRAZENECA,,58.0,YR,,M,Y,,,20201204.0,,PH,GB,GB,2020,Q4,Adult
185817851,18581785,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,5 MG,,,Y,,,,202293.0,,,TABLET,,2020,Q4,Diabetic ketoacidosis,,2020,Q4,1,I,,20201124.0,20201204,20201204,EXP,,GR-ASTRAZENECA-2020SF55419,ASTRAZENECA,,54.0,YR,,F,Y,,,20201204.0,,HP,GR,GR,2020,Q4,Adult
185879901,18587990,2,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Carcinoid crisis,,2020,Q4,1,I,,20201123.0,20201207,20201207,EXP,,DE-B.BRAUN MEDICAL INC.-2100703,B BRAUN,"MALICEK D, WAGNER S, KAISER S, KHANDOGA A, MEININGER D. SEVERE CONDITION OF SHOCK WITH COMBINED LACTIC AND KETOACIDOSIS IN A PATIENT AFTER LEFT-SIDED PANCREAS RESECTION UNDER PERMANENT THERAPY WITH METFORMIN AND DAPAGLIFLOZIN. [GERMAN]. ANASTHESIOL-INTENSIVMED 2020;61(10):472-478.",76.0,YR,,M,Y,,,20201207.0,,HP,DE,DE,2020,Q4,Elderly
185906961,18590696,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q4,Euglycaemic diabetic ketoacidosis,,2020,Q4,1,I,20201023.0,20201201.0,20201208,20201208,EXP,,DE-ASTRAZENECA-2020SF60458,ASTRAZENECA,,59.0,YR,,M,Y,70.0,KG,20201208.0,,MD,DE,DE,2020,Q4,Adult
185962901,18596290,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,60.0,MG,Y,, MB2544,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Urine ketone body present,,2020,Q4,1,I,20201117.0,20201201.0,20201209,20201209,EXP,,CN-ASTRAZENECA-2020SF62583,ASTRAZENECA,,15869.0,DY,,M,Y,78.0,KG,20201209.0,,HP,CN,CN,2020,Q4,Elderly
186068831,18606883,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,5380.0,MG,,, S/I,,202293.0,10.0,MG,TABLET,QD,2020,Q4,COVID-19,,2020,Q4,1,I,20201109.0,20201203.0,20201211,20201211,EXP,,CO-ASTRAZENECA-2020SF63877,ASTRAZENECA,,25155.0,DY,,F,Y,,,20201211.0,,,CO,CO,2020,Q4,Elderly
186094423,18609442,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2020,Q4,Alopecia areata,,2020,Q4,3,F,,20201214.0,20201214,20201223,EXP,,DE-AUROBINDO-AUR-APL-2020-060100,AUROBINDO,,64.0,YR,,M,Y,,,20201223.0,,HP,DE,DE,2020,Q4,Adult
186094423,18609442,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2020,Q4,Alopecia universalis,,2020,Q4,3,F,,20201214.0,20201214,20201223,EXP,,DE-AUROBINDO-AUR-APL-2020-060100,AUROBINDO,,64.0,YR,,M,Y,,,20201223.0,,HP,DE,DE,2020,Q4,Adult
186110421,18611042,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,2320.0,MG,U,, MB3095,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Asthenia,,2020,Q4,1,I,20201117.0,20201206.0,20201214,20201214,EXP,,CN-ASTRAZENECA-2020SF66289,ASTRAZENECA,,24419.0,DY,,F,Y,60.0,KG,20201214.0,,HP,CN,CN,2020,Q4,Elderly
186110421,18611042,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,2320.0,MG,U,, MB3095,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Cachexia,,2020,Q4,1,I,20201117.0,20201206.0,20201214,20201214,EXP,,CN-ASTRAZENECA-2020SF66289,ASTRAZENECA,,24419.0,DY,,F,Y,60.0,KG,20201214.0,,HP,CN,CN,2020,Q4,Elderly
186110421,18611042,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,2320.0,MG,U,, MB3095,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Decreased appetite,,2020,Q4,1,I,20201117.0,20201206.0,20201214,20201214,EXP,,CN-ASTRAZENECA-2020SF66289,ASTRAZENECA,,24419.0,DY,,F,Y,60.0,KG,20201214.0,,HP,CN,CN,2020,Q4,Elderly
186110421,18611042,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,2320.0,MG,U,, MB3095,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Weight decreased,,2020,Q4,1,I,20201117.0,20201206.0,20201214,20201214,EXP,,CN-ASTRAZENECA-2020SF66289,ASTRAZENECA,,24419.0,DY,,F,Y,60.0,KG,20201214.0,,HP,CN,CN,2020,Q4,Elderly
186110421,18611042,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,2320.0,MG,U,, MB3095,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Asthenia,,2020,Q4,1,I,20201117.0,20201206.0,20201214,20201214,EXP,,CN-ASTRAZENECA-2020SF66289,ASTRAZENECA,,24419.0,DY,,F,Y,60.0,KG,20201214.0,,HP,CN,CN,2020,Q4,Elderly
186110421,18611042,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,2320.0,MG,U,, MB3095,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Cachexia,,2020,Q4,1,I,20201117.0,20201206.0,20201214,20201214,EXP,,CN-ASTRAZENECA-2020SF66289,ASTRAZENECA,,24419.0,DY,,F,Y,60.0,KG,20201214.0,,HP,CN,CN,2020,Q4,Elderly
186110421,18611042,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,2320.0,MG,U,, MB3095,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Decreased appetite,,2020,Q4,1,I,20201117.0,20201206.0,20201214,20201214,EXP,,CN-ASTRAZENECA-2020SF66289,ASTRAZENECA,,24419.0,DY,,F,Y,60.0,KG,20201214.0,,HP,CN,CN,2020,Q4,Elderly
186110421,18611042,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,2320.0,MG,U,, MB3095,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Weight decreased,,2020,Q4,1,I,20201117.0,20201206.0,20201214,20201214,EXP,,CN-ASTRAZENECA-2020SF66289,ASTRAZENECA,,24419.0,DY,,F,Y,60.0,KG,20201214.0,,HP,CN,CN,2020,Q4,Elderly
186116231,18611623,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,5.0MG UNKNOWN,,,U,,,,,5.0,MG,TABLET,,2020,Q4,Diabetic ketoacidosis,,2020,Q4,1,I,,20201204.0,20201214,20201214,EXP,,GB-ASTRAZENECA-2020SF63163,ASTRAZENECA,,62.0,YR,,M,Y,70.0,KG,20201214.0,,PH,GB,GB,2020,Q4,Adult
186149971,18614997,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Abdominal distension,,2020,Q4,1,I,20171101.0,20181115.0,20201214,20201214,EXP,,US-SHIRE-US201844848,TAKEDA,,59.0,YR,,F,Y,43.99,KG,20201214.0,,HP,US,US,2020,Q4,Adult
186149971,18614997,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Abdominal pain,,2020,Q4,1,I,20171101.0,20181115.0,20201214,20201214,EXP,,US-SHIRE-US201844848,TAKEDA,,59.0,YR,,F,Y,43.99,KG,20201214.0,,HP,US,US,2020,Q4,Adult
186149971,18614997,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Dehydration,,2020,Q4,1,I,20171101.0,20181115.0,20201214,20201214,EXP,,US-SHIRE-US201844848,TAKEDA,,59.0,YR,,F,Y,43.99,KG,20201214.0,,HP,US,US,2020,Q4,Adult
186149971,18614997,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Diarrhoea,,2020,Q4,1,I,20171101.0,20181115.0,20201214,20201214,EXP,,US-SHIRE-US201844848,TAKEDA,,59.0,YR,,F,Y,43.99,KG,20201214.0,,HP,US,US,2020,Q4,Adult
186149971,18614997,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Hypovolaemia,,2020,Q4,1,I,20171101.0,20181115.0,20201214,20201214,EXP,,US-SHIRE-US201844848,TAKEDA,,59.0,YR,,F,Y,43.99,KG,20201214.0,,HP,US,US,2020,Q4,Adult
186149971,18614997,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Nausea,,2020,Q4,1,I,20171101.0,20181115.0,20201214,20201214,EXP,,US-SHIRE-US201844848,TAKEDA,,59.0,YR,,F,Y,43.99,KG,20201214.0,,HP,US,US,2020,Q4,Adult
186149971,18614997,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Pancreatitis acute,,2020,Q4,1,I,20171101.0,20181115.0,20201214,20201214,EXP,,US-SHIRE-US201844848,TAKEDA,,59.0,YR,,F,Y,43.99,KG,20201214.0,,HP,US,US,2020,Q4,Adult
186149971,18614997,8,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Vomiting,,2020,Q4,1,I,20171101.0,20181115.0,20201214,20201214,EXP,,US-SHIRE-US201844848,TAKEDA,,59.0,YR,,F,Y,43.99,KG,20201214.0,,HP,US,US,2020,Q4,Adult
186186431,18618643,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,5.0,MG,TABLET,QD,2020,Q4,Euglycaemic diabetic ketoacidosis,,2020,Q4,1,I,,20201208.0,20201215,20201215,EXP,,CN-ASTRAZENECA-2020SF66477,ASTRAZENECA,,57.0,YR,,F,Y,65.0,KG,20201215.0,,MD,CN,CN,2020,Q4,Adult
186186481,18618648,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,Y,,,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Euglycaemic diabetic ketoacidosis,,2020,Q4,1,I,,20201208.0,20201215,20201215,EXP,,CN-ASTRAZENECA-2020SF66454,ASTRAZENECA,,46.0,YR,,M,Y,78.0,KG,20201215.0,,MD,CN,CN,2020,Q4,Adult
186186511,18618651,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,TABLET,QD,2020,Q4,Diabetic ketoacidosis,,2020,Q4,1,I,,20201210.0,20201215,20201215,EXP,,GB-ASTRAZENECA-2020SF65100,ASTRAZENECA,,64.0,YR,,M,Y,,,20201215.0,,PH,GB,GB,2020,Q4,Adult
186196071,18619607,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,4060.0,MG,U,, UNKNOWN,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Death,,2020,Q4,1,I,20200910.0,20201210.0,20201215,20201215,EXP,,CO-ASTRAZENECA-2020SF66380,ASTRAZENECA,,34796.0,DY,,M,Y,,,20201215.0,,,CO,CO,2020,Q4,Elderly
186206751,18620675,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q4,Blood triglycerides increased,,2020,Q4,1,I,20201008.0,20201207.0,20201215,20201215,EXP,,CN-ASTRAZENECA-2020SF66230,ASTRAZENECA,,13143.0,DY,,M,Y,,,20201215.0,,,CN,CN,2020,Q4,Elderly
186238551,18623855,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",100.0,MG,Y,, MB2547,,,10.0,MG,TABLET,QD,2020,Q4,Dry mouth,,2020,Q4,1,I,20201113.0,20201209.0,20201216,20201216,EXP,,CN-TAKEDA-2020TJP026449,TAKEDA,,58.0,YR,,F,Y,54.0,KG,20201216.0,,HP,CN,CN,2020,Q4,Adult
186238551,18623855,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",100.0,MG,Y,, MB2547,,,10.0,MG,TABLET,QD,2020,Q4,Pruritus,,2020,Q4,1,I,20201113.0,20201209.0,20201216,20201216,EXP,,CN-TAKEDA-2020TJP026449,TAKEDA,,58.0,YR,,F,Y,54.0,KG,20201216.0,,HP,CN,CN,2020,Q4,Adult
186238551,18623855,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",100.0,MG,Y,, MB2547,,,10.0,MG,TABLET,QD,2020,Q4,Rash,,2020,Q4,1,I,20201113.0,20201209.0,20201216,20201216,EXP,,CN-TAKEDA-2020TJP026449,TAKEDA,,58.0,YR,,F,Y,54.0,KG,20201216.0,,HP,CN,CN,2020,Q4,Adult
186328761,18632876,12,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,,,,,,,,,,,,,2020,Q4,Lymphopenia,,2020,Q4,1,I,20201123.0,20201210.0,20201218,20201218,EXP,GB-MHRA-ADR 24538757,GB-ACCORD-211274,ACCORD,,39.0,YR,,F,Y,65.0,KG,20201218.0,,PH,GB,GB,2020,Q4,Adult
186363071,18636307,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,20.0,MG,Y,, 2008148/MC3237,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Asthenia,,2020,Q4,1,I,20201209.0,20201211.0,20201218,20201218,EXP,,CN-ASTRAZENECA-2020SF68179,ASTRAZENECA,,23742.0,DY,,M,Y,79.0,KG,20201218.0,,HP,CN,CN,2020,Q4,Elderly
186363071,18636307,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,20.0,MG,Y,, 2008148/MC3237,,202293.0,10.0,MG,TABLET,QD,2020,Q4,Pain,,2020,Q4,1,I,20201209.0,20201211.0,20201218,20201218,EXP,,CN-ASTRAZENECA-2020SF68179,ASTRAZENECA,,23742.0,DY,,M,Y,79.0,KG,20201218.0,,HP,CN,CN,2020,Q4,Elderly
186389991,18638999,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,U,,,,,10.0,MG,,QD,2020,Q4,Acute myocardial infarction,,2020,Q4,1,I,20201207.0,20201208.0,20201218,20201218,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-107734,BRISTOL MYERS SQUIBB,,72.0,YR,,M,Y,,,20201218.0,,HP,BR,BR,2020,Q4,Elderly
186389991,18638999,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,U,,,,,10.0,MG,,QD,2020,Q4,Infusion related reaction,,2020,Q4,1,I,20201207.0,20201208.0,20201218,20201218,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-107734,BRISTOL MYERS SQUIBB,,72.0,YR,,M,Y,,,20201218.0,,HP,BR,BR,2020,Q4,Elderly
186479792,18647979,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,TABLET,,2020,Q4,Alopecia universalis,,2020,Q4,2,F,,20201214.0,20201222,20201228,EXP,,DE-MYLANLABS-2020M1102338,MYLAN,"KOHLMANN J, FERRER RA, MARKOVIC A, ILLES M, KUNZ M. ALOPECIA AREATA UNIVERSALIS UNDER TREATMENT WITH SITAGLIPTIN: POSSIBLE IMMUNOLOGICAL EFFECT OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS. HAUTARZT. 2020",64.0,YR,,M,Y,,,20201228.0,,MD,DE,DE,2020,Q4,Adult
186479792,18647979,4,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,TABLET,,2020,Q4,Diabetes mellitus inadequate control,,2020,Q4,2,F,,20201214.0,20201222,20201228,EXP,,DE-MYLANLABS-2020M1102338,MYLAN,"KOHLMANN J, FERRER RA, MARKOVIC A, ILLES M, KUNZ M. ALOPECIA AREATA UNIVERSALIS UNDER TREATMENT WITH SITAGLIPTIN: POSSIBLE IMMUNOLOGICAL EFFECT OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS. HAUTARZT. 2020",64.0,YR,,M,Y,,,20201228.0,,MD,DE,DE,2020,Q4,Adult
186488341,18648834,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q4,Diabetic ketoacidosis,,2020,Q4,1,I,20201202.0,20201216.0,20201222,20201222,EXP,,GB-ASTRAZENECA-2020SF69091,ASTRAZENECA,,49.0,YR,,M,Y,,,20201222.0,,,GB,GB,2020,Q4,Adult
186494811,18649481,9,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2020,Q4,Hypercalcaemia,,2020,Q4,1,I,,20200603.0,20201222,20201222,PER,,US-LUPIN PHARMACEUTICALS INC.-2020-02828,LUPIN,,61.0,YR,,M,Y,,,20201222.0,,HP,US,US,2020,Q4,Adult
186514061,18651406,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,D,,,,,10.0,MG,TABLET,,2020,Q4,Acute myocardial infarction,,2020,Q4,1,I,2010.0,20201209.0,20201222,20201222,EXP,,DE-MYLANLABS-2020M1103787,MYLAN,,78.0,YR,,M,Y,,,20201222.0,,MD,DE,DE,2020,Q4,Elderly
186514061,18651406,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,D,,,,,10.0,MG,TABLET,,2020,Q4,Aortic valve incompetence,,2020,Q4,1,I,2010.0,20201209.0,20201222,20201222,EXP,,DE-MYLANLABS-2020M1103787,MYLAN,,78.0,YR,,M,Y,,,20201222.0,,MD,DE,DE,2020,Q4,Elderly
186514061,18651406,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,D,,,,,10.0,MG,TABLET,,2020,Q4,Chronic kidney disease,,2020,Q4,1,I,2010.0,20201209.0,20201222,20201222,EXP,,DE-MYLANLABS-2020M1103787,MYLAN,,78.0,YR,,M,Y,,,20201222.0,,MD,DE,DE,2020,Q4,Elderly
186514061,18651406,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,D,,,,,10.0,MG,TABLET,,2020,Q4,Cough,,2020,Q4,1,I,2010.0,20201209.0,20201222,20201222,EXP,,DE-MYLANLABS-2020M1103787,MYLAN,,78.0,YR,,M,Y,,,20201222.0,,MD,DE,DE,2020,Q4,Elderly
186514061,18651406,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,D,,,,,10.0,MG,TABLET,,2020,Q4,Diastolic dysfunction,,2020,Q4,1,I,2010.0,20201209.0,20201222,20201222,EXP,,DE-MYLANLABS-2020M1103787,MYLAN,,78.0,YR,,M,Y,,,20201222.0,,MD,DE,DE,2020,Q4,Elderly
186514061,18651406,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,D,,,,,10.0,MG,TABLET,,2020,Q4,Dyslipidaemia,,2020,Q4,1,I,2010.0,20201209.0,20201222,20201222,EXP,,DE-MYLANLABS-2020M1103787,MYLAN,,78.0,YR,,M,Y,,,20201222.0,,MD,DE,DE,2020,Q4,Elderly
186514061,18651406,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,D,,,,,10.0,MG,TABLET,,2020,Q4,Haematoma,,2020,Q4,1,I,2010.0,20201209.0,20201222,20201222,EXP,,DE-MYLANLABS-2020M1103787,MYLAN,,78.0,YR,,M,Y,,,20201222.0,,MD,DE,DE,2020,Q4,Elderly
186514061,18651406,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,D,,,,,10.0,MG,TABLET,,2020,Q4,Hepatotoxicity,,2020,Q4,1,I,2010.0,20201209.0,20201222,20201222,EXP,,DE-MYLANLABS-2020M1103787,MYLAN,,78.0,YR,,M,Y,,,20201222.0,,MD,DE,DE,2020,Q4,Elderly
186514061,18651406,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,D,,,,,10.0,MG,TABLET,,2020,Q4,Hypoglycaemia,,2020,Q4,1,I,2010.0,20201209.0,20201222,20201222,EXP,,DE-MYLANLABS-2020M1103787,MYLAN,,78.0,YR,,M,Y,,,20201222.0,,MD,DE,DE,2020,Q4,Elderly
186514061,18651406,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,D,,,,,10.0,MG,TABLET,,2020,Q4,Neuropathy peripheral,,2020,Q4,1,I,2010.0,20201209.0,20201222,20201222,EXP,,DE-MYLANLABS-2020M1103787,MYLAN,,78.0,YR,,M,Y,,,20201222.0,,MD,DE,DE,2020,Q4,Elderly
186514061,18651406,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,D,,,,,10.0,MG,TABLET,,2020,Q4,Off label use,,2020,Q4,1,I,2010.0,20201209.0,20201222,20201222,EXP,,DE-MYLANLABS-2020M1103787,MYLAN,,78.0,YR,,M,Y,,,20201222.0,,MD,DE,DE,2020,Q4,Elderly
186514061,18651406,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,D,,,,,10.0,MG,TABLET,,2020,Q4,Polyneuropathy,,2020,Q4,1,I,2010.0,20201209.0,20201222,20201222,EXP,,DE-MYLANLABS-2020M1103787,MYLAN,,78.0,YR,,M,Y,,,20201222.0,,MD,DE,DE,2020,Q4,Elderly
186514061,18651406,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,D,,,,,10.0,MG,TABLET,,2020,Q4,Pulmonary congestion,,2020,Q4,1,I,2010.0,20201209.0,20201222,20201222,EXP,,DE-MYLANLABS-2020M1103787,MYLAN,,78.0,YR,,M,Y,,,20201222.0,,MD,DE,DE,2020,Q4,Elderly
186514061,18651406,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,D,,,,,10.0,MG,TABLET,,2020,Q4,Right ventricular failure,,2020,Q4,1,I,2010.0,20201209.0,20201222,20201222,EXP,,DE-MYLANLABS-2020M1103787,MYLAN,,78.0,YR,,M,Y,,,20201222.0,,MD,DE,DE,2020,Q4,Elderly
186514061,18651406,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,D,,,,,10.0,MG,TABLET,,2020,Q4,Tricuspid valve incompetence,,2020,Q4,1,I,2010.0,20201209.0,20201222,20201222,EXP,,DE-MYLANLABS-2020M1103787,MYLAN,,78.0,YR,,M,Y,,,20201222.0,,MD,DE,DE,2020,Q4,Elderly
186514061,18651406,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,D,,,,,10.0,MG,TABLET,,2020,Q4,Vascular stent thrombosis,,2020,Q4,1,I,2010.0,20201209.0,20201222,20201222,EXP,,DE-MYLANLABS-2020M1103787,MYLAN,,78.0,YR,,M,Y,,,20201222.0,,MD,DE,DE,2020,Q4,Elderly
186514061,18651406,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,D,,,,,10.0,MG,TABLET,,2020,Q4,Weight decreased,,2020,Q4,1,I,2010.0,20201209.0,20201222,20201222,EXP,,DE-MYLANLABS-2020M1103787,MYLAN,,78.0,YR,,M,Y,,,20201222.0,,MD,DE,DE,2020,Q4,Elderly
186578161,18657816,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,3700.0,G,Y,, MB2554,,,10.0,G,TABLET,QD,2020,Q4,Ketoacidosis,,2020,Q4,1,I,20201201.0,20201210.0,20201223,20201223,EXP,,CN-ASTRAZENECA-2020SF67248,ASTRAZENECA,,20231.0,DY,,M,Y,65.0,KG,20201223.0,,HP,CN,CN,2020,Q4,Elderly
186594531,18659453,10,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2020,Q4,Amaurosis,,2020,Q4,1,I,20201207.0,20201218.0,20201223,20201223,EXP,,CN-PFIZER INC-2020503707,PFIZER,,75.0,YR,,F,Y,71.0,KG,20201223.0,,CN,CN,CN,2020,Q4,Elderly
186594531,18659453,10,C,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2020,Q4,Dizziness,,2020,Q4,1,I,20201207.0,20201218.0,20201223,20201223,EXP,,CN-PFIZER INC-2020503707,PFIZER,,75.0,YR,,F,Y,71.0,KG,20201223.0,,CN,CN,CN,2020,Q4,Elderly
186610381,18661038,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,80.0,MG,Y,, 2006209,,,10.0,MG,TABLET,QD,2020,Q4,Ketoacidosis,,2020,Q4,1,I,20201207.0,20201215.0,20201224,20201224,EXP,,CN-ASTRAZENECA-2020SF70412,ASTRAZENECA,,81.0,YR,,F,Y,,,20201224.0,,HP,CN,CN,2020,Q4,Elderly
186632501,18663250,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1000.0,MG,Y,, MC3225,,202293.0,5.0,MG,TABLET,QD,2020,Q4,Renal cyst,,2020,Q4,1,I,20201204.0,20201216.0,20201224,20201224,EXP,,CN-ASTRAZENECA-2020SF71430,ASTRAZENECA,,27480.0,DY,,F,Y,54.0,KG,20201224.0,,HP,CN,CN,2020,Q4,Elderly
186632501,18663250,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,1000.0,MG,Y,, MC3225,,202293.0,5.0,MG,TABLET,QD,2020,Q4,Urinary tract infection,,2020,Q4,1,I,20201204.0,20201216.0,20201224,20201224,EXP,,CN-ASTRAZENECA-2020SF71430,ASTRAZENECA,,27480.0,DY,,F,Y,54.0,KG,20201224.0,,HP,CN,CN,2020,Q4,Elderly
186655421,18665542,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q4,Acute kidney injury,,2020,Q4,1,I,,20201216.0,20201226,20201226,EXP,,KR-ASTRAZENECA-2020SF70884,ASTRAZENECA,,54.0,YR,,M,Y,69.2,KG,20201226.0,,HP,KR,KR,2020,Q4,Adult
186655421,18665542,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q4,Dehydration,,2020,Q4,1,I,,20201216.0,20201226,20201226,EXP,,KR-ASTRAZENECA-2020SF70884,ASTRAZENECA,,54.0,YR,,M,Y,69.2,KG,20201226.0,,HP,KR,KR,2020,Q4,Adult
186655421,18665542,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q4,Hypernatraemia,,2020,Q4,1,I,,20201216.0,20201226,20201226,EXP,,KR-ASTRAZENECA-2020SF70884,ASTRAZENECA,,54.0,YR,,M,Y,69.2,KG,20201226.0,,HP,KR,KR,2020,Q4,Adult
186655421,18665542,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,Y,,,,202293.0,10.0,MG,TABLET,,2020,Q4,Weight decreased,,2020,Q4,1,I,,20201216.0,20201226,20201226,EXP,,KR-ASTRAZENECA-2020SF70884,ASTRAZENECA,,54.0,YR,,M,Y,69.2,KG,20201226.0,,HP,KR,KR,2020,Q4,Adult
186664971,18666497,14,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,5 MG,,,U,,,,,5.0,MG,,,2020,Q4,Blood sodium decreased,,2020,Q4,1,I,,20201201.0,20201227,20201227,EXP,,NVSJ2020JP013426,NOVARTIS,,60.0,YR,,M,Y,81.0,KG,20201227.0,,MD,JP,JP,2020,Q4,Adult
186664971,18666497,14,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,5 MG,,,U,,,,,5.0,MG,,,2020,Q4,Hypotension,,2020,Q4,1,I,,20201201.0,20201227,20201227,EXP,,NVSJ2020JP013426,NOVARTIS,,60.0,YR,,M,Y,81.0,KG,20201227.0,,MD,JP,JP,2020,Q4,Adult
186664971,18666497,14,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,5 MG,,,U,,,,,5.0,MG,,,2020,Q4,Product use issue,,2020,Q4,1,I,,20201201.0,20201227,20201227,EXP,,NVSJ2020JP013426,NOVARTIS,,60.0,YR,,M,Y,81.0,KG,20201227.0,,MD,JP,JP,2020,Q4,Adult
186664971,18666497,14,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,DAPAGLIFLOZIN PROPANEDIOL,1,Oral,5 MG,,,U,,,,,5.0,MG,,,2020,Q4,Renal impairment,,2020,Q4,1,I,,20201201.0,20201227,20201227,EXP,,NVSJ2020JP013426,NOVARTIS,,60.0,YR,,M,Y,81.0,KG,20201227.0,,MD,JP,JP,2020,Q4,Adult
186708071,18670807,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,20.0,MG,Y,, 2005188,,,5.0,MG,TABLET,QD,2020,Q4,Ketosis,,2020,Q4,1,I,20201123.0,20201202.0,20201228,20201228,EXP,,CN-ASTRAZENECA-2020SF63492,ASTRAZENECA,,57.0,YR,,F,Y,,,20201228.0,,HP,CN,CN,2020,Q4,Adult
186708071,18670807,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,20.0,MG,Y,, 2005188,,,5.0,MG,TABLET,QD,2020,Q4,Nausea,,2020,Q4,1,I,20201123.0,20201202.0,20201228,20201228,EXP,,CN-ASTRAZENECA-2020SF63492,ASTRAZENECA,,57.0,YR,,F,Y,,,20201228.0,,HP,CN,CN,2020,Q4,Adult
186708071,18670807,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,20.0,MG,Y,, 2005188,,,10.0,MG,TABLET,QD,2020,Q4,Ketosis,,2020,Q4,1,I,20201123.0,20201202.0,20201228,20201228,EXP,,CN-ASTRAZENECA-2020SF63492,ASTRAZENECA,,57.0,YR,,F,Y,,,20201228.0,,HP,CN,CN,2020,Q4,Adult
186708071,18670807,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,20.0,MG,Y,, 2005188,,,10.0,MG,TABLET,QD,2020,Q4,Nausea,,2020,Q4,1,I,20201123.0,20201202.0,20201228,20201228,EXP,,CN-ASTRAZENECA-2020SF63492,ASTRAZENECA,,57.0,YR,,F,Y,,,20201228.0,,HP,CN,CN,2020,Q4,Adult
186709251,18670925,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,280.0,MG,Y,,,,,10.0,MG,TABLET,QD,2020,Q4,Diabetic ketoacidosis,,2020,Q4,1,I,20201203.0,20201219.0,20201228,20201228,EXP,,CN-ASTRAZENECA-2020SF72934,ASTRAZENECA,,14245.0,DY,,M,Y,80.0,KG,20201228.0,,HP,CN,CN,2020,Q4,Elderly
186771621,18677162,10,C,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE;METFORMIN HYDROCHLORIDE,DAPAGLIFLOZIN PROPANEDIOL\METFORMIN HYDROCHLORIDE,1,Oral,"1 DF, QD",,,,,,,,1.0,DF,,QD,2020,Q4,Gastric ulcer,,2020,Q4,1,I,20201023.0,20201223.0,20201229,20201229,EXP,,KR-JNJFOC-20201250604,JOHNSON AND JOHNSON,,73.0,YR,E,M,Y,71.6,KG,20201229.0,,MD,KR,KR,2020,Q4,Elderly
186891761,18689176,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"UNK, SINGLE",,,U,,,,,,,TABLET,QD,2020,Q4,Intentional overdose,,2020,Q4,1,I,20191019.0,20191031.0,20201231,20201231,EXP,,DE-TOPROL-2019001163,TOPROL ACQUISITION,,78.0,YR,,F,Y,,,20201231.0,,CN,SE,DE,2020,Q4,Elderly
186891761,18689176,3,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,"UNK, SINGLE",,,U,,,,,,,TABLET,QD,2020,Q4,Suicide attempt,,2020,Q4,1,I,20191019.0,20191031.0,20201231,20201231,EXP,,DE-TOPROL-2019001163,TOPROL ACQUISITION,,78.0,YR,,F,Y,,,20201231.0,,CN,SE,DE,2020,Q4,Elderly
186891761,18689176,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,TABLET,,2020,Q4,Intentional overdose,,2020,Q4,1,I,20191019.0,20191031.0,20201231,20201231,EXP,,DE-TOPROL-2019001163,TOPROL ACQUISITION,,78.0,YR,,F,Y,,,20201231.0,,CN,SE,DE,2020,Q4,Elderly
186891761,18689176,4,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,TABLET,,2020,Q4,Suicide attempt,,2020,Q4,1,I,20191019.0,20191031.0,20201231,20201231,EXP,,DE-TOPROL-2019001163,TOPROL ACQUISITION,,78.0,YR,,F,Y,,,20201231.0,,CN,SE,DE,2020,Q4,Elderly
186897801,18689780,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,17.0,DF,Y,, MC3233,,202293.0,1.0,DF,TABLET,QD,2020,Q4,Blood potassium increased,,2020,Q4,1,I,20201201.0,20201225.0,20201231,20201231,EXP,,CN-ASTRAZENECA-2020SF75085,ASTRAZENECA,,23456.0,DY,,M,Y,67.0,KG,20201231.0,,HP,CN,CN,2020,Q4,Elderly
186897801,18689780,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,17.0,DF,Y,, MC3233,,202293.0,1.0,DF,TABLET,QD,2020,Q4,Dizziness,,2020,Q4,1,I,20201201.0,20201225.0,20201231,20201231,EXP,,CN-ASTRAZENECA-2020SF75085,ASTRAZENECA,,23456.0,DY,,M,Y,67.0,KG,20201231.0,,HP,CN,CN,2020,Q4,Elderly
186897801,18689780,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,17.0,DF,Y,, MC3233,,202293.0,1.0,DF,TABLET,QD,2020,Q4,Dry mouth,,2020,Q4,1,I,20201201.0,20201225.0,20201231,20201231,EXP,,CN-ASTRAZENECA-2020SF75085,ASTRAZENECA,,23456.0,DY,,M,Y,67.0,KG,20201231.0,,HP,CN,CN,2020,Q4,Elderly
186897801,18689780,1,PS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,17.0,DF,Y,, MC3233,,202293.0,1.0,DF,TABLET,QD,2020,Q4,Pain in extremity,,2020,Q4,1,I,20201201.0,20201225.0,20201231,20201231,EXP,,CN-ASTRAZENECA-2020SF75085,ASTRAZENECA,,23456.0,DY,,M,Y,67.0,KG,20201231.0,,HP,CN,CN,2020,Q4,Elderly
186897801,18689780,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,17.0,DF,Y,, MC3233,,202293.0,1.0,DF,TABLET,QD,2020,Q4,Blood potassium increased,,2020,Q4,1,I,20201201.0,20201225.0,20201231,20201231,EXP,,CN-ASTRAZENECA-2020SF75085,ASTRAZENECA,,23456.0,DY,,M,Y,67.0,KG,20201231.0,,HP,CN,CN,2020,Q4,Elderly
186897801,18689780,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,17.0,DF,Y,, MC3233,,202293.0,1.0,DF,TABLET,QD,2020,Q4,Dizziness,,2020,Q4,1,I,20201201.0,20201225.0,20201231,20201231,EXP,,CN-ASTRAZENECA-2020SF75085,ASTRAZENECA,,23456.0,DY,,M,Y,67.0,KG,20201231.0,,HP,CN,CN,2020,Q4,Elderly
186897801,18689780,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,17.0,DF,Y,, MC3233,,202293.0,1.0,DF,TABLET,QD,2020,Q4,Dry mouth,,2020,Q4,1,I,20201201.0,20201225.0,20201231,20201231,EXP,,CN-ASTRAZENECA-2020SF75085,ASTRAZENECA,,23456.0,DY,,M,Y,67.0,KG,20201231.0,,HP,CN,CN,2020,Q4,Elderly
186897801,18689780,2,SS,DAPAGLIFLOZIN.,DAPAGLIFLOZIN,1,Oral,,17.0,DF,Y,, MC3233,,202293.0,1.0,DF,TABLET,QD,2020,Q4,Pain in extremity,,2020,Q4,1,I,20201201.0,20201225.0,20201231,20201231,EXP,,CN-ASTRAZENECA-2020SF75085,ASTRAZENECA,,23456.0,DY,,M,Y,67.0,KG,20201231.0,,HP,CN,CN,2020,Q4,Elderly
